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AMC: 7-amino-4-methyl-coumarin 
AMSH: associated molecule with the SH3 domain of STAM 
AMSH-LP: AMSH-like protein 
An: Aspergillus nidulans  
At: Arabidopsis thaliana  
BRCA1/2: Breast Cancer 1/2 
BRCC36: BRCA1/BRCA2-Containing Complex subunit 36 
BRCC45: BRCA1/BCRA2-containing complex subunit 45 
BS3: bis-(sulfosuccinimidyl)suberate  
BSA: bovine serum albumine  
CAND1: Cullin-associated NEDD8-dissociated protein 1  
CDK: Cyclin-dependent kinase  
CDKN1C: Cyclin-dependent kinase inhibitor 1C 
Ce: Caenorhabditis elegans  
CRL: Cullin RING E3 ubiquitin ligase 
CSN: COP9 signalosome 
COP9: COnstitutive Photomorphogenesis 9 
Cul1: Cullin 1 
CX: cross-linking 
CYLD: cylindromatosis gene product  
Dm: Drosophila melanogaster 
DSS: disuccinimidyl suberate 
DUB: deubiquitinating enzyme 
eIF3: eukaryotic translation initiation factor 3  
EM: electron microscopy 
HECT: homologous to E6-associated carboxyl terminus 
HIF-1: hypoxia-inducible factor 1- 
HSQC: Heteronuclear single quantum coherence spectroscopy 
Hs: Homo sapiens  
hVIP: human immunodeficiency virus 1 accessory protein  
 E
Id1: Inhibitor of DNA binding 1 
ITC: isothermal titration calorimetry 
Jab1: Jun-activatory binding protein 1 
JAMM: Jab1-MPN-Mov34 
KD: dissociation constant 
KO: knockout  
Mdm2: Double minute 2 protein  
MEF: mouse embryonic fibroblasts  
MERIT40: Mediator of RAP80 interactions and targeting subunit of 40 kDa 
Mm: Mus musculus 
MPN: Mpr1/Pad1 N-terminal 
NAE: Nedd8-specific activating enzyme 
Nc: Neurospora crassa  
Nedd8: neural precursor cell expressed developmentally down-regulated protein 8 
NEDP1: Nedd8-specific protease 1 
NMR: nuclear magnetic resonance 
OUT: ovarian-tumor  
PCI: Proteasome COP9 eIF3 
Pro-Nedd8: precursor Nedd8 
RAP80: Receptor-associated protein 80 
RING: really interesting new gene 
RBR: RING-between-RING 
Runx3: Runt-related transcription factor 3 
Rbx1: RING-box protein 1 
Sc: Saccharomyces cerevisiae  
SUMO: Small Ubiquitin-related MOdifier 
Skp1: S-phase kinase-associated protein 1 
Skp2: S-phase kinase-associated protein 2 
SCF: Skp1-Cullin1-F-box 
Smad7: Mothers against decapentaplegic homolog 7 
Sp: Schizosaccharomyces pombe  
STAM1: signal transduction adaptor molecule 1 
Ub: ubiquitin 
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UBL: ubiquitin-like molecule 
UCH: Ub C-terminal hydrolases  
UPS: ubiquitin proteasome system 
USP: Ub-specific protease 
WH: winged-helix  
-TrCP: -transducin repeat-containing protein
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Le COP9 (Constitutive photomorphogenesis 9) signalosome (CSN) est un complexe 
multiprotéique contenant huit sous-unités (320 kDa), impliqué dans des processus cellulaires 
divers allant de la progression du cycle cellulaire, à l’expression des gènes et la réparation de 
l’ADN, à travers sa fonction au sein du système ubiquitine-protéasome. Il s’agit d’un 
complexe fortement conservé au cours de l’évolution chez les eucaryotes supérieurs chez qui 
son activité catalytique est essentielle. Au cours des années d’études biologiques et 
biochimiques qui ont permis d’élucider le rôle du CSN, sa fonction la mieux étudiée et la 
mieux comprise est celle liée au contrôle de l’ubiquitylation des protéines (une modification 
post-traductionnelle qui implique la liaison covalente d’une protéine cible par une molécule 
d’ubiquitine) par une classe d’E3 ubiquitine ligases. L’activité catalytique du CSN régule 
spécifiquement les E3 culline RING ubiquitin ligases (CRLs) via la suppression d’une 
molécule ressemblant à l’ubiquitine, Nedd8 (cullin-neural precursor cell expressed 
developmentally downregulated gene 8) des CRLs au cours d’une réaction de déneddylation. 
Les cycles de neddylation/déneddylation sont essentiels au fonctionnement correct des CRLs 
et le CSN joue un rôle central dans ce processus à travers sa fonction de déneddylase. Une 
similarité globale lie le CSN, le chapeau du protéasome (19S) et le complexe eIF3 (eukaryotic 
initiation factor-3). Ces assemblages multi-protéiques comprennent tous six sous-unités 
contenant un domaine PCI (proteasome COP9 eIF3) et deux sous-unités contenant un 
domaine MPN (Mpr1–Pad1–N-terminal). L’activité catalytique du CSN est portée par la 
sous-unité 5, CSN5, qui hydrolyse la liaison isopeptidique entre Nedd8 et la CRL. CSN5 
contient un cœur catalytique dépendent d’un zinc et comprenant un motif JAMM 
(Jab1/MPN/Mov34).  
L’incorporation de CSN5 dans le CSN révèle son activité isopeptidasique, alors qu’à l’état 
isolé, CSN5 n’est pas actif. Le travail réalisé au cours de ces trois ans a abouti à quatre 
aspects principaux qui ont contribué à une meilleure compréhension globale du système CSN. 
(i) S’appuyant sur la structure du domaine catalytique de CSN5, des études in vitro et in silico 
ont abouti à l’identification d’un élément moléculaire permettant à CSN5 de passer de la 
forme inactive à la forme active. Ceci a débouché sur la conception et validation d’un variant 
constitutivement actif de CSN5. (ii) La capacité de CSN5 à homodimériser a été étudié en 
solution, in silico et dans des extraits cellulaires et a apporté des perspectives potentiellement 
intéressantes concernant la fonction de CSN5. (iii) Au delà de ce travail et pour aborder la 
question de la régulation de l’activité de CSN5 dans le CSN, la contribution de la sous-unité 
6, CSN6 qui interagit directement avec CSN5 a été évaluée et ceci a abouti à l’identification 
de CSN6 comme sous-unité activatrice de CSN5. (iv) La caractérisation biochimique et 
biophysique du complexe CSN5-CSN6 a été utilisée pour explorer les bases moléculaires de 
cette association, non seulement, dans le contexte de son interaction avec Nedd8, mais aussi, 
de son intégration au sein du CSN, à travers une approche intégrée alliant des techniques 
biochimiques, structurales, biophysiques et computationnelles. 
En résumé, ce travail a permis d’améliorer la compréhension des déterminants de l’activité et 
des mécanismes de régulation auxquels la sous-unité catalytique du CSN, CSN5 est soumise.  
 
Mots clés: système ubiquitine-protéasome ; Cop9 signalosome; activité isopeptidasique; 
ubiquitin E3 ligase; régulation de Cullin, Rpn11, pro-Nedd8   
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L’ubiquitination des protéines est une modification post-traductionnelle qui est au 
cœur du système ubiquitine-protéasome et qui intervient dans la quasi-intégralité des voies de 
signalisation cellulaires chez les eucaryotes. La plus connue des conséquences de 
l’ubiquitination est l’adressage des protéines marquées vers la machinerie de dégradation 26S 
protéasome, mais l’ubiquitination des protéines peut induire d’autres effets, comme la 
modification de l’interactome de la protéine modifiée, de son activité. Le contrôle de 
l’ensemble de ces processus liés au système ubiquitine-protéasome est un aspect central à 
l’homéostasie cellulaire. L’ubiquitination d’une molécule fait intervenir trois réactions en 
cascade (E1, E2, E3). La fonction carboxylique de la glycine d’une ubiquitine est d’abord 
activée par l’enzyme E1 (ubiquitin activating enzyme). La seconde étape comprend le 
transfert de l’ubiquitine activée de l’E1 vers la cystéine catalytique de l’enzyme E2 (ubiquitin 
conjugating enzyme). L’enzyme E2 chargée avec l’ubiquitine s’associe à l’E3 en interaction 
avec le substrat et ensemble l’E2 et l’E3 coopèrent pour le transfert de l’ubiquitine sur la 
chaine latérale d’une lysine de surface de la protéine cible, formant une liaison isopeptidique. 
C’est le dernier protagoniste de cette réaction multi-étape de transfert des ubiquitines sur les 
protéines cibles, les E3 ligases qui nous intéressent tout particulièrement dans le contexte de 
ce travail.  
 
Il existe plusieurs classes d’E3 ligases définies selon leur composition protéique. Les 
E3 Culline RING ubiquitine ligases (CRLs ; RING for really interesting new gene) 
constituent une des classes majeures d’E3 ubiquitine ligases. Ces CRLs comprennent 
plusieurs sous-unités, parmi lesquelles la protéine d’échafaudage, culline et la sous-unité 
RING porteuse de l’activité enzymatique. L’activité de ces CRLs est régulée par des cycles de 
neddylation/déneddylation (attachement covalent d’une molécule proche de l’ubiquitine, 
Nedd8) sur la sous-unité culline. 
Les CRLs possèdent une architecture complexe et dynamique qui reflète les différents 
mécanismes de régulation dont elles sont l’objet. Parmi ces voies de contrôle, la neddylation 
des CRLs au niveau de la sous-unité d’échafaudage, Culline, stimule l’activité 
d’ubiquitylation des CRLs à travers de larges changements conformationnels de leur structure 
globale et empêche la fixation de l’inhibiteur naturel des CRLs, CAND1 (Cullin-associated 
NEDD8-dissociated protein 1). Les cycles de neddylation/déneddylation sont strictement 
régulés et un élément central de cette régulation est le complexe COP9 signalosome (CSN) 
qui déneddyle les Cullines (c’est à dire hydrolyse la liason isopeptidique qui lie Nedd8 à la 
Culline). En effet, il a été montré que le CSN joue un rôle critique dans le contrôle de l’état de 
neddylation des CRLs. Au delà de l’activité catalytique de déneddylation du CSN sur les 
CRLs, CSN peut aussi interagir de manière non-catalytique avec les CRLs. Ce mode de 
régulation non-catalytique, encore mal compris, pourrait augmenter encore la complexité de 
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ce système de régulation liant le CSN aux CRLs qui échappe toujours à une compréhension 
parfaite. Bien que le CSN soit in vitro un inhibiteur des CRLs, il a été montré que l’activité du 
CSN est essentielle aux CRLs in cellulo. Plusieurs mécanismes, non mutuellement exclusifs, 
permettant de comprendre ce paradoxe ont été proposés. (i) Le CSN pourrait par son activité 
déneddylase empêcher l’auto-ubiquitination des CRLs qui conduit à leur dégradation. (ii) La 
nécessité non seulement de la liaison covalente de Nedd8 mais aussi de son hydrolyse suggère 
qu’in vivo les CRLs sont sujettes à des cycles rapides de neddylation/déneddylation. Un cycle 
de neddylation/déneddylation pourrait correspondre à un évènement de fixation du substrat, 
évènement lié à la neddylation de la Culline auquel ferait suite l’ubiquitination du substrat, sa 
dissociation et la déneddylation de la CRL. A la fin de ce cycle, un nouveau cycle serait 
entamé par la fixation du substrat. (iii) Le CSN joue aussi un rôle dans la régulation de la 
fixation d’un inhibiteur naturel des CRLs, CAND1. CAND1 interagit spécifiquement avec les 
sous-unités Cullines qui sont libérées de leur modification par Nedd8 et de la sous-unité de 
recrutement du substrat. Le CSN pourrait, dans ce cas, en déneddylant les CRLs, permettre 
l’association avec CAND1. Bien que de très notables avancées aient été réalisées ces 
dernières années dans la compréhension du rôle physiologique exacte du CSN, il reste 
néanmoins encore beaucoup de travail pour unifier ces données et produire un modèle de leur 
mécanisme fonctionnel. 

Le CSN est un complexe très bien conservé chez les eucaryotes, composé de huit 
sous-unités (CSN1 à 8 ; de la plus grande à la plus petite des sous-unités) d’un poids 
moléculaire total de 320 kDa. L’importance de ce complexe CSN dans les cellules eucaryotes 
se manifeste aussi par les résultats d’études génétiques où le Knock-Out (K.O.) des sous-
unités 2, 3, 5 ou 8 chez la souris n’est pas viable au stade embryonnaire. Parmi les sous-unités 
du CSN, la sous-unité 5, CSN5 (connue aussi sous le nom de Jab1 pour Jun binding activation 
protein 1) porte l’activité de déneddylation, la fonction la plus étudiée du complexe CSN. Par 
son rôle central dans l’homéostasie cellulaire, le complexe CSN est souvent associé à la 
régulation de fonctions cellulaires diverses, comme le contrôle du cycle cellulaire, 
l’expression génique, l’immunité et la réparation des dommages à l’ADN.  
La fonction la plus étudiée jusqu’à présent du complexe CSN à 8 sous-unités 
correspond à l’hydrolyse de la liaison isopeptidique entre la Culline et Nedd8, qui a, pour 
conséquence, comme détaillé plus haut, de permettre le turn-over des complexes CRL. CSN5, 
enzyme de la famille des isopeptidases à zinc, qui correspond au centre catalytique du CSN 
possède un domaine catalytique dans sa partie N-terminale, le domaine MPN (Mpr1 and 
Pad1p N-terminal), agrémenté du motif JAMM (Jab1/MPN domain metalloenzyme) qui 
correspond au motif catalytique. De manière intéressante, l'activité déneddylase portée par 
CSN5 est dépendante de son intégration au sein du complexe CSN. Prise en dehors de ce 
complexe, la sous-unité CSN5 est dépourvue de cette activité enzymatique. 
De manière notable, le CSN partage avec le chapeau du 26S proteasome et, de manière 
moins marquée, avec le complexe eIF3, une composition et une architecture communes. Ces 
trois complexes multiprotéiques contiennent tous six sous-unités comprenant un domaine PCI 
(Proteasome, COP9, eIF3) et deux sous-unités comprenant un domaine MPN. Leurs activités 
catalytiques sont liées au système ubiquitine-protéasome. En effet, le chapeau du 26S 
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proteasome et le complexe eIF3 expriment tous les deux une activité déubiquitylase (DUB), 
tandis que le CSN a une activité déneddylase. La caractérisation structurale de ces complexes 
confirme une architecture similaire avec les sous-unités PCI formant de longues ‘pattes’ sur 
lesquelles sont posées les sous-unités MPN. 
Le complexe CSN, mis en évidence il y a 20 ans d’abord chez les plantes, est étudié 
par de nombreuses équipes dans le monde. Ces efforts globaux se sont principalement axés 
sur la génétique et la biologie cellulaire du complexe, mais ce n’est que relativement 
récemment que les aspects moléculaires et structuraux de ce complexe ont commencé à être 
exploré, probablement du fait de sa complexité. Le projet concerne la caractérisation 
structurale et moléculaire du complexe, en prenant comme fil directeur la sous-unité CSN5. 
Cette sous-unité présente un intérêt prononcé du fait de son activité catalytique et du fait 
qu’elle semble largement impliquée dans différents types de cancers. 
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2.1 L’état inactif de CSN5 dans sa forme isolée est maintenu par l’intermédiaire 
d’un pont salin. 
La structure cristalline du domaine catalytique de CSN5 a été déterminée en amont du 
démarrage de ce projet. L’analyse de cette structure cristalline a permis de comprendre 
pourquoi et comment CSN5 dans sa forme isolée est dénuée d’activité. 
 L’analyse de la structure de CSN5 confirme qu’elle adopte un repliement de type 
MPN, complété par des extensions N- et C-terminales qui rendent la surface de CSN5 
spécifique. La structure de CSN5 dans sa forme isolée a permis de comprendre les bases 
moléculaires de sa régulation. Le site actif de CSN5, par comparaison avec d'autres métallo-
dependent isopeptidases et en particulier, la DUB homologue, AMSH-LP (seule enzyme à 
domaine MPN dont la structure était connue à cette période), est compatible avec la catalyse : 
la position des résidus du motif catalytique JAMM est compatible avec l’hydrolyse d’une 
liaison peptidique, comme l’a montrée la comparaison avec l’enzyme AMSH-LP.  
Cette analyse ayant montré l’intégrité du site de fixation du zinc, cela laisse donc envisager 
que l’absence d’activité de CSN5 pourrait être due à son incapacité à recruter le substrat 
Nedd8. La fixation de celui-ci devra être accompagnée par de vastes changements 
conformationnels nécessaires pour la création de ce site. Le segment Ins-1 qui correspond à 
une région impliquée dans le recrutement du substrat dans AMSH-LP est replié sur le site 
catalytique et fait obstruction à la fixation du substrat Nedd8. Ces observations impliquent 
que le segment Ins-1 doit changer de position et de conformation pour aboutir à une forme 
active de CSN5. Allant plus loin dans l’analyse des propriétés de CSN5, nous avons étudié sa 
flexibilité par dynamique moléculaire. Ce remodelage structural est compatible avec les 
propriétés de flexibilité et de plasticité de la zone concernée que nous avons exploré in silico, 
montrant une propension de la région Ins-1 à s’ouvrir sur le solvant. Ce travail a permis 
d’appréhender le degré de flexibilité de cette région de CSN5 et d’attribuer un aspect 
fonctionnel à cette plasticité. De plus, le fait que le segment Ins-1 adopte des conformations 
variées dans les différentes structures de protéines à MPN renforce le caractère plastique de 
cette région de CSN5. 

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Ce segment Ins-1 de CSN5 présente, au cours des simulations de dynamiques 
moléculaires, des propriétés de flexibilité élevées de part et d’autre du résidu arginine 106 
(R106), qui semble ancrer le segment au site de fixation du zinc via un pont salin avec le 
résidu acide aspartique 151 (un des résidus en interaction avec le zinc ; D151). La substitution 
in silico de ce résidu confirme à la fois son rôle d’ancre et l’ouverture du segment Ins-1 sur le 
solvant lors de la perte du pont salin R106-D151. La confirmation expérimentale du rôle de ce 
résidu dans le mécanisme d’activation de CSN5 a été établie par le fait que le variant R106T 
de CSN5 est pourvu d’activité isopeptidase. En effet, en utilisant un substrat synthétique soit 
LRGG-AMC (peptide correspondant aux quatre derniers résidus de l’ubiquitine et de Nedd8 
couplé par une liaison isopeptidique à un fluorophore dérivé de la coumarine), soit Nedd8-
AMC (substrat synthétique formé de la conjugaison de la protéine Nedd8 avec une molécule 
fluorescente dérivée de la coumarine), la mutation de l’arginine 106 en thréonine (R106T) 
confère à CSN5 une nette augmentation de son activité isopeptidasique. La comparaison avec 
l’activité du complexe CSN entier montre que, bien que il y ait effectivement une activation 
de l’enzyme par cette substitution, cette activité est relativement modeste par rapport à celle 
du complexe CSN. Ces observations peuvent être interprétées par le fait que la rupture du 
pont salin joue probablement un rôle important dans l’activation, mais que le segment Ins-1 
peut ne pas se restructurer de manière optimale pour former l’autre moitié du site de fixation 
du substrat. De plus, il a été montré dans le cadre de nombreuses études que les autres sous-
unités du complexe CSN sont elles aussi importantes pour l’expression de cette activité 
isopeptidase. 
 
2.2 L’association de CSN5 en homo-dimère. 
CSN5 forme des dimères de dimères dans le cristal. La présence de dimères en 
solution a été explorée et vérifiée par différentes techniques de biochimie (gel filtration 
analytique ; pontage chimique) et de biophysique qui incluent des expériences 
d’ultracentrifugation analytique (en collaboration avec le Dr. C. Ebel, IBS, Grenoble). 
L’organisation de CSN5 en homo-dimère en solution pourrait suggérer un nouveau niveau de 
régulation jusqu’alors ignoré. Du fait de l’intérêt potentiel de l’état d’oligomérisation dans les 
fonctions et la régulation, nous avons exploré cet aspect dans des extraits cellulaires 
eucaryotes en collaboration avec le Dr. F.-X. Claret (University of Texas, Etats-Unis). 
Effectivement, par immuno-précipitation utilisant une double étiquette Flag/His, la présence 
d’homo-oligomères de CSN5 a été identifiée dans ces extraits cellulaires, laissant envisager la 
possibilité de la présence de tels assemblages in vivo.  
L’analyse détaillée de l’interface entre les monomères, grâce à la structure cristalline et par 
l’intermédiaire de calculs de dynamiques moléculaires, nous a permis de proposer la 
prépondérance d’un des deux dimères par rapport à l’autre et d’identifier des positions 
susceptibles d’affaiblir le dimère proposé (contenu dans l’unité asymétrique). Des expériences 
d’ultracentrifugation analytique et d’immuno-précipitation sur lysats cellulaires confirment, 
grâce à l’utilisation de variants d’interface, que l’assemblage dimérique prépondérant 
correspond au dimère A-B observé in crystallo. Nous avons mis en évidence la prédisposition 
de CSN5 à former des homo-oligomères, mais beaucoup reste à faire. En effet, la fonction, le 
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rôle, la distribution et la prépondérance in vivo des homodimères sont encore entièrement 
inconnus. 
 
 
2.3 Le domaine MPN de la sous-unité CSN6 est capable d’activer CSN5. 
Après avoir examiné les déterminants expliquant le manque d’activité de CSN5 dans 
sa forme isolée, nous avons exploré l’activation de CSN5 dans le cadre du CSN. Pour cela, 
nous avons choisi de tester la sous-unité CSN6. En effet, plusieurs études ont montré que 
CSN5 et CSN6 sont voisins dans le CSN. De plus, une association similaire a été démontrée 
pour les sous-unités paralogues du chapeau du protéasome, Rpn11 et Rpn8. Après 
optimisation de l’expression recombinante du domaine MPN de CSN6, nous avons pu 
montrer que les domaines MPN de CSN5 et de CSN6 sont capables de s’associer et de former 
un complexe stable sur colonne de gel filtration et par pontage chimique. L’exploration 
biophysique de ce complexe a permis de montrer que la constante de dissociation de celui-ci 
est de l’ordre de 6 µM pour la forme sauvage, aussi bien que pour le variant R106T 
constitutivement activée. CSN6 est une sous-unité du CSN qui possède un domaine MPN 
sans motif JAMM et qui est donc intrinsèquement dénué d’activité catalytique. Ayant montré 
que les deux domaines MPN s’associent directement, l’effet de CSN6 sur l’état d’activation 
de CSN6 a été mesuré sur une panoplie de substrats (quatre au total : LRGG-AMC ; Nedd8-
AMC ; pro-Nedd8 (précurseur de Nedd8 qui possède une extension C-terminale de cinq 
acides aminés) ; Nedd8-Cul1/Rbx1 (un des substrats physiologiques de CSN obtenu par 
neddylation in vitro de la sous-unité Cul1 associée à la sous-unité Rbx1)) de nature et 
complexité variées. Pour l’ensemble de ces substrats, pour lesquels nous avons mis en place et 
optimisés les conditions de mesure, la sous-unité CSN6 stimule fortement l’activité 
enzymatique de CSN5. La comparaison du niveau d’activité catalytique atteint par CSN5 en 
présence de CSN6 avec l’activité du CSN pour trois substrats différents montre que le 
complexe CSN5/CSN6 possède une activité comparable, si ce n’est légèrement plus efficace 
que celle du CSN pour le substrat Nedd8-AMC. Bien que cela n’ait pas été anticipé à travers 
les études décrites dans la littérature, le complexe CSN5/CSN6 possède aussi une activité 
hydrolytique sur le précurseur de Nedd8, pro-Nedd8, qui approche celle de NEDP1 (NEDD8-
specific protease 1 ; aussi connue sous le nom de DEN1 ou SENP8), enzyme à laquelle est 
généralement attribuée la maturation de pro-Nedd8 dans les cellules. En ce qui concerne le 
substrat physiologique Nedd8-Cul1/Rbx1, l’hétérodimère CSN5/CSN6 montre une capacité à 
hydrolyser ce substrat, mais considérablement moindre que celle affichée par le CSN. A 
travers l’utilisation de ces substrats, une échelle moléculaire a pu être créée et employée pour 
identifier et caractériser l’activité du complexe CSN5/CSN6. L’ensemble de ces données a 
conduit à proposer le dimère CSN5/CSN6 comme le cœur catalytique du CSN. 
De plus, l’utilisation du variant R106T de CSN5 en présence de CSN6 a mis en 
évidence un effet synergétique entre la relaxation conformationnelle du segment Ins-1 et 
l’association de CSN6 concernant l’activation de CSN5. 
Il existe d’autres exemples d’association entre une enzyme à domaine MPN et une protéine 
non-catalytique à domaine MPN dans lesquels la sous-unité catalytique nécessite, pour son 
activation, la présence de la sous-unité MPN non-catalytique. C’est le cas de la paire 
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Rpn11/Rpn8 du chapeau du protéasome ou encore de BRCC36 (BRCA1/BRCA2-containing 
complex subunit 36 ; protéine MPN à activité DUB) qui nécessite soit Abraxas, soit Abro1 
dans le cadre des complexes Rap80 ou BRISC, respectivement (BRCC36 isopeptidase 
complex). 
 
2.4 L’activation de CSN5 s’accompagne d’une augmentation de l’affinité pour 
Nedd8. 
Pour mieux comprendre les bases moléculaire et mécanistique de l’activation de CSN5 
par CSN6, l’affinité de CSN5 pour Nedd8 a été évaluée par anisotropie de fluorescence, en 
utilisant Nedd8 étiqueté avec le fluorophore Alexa Fluor 488. L’ensemble des données 
obtenues montre que (i) le variant R106T de CSN5 possède une affinité augmentée pour 
Nedd8 par rapport à la forme sauvage, confirmant notre hypothèse que la relaxation 
conformationnelle du segment Ins-1 est liée à l’interaction avec Nedd8, (ii) l’association de 
CSN5 avec CSN6 augmente l’affinité pour Nedd8 par rapport à CSN5 seule, (iii) l’affinité 
pour Nedd8 est comparable pour le variant R106T de CSN5 dans sa forme isolée et pour le 
complexe CSN6/CSN6, (iv) l’association du variant R106T de CSN5 avec CSN6 induit une 
augmentation d’affinité pour Nedd8 supérieure à celle du complexe CSN5/CSN6. Pris dans 
leur ensemble en conjonction avec les données d’activité obtenues, ces résultats suggèrent que 
le mécanisme par lequel CSN6 contribue à l’activation de CSN5 procède par l’augmentation 
de l’efficacité de recrutement du substrat, mais que cet aspect n’est probablement qu’une 
partie du mécanisme d’activation. Il est possible que CSN6 aide à positionner de manière 
compétente la liaison à hydrolyser par CSN5. 
 
2.5 Identification de la surface d’interaction du complexe CSN5/CSN6. 
Ayant mis en évidence le rôle central de CSN6 dans l’activation de CSN5, sa structure 
cristalline fut déterminée par remplacement moléculaire, en utilisant Rpn8 humaine comme 
modèle. En effet, alors que la structure cristalline d’un fragment de CSN6 de Drosophile avait 
déjà été déterminée, le fait que cette dernière soit particulièrement courte et comprenne de 
nombreuses boucles désordonnées empêchait son analyse détaillée. C’est pourquoi il a été 
décidé de produire, de manière recombinante, (la protéine intégrale ne s’exprime pas de 
manière soluble chez la bactérie) des fragments plus importants de la protéine humaine et de 
cristalliser l’un d’entre eux. La structure de CSN6 humaine que nous avons déterminée amène 
de nombreuses informations qui seront largement utilisées dans la suite du projet, comme 
décrit ci-dessous : (i) cette structure comprend l’intégralité du domaine MPN, contrairement à 
celle de Drosophile et permet ainsi une étude plus fine de la repliement et des propriétés de 
surface ; (ii) dans la structure de CSN6 humaine, la protéine forme un homo-dimère stabilisé 
par un motif ‘helix swap’ où la dernière hélice d’un monomère se fixe dans un sillon de 
l’autre monomère et vice versa. A la fois le mode de dimérisation et la présence de cet 
échange d’hélices sont tous les deux retrouvés dans l’homo-dimère de Rpn8 humain. 
En complément à ce travail biochimique et structural, nous avons entrepris de 
caractériser le mode d’association de CSN5 et CSN6. Pour cela, des essais de cristallisation 
extensifs ont été menés, mais n’ont abouti qu’à l’obtention de cristaux de taille et/ou qualité 
insuffisante pour diffracter les rayons X. En parallèle de ces tentatives, une collaboration avec 
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la plateforme RMN du Centre de Biochimie Structurale, dirigée par le Dr. A. Padilla, a été 
établie dans le but de cartographier l’interface d’interaction entre les deux protéines. Très 
rapidement, l’étude de CSN5 par RMN a du être abandonnée pour des raisons techniques. En 
effet, CSN5 a la propension de dimériser, comme développé dans un des paragraphes 
précédents, ce qui rend difficile l’obtention de spectres RMN exploitables. L’utilisation d’un 
variant principalement monomérique, bien qu’améliorant la qualité des spectres, n’a pas suffi 
à régler ce problème. Nous avons donc concentré nos efforts sur CSN6, d’abord par la 
réalisation de son attribution et ensuite par l’optimisation de conditions expérimentales 
favorables à l’acquisition de spectres HSQC (Heteronuclear single quantum coherence 
spectroscopy) pour cartographier la surface d’interaction de CSN6 avec CSN5. L’ajout de 
CSN5 à CSN6 marqué à l’azote 15 induit de profonds changements dans les spectres HSQC 
de ce dernier ; ceci inclut le déplacement, l’élargissement, la diminution d’intensité et la 
disparition de nombreux pics. Le complexe CSN5/CSN6 atteint 50 kDa, ce qui le place à la 
limite des objets étudiables par la méthode traditionnelle HSQC. Il est donc normal que les 
spectres HSQC de ce complexe soient difficiles à interpréter. C’est pourquoi et par mesure de 
prudence que nous avons choisi non pas d’identifier les acides aminés perturbés par l’ajout de 
la protéine partenaire, comme ce qui est normalement fait, mais, au lieu de cela, d’identifier 
ceux qui ne subissent pas de modifications dans leurs déplacements chimiques 1H/15N. Cette 
approche opposée a permis d’identifier deux surfaces potentielles d’interaction. La surface la 
plus probable d’interaction de CSN6 avec CSN5 fut sélectionnée sur la base de l’analyse de la 
conservation de séquence de CSN6 et de la surface d’homo-dimérisation utilisée par Rpn8 
(paralogue de CSN6 dans le chapeau du protéasome). Nous avons ensuite validé cette 
interface par mutagénèse et par mesure de l’effet de ces variants sur l’association avec CSN5 
et sur l’activation de CSN5. Il est important de noter que cette analyse a mis en évidence que 
CSN6 interagit avec CSN5 via la même surface que celle utilisée dans le contexte de sa 
propre homo-dimérisation et que celle utilisée dans le contexte de l’homo-dimérisation de 
Rpn8. Ceci nous a permis d’en déduire une surface potentielle d’interaction de CSN5 avec 
CSN6. Ces deux surfaces - celle de CSN6 avec CSN5 et celle de CSN5 avec CSN6 - furent 
par la suite confirmées par la résolution de la structure du complexe paralogue Rpn11/Rpn8 
par deux laboratoires différents. 
 
2.6 Un modèle du complexe CSN5/CSN6 obtenu par amarrage guidé par des 
données expérimentales. 
Pour pallier la difficulté d’obtention de la structure cristalline du complexe 
CSN5/CSN6, un modèle moléculaire de cet hétérodimère fut construit par amarrage 
moléculaire et filtrage des solutions par les données expérimentales. 
Pour cela, au vu de l’augmentation de l’affinité de CSN5 pour Nedd8 en présence de 
CSN6, nous avons décidé d’utiliser un assemblage CSN5-Nedd8 pour les calculs d’amarrage. 
Effectivement, l’utilisation d’un module CSN5-Nedd8 au lieu de CSN5 seul permet de 
réduire la surface explorée. Pour la construction de ce module, plusieurs étapes ont été 
utilisées. La construction du module CSN5-Nedd8 repose sur l’hypothèse que Nedd8 se lie à 
CSN5 d’une manière similaire à l’ubiquitine distale à AMSH-LP, complexe pour lequel il 
existe une structure cristalline. Dans un premier temps, nous avons donc vérifié la plausibilité 
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de cette hypothèse en mesurant l’effet sur l’activité hydrolytique de CSN5 de substitutions à 
des points de Nedd8 correspondant à des points d’interaction importants entre l’ubiquitine 
distale et AMSH-LP. L’ensemble de ce travail de mutagenèse a confirmé que les positions 
importantes de l’ubiquitine distale pour l’interaction avec AMSH-LP correspondent à des 
positions de Nedd8 qui sont aussi importantes pour la catalyse. Dans une deuxième étape, la 
conformation du segment Ins-1 que nous avons montré flexible et importante pour l’activation 
de CSN5 a été modifiée par modélisation pour permettre la fixation de Nedd8 dans le sillon 
de recrutement du substrat. Les deux partenaires, c’est-à-dire la forme modifiée de CSN5 et 
Nedd8, ont ensuite été assemblée pour respecter le mode de fixation illustré dans la structure 
cristalline d’AMSH-LP et ubiquitine. 
La construction d’un modèle CSN5-Nedd8 ayant été réalisée, le processus d’amarrage 
par le programme ZDock a été lancé et analysé. Les 2000 poses ayant les meilleurs scores 
furent ensuite soumis à une procédure de sélection basée sur les données expérimentales 
obtenues précédemment. Le tri de ces 2000 solutions a été fortement accéléré par l’utilisation 
d’un programme informatique d’évaluation spécifiquement conçu et écrit pour cette tâche. 
Cette procédure a permis l’obtention de modèles compatibles avec l’ensemble des données et 
très proches de la topologie des homo-dimères des protéines humaines Rpn8 et CSN6. 
La publication de deux structures du complexe Rpn11/Rpn8 de levure par deux 
groupes distincts, concomitante avec notre sélection du modèle le plus plausible du complexe 
CSN5/CSN6 a permis de comparer le mode d’interaction proposé pour notre dimère avec 
celui du chapeau du protéasome. Le fragment CSN5 (1-257) utilisé pour la quasi-intégralité 
de nos études dont les études cristallographiques possède un domaine MPN qui correspond 
aux résidus 51 à 232 autour duquel s’enroulent les extensions N- et C-terminales. De manière 
notable, ces extensions sont agrafées par des interactions principalement hydrophobes. Dans 
les fragments utilisés pour déterminer les structures de Rpn11/Rpn8, les extensions N- et C-
terminales sont réduites. La comparaison du mode d’interaction proposé pour CSN5 et CSN6 
et observée pour Rpn11/Rpn8 révèle que les deux topologies sont très proches, mais que la 
présence des extensions N- et C-terminales présentes dans CSN5 empêche les deux topologies 
d’être identiques. A la suite de cette analyse, une nouvelle procédure d’amarrage fut réalisée 
en utilisant un fragment de CSN5 débarrassé de ses extrémités N- et C-terminales. L’analyse 
des solutions les plus probables confirme l’obtention d’un modèle du complexe CSN5/CSN6 
dont la topologie générale est identique à celle du complexe Rpn11/Rpn8. 
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L’ubiquitylation des protéines et les voies de signalisation qui lui sont liées constituent 
des processus fondamentaux à l’homéostasie cellulaire. Une des preuves les plus flagrantes de 
l’importance du système ubiquitine-protéasome réside dans sa dérégulation pathologique 
récurrente. Le système ubiquitine-protéasome est maintenant le cœur d’efforts globaux pour 
cibler ses fonctions dans le cadre d’interventions thérapeutiques, comme l’illustre le succès de 
la molécule bortezomib (ou Velcade) qui inhibe l’activité du protéasome et dont l’utilisation a 
été autorisée dans le traitement de certaines pathologies hématologiques. Néanmoins la 
toxicité et l’émergence de résistances contre cette molécule motivent la recherche de dérivés 
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de celle ci, ainsi que de nouvelles voies d’interventions thérapeutiques. Le ciblage rationnel 
d’une voie de signalisation nécessite une compréhension détaillée, à différents niveaux de ses 
fonction et de ses mécanismes de régulation. C’est dans cette perspective de recherche 
fondamentale pour aider et accompagner de possibles progrès dans le traitement de maladies 
humaines liées à la dérégulation du système ubiquitine-protéasome que l’étude du CSN 
s’inscrit. 
Au cours de ces trois ans de thèse, le projet de recherche fut principalement centré sur 
la sous-unité catalytique du CSN, CSN5. Grâce à une stratégie de recherche large incluant des 
approches de biochimie préparative, analytique, biophysique, bio-informatique, de biologie 
structurale et de biologie moléculaire, ce projet a permis (i) de caractériser CSN5 dans sa 
forme isolée, et en complexe avec sa sous-unité régulatrice, CSN6, (ii) de concevoir des outils 
moléculaires pertinents pour l’étude de ce système et (iii) de mettre en lumière certains 
mécanismes de régulation et de la fonction de l’activité catalytique de CSN5 et donc du CSN. 
Ainsi, nous avons établi la raison pour laquelle CSN5 ne présente pas d’activité isopeptidase 
dans sa forme isolée du complexe CSN, répondant à une interrogation formulée il y a plus de 
dix ans. Allant plus loin dans la connaissance du modèle, il a été possible de concevoir un 
variant constitutivement actif de CSN5, ce qui ouvre des perspectives intéressantes dans le 
domaine de la compréhension cellulaire de la fonction de CSN5 et dans l’optimisation 
rationnelle d’inhibiteurs de CSN5 avec l’utilisation de ce mutant d’activité. De plus, la sous-
unité CSN6 du CSN a été identifiée comme stimulant l’activité catalytique de CSN5. A 
travers une caractérisation enzymatique détaillée couplée à des mesures biophysiques, il a été 
possible de proposer un mécanisme d’activation de CSN5 par CSN6, ainsi que l’interface 
d’interaction impliquée dans cette association. Ce travail de cartographie de l’interface a 
permis de pallier le manque de données structurales de ce complexe et d’établir un modèle 
moléculaire obtenu par amarrage guidé par nos données expérimentales.  
L’ensemble de ces travaux a permis de se confronter à un domaine biologique 
compétitif, nécessitant l’utilisation de nombreuses techniques, certaines dans le cadre de 
collaboration. Mais comme souvent, bien qu’ayant permis de fournir quelques ébauches de 
réponses à des question biologiques, ces travaux ont aussi abouti à la formulation de 
nouvelles questions. Et il reste par conséquent de nombreux aspects à couvrir concernant cette 
protéine de 334 acides aminés. En particulier, notre travail principalement cantonné à une 
approche in vitro devra être prolongé et étoffé par des expériences in cellulo. Nous voyons 
certaines questions biologiques qui devront être examinées et notre travail, ainsi que celui 
d’autres laboratoires, aura peut-être permis d’aider à commencer à y répondre et/ou à 
concevoir des outils moléculaires ou chimiques pour y réussir : (i) Quelle est la fonction et 
l’occurrence cellulaire de la forme isolée de CSN5 ?; (ii) Comment le CSN est assemblé in 
vivo ?; (iii) L’activité catalytique de CSN5 est-elle associée à d’autres fonctions que la 
régulation des CRLs ? 
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The COP9 (Constitutive photomorphogenesis 9) signalosome (CSN) is an eight-subunit-
containing multiprotein complex (320 kDa) implicated in diverse cellular processes including, 
cell cycle progression, gene expression and DNA repair via its function in the ubiquitin-
proteasome pathway. It is a highly evolutionary conserved protein complex in higher 
eukaryotes for which its activity is essential. Over years of biochemical and biological studies 
to elucidate the role of the CSN, its most studied and best understood function is linked to the 
control of protein ubiquitylation (post-translational modification corresponding to the 
covalent conjugation of an ubiquitin molecule) by a class of E3 ubiquitin ligases. The CSN 
exhibits catalytic activity to regulate E3-cullin RING ubiquitin ligases (CRLs) by the removal 
of an ubiquitin-like protein, Nedd8 (cullin-neural precursor cell expressed developmentally 
downregulated gene 8), from CRLs. Cycles of neddylation/deneddylation are essential for 
CRL function and the CSN is central in this process through its activity as a CRL deneddylase. 
Structural and functional similarities link the CSN, the 19S lid of the 26S proteasome and the 
eukaryotic initiation factor-3 (elF3). These multi-subunit assemblies comprise six PCI 
(proteasome COP9 eIF3) domain subunits and two MPN (Mpr1–Pad1–N-terminal) domain-
containing subunits. The catalytic activity of the CSN is centred on its subunit 5 (CSN5/Jab1), 
which hydrolyses the Nedd8-CRL isopeptide bond. CSN5 contains a zinc-dependent 
isopeptidase catalytic centre constituted of a JAMM (Jab1/MPN/Mov34) motif. 
 
CSN5 incorporation within the CSN complex unleashes its isopeptidase activity, whereas it 
remains inactive in isolation. The work carried out in the last three years led to several main 
findings. (i) Having elucidated the crystal structure of CSN5 catalytic domain, biochemical 
and in silico investigations that furthered the understanding of CSN5 molecular regulation led 
to the identification of a potential molecular trigger enabling CSN5 to be active and the 
design of a constitutively active CSN5 variant form. (ii) The ability of CSN5 to homodimerise 
was investigated in solution, in silico and in cellular extracts and brought information that 
could be important for its function. (iii) Further to that work, to address CSN5 activity within 
the CSN, the contribution of another CSN subunit, mainly CSN6, shown to interact directly 
with CSN5 was evaluated and this led to the identification of CSN6 as the CSN5 activating 
subunit. (iv) The biochemical and biophysical characterisation of the CSN5-CSN6 complex 
was exploited to explore at the molecular level this complex in the context of its binding to 
Nedd8 and of its integration within the holo-CSN assembly through an integrated approach 
that includes biochemical, structural, biophysical and computational techniques. 
 
Overall this work allowed to gain an in-depth understanding of the activity determinants and 
of the regulatory mechanisms that the CSN catalytic subunit CSN5 is subjected to. 
Keywords: ubiquitin-proteasome system; proteasome; COP9 signalosome; isopeptidase 
activity; ubiquitin E3 ligase; cullin regulation, MPN, Rpn11, pro-Nedd8 
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Ubiquitin (Ub) is a small and conserved 76-residue (8.5 kDa) protein which is post-
translationally conjugated to lysine residues of a wide assortment of proteins. This protein 
retains a powerful role in mediating and regulating a range of fundamental cellular processes. 
Although not restricted to this, the best known effect of the Ub molecule is linked to its 
function as a degradation mark. These include cell cycle progression [1], oncogenesis [2], 
endocytosis [3] and antigenic peptide production [4]. Ubiquitination, which corresponds to 
the covalent attachment of an Ub molecule, comprises a three-step cascade and thus 
implicates three different enzymes (Fig. 1-1). Initially the C-terminal carboxylate of the distal 
glycine residue of Ub requires activation by sequential adenylation and thioesterification 
reactions mediated by the Ub activating enzyme, E1. The second step encompasses the 
transfer of activated Ub from E1 to an activated cysteine residue on the Ub conjugating 
enzyme, E2, via a transthiolation reaction. The Ub charged E2 associates with the substrate-
bound Ub ligase, E3, and together they collaborate to transfer the thioesterified Ub to the -
amino group of lysine residue on the substrate, forming an isopeptide linkage [5-7].  
 
Ub conjugation can either be attached to the substrate as a monomer or form different poly-
Ub chains. In the former case, the target protein is mono-ubiquitinated; in the latter case, 
poly-ubiquitinated. Ub contains seven lysines with the potential to attach to other Ub 
molecules and the topology of the poly-Ub chains has been shown to generally determine 
their functional role. For example, modification of a target protein with Ub via Lys48 residue 
forms an Ub Lys48 chain of generally four or more Ub molecules linked through their Lys-48 
residue, which effectively acts as a recognition tag for proteasomal degradation [8]. Whereas, 
Lys63-linked mono- or poly-Ub chain on the substrate, instead, results in the altered transport 
or function of the target [9, 10], DNA repair [11], activation of NF-B [12], and polysome 
stability [13]. Recent studies have suggested that Ub can also covalently conjugate to N-
terminal -amino groups via a peptide linkage. This type of Ub conjugation yields to linear 
poly-Ub chains [14] or N-terminal Ub fusions [15, 16]. The combinatory of ubiquitination 
modification offers a complex range of regulatory responses. 
 
The Ub-Proteasome System (UPS) is a complicated and highly regulated mechanism 
discovered in the eighties and for which Hershko, Ciechanover and Rose received the Nobel 
Prize in 2004. However the complexity of this system has made it challenging to gain 
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complete understanding. Given the essential role of the Ub system in diverse cellular 
processes, it is not surprising that its dysfunction contributes to cancer, neurodegenerative and 
immunological disorders. The first anti-cancerous treatment based on proteasome inhibition 
that has received approval from the Food and Drug Administration in 2008 under the 
commercial name of Velcade (Bortezomib), provides a proof-of-principle that targeting the 
UPS is a therapeutic intervention avenue to further explore [17]. Toxicity effects and the 
emergence of resistance against bortezomib led to the development of bortezomib derivatives, 
as well as the identification of other therapeutic intervention lines within the UPS. However 
novel therapeutic intervention avenues to treat of these diseases would require a better 
understanding of this system. More specifically, within our work, we focus to gain 
understanding on the regulation of E3 ligases. Here we discuss key components linked to the 
controlled mechanism of E3 ligase activation via the 
neddylation modification. 

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Figure 1-1. Schematic overview of 
the UPS. 
A. The three-enzyme cascade for 
substrate ubiquitination. The first step 
involves the activation of Ub by E1 
(Ub activating enzyme). B. The 
activated Ub conjugates to E2 (Ub-
conjugating enzyme) and subsequently 
transferred to the E3 ligase. The 
substrate is recruited to the E2-Ub 
loaded-E3 ligase. C. Ub is transferred 
from the E2 to the substrate. Several 
cycles of E1-E2-E3 reactions allow the 
poly-ubiquitination of the substrate. D. 
A poly-ubiquitinated substrate is 
released from the E3. Depending on 
the Lys linkage the proteasome 
recognises the poly-Ub chain as a 
signal to de-ubiquitinate and destroy 
the substrate protein. E. The unfolding 
of the substrate by the proteasome is 
an ATP-dependent process that 
includes the removal of the Ub chain 
through the hydrolase activity of the 
19S proteasome lid. The substrate is 
then threaded and unfolded into the 
proteasome chamber where the 
proteases are located. Ub molecules 
and amino acids can be recycled. 
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Mammalian cells express one or two E1 activating enzymes, 37 E2 conjugating enzymes and 
more that 600 E3 ligases. The E3 ligase is responsible for binding to both the E2-Ub complex 
and the target substrate. It functions to catalyse the transfer of Ub from the active site cysteine 
of the E2 enzyme to the substrate lysine residue or the N-terminus [18]. As such the E3 ligase 
contains dual roles, both molecular matchmaking and catalysis (or enhancement of Ub 
transfer to substrate), assembling the appropriate E2 with the correct substrate and vastly 
increasing the rate of Ub transfer. The increase in rate of Ub transfer by E3s was found to 
range up to 87-fold in the case of the E2, UbcH5b by the E3, C-NOT4 [19]. The presence of a 
large pool of E3 ligases accounts to the requirement to specifically target a broad array of 
substrates, although the determinants and regulation of substrate recognition are not yet 
entirely known [20].  
 
The E3 ligase family is commonly classed into three different types, namely the RING (really 
interesting new gene)-finger, RBR (RING-between-RING) and HECT (homologous to E6-
associated carboxyl terminus), each of which is characterised according to their conserved 
structural domains and the mechanism, which they employ to mediate Ub transfer from the 
E2 to the substrate (Fig. 1-2). The general role of E3s is to bring an E2-Ub into the proximity 
of the target protein. However different types of E3 ligases use different molecular 
interactions. The RBR and HECT subfamilies utilise a two-step reaction to ubiquitinate the 
substrate, in which the Ub is initially transferred from the E2 to an active site cysteine located 
on the E3 and the Ub is then moved from the E3 to the target protein [21, 22]. The RING 
subfamily members however bind simultaneously to both the E2-Ub thioester and the 
substrate and are thus able to directly catalyse the transfer of the Ub from the E2 enzyme to 
the substrate [18, 23].  

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The RING-finger domain is a subtype of zinc-finger domain often found in proteins in 
mammals [24]. Around 0.7 to 0.75% of the mammalian genome encodes for RING-finger-
domain proteins where more than 600 of them are potential RING-finger E3s [20, 25]. Within 
the E3 ligases, RING-finger proteins constitute the largest class and can further be divided 
into two major sub-classes: simple RING-finger ligases and Cullin-based RING-finger ligases 
(CRL). In the simple RING-finger E3s, the RING-finger and the substrate-binding domain are 
located within the same polypeptide, whilst CRLs are multiprotein complexes and utilise 
RING-box protein 1 (Rbx1) or Rbx2, in complex with a Cullin scaffolding protein and a 
Figure 1-2. E3 ligases. 
Classes of E3 ligases: RBR, HECT, 
RING-finger. The RBR type, a 
monomeric E3 contains a RING-finger 
domain that binds to E2s. The HECT 
E3s contain a HECT domain that 
associates with E2. RING-finger E3s 
are multimeric RING-finger E3s that 
bind to E2 enzymes via their RING-
finger domain, Rbx1. This type of E3s 
also contains the scaffold protein Cullin 
and a F-box protein that binds to an 
adaptor protein and recognises the 
substrate. 
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substrate receptor module (that comprises either one polypeptide or two). The CRLs are thus 
heteromeric enzymes containing the scaffolding subunit, a RING-box protein and a bridging 
protein known as the F-box protein. The RING-box contains a RING-like domain and is 
responsible for both binding to the E2 conjugating enzyme and also simulates Ub transfer, 
whilst the F-box is the site for substrate binding [26, 27].   

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The multimeric CRL subclass comprises of up to 240 enzymes that exert a profound effect on 
eukaryotic cells and organisms through the regulation of proteins key to cell homeostasis. 
Approximately 20% of the total protein degradation performed in cells by the UPS is 
accounted to CRLs [28]. Additionally CRLs are also implicated in numerous processes that 
underlie normal development and physiology through ubiquitination reactions that are not 
linked to target protein degradation [29]. Much of the architecture and regulation of the CRLs 
have been contributed by the laboratory of Professor B. Schulman (St. Jude Children's 
Research Hospital, USA). The Cullin subunit of CRLs, an elongated protein, forms the 
backbone of this multisubunit complex, on which are recruited the other subunits. The C-
terminal end of Cullin is comprised of a globular domain that wraps itself around the RING 
protein subunit. In turn, the RING protein binds the E2-Ub complex to form the enzymatic 
core. On the elongated Cullin structure, the long stalk-like N-terminal part consisting of 
several Cullin repeats utilises adapter proteins to recruit target substrate(s). The most 
structurally and functionally characterized mammalian CRL is the SCF (Skp1 (for S-phase 
kinase-associated protein 1)-Cullin1-F-box) Ub ligase. This E3 ligase comprises of Cullin1 
(Cul1; there are seven different Cullins, from Cul1 to Cul7 in human), the RING domain 
protein Rbx1 (also named Roc1 or Hrt1), the adapter protein Skp1 and a substrate receptor 
protein (F-box protein), where examples include Skp2 (for S-phase kinase-associated protein 
2) or -TrCP (for -transducin repeat-containing protein). A common F-box motif is shared 
between the substrate receptor proteins of the SCF complexes mediating their association to 
Skp1. Substrate specificity of the SCF is largely mediated through the F-box protein, which 
commonly recognises phosphorylated target proteins [30], whilst the Cul1-Rbx1 harbours the 
core ligase activity by catalysing the Ub transfer from the E2 enzyme to the substrate [31].  
 
Given their predominant roles in controlling myriad of cellular processes and the profound 
dysregulation of some elements of CRLs in proliferative diseases [32], there is a strong 
rationale in gaining insight in the function and regulation of CRLs. To date, all CRLs appear 
to be under the control of a number of common regulatory mechanisms [24]. The most 
documented regulatory mechanism of CRLs accounts for the conjugation of the Cullin 
subunit with an Ub-like protein, Nedd8 (for Neural precursor cell expressed, developmentally 
down-regulated 8; known as Rub1 in plants and budding yeast) [33]. It is now well 
established through numerous biochemical and structural studies that CRLs are covalently 
modified with a Nedd8 protein at a conserved lysine residue located at the C-terminus of the 
Cullin subunit. Neddylation of Cullin proteins is carried out via an analogous pathway to the 
ubiquitination of proteins. A Nedd8-specific activating enzyme, known as NAE, activates 
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the Nedd8 protein which is then transferred to a Nedd8-conjugating enzyme, Ubc12, which 
associates with substrate specific Nedd8-E3 ligase to covalently conjugate the Nedd8 to the 
target substrate [34, 35]. Rbx1 (Roc1), the RING domain-containing protein accountable for 
the E3 Ub ligase activity is also necessitated for the neddylation of Cullins [36]. In vivo, the 
neddylation of CRLs is required for their E3 ligase activity and is suggested to play a role in 
E2-Ub complex recruitment to the E3 ligase complex and thus stimulating the formation of 
poly-Ub chains [37-39]. It is also thought that CRL neddylation could promote the selective 
recruitment of specific substrates, such as Ubxd7 [40, 41] 
 
Another regulatory mechanism of Cullin-based E3 ligase activity implicates the CAND1 (for 
Cullin-associated NEDD8-dissociated protein 1) protein. This protein binds to the Cullin 
subunit and specifically associates with the deneddylated form of the protein [36, 42-44]. 
Thereby the binding of CAND1 to Cullin disrupts the CRL assembly and, in particular, the 
association of the Cullin subunit with the adaptor and substrate recognition subunits. This 
consequently results in the inhibition of CRL E3 ligase activity. Although detailed insights 
into the interaction between Cul1 and CAND1 has been reported [44], the mechanism by 
which CAND1 competes with the substrate recognition subunit is not yet fully understood 
[44-46]. 
 
Moreover, the COP9 (for COnstitutive Photomorphogenesis 9) signalosome (CSN), a highly 
conserved multiprotein complex, also interacts with CRLs and functions to deneddylate 
neddylated CRLs, cleaving the Nedd8-Cullin isopeptide bond [47, 48]. The requirement of 
Cullin neddylation of E3 ligase activity and the implication of the CSN complex suggested 
that, in vivo, Cullin proteins undergo complex cycles of neddylation and deneddylation [24]. 
The CSN complex and its contribution in the UPS are further detailed in the sections to follow. 

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The 26S proteasome is a highly conserved 2.5 MDa-protein complex comprising two copies 
each of at least 32 different subunits. This protease machinery functions primarily to degrade 
proteins that have been modified by the attachment of poly-Ub chains. The overall structure 
of this multi-protein complex can be divided two major subcomplexes: the 20S core particle 
containing the protease subunits and the 19S regulatory particle, which regulates the function 
and activity of the CP. Structurally the core particle forms a barrel-shaped assembly 
composed of four rings, each of seven subunits. The proteolytic active sites, facing into a 
sequestered proteolytic chamber, are located on the two inner -rings [49, 50]. The isolated 
internal chamber ensures that protein substrates can access it only after their deubiquitination, 
unfolding and translocation performed by the regulatory particle. The outer -rings of the 20S 
core particle accommodate either one or two regulatory particles to form the holo-26S 
proteasome. The 19S regulatory particle is further composed of two different multisubunit 
substructures, known as the base and the lid [51]. The base of the 19S regulatory particle 
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contains 6 homologous ATPases, Rpt1 through to Rpt6 and 4 non-ATPases subunits, Rpn1, 
Rpn2, Rpn10, and Rpn13. The ATPases form a direct interaction with the -subunit of the 
core particle and function to unfold substrates and are required for channel opening before the 
translocation of substrate through the gated channel into the 20S cavity. Rpn10 and other Ub 
receptor proteins, including Rad32 and Dsk2, that reversibly interact with the proteasome are 
implicated in delivery the ubiquitinated substrate to the proteasome. The second substructure 
of the regulatory particle, the lid, is a 400 kDa complex, composed of eight subunits, Rpn3, 
Rpn5 to Rpn9, Rpn11 and Rpn12. Six of the lid subunits contain a PCI (for Proteasome, 
COP9, eIF3) domain, whilst the other two contain a MPN (for Mpr1 and Pad1p N-terminal) 
domain. The lid is responsible for cleaving the Ub chain from the substrate via its 
deubiquitinating activity.  
 
In eukaryotes, the proteasome-dependent degradation pathway is essential for the elimination 
of damaged or misfolded proteins, the degradation of short-lived regulatory proteins and the 
definition of signalling rhythms, such as the cell division cycle, during which specific proteins 
are degraded at specific times. The proteasome operates via a multistep mechanism, with 
peptide bond hydrolysis being only the last step in this complex machinery. Additionally 
critical upstream processes include substrate, recognition, deubiquitination, unfolding and 
translocation. These processes take place at a distance from the proteolytic core site and are 
mediated by the regulatory particle subcomplex.  Proteasomal substrates are initially selected 
by the 19S regulatory particle via the recognition of the poly-Ub chains attached to the 
substrate protein destined to be degraded. Several subunits or proteins associated to the lid 
specifically recognise Ub, but a complete understanding of the role of each of these is yet to 
be unravelled. However, it is clear that the Rpn11 subunit of the proteasome lid plays an 
essential role in protein degradation. Indeed, following the selection of the labelled substrate, 
the poly-Ub chain is cleaved off by the deubiquitination activity of the lid subunit, Rpn11. 
The substrate protein is then unfolded and translocated into the 20S cavity where it is 
hydrolysed. 
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The timely, transient and subtle regulation of cellular processes including, for example, 
protein activity, function, stability, and localisation is required for cellular homeostasis. Post-
translational modifications, reversible in nature, are a widely used strategy for these controls. 
In some cases, post-translational modification may include a small chemical substitution, as is 
the case for phosphorylation, acetylation, and methylation, whilst, in others, it includes the 
covalent attachment of another polypeptide chain. Ubiquitination, for example, also described 
in earlier sections, corresponds to the latter, a post-translational modification with the 
covalent attachment of an Ub molecule to a target protein. Ub is the first described molecule 
of this type, but since its discovery, many other proteins that share its distinctive structure, 
known under the collective name of Ub-like molecules (Ubl) have been reported. The 
covalent modification of target proteins by these Ubl is multiple. For example sumoylation 
and neddylation refer to the covalent modification of proteins by one of the SUMO (Small 
 ?E
Ubiquitin-related MOdifier) proteins and by Nedd8, respectively. Post-translational 
modification of proteins by Ub and Ubl is an essential mechanism regulating various cellular 
processes (Fig. 1-3A). 
 
 
In eukaryotes, the conserved NEDD8 gene is encoded as a non-conjugatable precursor, named 
pro-Nedd8, that contains one or more additional residues (depending on the considered 
organism; 5 amino-acid extension in Hs and in Mus musculus (Mm)) in C-terminal of its 
functionally mature C-terminus at position 76. In their immature form, pro-Nedd8 requires 
proteolytic processing of its C-terminus to generate mature Nedd8 exposing a C-terminal 
glycine residue essential for the conjugation of Nedd8 to its substrate protein. The expression 
of a non-functional precursor is a feature also found in Ub, as well as in other UBLs, where 
their C-terminal extension is proposed to serve as a prevention of unprocessed proteins from 
entering the conjugation pathway. However, experimental evidence supporting this 
hypothesis is still lacking. Nevertheless, precursor processing is strictly required for the 
recognition of Nedd8 by the E1 enzyme responsible for Nedd8 activation, making Nedd8 
processing enzymes essential for Nedd8 function. The Nedd8 processing activity is carried 
out by members of the Ub C-terminal hydrolases (UCH) subfamily from the family of 
deubiquitinating enzymes (DUBs). Members of the UCH subfamily, Yuh1 in yeast and 
UCHL3 in human and mouse, possess dual specificity by processing both Nedd8 and Ub [52]. 
NEDP1 (Nedd8-specific protease 1), also known as DEN1 and SENP8, is a member of the 
C48 peptidase family of proteins and is the sole isopeptidase known to date to function 
exclusively in Nedd8 processing and deneddylation [53].   

Figure 1-3. Structure of Ub and Ubl proteins. 
A. Crystal structures and Ub (PDB code: 1UBQ), Nedd8 (PDB code: 1NDD) and SUMO (PDB code: 
1TGZ), all containing a common secondary structure. The last 5 C-terminal residues are presented in 
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stick mode. B. Superimposition of Ub and Ubl proteins. High spatial homology is observed for all 
proteins.  

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The CSN was initially discovered upon mutant screening in At for candidates displaying a 
constitutive photomorphogenic phenotype [54]. This described a phenotype where plants 
grown in the dark resembled those cultivated under light conditions. Following this 
observation, cloning of all the genes implicated in this process was performed and indicated 
that they are extremely conserved from fission yeast to humans [54]. Most interestingly, the 
CSN complex is an eight subunit complex, CSN1 through CSN8, (named according to the 
order of descending molecular weight), where all eight subunits show high homology to the 
eight subunits of the 19S proteasome lid and more distantly to the eukaryotic translation 
initiation factor 3 (eIF3) [54].  
 
Structurally two distinct domains can be defined in the CSN and similarly in the 19S 
proteasome lid and the eIF3 complex. These include the PCI and the MPN domains [48]. Six 
CSN subunits (CSN1-4 and CSN7-8) contain a PCI domain, which has been characterised to 
hold N-terminal bihelical repeats followed by a winged-helix (WH) subdomain [55-58]. 
Previously suggested by cryo-electron microscopy (EM) data and more recently shown by the 
crystal structure of the human CSN complex, the PCI proteins arrange to form an open ring 
structure by associating through their WH subdomains [46, 58-61]. In the CSN complex, the 
N-terminal helical repeats of the some of the PCI subunits function in accommodating the 
SCF substrate. In particular, subunits CSN1, CSN2, CSN3, CSN4 and CSN8 are thought to be 
the main contributors in the interaction of the CSN with SCF [46, 61]. Additionally, PCI 
proteins are considered to be important for maintaining the integrity of the complex via 
protein-protein interactions. Further roles of these PCI-containing subunits have been 
proposed, particularly via the recruitment of associated activities, such as protein kinases 
(examples include, protein kinase D, AKT, casein kinase 2) [62]. The physiological role and 
regulation of these associated activities are yet to be documented, but it appears that the 
biology of the CSN is not limited to its eight subunits. 
 
The remaining two subunits of the complex, CSN5 and CSN6, are MPN domain-containing 
proteins exposing a metalloprotease fold [63-66]. The two MPN subunits share sequence and 
structural similarities, however only CSN5 contains the complete zinc-metalloprotease motif, 
known as the JAMM (Jab1 (for JUN activating binding protein 1)/MPN domain 
metalloenzyme) motif. As such findings have implied that two kinds of MPN domains are 
present; a catalytic one that coordinates a Zn2+ ion, known to have a MPN+ domain, and 
another, void of catalytic activity referred to as a MPN- domain [67]. The JAMM motif of 
CSN5 is essential for pursuing isopeptidase activity and constitutes the catalytic centre of the 
CSN complex. MPN domain-containing subunits comprise a N-terminal MPN fold that 
precedes a helical bundle. A similar organisation has been described for the 26S proteasome 
lid and the eIF3 complex. 
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Initial insight on the molecular basis of the CSN complex function emerged with the 
identification that, in human cells, the CSN forms a stable complex with CRL. This stable 
association was shown in the context of the SCF complex [47]. Similarly, in At, the same 
interaction between the two multiprotein complexes was detected [68]. To date, the most 
documented function of the CSN complex is attributed to the deneddylation of Cullins, ie the 
removal of the Nedd8 modification of the Cullin [47]. However, this function might not be 
limited to the actual deneddylation of Cullins, but in the light of recent discovery [46] could 
extend to the non-enzymatic sequestering of CRLs. 

9393?'*!)$#.)$"%!-

The CSN complex forms a stable complex with SCF and accounts to its regulatory 
mechanism. The CSN was shown to play a critical role in controlling the modification of the 
Cul1 subunit of the SCF [47]. Whilst approximately 10-20% of Cul1 are typically modified 
by Nedd8, CSN-deficiency in cells results in the complete neddylation of the entire 
population of Cul1 and in reduced SCF activity [69]. The reason for this outcome was 
identified to be that CSN-deficient cells lack the enzymatic activity required to cleave the 
Nedd8 from the Cul1, thus to deneddylate. It was subsequently shown that this enzymatic 
activity resides on the 5th subunit, CSN5, of the CSN complex [70]. Today it is widely 
considered that the CSN complex primary function is to mediate deneddylation of Cullins and 
appears to be the most efficient enzyme for this job, if not the only one [33, 71]. The interplay 
between the CSN and CRLs determines the activity and specificity of CRL ubiquitination and 
contributes to the correct functional cycle of CRLs (Fig. 1-4). This mechanism catalyses the 
specific ubiquitination of substrates that are after subsequently degraded by the 26S 
proteasome. In vitro the process of ubiquitination is stimulated upon the neddylation of the 
Cullin subunit, whilst the removal of Nedd8 carried out by the CSN5 subunit of the CSN 
complex, deactivates the CRLs. Beside the inhibitory effect of the CSN within this catalytic 
mechanism observed in vitro, further CSN-mediated inhibition of CRL function is also 
observed in a noncatalytic mode [46, 72]. This mode of inactivation carried by the CSN 
prevents the CRL substrate adaptors from auto-catalytic degradation and enables the 
reassembly of the CRLs, maintaining their optimal activity [45]. Cullin deneddylation is 
thought to be an essential step for the CRLs to display the various substrate specificity 
necessary for controlled protein substrate ubiquitination. The stability of the complex formed 
between the CSN and the CRL is further dependent on substrate availability [46, 73, 74]. This 
has been demonstrated in the case of the natural cell cycle inhibitor, p27Kip1 (also known as 
CDKN1B (for Cyclin-dependent kinase inhibitor 1B); referred to as p27 in the rest of the 
manuscript), which, upon its phosphorylation stimulates the activity of SCF thus controlling 
its own ubiquitination and degradation [74].   

Various mechanisms have been proposed to explain the positive regulation of CRL activity by 
the CSN that has been unravelled in vivo and that is in sharp contrast with in vitro results. As 
 @>
mentioned above, studies have shown that through Cullin deneddylation and subsequent CRL 
inactivation, the CSN prevents the auto-ubiquitination of a number of Cullin substrate-
receptor subunits in the absence of bound substrate [33, 45]. The requirement of both Nedd8 
conjugation and deconjugation for optimal CRL function suggests that in vivo CRLs undergo 
rapid cycles of neddylation and deneddylation [75]. Based on this hypothesis, a model of the 
CRL functional cycle has been developed, in which substrate binding to the CRL complex 
induces Cullin neddylation, thereby resulting in CRL activation. Following substrate 
ubiquitination and dissociation, the deneddylation event performed by the CSN may complete 
this functional cycle that will resume upon the binding of a new substrate. Cullin 
deneddylation would protect CRL against auto-catalytic ubiquitination and promote the 
dissociation of the CRL substrate-receptor subunit. Moreover, it has also been suggested that 
the CSN could be implicated in the regulation of CAND1 binding [33, 75]. CAND1 interacts 
exclusively with Cullin subunits in a deneddylated form. Additionally, the binding of CAND1 
to the Cullin subunit and the binding of substrate-receptor subunit are mutually exclusive. As 
such, the deneddylation activity of the CSN may function to promote CAND1 binding to 
Cullin and further prevent CRL disassembly mediated by CAND1 [45]. Furthermore, the 
CSN may play a regulatory role in the dissociation of poly-ubiquitinated substrate proteins 
from the CRL complex [76]. Lastly, it was proposed that the CSN might intervene in 
recruiting critical binding proteins to CRL complexes. It has been repeatedly reported that the 
CSN associates with various protein kinases that may arbitrate essential functions in the CRL 
activation cycle including the exchange of substrate-receptor subunits. As such, deneddylation 
by the CSN may be crucial for promoting its own dissociation to enable efficient progression 
through CRL functional cycle [77]. 
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Figure 1-4. CRL functional cycle. 
A. Substrate binding to the CRL complex induces Cullin neddylation. B. Nedd8 binds to and activates 
the CRL complex. C. and D. Either the neddylated CRL complex binds to the CSN complex (C) of the 
E2-Ub complex associates with the RING-finger protein, Rbx1, and ubiquitin transfer to the substrate 
is performed (D). E. The CSN deneddylates the CRL complex resulting in loss of CRL activity. The 
CRL complex is disassembled, substrate binding is required for the neddylation cycle to restart. F. 
CAND1 binds to the Cullin by competing off the F-box and Skp1 proteins. 
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Deregulation of the CSN complex or of its interactions with other proteins can affect one of 
many cellular functions, including DNA repair, cell cycle control, angiogenesis, and 
microenvironmental homeostasis, all of which appear crucial for tumour development [78, 
79]. In the recent years, accumulating evidence suggests a correlation between the aberrant 
functioning of the CSN complex and its significant role in multiple cancers. The CSN and its 
implication in cancers have readily made it an attractive target for therapeutic intervention [79, 
80]. In many types of cancers, including glioblastoma, breast cancer, myeloma, and leukemia, 
frequent overexpression of CSN subunits has been identified. Overexpression has been most 
evidently observed for the MPN domain-containing proteins, CSN5 and CSN6, of the 
complex, which, in a variety of cancers, appears correlated with cancer progression and poor 
survival [81-84], whilst inhibition or knockdown of the CSN5 subunit resulted in suppressed 
tumour growth in mice [81, 85] and in human cancer cell lines [85]. In-depth understanding 
of the processes that regulate the mode of action of the CSN complex is required for targeting 
this complex for cancer intervention. Considering the essential cellular functions associated to 
the CSN, it is reasonable to assume that potentially multiple regulatory mechanisms exist that 
allow its coordinated action. The understanding of such regulatory mechanisms at the 
molecular detail remains unclear, however recent structural findings will provide valuable 
insight into the regulation of this essential complex in the protein degradation pathway. 

Given its critical link with the Ub-mediated protein degradation pathway, the CSN complex is 
implicated in the degradation of various tumour suppressor and oncogene products [79]. 
These include p27 [86, 87], p53 [84, 88], Mdm2 (for Double minute 2 protein) [84, 89], 
Smad7 (for Mothers against decapentaplegic homolog 7) [90], Runx3 (for Runt-related 
transcription factor 3) [91], Id1 (for Inhibitor of DNA binding 1) [92], Skp2 [93] and HIF-1 
(for hypoxia-inducible factor 1-) [79, 94].  
 
CSN6 has been an interesting candidate due to its involvement in signalling pathways during 
tumorigenesis. Although the detailed mechanism remains unclear, CSN6 is thought to be 
implicated in carcinogenesis and tumour development. Overexpression of this subunit is 
revealed in many types of cancer including, glioblastoma, breast cancer, myeloma and 
leukemia, where amplification of the CSN6 genomic region has been detected [80]. Studies 
have also shown that the gene amplification of CSN6 in breast cancer is positively correlated 
with tumour size. Human CSN6 was also identified to bind with the human 
immunodeficiency virus 1 accessory protein Vpr (hVIP) and found to be implicated in cell 
proliferation and the G2/M phase transition of the cell cycle [95]. An additional link has 
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been identified between the RING domain-containing p53 ubiquitin ligase, MDM2 and CSN6. 
CSN6 was also shown to be implicated in the COP1 driven ubiquitination and proteasomal 
degradation of p53. 
 
Although overexpression of CSN5 and CSN6 has been documented and is detailed here in the 
following sections, little is known about the implication of other subunits in cancer. For 
example, the overexpression of the CSN2 subunit can lead to VEGF production [96] and, by 
affecting the anaphase-promoting complex, can increase the stability of cyclin A, the 
activatory subunit of cell cycle cyclin-dependent kinases (CDKs). CSN2 overexpression can 
further result in chromosome instability [97], however the CSN2 gene is lacking in numerous 
cancers [98]. The CSN3 subunit is found to be involved in myeloid leukemia factor 1-
mediated growth arrest [99]. Deficiency of CSN3 leads to dampened p53 activation, easing 
cell proliferation and affecting COP1-mediated p53 degradation [99]. However increased cell 
death in Csn3-knockout mouse embryos where reduced CSN3 expression was observed and 
correlates with enhanced survival in cancer patients carrying the Ras oncogene [100]. 
Moreover, Csn4 deficiency was reported to downregulate Skp2 which is implicated in p27 
degradation [93, 101]. Although CSN subunits could have roles in cancer, further 
characterisation of their implication is required. 

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Through CSN function as a direct regulator of SCF, several essential products of oncogene or 
tumour suppressor genes appear to be deregulated as a result of CSN overexpression. One 
such example includes the function and regulation of the tumour suppressor p27. p27, a client 
of SCFSkp2 is a key protagonist in the control of cell cycle, as a natural inhibitor of the pro-
proliferative activity of cell cycle CDKs. Its controlled degradation triggered by CDK2-
dependent phosphorylation and subsequent ubiquitination is permissive for cell cycle 
progression. p27 is often downregulated in human cancers and it has also recently been found 
mutated [102, 103]. It functions to protect healthy cells from undergoing anarchical cell 
proliferation. Given the central role of p27 in cell proliferation control, many regulatory 
mechanisms target this protein, among which, phosphorylation and sub-cellular localisation. 
Deregulation of p27 affects the stability of this protein which is required for the maintenance 
of its tumour suppressor function and would thus consequently cause an impact on 
tumorigenesis. Ubiquitination of p27 is carried out by SCFSkp2 ubiquitin ligase containing the 
Skp2 substrate-recognition component necessary for associating with p27 [104]. Several lines 
of evidences link p27 downregulation and the CSN. The human CSN complex together with 
SCFSkp2 is implicated in regulating the degradation of p27 through ubiquitination [93]. 
Interestingly, studies have now shown that p27 downregulation is correlated with CSN5 
overexpression in cancers [105, 106]. The CSN5 subunit has also been identified to bind 
directly to and to regulate the export of p27 from the nucleus to the cytoplasm [107]. 
Resistance to CSN5-mediated degradation of p27 is gained upon CSN5 knockdown [108] or 
deletion of the CSN5 binding domain [108]. In which case, modified p27 proteins can then 
efficiently inhibit HER2-activated cell growth, CDK2 activity, cell proliferation and 
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transformation [108]. Although the contribution of CSN5 has been characterised, the general 
mechanism of CSN5-mediated p27 downregulation, as well as the implication of other CSN 
subunits is unknown.  
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Recent studies have shown that both MPN domain-containing proteins of the CSN complex, 
CSN5 and CSN6, are involved in the regulation of p53 levels in cells, by controlling p53 
ubiquitination. p53 plays a central role in the regulation of cell cycle progress upon DNA 
damage detection. Indeed p53 acts as a G1/S checkpoint, halting the cell cycle to allow repair 
time and thus prevents mutations from being propagated. This function of p53 warranted its 
name ‘The Guardian of the Genome’. TP53, corresponding to the gene coding for the p53 
protein is the most commonly mutated gene in human cancers [109]. Mutations of TP53 occur 
throughout the gene product and results in a loss or alteration of the function/regulation of 
p53. Factors that control p53 function, such as CSN5 and CSN6 are therefore of upmost 
importance to understand the complexity of p53 biology. However, at the moment, only little 
is known of these functional relationships, as described below. 
 
Initial findings indicating the implication of CSN5 in the stability regulation of p53 were 
obtained from experiments using Csn5-null mice embryos highlighting an accumulation of 
p53 protein levels [110]. Additional evidence suggesting a link between CSN5 and p53 was 
also found from experiments focused on the CSN-associated kinase inhibitor, curcumin 
(chemical IUPAC name: (1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-
dione), a natural pigment isolated from the plant Curcuma longa [89]. Currently, curcumin in 
a combination therapy with gemcitabine, and celebrex, is used in phase III clinical trials as 
treatment for pancreatic cancer therapy. Although the tumour suppressive effect of curcumin 
has been reported, the way this effect is mediated remains unclear. It was suggested that 
curcumin downregulates both CSN5 and p53 [89], but the molecular mechanism of this effect 
is currently not known. Further biochemical studies indicate that CSN5 interacts with p53 
through its MPN domain which is sufficient for p53 downregulation [89]. Mdm2 is the E3 
ligase responsible for the ubiquitination of p53. Studies have shown that MDM2-null cells 
also display lack of CSN5-mediated p53 degradation thus indicating that Mdm2 is required 
for the degradative function of CSN5 [89]. Moreover, through an unknown mechanism, 
CSN5 expression increases Mdm2 stability by reducing MDM2 self-ubiquitination [111, 112]. 
Interestingly, as for other proteins such as p27, CSN5 can mediate the translocation of p53 
from the nucleus to the cytoplasm, thereby facilitating p53 degradation [89, 113]. As such it 
can be concluded that CSN5 is implicated in the enhancement of nuclear export and 
degradation of p53 via Mdm2-mediated p53 ubiquitination leading to the impairment of DNA 
damage checkpoint. 
 
Similarly, the comparison of expression levels of Mdm2 and CSN6 in normal and cancerous 
breast tissues revealed that the expression of CSN6 was concurrently overexpressed with 
Mdm2 in these tissues [84]. Mechanistically Zhao et al. proposed that CSN6 could prevent 
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Mdm2 auto-ubiquitination at lysine 364 and thus results in its stabilisation and subsequent 
degradation of p53. Further, they claim that the lack of p53 degradation observed in Mdm2-
null mouse embryonic fibroblasts (MEFs) could be indicative that CSN6-mediated 
degradation of p53 is Mdm2-dependent [84]. These results suggested that CSN6 is an 
oncogene with positive activity toward Mdm2 function within the MDM2-p53 signalling 
pathway. CSN6 has also been reported to interact with another p53-specific E3 ligase, COP1. 
This E3 ligase targets p53 for degradation by the UPS and is therefore reported as a negative 
regulator of p53 and thus maintains low levels of p53 in unstressed cells and inhibits p53-
dependent transcription and apoptosis events [114]. Besides interacting with COP1, CSN6 
was also reported to be involved in the degradation of the 14-3-3 gene product (a gene that is 
upregulated by p53) [115]. In a manner reminiscent to that proposed for Mdm2, CSN6 was 
found to stabilize COP1 by reducing COP1 auto-ubiquitination and thus decreasing the rate of 
COP1 turnover [115]. Two putative physiological effects of CSN6 in the COP1-p53 pathway 
have been suggested. These include that (i) the stabilisation of COP1 essentially enhances 
COP1-mediated p53 ubiquitination and subsequent degradation and (ii) the implication of 
CSN6 results in the degradation of the 14-3-3 protein. 

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Recently it was reported that the CDK inhibitor, p57Kip2 (also known as CDKN1C (for 
Cyclin-dependent kinase inhibitor 1C); referred to as p57 in the rest of manuscript) is a newly 
identified interacting partner of CSN6 [116]. As p27, p57 is a potent natural inhibitor of 
several G1 CDKs. Overexpression of p57 was shown to completely arrest the cell cycle at G1 
phase, whereas decreased levels of p57 were identified in many types of cancers [117]. The 
degradation of p57 is ubiquitination-dependent and is mediated by the SCFSkp2 complex [118]. 
It was found that CSN6 is involved in p57 downregulation and results in an increase in p57 
ubiquitination levels [116]. CSN6 interacts with both p57 and Skp2, which, in return, 
enhances Skp2-mediated p57 ubiquitination and as such results in a decrease in p57 
expression levels. Importantly, increased expression levels of CSN6 in addition to decreased 
p57 expression levels correlate with poor human tumour survival [116], which is reminiscent 
to the observed negative correlation between CSN5 and p27 in various cancers, as described 
above.   
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The CSN complex was initially identified in At, as a negative regulator of the 
photomorphogenesis developmental, which occurs in response to light sensitivity in the team 
of Xing Wang Deng at the University of Yale (USA) by Ning Wei. Later on, during the 
course of the purification of proteasomes from mammalian red blood cell lysate, the CSN was 
further isolated [119]. Moreover, the complex was also purified from pig spleen [120]. The 
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presence of the CSN in both plants and mammals indicated a function that lies beyond the 
control of light-mediated plant signal transduction. Further discoveries of the CSN complex 
were later reported in a variety of eukaryotic organisms, from unicellular to chordates, 
including Saccharomyces cerevisiae (Sc), Schizosaccharomyces pombe (Sp), Aspergillus 
nidulans (An), Neurospora crassa (Nc), Caenorhabditis elegans (Ce), Drosophila 
melanogaster (Dm) and Hs. To date, the CSN complex has been identified in mammals, 
plants, and yeast and functionally has been shown to physically associate with SCFs [47, 121]. 

The subunit composition of the CSN complex, responsible for the structure and function of 
the complex displays a considerable variation in different species (Table. 1). The CSN 
complex in mammals, plants and insects typically comprises eight subunits, six of which are 
PCI domain-containing and two are MPN domain-containing subunits [122]. In addition the 
archaetypal CSN shares structural features with the 19S proteasome lid or the eIF3 complex. 
Yeast CSN appears to be more divergent in its composition, potentially lacking two subunits.  
 
Table 1-1. CSN and 19S proteasome lid subunit composition in different organisms.  
* Subunit dually present in both the CSN and the 19S proteasome lid 
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Several mammalian CSN subunits were originally identified as independent interactors of 
various signalling proteins. Particularly, the CSN5 subunit was initially reported as Jab1 in a 
potentially CSN-independent form that reflects its ability to directly interact with and 
stimulates c-JUN transcriptional activity [123]. Further studies found CSN5 interacting with 
various intracellular regulators where examples include, p27 [107], as described above, the 
leucocyte antigen receptor [124], various transcription factors and tumour suppressors like 
Subunit Sc Sp Ce Dm Hs At 
PCI Csn11 
Rpn7 
Csn1 
Rpn7 
CSN1 
RPN-7 
CSN1 
Rpn7 
CSN1 
Rpn7 
CSN1/FUS6 
RPN7 
PCI Csn10 
Rpn6 
Csn2 
Rpn6 
CSN2 
RPN-6 
CSN2 
Rpn6 
CSN2 
Rpn6 
CSN2/FUS12 
RPN6 
PCI - 
Rpn3 
Csn3 
Rpn3 
CSN3 
RPN-3 
CSN3 
Rpn3 
CSN3 
Rpn3 
CSN3/FUS11 
RPN3 
PCI  Rpn5* 
Rpn5 
Csn4 
Rpn5 
CSN4 
RPN-5 
CSN4 
Rpn5 
CSN4 
Rpn5 
CSN4/COP8 
RPN5 
MPN+ Csn5 
Rpn11 
Csn5 
Rpn11 
CSN5 
RPN-11 
CSN5 
Rpn11 
CSN5 
Poh1 
CSN5 
RPN11 
MPN- Csi1 
Rpn8 
- 
Rpn8 
CSN6 
RPN-8 
CSN6 
Rpn8 
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p53 [88]. In mammalian cells, besides the holo-CSN complex containing eight subunits, the 
presence of smaller CSN subcomplexes was identified by analytical gel filtration analysis of 
cell lysate [125-128]. Although these sub-complexes could be intermediates along the CSN 
assembly/disassembly pathways, some have been shown to hold specific biological roles 
[127]. However, the molecular identity and functions of CSN subcomplexes remain to be 
clarified, although they may contribute to the multifunctionality of the mammalian CSN 
subunits. Interestingly, in mammalian cells, the CSN7 subunit exists as an isoform, CSN7a 
and CSN7b, which could define different types of CSN complexes with different functions, 
although this has not been investigated to date [129]. Proteomic analysis performed on the 
mammalian CSN complex demonstrates that, as expected by the typical composition of the 
CSN (one copy of each of the eight CSN subunits), CSN7b is not part of complexes 
containing CSN7a, indicating that CSN7a and CSN7b are indeed components of different 
CSN complexes [130].  
 
To date, probably through its regulatory role of CRLs, the mammalian CSN was shown to be 
involved in a range of biological responses. However, in contrast to the CSN identified in the 
plant kingdom, the mammalian CSN is closely involved in cell proliferation and maintenance. 
Studies reported that knockout (KO) of various CSN genes, including those of CSN2, CSN3, 
CSN5 and CSN8, lead to lethality at an early embryonic development stage in mice, mainly 
due to defects in cell proliferation and survival [110, 131-133]. In addition, for the CSN2 gene 
KO experiments, the poor levels of substrate proteolysis in these KO mice, lead to elevated 
levels of p53 and cyclin E cell cycle regulators [131]. Moreover, CSN knockouts in mouse T 
cell lineages show reduced T cell receptor activation and proliferation, whilst CSN8 KO cells 
demonstrate higher levels of neddylated Cul2 and of cyclin E [134].  

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In At, and as in all identified higher organisms, the CSN complex comprises eight subunits, 
six of which were genetically identified as pleiotropic, constitutively photomorphogenic/de-
etiolated/fusca (COP/DET/FUS) mutants [135]. Although this class of mutants showed 
survival through embryogenesis, their growth is severely limited, defects that arrest growth at 
the seedling stage was identified and simultaneously irregular gene expression patterns was 
detected. Interestingly, in At, the CSN5 and CSN6 subunits are both encoded by two 
homologous genes, CSN5a and CSN5b or CSN6a and CSN6b, respectively [125]. For both 
CSN5 and CSN6, mutants generated that lack one of the homologous genes are viable, 
highlighting their functional redundancy. However, KO of both homologous genes results in 
lethality, showing the common phenotype obtained in multicellular organisms [136-138]. 
Besides At, several other plant species also possess two CSN5 and CSN6 genes, however 
duplication of these genes has only been observed in the plant kingdom [139]. The functional 
reason for these gene duplications in the AtCSN system remains undetermined, although in 
general, gene duplications are commonly present to produce functional diversification or 
specialisation.  
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Functional studies in higher eukaryote organisms, summarised in the section above, have 
shown that the complex is essential for development and that defects in the CSN are 
responsible for embryonic death. The CSN complex has been identified in various fungal 
species including Nc, Sp, and Sc, showing significant differences in the composition of the 
complex with fewer than eight subunits in comparison to the canonical eight-subunit complex 
observed in higher eukaryote organisms.  
 
Purification of the CSN complex from Nc identified a complex composed of subunits 1-7, 
whilst the CSN8 subunit was found to be lacking not only in the purification experiment but 
also in the genome sequence [140, 141]. This study further suggested the implication of the 
CSN in Nc circadian clock and showed that the CSN is required for the stability of SCF 
complexes in Nc [140, 141].  
The CSN in Sc is largely divergent containing one MPN domain-containing protein which is 
the ortholog of the CSN5 subunit, Rri1, and four PCI subunits, CSN9, CSN10, CSN11 and 
CSN12, which show only few similarities to subunits present in higher eukaryotes [142]. An 
additional interactor, Csi1, has been found to associate with the 5-subunit CSN-like complex 
found in Sc [142]. Interestingly, the Csi1 displays significant homology with the C-terminal 
domain of the canonical CSN6 subunit found in mammalian CSNs, but lack the N-terminal 
MPN domain [143]. It was further proposed that the Csi1 comprises the functional equivalent 
of the canonical CSN6 [143]. 
 
Further disparities have been reported in the Sp CSN complex, which is composed of subunits 
CSN1-5 and CSN7a, whilst the subunits CSN6 and CSN8 as missing and neither subunit 
appear to contain any recognizable homolog [144]. In these organisms, the CSN complex is 
involved in regulation of diverse pathways [140, 145, 146]. Interestingly, csn1 and csn2 
mutants in Sp identified a delay in S phase progression and showed hypersensitivity to UV -
and -radiation [146], whilst deletions of csn4 and csn5 in this organism revealed that both 
subunits are required for deneddylation of the Sp Cullin Pcu1. However, neither csn4 nor csn5 
showed to share common phenotypes with csn1 and csn2 mutants [144]. These findings 
indicate a large variation in the CSN complex composition and function between fungi and 
higher eukaryotes. However, more recently, it was shown that the mold An also contained the 
eight-subunit CSN complex and most interestingly defects showed to result in the 
abolishment of the potential to form fruit bodies, producing a phenotype reminiscent to that of 
higher organisms [147]. The fungal kingdom is thus diverse in itself, as well as showing the 
largest variation. 
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As for other post-translational modifications, the conjugation of Ub and Ubl molecules to 
their substrate is a reversible process [148]. The isopeptidase family classifies a diverse 
population of proteolytic enzymes involved in counteracting these modifications. The generic 
name of these enzymes is generally defined by their substrate. This family of proteins counts 
DUBs, which in principle are specifically implicated in the cleavage of Ub linkages. Likewise, 
enzymes that hydrolyse isopeptide bonds implicating Nedd8, ISG15 or SUMO are referred to 
as deNEDDylating, deISGylating, or deSUMOylating enzymes, respectively. In general terms, 
they can also be viewed as agonists of E3 ligases, but they can also remodel Ub or Ubl chains.  
 
Based on their catalytic mechanism, proteases have been divided into five classes, comprising 
of aspartic, cysteine, metallo, serine and threonine proteases [149]. The cysteine and metallo 
protease classes contain DUBs [149]. Genomic studies have identified 95 human genes 
encoding for putative DUBs, among which the majority are cysteine proteases [150]. Whilst 
all metalloprotease domain DUBs hold a JAMM/MPN+ domain, cysteine proteases can be 
further subdivided according to their Ub protease domains into the UCHs, Ub-specific 
proteases (USPs), ovarian-tumor (OTU) domain proteases, and Machado-Joseph domain 
proteases (Fig. 1-5) [149]. In this section, we mainly focus on the metalloprotease DUBs and 
specifically on members of this subfamily, which within our work we highly referenced, in 
order to provide functional understanding of our system. However, further functional and 
structural properties of DUBs are addressed in Chapter 3. 
 
The large diversity observed in DUBs is suggestive of considerable substrate specificity [151]. 
Linkage-specific cleavage, sensitivity for poly-Ub chains and variation in efficiency ensure 
another level of specificity of isopeptidases [152, 153]. Examples include the isopeptidases, 
USP8 and USP14 which cleave K48 but not K63 polymers of Ub [149], whilst K63-linked Ub 
is hydrolysed by the cylindromatosis gene product (CYLD) [154]. Moreover, some DUBs are 
able to deconjugate both Ub and Ubls from their substrate [155]. This is the case for USP21 
and UCH-L3 that can cleave Ub, as well as Nedd8 [156]. Although these enzymes show to 
contain low specificity in vitro, their ability to cleave both modifiers suggests a crosstalk 
between levels of DUBs. It has further been shown that the subcellular localisation and other 
scaffolding partners of DUBs influence their specificity and potentially regulate their 
activation [151, 157]. A study investigating the DUB interaction landscape using proteomic 
analysis investigated 75 of the 95 DUBs encoded in the human genome and identified 774 
unique high-confidence candidate interacting proteins. This work led to the interesting 
observation indicating that a good number of DUBs are associated with multi-subunit 
complexes and further supports the hypothesis that the incorporation of DUBs with other 
interacting partners is required for their activation and specificity [150]. Indeed it has been 
shown to be the case for the catalytic subunits of the 19S proteasome lid, the CSN complex, 
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and BRAC1-RAP80 and BRISC complexes, Rpn11, CSN5, and BRCC36, respectively (Fig. 
1-6) for JAMM DUBs [47, 75, 150, 158-160].  
 
 
 
Figure 1-5. The human DUBomes. 
Adapted from Ubiquigent (www.http://ubiquigent.com). 
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From a functional point of view, the isopeptidase activity of DUBs serves for various 
purposes [148]. Since most Ub and Ubls are encoded as a precursor, there are DUBs 
implicated in their processing that is required for their function as post-translational modifiers. 
Second, DUBs are involved in the deconjugation of Ub or UBLs from their substrate 
influencing protein stability or their involvement in signalling events. These can be described 
as DUBs that operate as negative regulators of the post-translational modifications as they 
antagonise the E3 ligase activities. Additionally, some DUBs function to cleave Ub from 
proteins that are tagged for degradation, required for efficient substrate degradation within the 
UPS and also for recycling the pool of unconjugated Ub [148]. Lastly, some DUBs are also 
involved in the remodelling of Ub and Ubl chains, prior for example to substrate degradation 
[159, 161, 162]. In the following sections, a detailed overview of examples of DUBs is given, 
focusing on the function of their isopeptidase activity. Whilst the activity of some DUBs 
requires their incorporation within larger complexes, this is not the case for all (Fig. 1-5). 
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The major function of the CSN encompasses the proteolytic cleavage of the isopeptide bond 
between Nedd8 and the C-terminal conserved lysine residue of the Cullin subunit [47, 70, 
163]. Neddylation of Cullins is a reversible reaction counteracted by the reaction of 
deneddylation that removes the Nedd8 moiety by the isopeptidase activity of the CSN [47]. 
The isopeptidase activity of the CSN complex is centred on its CSN5 subunit containing a 
JAMM/MPN+ domain. Specific mutation performed on CSN5 that abolish its enzymatic 
activity results in accumulation of neddylated Cul1 in Sp [75], At [137, 138] and Dm [164] 
and neddylated Cul3 in Ce [165]. The effect on other Cullins has not been addressed. 
Moreover, in plants, loss of CSN activity as a result of deletion of various subunits was 
reported to lead to constitutive photomorphogenic phenotype. Such experiments in Ce 
resulted in sterility, whilst were found lethal in Dm and Mm [132, 166, 167].   
 
As reported for other JAMM/MPN+ proteins, the CSN5 subunit alone does not possess in 
vitro any isopeptidase activity and requires to be recruited within the CSN complex to display 
its deneddylase activity [70, 159, 168]. Deneddylation performed by the CSN is strictly 
conserved among all eukaryotes, although, as previously discussed, the subunit composition 
of CSN complexes differ between lower and higher eukaryotic species. Given the crucial role 
of the CSN5 subunit in the deneddylase activity of the CSN, its ability to associate with a 
range of cell regulators, the correlation of its expression level with cell proliferation, all 
suggest that the dynamics of CSN5 association is likely to be highly regulated. The lack of 
structural information available regarding the auto-inhibited nature of CSN5 in the stand-
alone state challenged, until recently, the understanding of the CSN activity regulation. 
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In cells, Ub signalling is essential and is implicated in diverse functions. It is thus inevitable 
that a highly controlled mechanism is required to prevent undesired deubiquitination of 
proteins by the proteasome. Within the proteasome lid, the enzyme responsible for removing 
the poly-Ub chain is Rpn11 (it can also be known as POH1 in Hs) [159, 161]. It is therefore 
entirely coherent that the DUB activity of Rpn11 is inhibited, until the lid is incorporated into 
the regulatory particle. Once bound to the 26S proteasome, via an Ub receptor, cleavage of 
the isopeptide bond between the protein substrate and the poly-Ub chain is required prior to 
subsequent substrate translocation through the axial pore of the proteolytic 20S chamber. 
Rpn11 cleaves the poly-Ub chain at the proximal Ub to permit subsequent fast degradation 
and recycles Ub for further use [161]. Failure to remove the poly-Ub chain from the substrate 
protein is thought to obstruct the entry of the substrate through the pore of the proteasome. 
This would result in a delay in the translocation of the substrate due to steric hindrance by the 
poly-Ub chain and additionally accumulate poly-Ub [169]. It has thus been shown that 
deubiquitination of the substrate by Rpn11 is required for efficient substrate proteolysis. 
Intriguingly, the DUB activity of Rpn11 is found to be ATP-dependent although it lacks an 
ATPase domain signature. As such it is suggested that the DUB activity is coupled to protein 
unfolding performed by the base ATPases neighbouring the lid [159, 170-172].  
 
EM reconstruction studies revealed the six PCI domain-containing proteins of the lid 
assemble in a horseshoe-shaped arrangement that is suggested to act as a scaffold to stabilize 
the lid via substantial lateral interactions between the C-termini of PCI domain subunits [173-
175]. The MPN domain-containing proteins, Rpn11 and Rpn8 (it can also be known as 
MOV34 in Hs), form a heterodimer and accommodate above the opening of the AAA-
ATPase ring and incorporate into the scaffold formed by the PCI domain-containing subunits 
[175]. As observed for various macromolecular assemblies, the catalytic activity of the 19S 
proteasome lid is only imparted upon complete maturation of the complex [159]. 
The 19S proteasome lid and more specificity the DUB activity of the Rpn11 subunit is 
regularly referred to within our work. The common structural and architectural relevance with 
the CSN and CSN5 makes it suitable for comparison and for complementing our work. 
Initially, structural information on the MPN domain-containing proteins of the proteasome lid 
was restricted to the crystal structure of HsRpn8 MPN domain in the stand-alone state [176]. 
However the recently report structure and biochemical study of the MPN heterodimer, 
Rpn11-Rpn8, expanded the structural characterisation of this family and allowed validation of 
our work and a fine comparison [158, 160]. This aspect of our work is developed in Chapter 3.  

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The eIF3 complex is functionally implicated in the assembly of translation initiation 
complexes. It commonly acts as a docking site for various eIFs that assemble on the 40S 
ribosomal subunit [177]. This multi-protein complex contains a molecular mass of 800 kDa 
and comprises of 13 different subunits, namely eIF3a to eIF3m, within which six are PCI 
domain-containing proteins (eIF3a, c, e, k, l, and m), two are MPN domain-containing 
proteins (eIF3f and h), whilst the remaining are eIF3-specific subunits [57]. To date, structural 
insight into the eIF3 complex organization was obtained by cryo-EM studies, which 
highlighted the direct interaction between the MPN domain-containing subunits [178]. The 
enzymatic activity of the eIF3 complex has not yet been clearly characterised, however its 
intriguing resemblance in terms of subunit composition and topology, with the 19S 
proteasome lid and the CSN, has suggested potential to harbour DUB activity. Conversely, 
the JAMM motif constituting the catalytic site of DUBs does not appear strictly conserved in 
the putative MPN+ subunit, eIF3f, of this complex. However, it has been demonstrated that 
the MPN domain of the eIF3f subunit exhibits DUB activity specific for the activation 
regulation of the transmembrane receptor Notch. This work was further validated by 
mutational work on the active site residues of this subunit [179].

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For JAMM/MPN+ domain-containing subunits that are part of a large multi-protein complex, 
a recurrent principle is that they are catalytically inactive when in their stand-alone state. 
Concerning CSN5 and Rpn11 that are part of the CSN complex and the 19S lid complex, 
respectively, their incorporation into their respective complexes is required for their 
isopeptidase activity. A third multi-subunit complex containing a JAMM/MPN+ subunit 
includes the eIF3 complex that has recently been reported to express isopeptidase activity 
[179]. Besides containing a catalytic MPN domain-containing subunit, these complexes also 
have a MPN- subunit and six PCI proteins. Pairs of MPN+/MPN- proteins appear to be often 
present in these assemblies, although this does not seem to be the case for BRCC36 (for 
BRCA1 (for Breast cancer type 1 susceptibility protein 1)/BRCA2 (for Breast cancer type 1 
susceptibility protein 2)-containing complex subunit 36)-containing complexes described to 
date. BRCC36 is an MPN+ protein functioning as a DUB in two large, possibly related, DNA 
repair complexes, the BRCA1-RAP80 (for Receptor-associated protein 80) complex and the 
BRCC36-containing isopeptidase complex (BRISC) [65, 159, 161]. In both complexes, 
BRCC36 possesses DUB activity, specifically for Lys63-linked poly-Ub chains [180-182].  
 
The BRCA1-RAP80 is a five-member complex comprising of RAP80, BRCC36, BRCC45 
(for BRCA1/BCRA2-containing complex subunit 45), Abraxas and MERIT40 (for Mediator 
of RAP80 interactions and targeting subunit of 40 kDa; also known as BRISC and BRCA1-A 
complex member 1). RAP80 contains an Ub-interacting motif that interacts with DNA double 
strand breaks and specifically recognize Lys63-linked chains [183, 184]. Together with the 
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isopeptidase activity of BRCC36, this complex is implicated in Lys63-linked Ub synthesis 
and hydrolysis at DNA double strand breaks thus regulating the recruitment and maintenance 
of DNA repair factors [181, 185].
Recently, the BRISC complex was identified and share three subunits in common with 
BRCA1-RAP80 including, BRCC36, BRCC45, and MERIT40, whereas the fourth subunit 
namely Abrol (also known as KIAA0157) is a paralog of the Abraxas subunit from the 
BRCA1-RAP80 complex [182]. The DUB activity of BRCC36 in these complexes was 
individually characterised revealing that BRCC36 activity requires different interactions 
within the context of each protein complex. Within the BRCA1-RAP80 complex, the 
interactions of Abraxas and BRCC45 are essential for the DUB activity of BRCC36, whilst 
KIAA0157 is the only interaction necessary for BRCC36 DUB activity in the BRISC 
complex. Interestingly, both complexes require a protein-protein interaction with a MPN- 
domain-containing protein, that is the subunits Abraxas and KIAA0157, in BRCA1-RAP80 
and in BRISC, respectively [168]. Regulation of DUB activity via protein-protein interactions 
was further validated by activity measurements of HsRpn11 in the presence of the MPN- 
subunit of the proteasome lid, HsRpn8, revealing a catalytically active Rpn11 [160, 168]. 
These findings are suggestive of a common regulatory mechanism in this class of DUBs, 
where interactions between MPN+/MPN- proteins are essential for their isopeptidase activity. 

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The structure of AMSH-LP (associated molecule with the SH3 domain of STAM (AMSH)-
like protease; also known as STAMBPL1) bound to a K63-linked di-Ub substrate and its 
biochemical characterisation led to the hypothesis that the mechanism of JAMM/MPN+ 
isopeptidases is presumed to be comparable to that of typical metalloproteases, in particular 
thermolysin [186]. However, the main difference is that proteases cleave peptide bonds, 
whilst JAMM/MPN+ enzymes are suited for the hydrolysis of the amide bond conjugating the 
C-terminus of distal Ub with an amino group on the proximal Ub moiety. In this study, two 
histidines, an asparate and a water molecule are shown to coordinate the zinc ion. 
Mechanistically, it was deduced that an active site located glutamate residue activates the 
water molecule by accepting a proton from the catalytic water and thus transforms it to a more 
potent nucleophile. The resulting hydroxyl ion in return is able to attack the isopeptide bond 
of the substrate at the carbonyl carbon. A conserved serine present in the MPN+ motif 
stabilises the oxyanion formed. This mechanism results in the collapse of the transient 
tetrahedral bond of the substrate [186]. Sequence conservation of JAMM/MPN+ domain-
containing proteins supports this mechanism for the other JAMM/MPN+ proteins discussed in 
this Chapter and following ones, including Rpn11, CSN5 and BRCC36. Moreover, the 
requirement of zinc for catalysis by these proteins has been demonstrated by inhibition of 
their activity in the presence of zinc chelators [70, 159].   

The function of AMSH-LP DUBs has not yet been clearly understood. Their common 
structural characteristic with AMSH and high sequence identity suggests that it may carry out 
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a related function. These two proteins share 53% sequence identity and both contain a nuclear 
localisation signal and a JAMM/MPN+ domain [187]. Additionally both enzymes hydrolyse 
both Lys63- and Lys48-linked di-Ub substrate and are active in their stand-alone form, 
although domains outside of the DUB domain could affect the isopeptidase activity. The main 
difference between the two lies on the AMSH ability to associate with the SH3 domains of 
STAM1 (signal transduction adaptor molecule 1) and to clathrin. Although SH3-like domains 
are also present in AMSH-LP, it does not interact with STAM, suggesting that AMSH and 
AMSH-LP may have differing cellular functions. The function of AMSH encompasses the 
regulation of receptor endocytosis and contributes to the dynamics of receptor trafficking by 
deubiquitinating receptors tagged with a poly-Ub chain, thereby antagonising E3 ligase 
activity.  

Figure 1-6. Schematic representation of MPN+/MPN- domain-containing multi-protein 
complexes. 
Although MPN+ proteins are not all found in large protein complexes (including AMSH, AMSH-LP, 
MPND, MYSM1) here we focus on those that do. Additionally the MPN- protein, Prp8 also forms a 
complex with other protein, but lacks the MPN+ protein. In this schematic, color codes are used to 
characterise the domains present. JAMM/MPN+ subunits are in light purple, MPN- subunits in dark 
purple and PCI domain subunits in grey. The additional components present in the BRCC36-
containing complexes are colored as indicated in the image. A. The human CSN complex. The 
complex contains the two MPN domain-containing proteins (CSN5 and CSN6) and six PCI subunits. 
B. The human 19S proteasome lid complex containing the two MPN subunits (HsRpn11 (POH1) and 
HsRpn8 (MOV34) that are the human orthologs of ScRpn11 and ScRpn8, respectively) and six 
additional PCI subunits. C. The human eIF3 core complex. The schematic represents the two MPN 
subunits (eIF3f and eIF3h) and six PCI subunits. Another five non-MPN or PCI subunits are also 
present in the holo-eIF3 complex, including eIF3b, -d, -g, -i, -j (non represented here for clarity). D. 
The core of the BRCA1-RAP80 complex, the two MPN subunits (BRCC36 and Abraxas) are 
indicated and decorated with three other proteins that together form the core structure. E. The BRISC 
composed of the two MPN subunits (BRCC36 and KIAA0157/Abrol) and further three other subunits. 
 
In our work, we use both AMSH and AMSH-LP as model systems to gain further insight on 
how MPN+ domain-containing proteins reach a catalytically competent form and more 
specifically addressing how the inactive stand alone CSN5 subunit is in an active 
conformation when incorporated into the CSN complex. Given that AMSH-LP bound di-
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Ub and AMSH bound di-Ub and Ub [188] are currently the sole MPN+/substrate complex 
structure available, we employ this system to understand substrate recruitment in the case of 
CSN5. This work is further described in Chapter 3.   

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cDNA coding sequence for full-length (FL; 1-334) and a truncated version of CSN5 cloned 
into the pGEX-6P1 vector (GE Healthcare) were used to recombinantly express CSN5. Site 
directed mutagenesis was performed using the QuikChange Lightning Site-Directed 
mutagenesis kit (Stratagene) and point mutation oligonucleotides (Eurogentec). All constructs 
and mutations were checked by DNA sequencing (Beckman Coulter Genomics). 
 
Expression and purification of CSN5 (fragment 1-257) and mutant forms in BL21pLysS E. 
coli cells (Novagen) were performed using standard conditions. Induced bacterial cells were 
resuspended in the purification buffer (20 mM Na-2-(N-morpholino)ethanesulfonic acid (Na-
MES), pH 6.5, 100 mM NaCl, 0.002% monothioglycerol (MTG)) supplemented with EDTA-
free protease inhibitor cocktail (Roche) and were lysed by sonication. Cell lysate was clarified 
by centrifugation and applied onto a gravity-flow Glutathione Sepharose 4B column (GE 
Healthcare). Glutathione S-transferase (GST)-tagged CSN5 was eluted by 20 mM reduced 
glutathione in the purification buffer and was cleaved overnight at 4 °C by GST-3C protease. 
The sample was concentrated and loaded onto a Superdex 75 gel filtration column (GE 
Healthcare). A final polishing step was used to separate CSN5 from contaminating GST. The 
resulting pure CSN5 was concentrated to 10 mg mL1 and stored at -80°C until further use. 
Protein concentrations were measured with a Nanodrop (ThermoScientific) at 280 nm using 
their theoretical extinction coefficient. 
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The human CSN6 cDNA was subcloned in pGEX-6P1 (Novagen®). Soluble heterologous 
expression of glutathione S-transferase (GST)-tagged full-length (FL) CSN6 in bacteria 
proved challenging. As a result, three C-terminal truncated forms of CSN6 were designed and 
the fragment comprising the residues 31 to 211 was selected for further work. Expression of 
CSN6 and its variants was performed in E. coli BL21pLysS cells (Novagen®) in LB or 
15NH4Cl-supplemented M9 minimal expression medium, as required for NMR experiments. 
Cells were induced with 0.3 mM isopropyl -D-1-thiogalactopyranoside (IPTG) overnight at 
18oC. Harvested cells were resuspended and lysed in purification buffer (20 mM Tris pH7.5, 
150 mM NaCl, 0.01% monothioglycerol (MTG)), supplemented with EDTA-free protease 
inhibitor cocktail (Roche) and later sonicated. Following centrifugation, clarified cell lysate 
was applied on a gravity-flow glutathione Sepharose 4B column (GE Healthcare). GST-
tagged CSN6 was eluted with 20 mM reduced glutathione in purification buffer. Cleavage of 
the fusion tag was obtained by incubation of the eluant, overnight, at 4oC, with GST-3C 
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protease (1/50 w/w). The sample was concentrated and applied onto a Superdex 75 gel 
filtration column (GE Healthcare), pre-equilibrated in the purification buffer supplemented 
with 5 mM benzamidine to avoid C-terminal proteolysis. The eluted fractions corresponding 
to CSN6 were further purified on a glutathione Sepharose 4B column to remove 
contaminating GST and GST-tagged proteins. Purified CSN6 was concentrated to 8 mg mL-1 
and stored at -80oC until further use. 
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Production of NEDP1 (Nedd8-specific protease 1; also known as DEN1 for Deneddylase-1 or 
SENP8 for SUMO/Sentrin Specific Peptidase Family Member 8) from the pGEX-2TK-nedp1 
vector (kind gift from Dr. D. Xirodimas) was carried out following the protocol described in 
[189]. The pOPIN-E-pro-nedd8 vector (kind gift from Dr. M. Banfield) was used to express 
pro-Nedd8 following the procedure described in [190].  
 
The Cullin1/Rbx1 complex was obtained by co-expressing the set of the two ‘split-an-express’ 
plasmids (pAL-hCul1-NTD, pCool-mRbx1-His-hCul1-CTP) kindly provided by N. Zheng 
(University of Washington) and distributed by Addgene, following the procedure described in 
[191]. GST-Rbx1/Cul1-CTP/Cul1-NTD was purified from a 0.9 L bacterial culture using a 
glutathione sepharose column. After thrombin cleavage, the protein solution was subjected to 
a separation on a Mono S 5/50 column. Fractions corresponding to the Rbx1/Cul1-CTP/Cul1-
NTD were pooled, concentrated and stored at -80°C until further use. 
In Chapter 4, the Cullin1-Nedd8/Rbx1 and CSN were kindly provided by Prof. M. Peter and 
Dr. R. I. Enchev (ETH Zürich), following procedures described in [46]. 
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For the isopeptidase assay using LRGG-AMC substrate performed in Chapter 3, GST-tagged 
CSN5 1-257 protein and different mutants were diluted to 0.2 µg µL-1 in reaction buffer (40 
mM Tris-HCl pH8.5, 5% glycerol, 1 mM DTT), in the presence of 250 µM LRGG-AMC. For 
the isopeptidase assay using Nedd8-AMC substrate, CSN5 1-257 WT protein and different 
variants (R106T, R106A, R106G, R106P, E76A, E76A/R106T) prepared in the same 
conditions were diluted to 0.2 µg µL-1 immediately before in the reaction buffer (40 mM Tris-
HCl pH8.5, 1 mM DTT). The CSN complex purified from erythrocytes and purchased from 
Enzo Life Sciences was used at 0.01 µg µL-1. The reactions setup on ice were started by the 
addition of the substrate (2 µM Nedd8-AMC) to the reaction mixture and followed at 28°C. 
Isopeptidase assays were monitored in duplicate in a 96-well fluorescence plate on a Tecan 
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Saphire, by following the increase of fluorescence intensity (excitation=380 nm; emission= 460 
nm), i.e. the hydrolysis of the isopeptide bond between LRGG/Nedd8 and AMC. 
 
For experiments performed in Chapter 4, initial rate measurements were carried out at 37°C 
by following the increase of fluorescence intensity (	excitation = 380 nm; 	emission = 460 nm), in 
non-binding surface, flat-bottom, black 384-well plates (Corning), in a reaction volume of 50 
µL on a Tecan safire2 plate reader. For the LRGG-AMC substrate, the following experimental 
conditions were used: reaction buffer (50 mM Tris-HCl pH7.5, 50 mM NaCl), LRGG-AMC 
concentrations (25 to 400 µM in 50 mM Tris-HCl pH7.5, 50 mM NaCl, 1.25% DMSO), 3.4 
µM CSN5/CSN6 binary complex (5.9 µM CSN5 and 10.0 µM CSN6 mixed prior to reaction), 
3.4 µM NEDP1. As saturating concentrations of LRGG-AMC were not reached, the value of 
the pseudo-second order rate constant (k2), corresponding to kcat/KM value was obtained by 
linear fitting of initial rate data. For the Nedd8-AMC substrate, the following experimental 
conditions were used: reaction buffer (50 mM Tris-HCl pH7.5, 50 mM NaCl), Nedd8-AMC 
concentrations (0.5 to 6.0 µM in 50 mM Tris-HCl pH7.5, 50 mM NaCl), 4 nM CSN5/CSN6 
binary complex (100 nM CSN5 and 169 nM CSN6 were mixed prior to reaction and the 
concentration of the binary complex was calculated using the value of the KD determined by 
ITC), 200 nM CSN5 alone. When saturating concentrations of Nedd8-AMC were observed, 
the initial rate data were fitted to the Michaelis-Menten equation using least square analysis to 
determine kcat and KM in the Prism software (GraphPad). When saturating concentrations of 
Nedd8-AMC were not observed, the value of k2, corresponding to kcat/KM value was obtained 
by linear fitting of initial rate data. 
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For this assay, CSN5 (WT or variants), alone or the CSN5/CSN6 complex was diluted to 900 
nM (for CSN5 alone) or to 4 nM (for the dimer: (100 nM CSN5 and 169 nM CSN6 were 
mixed prior to reaction and the concentration of the binary complex was calculated using the 
value of the KD determined by ITC). Using the measured affinity between CSN5 and CSN6, 
each subunit was added in excess to reach a final binary complex concentration of 4 nM.) in 
reaction buffer (20 mM Tris-HCl pH7.5, 50 mM NaCl) in the presence of 1 µM pro-Nedd8 
WT or variants. A time course at 37oC was performed in independent duplicates for each 
reaction. The reactions were stopped in SDS sample buffer and analysed on Tris-tricine gel 
stained by Instant Blue solution (Expedeon, UK). Bands of processed pro-Nedd8 were 
detected and quantified using Carestream Molecular Imaging instrument connected to the Gel 
Logic 2200PRO software (Equilab, Whitestone, NY). 
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The WT CSN5 protein and its R106T variant in the presence of CSN6, and recombinant CSN, 
were diluted to 4 nM in reaction buffer (20 mM Tris-HCl pH7.5, 50 mM NaCl) and incubated 
at 37oC in the presence of 1 µM Cullin1-Nedd8/Rbx1. A time course (0 to 120 minutes) 
 B>
was recorded for each reaction in independent duplicates. One time point was performed for 
CSN5R106T (900 nM) for 2 hours incubation time. Samples were analysed as described for 
pro-Nedd8 processing. 

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To obtain quantitative information about the affinity of CSN5 to its substrate and to 
understand the function of CSN6 in activating CSN5, fluorescence anisotropy measurements 
were performed at 28oC, using a TECAN safire2 plate reader (Tecan).  
For these experiments, Nedd8 (commercially available from BostonBiochem®) was tagged 
with Alexa488. Nedd8 at 160 M was incubated with 50 g of Alexa-488 dissolved in 
DMSO at room temperature on a rotator for 3 hours. The reaction was quenched wit the 
addition of 2 mM Tris-HCl, pH7.5. Free dye from the sample was removed by loading the 
sample onto a 2 ml Zeba Spin Desalting column (Thermo Scientific). The labelling was 
checked by running a 12% Tris-glycine SDS-page gel and visualising by fluorescence and by 
measuring absorption to obtain the ratio of Alexa-488-Nedd8: free Alexa-488. A labelling 
efficiency of 34% was obtained.  
 
The fluorescence anisotropy experiments were performed in 20 mM Hepes pH 7.5 and 75 
mM NaCl. Alexa-488-Nedd8 was used as the labelled protein, and the fluorescence was 
measured using excitation and emission wavelengths of 470 nm and 530 nm, respectively. 
Varying concentrations (0-600 M) of CSN5 and CSN5 R106T were incubated in the wells 
containing a constant concentration of 4nM Alexa-488-Nedd8. The same procedure was 
followed in the presence of CSN6 where a 1:1 ratio of CSN5/CSN6 was used to make the 
complex concentrations indicated. For each data point the measurement was repeated in 
triplicates and the recorded data corresponds to the average anisotropy.  The data obtained 
were plotted and analysed using the IgorPro software. The Hill Equation (1): 
 
f(X) = rB+(rAB-rB)*Xn/(KD
n+Xn)                      (1) 
 
was used for fitting the data in order to be able to deduct an estimate of the apparent 
equilibrium dissociation constant (KD) of each complex and the apparent cooperativity (n) 
between the protein and its ligand. The equation represented here uses the minimum (rB) and 
the maximum (rAB) signals as normalisation factors representing the lower and upper 
asymptote of the titration. As there exists no evidence of cooperativity, the binding was 
considered as not highly cooperative, and in all cases, the data were fit with values of 
cooperativity equal to 1. 
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Isothermal titration calorimetry (ITC) experiments were carried out on a MicroCal ITC200 
microcalorimeter (GE Healthcare, Piscataway, NJ) at 20oC. The protein samples were all 
buffer exchanged using PD-10 desalting column (GE Healthcare) into the ITC buffer (20 mM 
Na MES pH6.5, 75 mM NaCl). Protein concentrations were measured using a NanoDrop 
1000 spectrophotometer (Thermo Scientific, Wilmington, DE), with the following extinction 
coefficients: 18,450 M-1cm-1 and 56,840 M-1cm-1 for CSN6 and CSN5, respectively. Titration 
of CSN5 (WT and variants; 100 µM) in the cell (200 µL) was performed by sequential 
addition of CSN6 (WT and variants; 1 mM; 1.8 µL injection volume). Integrated raw ITC 
data were fitted to a one site nonlinear least squares fit model using the MicroCal Origin 
plugin as implemented in Origin 9.1 (Origin Lab) after the control experiments (titration of 
the ligand from the syringe into the buffer) were substracted. 

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Purified CSN6 at 8 mg mL-1 was subjected to nanolitre crystallisation trials using commercial 
screening kits. Crystals grown at 18°C, in 0.2 M Tri-Sodium citrate, 0.1 M Bis-Tris propane 
pH6.5 and 20% PEG3350, were harvested, cryo-protected in the crystallisation solution 
supplemented with 10% glycerol and immediately flash-frozen in liquid nitrogen. A dataset 
was collected at a 1.76 Å resolution at the ESRF beamline ID29 and processed using 
MOSFLM and SCALA from CCP4 suite [192]. The structure was solved by molecular 
replacement using Phaser with Mov34 as the search model (PDB code 2O95). The initial 
model was built into the electron density map using ARP/wARP [193]. Further refinement 
procedure was carried out by alternate cycles of manual rebuilding and REFMAC program. 
Data collection and refinement statistics are compiled in Table 4-1.  
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Microseeding. After obtaining micro crystals from the crystallisation screens performed for 
the CSN5-CSN6 complex, the seeding technique was used to grow crystals. The rational 
behind this technique is that seed provides a template on which further molecules can 
assemble and given the proper environment the seed will enlarge into a crystal.  The 
microcrystals observed in the hit in the Pro-complex screen (composition: 0.1 M MgCl2, 0.1 
M HEPES pH7, 15% PEG 4000) were fished from the well and were added in a 10 µL of 
mother liquor. A bead (known as a Seed Bead) was added into the mixture which was further 
vortexed to ensure the crystal crushing. The resulting mixture containing nuclei was used as 
the protein sample to screen the Pro-complex kit, and further kits including JSCG+ and PEGs 
Suite. Limited amount of kits were screened due to the limited number of microcrystals 
initially obtained. 
   
In situ limited proteolysis for crystallisation. Dynamic proteins and flexible regions within 
proteins make the crystallisation of these highly difficult. The presence of flexible regions in 
CSN5 encouraged us to employ in situ limited proteolysis to remove such regions. Prior to 
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performing the experiment, limited proteolysis was carried out. Using the limited proteolysis 
kit (implemented by Dr. François Hoh) we tested 12 different proteases. This procedure 
involved the use of each protease in three different dilutions, D1, 100, and D1000. Protein at 2 
µg was added to each dilution and then incubated at 37oC for 60 minutes. The samples were 
further run on a 15% Tris tricine SDS-PAGE gel, and the fragments obtained after proteolysis 
were analysed.  This approach identified trypsin as an optimum protease to use for in situ 
limited proteolysis during crystallisation. The protein sample was incubated with the protease 
in all three dilutions and incubated at room temperature for prior to being used for screening.  
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The A chain from the CSN5 (fragment 1-257) crystal structure was used as the initial 
structure for MD simulations on the WT protein and the R106 (T, G and P) variants. For the 
simulations run on CSN5 dimer A-B the oligomeric arrangement of the PDB file was used 
(PDB code: 4F7O), whilst the A-A’ dimer was built in chimera [194] using crystallographic 
operators. The missing loop (residues 198–218) was built using the MODELLER program 
[195]. All the water molecules from the initial model were removed except the one bound to 
the catalytic zinc. Rather than using covalent bonds or harmonic restraints to maintain the 
zinc environment, we employed the cationic dummy atom approach [196], which imposes 
orientational constraints for the four zinc ligands (H138, H140, G151 and water) in the 
tetrahedral configuration. For the simulations run on AMSH-LP, the initial structure from the 
PDB code: 2ZNR was used and the dummy atom approach was also employed for the two Zn 
binding sites. The remaining protocol for running the MD simulations was maintained for all 
the simulations. The protonation state of the other ionisable side chains was set to their 
normal values at pH7. The resulting structure was surrounded by a periodic octahedral box of 
TIP3P water. For CSN5 monomer, this procedure resulted in a total of 4,029 protein atoms, 
including the zinc ion and the catalytic water molecule, solvated by 17,000–18,500 water 
molecules. All MD simulations were performed with the AMBER11 program [197] with the 
ff03 force field parameters [198] and the additional force field for the zinc atom environment 
[196]. Optimization and relaxation of solvent were initially performed by means of energy 
minimizations and MD simulations while keeping the solute atoms constrained to their initial 
positions with weak force constants. 
 
After equilibration was established by gradually increasing the temperature from 100 to 300 
K for 50 ps, the system was subjected to short (100-ps) MD simulations with decreasing 
constraints at a constant temperature of 300 K and a constant pressure of 1 bar. The 40-ns 
production run was conducted with constrained bond lengths involving hydrogen atoms and 
using the Shake algorithm [199], the Verlet integrator with a 2 fs time step for seven the 
calculation of forces and Langevin dynamics for temperature control. A cut-off radius of 9 Å 
was used to compute the non-bonded steric interactions. The electrostatic interactions were 
calculated with the particle-mesh Ewald method [200]. The missing counterions were 
substituted with a net-neutralizing plasma over the periodic box. The ptraj module in the 
AmberTools package [201] was used to extract data from trajectories and to analyze 
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structural and dynamic properties. All computations including the minimizations and the MD 
simulations were performed on a HP Z800 workstation equipped with two GPU Tesla C1060 
and quad-core Xeon 2.4 GHz processors. 
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Uniformly 15N-labeled CSN6 protein samples were dissolved in 50 mM Tris buffer, 150 mM 
NaCl (pH adjusted to 6.8) in 90% H2O/10% D2O. In all experiments, the 
1H carrier was 
centred on the water resonance and a WATERGATE sequence [202, 203] was incorporated to 
suppress solvent resonances. 
 
Assignment of CSN6 (carried out by Dr. Y. Yang and Dr. A. Padilla). Spectra were acquired 
with a 600 M CSN6 protein sample on a 700 MHz Avance Bruker spectrometer equipped 
with triple-resonance (1H, 15N, 13C) z-gradient cryo-probe at 298 K. NMR data were 
processed using GIFA (v 4.0) [204], and Topspin (v. 2.1). The 3D 1H-15N-NOESY-HSQC 
spectrum was analysed using strip-plots with manual reordering of the sequential stretches 
according to the main chain assignment strategy [205-207]. Side chain assignments were 
carried out using the 1H-15N-TOCSY-HSQC spectrum. The first two residues glycine and 
proline in the N-terminal tag were not assigned. For the remaining of the sequence, 
assignments were obtained for 15N, HN and Ha atoms (excluding proline residues, stretches 
G40-L42, L59-L60 and D71, H130 residues). The overall assignment completeness for 1H 
resonances was 79%. 
 
CSN6/CSN5 complex (carried out by Dr. Y. Yang and Dr. A. Padilla). An HSQC spectrum at 
308 K was acquired starting from a 15N-labeled CSN6 sample at 100 M. After addition of 
200 M unlabeled CSN5 to the 15N-labeled CSN6 sample another HSQC was recorded. 
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CSN5 and CSN6 models were treated as rigid bodies and all six rotational and translational 
parameters were fully explored in the ZDOCK program using 6° sampling on Euler angles. A 
list of 30 ‘passive’ solvent-accessible residues of CSN6 excluded from the interface with 
CSN5 was derived from the analysis of non-shifted CSN6 peaks in HSQC experiments in the 
presence of CSN5 and incorporated in the filtering option of the ZDOCK procedure. Among 
the 54,000 models generated, the top 2,000 complexes, ranked according to ZDOCK were 
further analyzed. The ZDOCK scoring function combines pairwise shape complementarity, 
desolvation and electrostatics. The starting structures for human CSN5 and CSN6 proteins 
were the crystal structures solved at 2.5 Å and 1.8 Å resolution, respectively. Two docking 
pairs of protein models were used for docking simulations: the CSN5 (chain A, PDB code: 
4F7O), with Ins-1 segment (residues 98-132) fitted to the corresponding ubiquitin-liganded 
AMSH-LP Ins-1 structure (PDB code: 2ZNV) using MODELLER9 program [208], combined 
with the 31-200 CSN6 fragment (deletion of the swapping C-terminal helix); and the same 
 BB
CSN5 model with the N- and C-terminal appending segments removed (residues 2-51 and 
232-257) combined with the fragment 31-200 of CSN6. In order to choose a near-native 
structure from these ZDOCK predicted sets, we filtered and re-ranked the 2000 hits using a 
dedicated procedure incorporating experimental constraints derived from biophysical and 
biochemical data. Additional information was also incorporated in this scoring procedure; 
primary sequence conservation data for both CSN5 and CSN6, total buried area in the dimer 
interface (calculated using the Naccess program 
(http://www.bioinf.manchester.ac.uk/naccess/), surface shape complementarity (obtained by 
SC program [192, 209]) and interface parameters derived from the PISA program [210]. 
CSN5, CSN6 and Nedd8 sequence conservation scores were evaluated using the PAT server 
[211]. Docking simulations were performed on two Intel Linux cluster platforms.  
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Sedimentation velocity experiments were performed using a Beckman XL-I analytical 
ultracentrifuge and an AN-50 TI rotor (Beckman Coulter). The experiments were carried out 
at 20 °C for CSN51-257 WT or L237QL240K variant at 333.0, 167.0, 67.0, 33.0, 17.0 and 3.3 
µM in 20 mM NaMES pH 6.5, 100 mM NaCl. A volume of 50 µL (for the four most 
concentrated samples), 100 µL or 400 µL (for the most diluted one) was loaded into 1.5, 3.0 
or 12 mm path cells and centrifuged at 130,000  g (42,000 rpm). Scans were recorded every 
22 min, overnight, by absorbance at 250 and/or 280 nm and by interference. The Sednterp 
software (freely available at http://www.jphilo.mailway.com/) was used to estimate the partial 
specific volume of the polypeptide chain, = 0.734 mL g-1, the solvent density, 
 = 1.009 g 
mL-1, and the solvent viscosity,  = 1.02 mPa.s, at 20 °C. Sedimentation profiles were 
analyzed by the size-distribution analysis of Sedfit. The isotherm of the mean sedimentation 
coefficients was fitted in term of a monomer-dimer equilibrium constant using the program 
Sedphat. Sedfit and Sedphat are freely available at 
http://www.analyticalultracentrifugation.com.  

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Cell culture medium were from Mediatech Inc (Mannassas, VA) and fetal bovine serum 
(FBS) were obtained from Gibco (Grand Island, NY). The antibodies used were His- tag (Cell 
Signaling Technology, Beverly, MA); Flag-tag and -actin (Sigma-Aldrich, St. Louis, MO). 
The Lipofectamine Plus and Oligofectamine reagents were from Invitrogen (Carlsbad, CA). 
Western Lightning Chemiluminescence Plus reagent was from Thermo Scientific Pierce 
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(Rockford, IL). As described in (29), 293T cells were maintained in DMEM supplemented 
with 10% foetal bovine serum and 100 µg mL-1 penicillin and streptomycin. Transfection 
was carried out using the Lipofectamine Plus reagent (Invitrogen). For the co-
immunoprecipitation experiments, cells in the log-phase of growth were collected, washed 
twice in cold phosphate-buffered saline (PBS), and lysed as described previously (30). Cell 
lysates were incubated in RIPA buffer for 4 hours at 4 °C with either anti-Flag or anti-His 
antibodies. Proteins were separated by 12% SDS-PAGE, transferred to nitrocellulose 
membranes, and probed with anti-His, and anti-Flag antibodies. -actin was used as the 
internal positive control for all immunoblots. Immunoreactive bands were detected using 
HRP-conjugated secondary antibodies with the Western Lightning Chemiluminescence Plus 
reagent. The protein levels were quantified using ImageJ software (National Institute of 
Health, Bethesda, MD, USA. http://rsb.info.nih.gov/ij). 
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U2OS cells and NEDP1 MEFs were grown in DMEM medium supplemented with 10% FCS 
(Foetal calf serum) and antibiotics. U2OS cells were plated in 6-well plates and transfected 
with either control or NEDP1 or CSN5 siRNAs (Pools of 4 individual siRNAs for each target 
from Dharmacon). 48 hours post-transfection, cells were harvested and lysed in NP-40 lysis 
buffer. NEDP1 MEFs were plated in 10cm dishes and were harvested when reached 80% 
confluency and lysed as above. Total protein was measured by Bradford assay and cell 
extracts were used either in Nedd8 processing experiments or for western blotting to monitor 
expression of NEDP1 and CSN5.

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To check the pro-Nedd8 proccessing activity in NEDP1 MEFs, in si-RNA cells and in control 
cells, initially all the cells were lysed. The thawed cells were resuspended in 200 ml of lysis 
buffer (50 mM Tris pH7.5, 150 mM NaCl, 1% NP-40 and 2 mM DTT) by pipetting. The cells 
were left to incubate on ice for 30 mins before centrifuging at 13,000 rpm for 15 minutes at 4 
oC. The supernatant was then transferred and used for the enzymatic assays performed on pro-
Nedd8 substrate.  For the pro-Nedd8 assays using cell lysate, the amount of cell lysate added 
was adjusted according to the Bradford assay performed to use equal amounts of protein for 
each reaction. The cell lysates were spiked by 1 µM of pro-Nedd8 and the assay was run as 
described in section 2.2.2.  
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Gaining insights into the activity mechanism and the associated regulation by which the CSN 
promotes the cleavage of Nedd8 from Cul1 is being pursued and recent developments brought 
crucial elements. As mentioned in Chapter 1, CSN, through its activity in the UPS, is a critical 
player in a diverse range of cellular and developmental processes. The most studied function 
of the CSN complex is the regulation of CRLs through its deneddylating activity on Cullins, 
the scaffolding component of CRLs. CSN catalytic activity involves the hydrolysis of an 
isopeptide bond between a Nedd8 molecule and a specific C-terminal lysine residue of the 
Cullin scaffolding protein (K720 for human Cul1). The deneddylation of Cullins is thought to 
be a critical element for maintaining the stability and the continuous activity of CRLs in vivo, 
enabling spatial and time controlled of poly-ubiquitination of a large proportion of the 
ubiquitome [212]. The catalytic activity displayed by the CSN enables it to be classified as an 
isopeptidase, where it hydrolyses an isopeptide bond specifically between Nedd8 and an 
exposed lysine residue at the C-terminal of Cullins.  
 
In cells, Ub and most Ubls (including Nedd8 and SUMO) are generally expressed as inactive 
precursor proteins, which require specific DUB proteases to expose their C-terminal glycine 
residue essential for forming an isopeptide linkage with the target protein lysine. In these 
cases, these DUBs (or assimilated (as some of these DUBs are not specific of Ub, but use 
Ubls as substrate)) express a peptidase activity. Additionally, the removal of Ub and Ubls 
from their target proteins is also performed by these proteases. As such, DUBs (or 
assimilated) play a central role in Ub/Ubl homeostasis by regulating and maintaining a 
sufficient pool of Ub/Ubls and also in processing them for efficient conjugation. Based on 
their sequence similarity, DUBs (or assimilated) can further be subdivided into five distinct 
subfamilies (defined in Chapter 1): USPs, UCHs, OTUs, MJDs, and JAMM/MPN+ (Fig. 3-1) 
[148]. The USP, UCH, OTU and MJD families correspond to cysteine-dependent proteases, 
whereas the JAMM/MPN+ family groups zinc-dependent metalloenzymes. The catalytic 
domains amongst different families of DUBs (or assimilated) reveal a large diversity in 
secondary structure showing distinct structural folds. Examples of canonical folds 
encountered in DUBs (or assimilated) include USP domains, Ubl domains and JAMM/MPN+ 
domains [148]. Outside of the conserved catalytic domains, these enzymes also show a large 
variation in the number and type of additional domains that they contain [213]. Crystal 
structures of representatives of each of these five DUBs (or assimilated) families have been 
solved, some even in complex with Ub or Ubl derivatives [149]. Some accessory domains 
around the catalytic region have been structurally characterised, but this remains discreet and 
little is known of the role of these accessory domains on the DUB (or assimilated) activity. In 
various cases, DUBs (or assimilated) form part of larger protein complexes. Diversity is also 
present in the variety of protein-protein interactions in which these DUBs are involved, as 
well as in the substrate specificity displayed by these enzymes [213]. They can also 
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hydrolyse different kinds of chemical linkage, although, sometimes, with differing 
efficiencies. Members of this family of enzymes can cleave ester, peptide and isopeptide 
bonds to Ub [214]. In the following few pages, starting from the Cys-DUBs, the different 
members of the DUB (and assimilated) family will be described and their means of regulation, 
when known, discussed. 
 
Cysteine-dependent DUBs rely on two or three essential amino-acid residues forming a 
catalytic dyad or triad, respectively, also common to classical cysteine proteases, such as 
papain. During catalysis that comprises two main steps, the thiol group of the catalytic 
cysteine is responsible for performing a nucleophilic attack on the isopeptide bond of the 
ubiquitinated Lys residue. This activity is facilitated by the presence of an adjacent histidine 
side chain, which lowers the pKa of the cysteine by deprotonation. In some cases, a third 
residue, usually aspartate or asparagine, aligns and polarises the catalytic histidine. Enzymes 
that lack a third residue display other means to polarise the catalytic histidine [148]. In this 
reaction mechanism, an acyl intermediate is formed by the covalent linkage between the 
cysteine and the carboxyl group that is generated upon cleavage. The reaction results in the 
release of the target protein and the formation of a covalent intermediate between the cysteine 
protease and the Ub moiety. The intermediate formed undergoes a hydrolysis, resulting in the 
deconjugation of the Ub from the enzyme and the regeneration of the enzyme [149].  
 
Figure 3-1 Schematic representation of the active site of cysteine-dependent proteases showing 
the mechanism of cleavage of an isopeptide bind.  
A. Schematic representation of the active site of cysteine-dependent proteases showing the 
mechanisms of cleavage of an isopeptide bond. The catalytic cysteine is aligned with a proton-
withdrawing group to facilitate nucleophilic attack on the substrate. B. Schematic view of the active 
site of metalloproteases. A water molecule is activated to serve as a nucleophile which is able to attack 
the carbonyl carbon of the isopeptide bond. 
 
Structural studies on the four cysteine-dependent DUBs subfamilies have revealed both 
striking similarities and differences [149]. As mentioned previously, they commonly share a 
papain-like catalytic triad comprising Cys-His-Asn/Asp [213]. 
 
The largest and most diverse DUBs have been classified in the USP sub-family. USPs, 
ranging from 38 kDa to 370 kDa in size, contain a catalytic domain of approximately 38 
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kDa. The catalytic core of USP enzymes is often decorated by various other domains, 
including protein interaction domains or domains that determine their subcellular localisation, 
where examples include USP19 and USP30 that are located in the endoplasmic reticulum and 
the outer membrane of mitochondria, respectively [215, 216]. Interestingly, various USP 
enzymes contain one or multiple Ubl domains, suggesting an auto-regulatory mechanism 
[217]. The various structures of USP family DUBs have indicated that the USP domain fold is 
highly conserved despite containing low sequence similarity. The USP domain generally 
comprises of three subdomains, commonly referred to as the Finger, Palm, and Thumb, 
although examples including CYLD (for Ubiquitin carboxyl-terminal hydrolase) (DUB 
implicated in the human benign tumour syndrome [218]) lack the finger sub-domain. The 
Palm and Thumb sub-domains harbour the catalytic centre, while the Finger sub-domain 
accounts for the interaction with the distal Ub [148, 219]. The molecular basis and the 
regulation of substrate recruitment in USP proteins have been addressed with structures bound 
to Ub. Comparison with apoenzymes of the USP family has indicated that the correct 
orientation of the catalytic residues is essential for their activity. This has been characterised 
for USP7, where Ub binding is required to induce conformation changes that are essential for 
the competent positioning the catalytic cysteine in the proximity of the catalytic histidine [220, 
221]. In contrast, USP14 and USP8 contain a catalytic triad that is already properly orientated 
in the absence their Ub substrate. However in the case of USP14, Ub binding results in the 
translocation of Ub-binding surface loops enabling the C-terminus of Ub to access the active 
site [222]. However, inactive forms of USP, due to catalytic ability or substrate accessibility, 
is not a global characteristic for this family of DUBs, as CYLD, for example, is both 
catalytically competent and structurally substrate permissive, even in the absence of its 
substrate [148, 223]. These findings depict that this sub-family of DUBs displays 
heterogeneity in its regulatory mechanism. 
 
The UCH sub-family of DUBs consists of four members: UCH-L1, UCH-L3, UCH-L5, and 
BAP1 (BRCA1-associated protein-1). All UCH enzymes expose a conserved catalytic domain 
(230 amino acid residues) and, similarly to the USP family, three conserved residues, Cys, 
His, and Asp. UCH37 and BAP1 contain unique C-terminal extensions of lengths 100 and 
500 residues, respectively. An additional BRCA1 interaction domain is present in BAP1 [224]. 
In contrary to USP enzymes, which are able to cleave large protein substrates, the UCH 
family preferentially shows activity on smaller leaving groups, for instance by-products of 
proteasomal or lysosomal degradation or short C-terminal extensions of polymeric Ub 
precursors [225, 226]. The most apparent structural feature of UCH enzymes is the presence 
of a large surface loop, which, upon Ub binding, folds over the active site. As such the C-
terminus of Ub needs to thread through this loop which causes significant steric constraint on 
the size of the ubiquitinated substrate that can be cleaved [227]. Indeed, in vitro studies have 
shown that the restricted accessibility of UCH enzymes results in negligible activity against 
poly-Ub chains of any linkage type [152, 225]. By contrast, UCH-L5 can act on larger 
substrates, such as poly-Ub chains despite containing an analogous large active site loop. 
UCH-L5 binds to the Rpn13 subunit of the 26S proteasome via its C-terminal extension and 
functions in recycling Ub chains from proteasome substrates. UCH-L5 does not cleave poly-
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Ub chains ‘en bloc’, but progressively shortens them [228]. This suggests that either the 
binding to the proteasome induces conformational rearrangement of the active site loop or 
that the proteasome significantly unfolds the Ub polymers allowing their entry through the 
obstructing loop. Taken together, the structural and biochemical data on these DUBs reiterate 
the subtle regulatory and specificity principles observed in DUBs.  
 
The size of the OTU domain sub-family members ranges from 25 to 135 kDa, where the 
OTU core domain comprises 150 to 200 residues, although the catalytic core of some 
members can extends to 360 residues [148, 229]. This family of enzymes is largely implicated 
in cell signalling processes. Similar to the USP family, OTU enzymes contain additional Ub 
interacting motifs, Ub-associated domains, and Ubl folds. Although the structure of the 
inactive OTU domain is considerably different to that of the USP domain, upon activation the 
catalytic residues of the OTU DUBs are well superimposed with that of the USPs [230]. 
Indeed, as commonly observed for DUBs, active site rearrangement is also a requirement for 
various OTU family members and characterised examples include OTUB1, which undergoes 
conformational changes upon Ub binding [231]. As shown for OTU members, the recurrently 
occurring catalytically resting state of cysteine-dependent DUBs was proposed to be a 
mechanism protecting the catalytic cysteine residue against oxidative stress. At an optimum 
catalytic state, the low pKa cysteine is prone for attack by a reactive oxygen species (ROS), 
reversibly inactivating the enzyme. This has been shown to be the case for many phosphatases, 
as well as redox proteins. Mechanistic and structural studies have indicated that ROS 
predominantly target cysteine residues located in the active site. Cysteine-dependent DUBs 
containing low pKa cysteine residues are thus speculated to be reversibly regulated by ROS 
[232]. This was shown to be most likely the case of members of the OTU sub-family, where 
examples include the Cezanne and A20 DUBs [233, 234].  
 
DUBs including Ataxin-3 and a number of Ataxin-3-like proteins, constitute the MJD sub-
family [149]. Although low sequence similarity is observed between the catalytic domains of 
Ataxin-3 and other DUBs, structural NMR studies have indicated a conserved overall 
arrangement of the catalytic triad [235]. A distinct structural feature of MJD enzymes is a 
large helical arm that, in the absence of Ub, restricts access to the active site [235, 236]. The 
structure of Ataxin-3 bound to two Ub molecules further indicated that the helical arm 
hindering the active site regulates substrate binding. Furthermore, the back of the helical arm 
locates the binding site for the second Ub molecule. It has been suggested that Ataxin-3 
interaction with a polymer of two distal Ub molecules is required for stabilising an open 
catalytic conformation [236]. 
 
The JAMM/MPN+ metalloprotease sub-family contain a Zn2+-bound polarised water 
molecule. Structurally, as well as mechanistically, this family differs to the cysteine-
dependent sub-families of enzymes. Metalloproteases contain a conserved, active-site 
comprising one aspartate, one serine and two histidine residues which together stabilise the 
metal through their coordination [169, 237]. The mechanism of these metalloisopeptidases is 
driven by the activation of the water molecule, through its binding to the zinc ion, to form a 
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hydroxide ion which in turn is able to attack the carbonyl carbon of the isopeptide linkage 
between Ub/Ubls and their target protein (which can be another Ub molecule). This reaction 
generates a transient non-covalent tetrahedral intermediate with the substrate. Proton transfer 
from a water molecule, resulting in the replacement of the amine with a hydroxyl group, is 
further responsible for c(%lapsing the intermediate and releasing from the DUB. In this 
catalytic mechanism, mainly based on the AMSH-LP/di-Lys63-Ub crystal structure, an 
adjacently located glutamate residue contributes as a proton acceptor and donor (Fig. 3-1)[149, 
186]. 
 
In human, eight DUBs (or assimilated) of the JAMM/MPN+ sub-family have been identified, 
including AMSH-LP, implicated in the ESCRT machinery and in membrane receptor 
trafficking. Structural studies on AMSH-LP alone and bound to a Lys63-linked di-Ub allowed 
the analytical investigation of the JAMM/MPN+ motif of metalloisopeptidases. The crystal 
structure of AMSH-LP (residues 264-436 (AMSH-LP numbering)) identified the JAMM 
motif and two insertions, referred to as Ins-1 (residues 314-339 (AMSH-LP numbering)) and 
Ins-2 (residues 393-415 (AMSH-LP numbering)) [186]. These structures further highlighted 
the AMSH-LP His347, His349 and Asp360 residues and a water molecule forming a 
hydrogen bond with Glu292, as the key players in Zn2+ coordination. A comparable 
coordination system had been identified in the structure of the prokaryote Archaeoglobus 
fulgidus (Af) JAMM [237]. Additionally, AMSH-LP binds two zinc ions; one of which is 
implicated in catalysis, as just described, and a second one bound to the large Ins-2 loop, 
shown to be responsible for recognising the proximal Ub of the K63 di-Ub. These 
observations have grouped both AfJAMM and AMSH-LP, as part of the subset of proteins 
containing a JAMM/MPN+ domain, which include a highly conserved EXnH(S/T)HPX7SX2D 
motif describing a distinct arrangement of two histidines and one aspartate preceded by a 
conserved glutamate [159]. Other JAMM/MPN+ family proteins include the BRCC36 [168], 
Rpn11 [159], MYSM1 [238], eIF3f [179], and CSN5 [70], enzymes reported to have activity 
on Ub and/or Ubls.  
 
Prior to structural studies, the role of the JAMM motif present in the Rpn11 subunit of the 
19S proteasome lid was probed by site-directed mutagenesis of the two conserved histidines 
[159], confirming their requirement for catalysis. A similar approach was also used to 
characterise the JAMM motif of CSN5, where mutations in its conserved JAMM residues 
abolished or severely comprised its catalytic activity. Dependence of the CSN deneddylase 
activity upon the presence of divalent cations was further confirmed by metal chelators [70]. 
Together these results emphasised that a functional JAMM motif of metalloisopeptidases is 
essential for their hydrolytic activity on substrate. In general, some JAMM/MPN+ also share 
the propensity to associate in large protein complexes, such as the 19S proteasome lid, the 
CSN complex, and the BRCC36-containing complexes (BRCA1-RAP80 and BRISC). 
Interestingly, most of these JAMM/MPN+ domain-containing enzymes have been shown to 
lack DUB (or assimilated) activity when not incorporated within their complexes [47, 70, 
168]. These observations raise the question about the regulation of DUB activities in general 
and a closer look into the potential mechanisms underlying their regulations is important. 
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Because of the importance of understanding the basis of CSN5 regulation, our group 
elucidated the structure of the catalytic N-terminal region of the human CSN5 subunit [63]. In 
addition to confirming that CSN5 is a metalloisopeptidase, the structure of this subunit 
displays, as often observed in various other DUBs (or assimilated), an auto-inhibited state. 
Low DUB activity is often observed in in vitro studies, suggesting the occurrence of imposed 
activation mechanisms in cells and possibly of activatory role of accessory domains or 
subunits in the case of multi-protein complexes. Additionally, in some instances, where 
hindrance of the substrate-binding site or where the catalytic site harbours an inactive 
conformation, conformational changes are necessary to occur in order to express the DUB 
activity. As this Chapter focuses on our work on the activity regulation of CSN5, three major 
regulatory mechanisms of DUBs reported in the literature are briefly presented below, 
illustrating strategies adopted by DUBs (or assimilated) to control their activity. 
(i) Post-translational modifications. A strong relationship has been described between 
the phosphorylation and the Ub signalling pathways. For example, upon phosphorylation, 
CYLD deubiquitination activity on TNF receptor-associated factor 2 (TRAF2) is inhibited, 
resulting in the suppression of the NF-kB signalling network [239]. Various studies have 
suggested the possibility that Ub or Ubl modifications could regulate the catalytic activity of 
various enzymes, both inside and outside the DUB family. For the ATXN3 and USP25 DUBs, 
ubiquitination activates ATXN3 catalytic activity, whilst SUMOylation of USP25 results in 
steric hindrance inhibiting its activity [240, 241]. Outside of the DUB family, there are many 
examples and one of them is the CRLs which show enhanced activity, through their 
modification by Nedd8 [242, 243].  
(ii) Subcellular localisation. At the cellular level, in a large amount of cases, there is 
an apparent coupling between subcellular localisation and enzyme activation, where the 
subcellular localisation can determine the substrates available for processing. This has been 
evident for AMSH, which shows both nuclear and cytosolic localisation, however exhibits 
activity solely after being recruited by its activator STAM into endosomes present in the 
cytosol [244]. Various other DUBs including USP8, undergo epidermal growth factor (EGF)-
dependent translocation into endosomes, where its activation triggered upon associates with 
STAM [245, 246]. From the DUB family, only two, USP19 and USP30, encompass a 
transmembrane domain, whilst several show nuclear accumulation including USP36, which 
localises to the nucleolus and plays a role in regulating its structure and function [216, 247].  
(iii) Auto-inhibition. In various cases, the activity and specificity of DUB activity is 
regulated via the presence of additional Ub-binding domains or motifs. Additionally, 
activation of many DUBs can be induced by their association with other partners, potentially 
increasing substrate binding. This is the case for AMSH and USP8, which are activated via 
their interaction with the UIM (for Ub interacting motif)-containing signal transducing 
adaptor molecule 2 (STAM2) making these enzymes more efficient in capturing their 
substrates [244]. This principle is largely used in the regulation of many other examples of 
DUBs, resulting in, either their activation or inhibition. For UCH37, its activity is reduced 
when associated with the INO80 chromatin-remodelling complex [248]. The cysteine 
isopeptidase USP5 contains a ZnF-UBP domain which is able to interact with a free Ub. This 
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results in conformational changes leading to an increase in the catalytic rate of Ub chain 
processing by USP5 [249]. For various metalloisopeptidases, the incorporation into large 
multi-protein complexes is required for their activation. This has been demonstrated in the 
case of Rpn11, CSN5, and BRCC36, which are part of the 26S proteasome, the CSN, and the 
BRCC36-containing complexes, respectively [70, 159, 160, 168]. In these examples, 
incorporation into large complexes has been suggested to serve as scaffolds, presenting DUBs 
(or assimilated) to their physiological substrates or, perhaps to play a role in regulating 
catalytic activity, potentially through conformational adjustments producing a catalytically 
competent enzyme. However, this is not the case for AMSH and AMSH-LP which do not 
require to associate within a complex to expose activity in vitro. However, in the case of 
AMSH, its interaction with STAM through its N-terminal domain contributes to its activity by 
holding Ubs simultaneously with AMSH [250].   
 
Despite the insight obtained regarding the catalytic activity of the CSN through mutagenesis, 
the molecular basis for its activation and activity has just started to be revealed. The most 
studied and known activity of the CSN complex is its deneddylase activity on neddylated 
Cullins and, more particularly, on Cul1. Our main focus has been to characterise the 
regulatory mechanisms implicated in the activity of the CSN complex. To address this, we 
took an approach that encompasses a detailed investigation of the catalytic activity of this 
complex, mostly from the perspective of the catalytic subunit CSN5. As with other 
JAMM/MPN+ containing multi-protein complexes, the CSN catalytic activity rests on its 
metalloprotease subunit CSN5. 
 
In mammals, CSN5, originally identified as an interactor and a co-activator of the AP-1 
transcription factor, has additional interactions with factors regulating signal transduction, 
proliferation and survival of cells, suggesting that CSN5 may be implicated in functions 
reaching further than the regulation of the CRLs [129, 251]. Notably, CSN5 has been 
repeatedly found to interact with and to control the nuclear export of the CDK inhibitor p27 
[86], the Rad9-Rad1-Hus1 complex [252], Runx3 [91], Smad7 [90], and the tumour 
suppressor p53 [253]. CSN5 contributes to the CRM1 (for Chromosome region maintenance 
1 protein homolog; also known as Exportin-1 or XPO1)-dependent translocation of some of 
these binding partners from the nucleus to the cytoplasm and to their subsequent increased 
proteasome-dependent-degradation. The detailed understanding of the exact role(s) of CSN5 
in these processes remains however to be investigated. Moreover, CSN5 that could act as a 
multi-functional protein appears to exist in various contexts, including, CSN5 in a stand-alone 
form (for more on that topic, please refer to Chapter 3 section 3.5), in smaller CSN sub-
complexes, and within the CSN complex. CSN5 was originally found to exist independently 
of the holo-Cop9 complex in At [254] and was later characterised in smaller CSN 
subcomplexes in mammalian cells [126]. Although the deneddylase function of CSN complex 
has been ascribed to its CSN5 subunit, the molecular composition, activity or function of 
these CSN sub-complexes and of CSN5 stand-alone form, have not been reported. 
Importantly and as detailed in Chapter 1, substantial evidence has accumulated that 
demonstrate a strong link between CSN5 and cancer. This has become evident with the high 
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expression levels of CSN5 found in many human cancers which, in some cases, correlates to 
poor prognosis and to reduced expression levels of p27 [82, 251]. The implication of CSN5 as 
an important player in such diverse cellular processes, including phosphorylation, 
deneddylation, and translocation, and the fact that it is found outside of the CSN complex 
could potentially explain why its activity is kept under tight regulation.  
 
For these reasons, obtaining a better understanding of the catalytic and regulatory mechanism 
of CSN5, within and outside the context of the CSN complex is essential. The elucidation of 
the CSN5 crystal structure by the group allowed, upon my arrival, to structurally and 
functionally investigate the catalytic subunit of the CSN complex. CSN5 has been reported in 
two catalytic forms, one incorporated within the CSN complex, catalytically active and the 
other found in a CSN-independent state, inactive. As previously described the activity 
regulation of DUBs (or assimilated) is essential for many members, where a recurrent 
principle is their auto-inhibition. To begin understanding how CSN5 expresses its 
isopeptidase activity, thorough structural comparison with relevant model systems, but mostly 
with AMSH-LP was performed. Structural analysis was complemented with biochemical, 
biophysical, and in silico characterisation. A constitutively catalytically active variant of 
CSN5 was designed and validated, unravelling a potential auto-inhibitory mechanistic 
requirement for the activity of CSN5 at the molecular level. Insights gained on the regulation 
of CSN5 in the stand-alone state could provide some clues as to how CSN5 harbours a 
catalytically competent conformation within the CSN complex.  
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The csn5 gene is located on the chromosome 8q13 and is highly conserved in Hs, Mm, Dm, 
Sp, and At. Orthologous proteins of CSN5 from Hs and At share more than 60% sequence 
identity. The main human CSN5 protein isoform consists of 334 amino acid residues (38 kDa). 
Two structural motifs are present in CSN5, a nuclear export signal (NES)-like sequence [255, 
256], and the catalytic JAMM motif. The NES-like sequence mediates the CRM1-dependent 
transportation of proteins from the nucleus to the cytosol, which has been demonstrated 
through CSN5 interaction with p27, while the MPN domain represents the catalytic domain of 
CSN5. Over the years, CSN5 has been implicated in numerous signalling pathways including 
those that regulate light signalling in plants, larval development in Dm, and integrin signalling, 
cell cycle control, and steroid hormone signalling in a variety of systems, although this 
implication might be due to its pleiotropic function of CRL regulator. Various studies have 
suggested that CSN5 is essential for development and survival of animal models and it was 
shown that csn5 gene K.O. in mice is embryonically lethal [110]. 
 
Within the CSN complex, a second subunit, namely CSN6, harbours a MPN domain, as it is 
the case for other MPN domain-containing large multi-protein complexes, such as the Rpn8 
subunit of the proteasome 19S regulatory lid and the eIF3h subunit of the translation initiation 
factor eIF3. This general organisation is illustrated in Fig. 1-5. Each of these multiprotein 
 CB
complexes displays two MPN domain-containing proteins, one belonging to the MPN+ 
subfamily and containing a JAMM motif (members include; CSN5, Rpn11, eIF3f) and the 
other from the MPN- subfamily and which lack the catalytic JAMM motif (members include; 
CSN6, Rpn8, eIF3h). It is noteworthy that other JAMM/MPN+ domain-containing proteins 
exist without an associated MPN- counterpart - this is the case of AMSH and AMSH-LP, 
which neither associate with MPN- domain-containing proteins, nor form multi-protein 
complexes with PCI domain-containing proteins. Similarly, an MPN- domain-containing 
protein, Prp8 lacks association with proteins of the JAMM/MPN+ family and exist within the 
U5 small nuclear ribonucleoprotein particle, which itself forms part of the spliceosome 
network [257].  
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In this part, the structure of CSN5 will be presented and key features are discussed in the light 
of the structure and biochemistry of other MPN family members. In the first section, the 
CSN5 structure containing the residues 1-257 will be considered, whilst, in the second one, 
the C-terminal region of CSN5 will be described through recent structural data [61]. We 
further aim to gain an in-depth understanding of the dynamics of the CSN5 MPN domain and 
identified key players in the regulation of CSN5 activity.  
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The crystal structure of the human CSN5 isopeptidase domain (residues 1-257) comprises a 
core JAMM/MPN+ motif and two insertions first defined in AMSH-LP [186], Ins-1 (residues 
97-131 (CSN5 numbering)), located in the vicinity of the active site and Ins-2 (residues 197-
219 (CSN5 numbering)), disordered in the crystal structure (Fig. 3-2 A). The heterogeneity of 
the sample, as well as its low expression levels guided us to work on the fragment 1-257 
which corresponds to the MPN core, flanked by an additional 50 residues extending from its 
N-terminus and 26 residues from its C-terminus. The structure of the 1-257 fragment of 
human CSN5 obtained thus lacks 77 amino acid residues at the C-terminal end. The catalytic 
core of CSN5 comprising the residues 51 to 230, includes an eight-stranded -sheet, 
numbered 1 to 8, further completed by three -helices (Fig. 3-2 B). The topology of the 
JAMM motif has previously been defined by structural studies of other MPN+ domain-
containing structures, including AMSH-LP. The conserved JAMM motif of CSN5 
tetrahedrally coordinates a Zn2+ via its active site residues, H138, H140 (located on the -
sheet 5 and on the loop immediately following it, respectively), D151 (located on the -helix 
5), and a water molecule which hydrogen bonds to residues E76 (located on the loop 
following the -helix 3) and S148 (on the loop between the -sheet 4 and the -helix 5). 
This results in a zinc coordination site bringing together residues from the helix 5, the 
central -sheets, 5, 6, and 7 and additional loops including those located between the -
sheet 4 and the -helix 5, and the Ins-1 segment (Fig. 3-2 A). The elucidated crystal 
structure contains additional N- and C-terminal appendices, which pack tightly against its 
core catalytic domain, profoundly modifying the properties of its surface (Fig. 3-2 A).  
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 Figure 3-2. Structure of CSN5 MPN 
domain. 
A. Overall monomeric crystal structure of 
CSN5 1-257
 
(PDB code: 4F7O)
 
revealing 
its core MPN domain (in blue) decorated 
with peripheral N- and C- terminal 
extensions (in yellow). Secondary 
structure elements are numbered and the 
catalytic residues forming the JAMM 
motif are displayed in ball-and-stick 
representation. The flexible Ins-1 
segment, shown in green, comprises 
residues 97-131 and the disordered Ins-2 
region comprises residues 197-219. Right 
panel: 180° rotated view of left Panel. B. 
Schematic representation of the CSN5 
domain organisation. The MPN domain is 
delineated in violet; the N- and C-
terminal extensions are yellow. The Ins-1 
and Ins-2 insertions are placed with 
respect to their location in the sequence. 
The secondary structure elements are 
indicated underneath. Regions that are 
either not ordered in the crystal structure 
or not included in the crystallised 
fragment are indicated by a black dotted 
line. C. Sequence alignment of CSN5 
sequences from 8 diverse organisms. The 
sequence alignment was carried out by 
retrieving CSN5 sequences with Blastp 
using human CSN5 as the search 
sequence and 8 diverse sequences from 
various organisms were selected. The 
alignment of these sequences was 
performed by Clustal Omega server 
(default parameters). The Uniprot website 
(www.uniprot.org) was used to carry out 
this alignment. Hs: (Uniprot entry: 
Q7L5N1); Mm (Uniprot entry: Q3UIT2); 
Xl: Xenopus laevis (Uniprot entry: 
Q6NUC2); Dm (Uniprot entry: 
Q9VCY3); Sm: Schistosoma mansoni 
(Uniprot entry: G4V7G0); Os: Oryza 
sativa (Uniprot entry: Q6ZKM2); Bm: 
Bombyx mori (Uniprot entry: Q2F614). 
The strictly conserved residues amongst 
the eight selected sequences are indicated 
in red. Highlighted in blue are the 
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HsCSN5      ----MAASGSGMAQKTWELANNMQEAQS-IDEIYKYDKKQQQEILAAKPWTKDHHYFKYC 55
MmCSN5      ----MAASGSGMAQKTWELANNMQEAQS-IDEIYKYDKKQQQEILAAKPWTKDHHYFKYC 55
XlCSN5      ------MAGSSVAQKTWELSNNMQEVQS-IDEIYKYDKKQQQEILAAKPWTKDHHYFKYC 53
DmCSN5      -------MDSDAAQKTWELENNIQTLPS-CDEIFRYDAEQQRQIIDAKPWEKDPHFFKDI 52
DdCSN5      ----MSKNGAADALKTFELENNIQTID--HDQLFKYDPQQYQQFLQSKPWSKDPHYFKHV 54
EnCSN5      ---------MQAAQLSWELENAVTLIDPQRDSLYRYDEETHKYLSDTRPWTKDPHYFKSV 51
CeCSN5      MEVDNVKPSSSVPQRNWEKENNVQNVDS----IFEYNNKQQVEIRNAKPWDKDPHYFKQI 56
SpCSN5      --------------MNNQLEN-----------VFRFDEEKERAKIRESPWKHDPEFFRSV 35
                                          
HsCSN5      KISALALLKMVMHARSGGNLEVMGLMLGKVDGETMIIMDSFALPVEGTETRVNAQAAAYE 115
MmCSN5      KISALALLKMVMHARSGGNLEVMGLMLGKVDGETMIIMDSFALPVEGTETRVNAQAAAYE 115
XlCSN5      KVSALALLKMVMHARSGGNLEVMGLMLGKVDGETMIIMDSFALPVEGTETRVNAQAAAYE 113
DmCSN5      KISALALLKMVMHARSGGTLEVMGLMLGKVEDNTMIVMDAFALPVEGTETRVNAQAQAYE 112
DdCSN5      KISAIALLKMVMHARSGGKLEVMGMLMGKVENNTMIIMDSFALPVEGTETRVNAQVEAYE 114
EnCSN5      RISAVALLKMVMHARSGGSLEVMGLMQGYILPNTFVVTDAFRLPVEGTETRVNAQDEANE 111
CeCSN5      KISAIALLKMTMHAKRGGNLEIMGLLQGRIDANSFIILDVFALPVEGTETRVNAQAQAYE 116
SpCSN5      KISAVALLKMLRHVSQGMPLEVMGYVQGKVEGASLIILDSFALPVEGTETRVNAHEEAQE 95
                          
HsCSN5      YMAAYIENAKQVGRLENAIGWYHSHPGYGCWLSGIDVSTQMLNQQFQEPFVAVVIDPTRT 175
MmCSN5      YMAAYIENAKQVGRLENAIGWYHSHPGYGCWLSGIDVSTQMLNQQFQEPFVAVVIDPTRT 175
XlCSN5      YMAAYIENAKQVGRLENAIGWYHSHPGYGCWLSGIDVSTQMLNQQFQEPFVAVVIDPTRT 173
DmCSN5      YMTAYMEAAKEVGRMEHAVGWYHSHPGYGCWLSGIDVSTQMLNQTYQEPFVAIVVDPVRT 172
DdCSN5      YMVEYLELIKQTGRLENALGWYHSHPGYGCWLSGIDVGTQSVNQQYSEPWLGIVIDPTRT 174
EnCSN5      YMVSYLQSCREAGRMENAVGWYHSHPGYGCWLSGIDVSTQDM-QQMSGPFVAVVIDPERT 170
CeCSN5      YMTVYSEMCDTEGRKEKVVGWYHSHPGYGCWLSGIDVSTQTLNQKFQEPWVAIVIDPLRT 176
SpCSN5      YSVQYHTLCKSVYRHENVIGWYHSHPNYGCWLSGVDVETQRQNQKYQDPFVAVVLDPKRS 155
                         
HsCSN5      ISAGKVNLGAFRTYPKG----YKPPDEGP--SEYQTIPLNKIEDFGVHCKQYYALEVSYF 229
MmCSN5      ISAGKVNLGAFRTYPKG----YKPPDEGP--SEYQTIPLNKIEDFGVHCKQYYALEVSYF 229
XlCSN5      ISAGKVNLGAFRTYPKG----YKPPDEGP--SEYQTIPLNKIEDFGVHCKQYYALEVTYF 227
DmCSN5      VSAGKVCLGAFRTYPKG----YKPPNEEP--SEYQTIPLNKIEDFGVHCKQYYPLEISYF 226
DdCSN5      VSAGKVEIGAFRTYPQG----YKPPNEGP--SEYQSIPLSKIEDFGVHCKQYYSLEITYF 228
EnCSN5      ISAGKVDIGAFRTFPKD----YTPPKEEQEEDEYQTVPLNKAEDFGAHASHYYSLEVSLF 226
CeCSN5      MSAGKVDIGAFRTYPEG----YRPPDDVP--SEYQSIPLAKIEDFGVHCKRYYSLDVSFF 230
SpCSN5      LESPYVNIGAFRTYPVGNDGSIRTKSRHHPSVLFKNLPSSKIEDAGAHAEAYYSLPITYF 215
                          
HsCSN5      KSSLDRKLLELLWNKYWVNTLSSSSLLTNADYTTGQVFDLSEKLEQSEAQLGRGSFMLGL 289
MmCSN5      KSSLDRKLLELLWNKYWVNTLSSSSLLTNADYTTGQVFDLSEKLEQSEAQLGRGSFMLGL 289
XlCSN5      KSSLDRKLLELLWNKYWVNTLSSSSLLTNAEYTTGQVFDLSEKLEQSEAQLGRGSFMLGL 287
DmCSN5      KSALDRRLLDSLWNKYWVNTLGSSGLLTNTEYTTGQIMDLSEKLEQSENFLGRG-----T 281
DdCSN5      KSSLDQQLLDKLWNKYWVNTLSSSPIFSNRDYITGQINDLSEKLEQAETQLSHSR---SS 285
EnCSN5      KSALDTEILSLLWNKYWVATLSQSPLFTTRDYGSKQMLDLSQKTRRVARGIESNPPRGGA 286
CeCSN5      KSQLDAHILTSLWNSYWISTLSSSPLFSNVEFLNNQIQDINQKLSAVDKKLQLND----- 285
SpCSN5      HSKAEKKVTEFLRNRNWSRSITECSILQNNEFLHD-----SEKLIDHLIHETGNN----- 265
                        
HsCSN5      ETHDRKSEDKLAKATRDSCKTTIEAIHGLMSQVIKDKLFN-----QINIS---------- 334
MmCSN5      ETHDRKSEDKLAKATRDSCKTTIEAIHGLMSQVIKDKLFN-----QINVA---------- 334
XlCSN5      ESHDRKSEDKLAKATRDSCKTTIEAIHGLMSQVIKDKLFN-----QINTF---------- 332
DmCSN5      DVNEKRSEDKLSKATRDCSRSTIELIHGLMAQIVKDKLFN-----KVGLGK--------- 327
DdCSN5      ILDKKKEESLLSKVSKDSSKVTIEQVQGIMSQVFKNSIFN-----ECQTTKQ-------- 332
EnCSN5      PTQVR--DQQLERVVKDGQRIVSEEVKGLLAAEVKMQLFQ-----GIGGKQTVEST---- 335
CeCSN5      --RSVDGHEALMKVVTDAKAVGDELETGRISHLVKQLLFARQAGGGCGCSHASAGSPMDI 343
SpCSN5      -------ELPVASAYEQSKACCNELSTFLSQIDVQDKLFKE------------------- 299
              
HsCSN5      -------------------------
MmCSN5      -------------------------
XlCSN5      -------------------------
DmCSN5      -------------------------
DdCSN5      -------------------------
EnCSN5      -------------------------
CeCSN5      AVATEPEKAGPSPSAPEPAVEMADA 368
SpCSN5      -------------------------
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As previously observed for the structure of AMSH-LP, the two additional features comprising 
the Ins-1 and Ins-2 segments also decorate the CSN5 MPN core. Sequence conservation 
across CSN5 orthologs indicates that the Ins-1 region is highly conserved, whilst the Ins-2 
one contains a small number of conserved residues (Fig. 3-2 C). In contrary to the Ins-1 
segment of AMSH-LP, which consists of a long helical portion and a pair of anti-parallel -
strands, CSN5 Ins-1 is mainly helical (4 and 5) [186]. Such insertions are also present in 
other members containing a MPN- domain, but the Ins-2 segment in MPN- members is 
generally much reduced in length, compared to its counterpart in MPN+ proteins. These 
include CSN6, Rpn8 and Prp8, where the Ins-1 insertion of the first two, similarly to AMSH-
LP, adopts a long helical segment and an anti-parallel -hairpin, whilst in the latter reveals an 
extended conformation. The large variety of conformations adopted by the Ins-1 portions 
among CSN5 paralogs, supported by a large variation in their sequence could be functionally 
important. In AMSH-LP and AMSH, the Ins-1 segment is involved in its interaction with 
distal Ub [188]  
 
The CSN5 Ins-1 segment is completely folded back over its active site (Fig. 3-2 A). As 
suggested by the comparison between CSN5 and AMSH-LP structures, the orientation of the 
Ins-1 region could hinder the access for the C-terminus of the substrate, thereby contributing 
to the auto-inhibitory state of CSN5 in the isolated state (Fig. 3-3). This would be consistent 
with the observation that CSN5 in the stand-alone form is void of catalytic activity. In our 
work, AMSH-LP has been used as a model system allowing the study of CSN5. The reason 
for this is two-fold; the structures of both the apo- and substrate bound forms of human 
AMSH-LP are available and, additionally, at the start of the work, it was the only MPN+ 
structure available that was supplemented with robust biochemical characterisation. Most 
recently, two studies on the structure of the Sc proteasome lid enzymatic subunit Rpn11 in 
complex with Rpn8 allowed further comparison and understanding [158] [160]. However, the 
Rpn11 structure in the context of a heterodimer with the Rpn8 subunit is somewhat different 
to that of stand-alone CSN5 and we preferred discussing these recent structural contributions 
in Chapter 4. 
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In the structure of CSN5, electron density is lacking for the region corresponding to its Ins-2 
segment, indicating a highly flexible segment. A disordered Ins-2 segment is also observed in 
the structure of Rpn11 within the Rpn11-Rpn8 dimer [48, 158, 160]. In this work, the role of 
the Ins-2 region was proposed to be linked to the contact with another subunit of the 19S 
regulatory particle of the proteasome, namely, Rpn2 [160]. A large variation in the size of the 
Ins-2 region amongst the various MPN family members is observed. CSN5 contains the 
largest Ins-2, made of 30 residues, whilst a 2-amino acid Ins-2 element is present in MPND 
[67]. Low levels of sequence conservation among MPN paralogs have been observed for the 
Ins-2 segment. In addition to differences in length, Ins-2 segments also show variation in 
composition and conformation, making it an interesting component of the MPN core to study. 
Furthermore, although well described for AMSH-LP, the role of Ins-2 in other members of 
the family remains largely uninvestigated. 
 
Amongst the structures of MPN domain-containing proteins elucidated to date, a number of 
them have shown the propensity to form oligomeric arrangements. These include the 
structures of Af JAMM, Hs Rpn8 from the 19S proteasome lid, Hs CSN5, Dm and Hs CSN6 
from the CSN complex. Despite their inclination to dimerise, these proteins assemble mostly 
via different surfaces [67]. In the analysis of all possible contacts within the human CSN5 
crystal structure, two different types of dimerisation interfaces can be observed, organised in 
dimer of dimers. One of these dimers related by a local twofold symmetry axis is contained 
within the asymmetric unit (A-B dimer), whereas the other is generated by crystallographic 
operators (A-A’ dimer). Structural analysis using the PISA Server [210] determined a 
solvation free energy for interface formation (Gint) at -14.0 kcal mo1-1 for the A-B type 
dimer and at -10.9 kcal mo1-1 for the type A-A’ dimer. The small difference in Gint 
determined (less than 10 kcal mo1-1) between the two CSN5 dimers challenges the 
discrimination of the crystallographic artefact and serves impossible, thus further criteria had 
to be considered (See Section 4-5).  
 
A 
C D 
B 
Figure 3-3. Comparison of AMSH-LP and CSN5 
Ins-1 region. 
A. The Ins-1 insertion of CSN5 (in green) hinders the 
access of Nedd8 C-terminus into the active site. A 
model of CSN5-Nedd8 (in grey) interaction by using 
the AMSH-LP/Ub (PDB code: 2ZNR) crystal 
structure to superimpose. B. The crystal structure of 
AMSH-LP/Ub (PBD code: 2ZNR) showing the 
binding mode of Ub (in grey) to AMSH-LP. The Ins-2 
segment is shown in magenta. 
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Up to very recently, the studies performed on the MPN members were, in general, limited to 
the core MPN domains of these proteins, sometimes a little extended or reduced [63, 64, 176]. 
A recurrent reason for this is the problems encountered in the recombinant expression of full-
length (FL) proteins, where, in most cases, their C-terminus is truncated prior to 
crystallisation. Evidence obtained from the lack of ordered density and from the observed 
truncations during expression and purification suggests an exposed highly flexible region 
allocated to the C-terminus of these proteins. Briefly, electron microscopy structures of the 
CSN complex [46] and of the 19S proteasome lid [175, 258] proposed that their MPN+ and 
MPN- subunits interact via their MPN domains, supported by earlier biochemical evidences 
[168, 259]. More recent work showed that their C-terminal regions are mainly involved in 
governing interaction with the other subunits within their complexes [259]. This hypothesis 
was further confirmed by biochemical characterisation. Furthermore, Förster and coworkers 
[258] were able to position the crystal structure of Rpn8 and a molecular model of Rpn11 into 
their corresponding location in an electron microscopy map. This allowed to resolve a 
hitherto unassigned density consisting of long twisted helices forming a coiled-coil bundle, 
which extrudes away from the MPN domain of the two proteins and form contacts with other 
PCI subunits [258]. Moreover the role of the C-terminus of MPN domain-containing proteins 
within the proteasome lid was also investigated, where findings demonstrated that the C-
terminus of both Rpn11 and Rpn8 are sufficient and essential for the assembly of the complex, 
forming a helical bundle together with the C-terminus of PCI subunits. It was also suggested 
that this role of the C-terminus of MPN domain containing proteins, described for the 
proteasome lid, may be a common feature used by the other Zomes complexes, the CSN and 
eIF3 complexes [59].   
Figure 3-4. N- and C-terminal extensions of CSN5. 
A. The N- and C-terminal extensions (in yellow) that flank the MPN core adopt a constrained 
topology that is stabilised by the presence of a hydrophobic core contributed by the helices 1, 3 and 
6. Specific residues involved in this core are shown in ball-and-stick mode. Elements from the MPN 
core are shown in blue. B. C-terminal extensions (in yellow) for the MPN CSN5. The MPN core is 
represented in blue, with the Ins-1 segment in green. C. C-terminal extensions (in yellow) for the FL 
CSN5 subunit in the context of the CSN crystal structure. The MPN core is represented in blue, with 
the Ins-1 segment in green. 
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In our work, FL CSN5 can be obtained, however various degradation products are also 
present in the sample. In general most MPN protein structures solved till very recently lacked 
the C-terminal extension, with the exception of Prp8 which contains a similar length of 
extension to that of CSN5, however adopts a very different position and conformation to that 
observed in CSN5. In the structure of CSN5 that we elucidated, the C-terminal helix (6, 
fragment 232 to 257) together with the N-terminal helix 1 wrap around and form extensive 
contacts with the MPN core (Fig. 3-2 A; B; Fig. 3-4 A,B). For context, the structure of CSN5 
containing the residues 24 to 333 part of the crystal structure of the CSN complex recently 
determined is presented in Fig. 3-4 C. This highlighted the helical content of the C-terminal 
portion of the protein. 
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In this section, we aim to present the MPN family from a structural point of view. The recent 
years have seen a wealth of MPN-domain structures being solved and provides a solid ground 
to better understand the architecture of this family and to identify structural elements 
potentially involved in the regulation of their functions. 
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To date, in eukaryotes, the number of proteins containing an MPN domain extends to fourteen, 
namely, Abraxas, Abro1, AMSH, AMSH-LP, BRCC36, CSN5, CSN6, eIF3f, eIF3h, Rpn8, 
MPND, MYSM1, Rpn11, Prp8, from which seven of them are JAMM/MPN+ motif 
containing DUBs [149]. Additionally, a number of prokaryotic MPN domain containing 
proteins have also been identified, these include; the phage tail assembly protein K coming 
from bacteriophage lambda, and its homologs found in other phages and prophages [169].  
 
Analysis of the MPN domain-containing structures elucidated to date allow to define the 
MPN fold as one consisting of up to eight-stranded -sheet which is further decorated by up 
to three -helices. Typically, the core -sheets are arranged to adopt a partially outspread 
barrel shape, protected by helices. The MPN core was initially defined by structural works on 
the prokaryote AfJAMM, and has later been confirmed through the structures of Rpn8, 
AMSH, AMSH-LP, Prp8, CSN6, CSN5 and Rpn11. Although considerable elaboration on the 
AfJAMM topology is observed in eukaryote member, comparison between these eukaryote 
structures shows little variation in the secondary structure content between their MPN core 
domains. In some members, such as Rpn8 and Prp8, the 7 and 8 strands are fused together, 
resulting in MPN domain containing structures which consist of seven -strands.  
 
In our work, structural comparison of the MPN domain present in the JAMM/MPN+ family 
of proteins, AMSH-LP, AMSH, Rpn11 and CSN5, was used to understand this family of 
 D>
proteins (Fig. 3-5 A-C). The structures of CSN5 and other MPN domain-containing proteins 
share a core, as highlighted in Table 3-1 that present the root mean square deviation (rmsd) 
values of pairwise structural superimposition carried out with Chimera.  
 
 
/+-. Rmsd values across the MPN sub-family against CSN5 (PDB code: 4F7O). 
Calculated in Chimera. In the four columns, CSN5 MPN core and the N-/C-terminal extensions are 
shown in beige and grey, respectively. Prp8 MPN appendices are also displayed in grey.
CSN5/ Rmsd value (Å) Number of C Superimposition 
AMSH-LP 3.7 135 
 
Dm CSN6 2.2 64 
 
Hs Rpn8 3.7 160 
 
Prp8 2.9 137 
 
Af JAMM 2.3 108 
 
 
The major differences present in the structures of these proteins locate on their Ins-1 and Ins-2 
segments. These elements show diversity in both length and composition.  
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To date from the seven JAMM/MPN+ DUBs known, only AMSH-LP, AMSH, and more 
recently CSN5 and Rpn11 (in complex with Rpn8) have solved crystal structures of their 
MPN domains. Here we built molecular models, using Phyre2 [260] of the unknown 
structures including that of BRCC36 and eIF3f and carried out structural analysis to compare 
JAMM/MPN+ proteins of known and unknown structures (Fig. 3-5. D,E). Although most of 
the MPN domain can be highly superimpose with other JAMM/MPN+ proteins, major 
differences are observed in the Ins-1 insertion of both modelled proteins, compared to the Ins-
1 regions of proteins such as CSN5 and AMSH-LP that have been crystallised. The 
differences observed in the Ins-1 region are both structural, as well as showing varying 
topology. The variation in the Ins-1 region both in proteins have been solved and also in the 
models, presented here suggests that the Ins-1 is a flexible region that can adopt various 
conformations. We further analyse the flexibility of these insertions in the following sections.  
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The JAMM motif observed in the DUBs of the JAMM/MPN+ family and which is found in 
all three domains of life (bacteria, archaea, eukarya), has suggested that this motif specifies a 
catalytic centre defining this family of metalloisopeptidases [149]. This has now been 
validated on a number of JAMM/MPN+ members (Fig. 3-5). Sequence analysis allows to 
identify a number of conserved polar residues within the MPN domain of the MPN+ subset. 
The initial studies determining the characteristic architecture of this motif explored the 
structure of AfJAMM [65, 66]. The JAMM motif typically contains a catalytic Zn2+ which is 
coordinated via a tetrahedral manner through the contribution of the N2 of two histidine 
residues located on the strand of one the main -sheets, the carboxylate from an aspartate 
residue situated on the 2 helix, and a water molecule (Fig. 3-1). Additionally, a glutamate 
residue located on the loop between 1 helix and 2 strand serves as an acid-base catalyst. A 
highly conserved serine residue present between the histidine ligands is able to form a 
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Figure 3-5. The JAMM/MPN+ 
members. 
The crystal structures or models of 
JAMM/MPN+ are presented; the MPN 
core is shown in blue, the Ins-1 region in 
green and the Zn-binding site residues 
are represented in ball-and-stick. Right 
panel: 180° rotated view of left Panel. 
A. AMSH-LP; PDB code: 2ZNR B. 
AMSH; PDB code: 3RZU C. Rpn11 (in 
complex with Rpn8); PDB code: 4O8X 
D. and E. Models of BRCC36 and eIF3f 
MPN+ proteins built using Phyre2 
[260]. 
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hydrogen bond interaction with the main chain of the glutamate and stabilises the 
intermediate state. Found in two positions upstream from this serine residue accommodates an 
aromatic residue, commonly a tryptophan. Overall theses residues form a pattern of 
EXnH(S/T)HPX7SX2D specific for the MPN+ subset of protein.  
 
Similarly to CSN5, the structures of AMSH-LP, AMSH, and Rpn11, all display, in their 
stand-alone forms or Rpn8-bound form in the case of Rpn11, the conserved JAMM motif (Fig. 
3-6). Being the sole JAMM/MPN+ isopeptidases to have been structurally elucidated in both 
its apo- and its substrate bound states, AMSH-LP and, more recently, AMSH, provide a 
model system to understand and compare the catalytic competence and enzyme-substrate 
interactions of metallo-dependent isopeptidases [186, 261]. Structural comparison of the zinc-
binding sites of these proteins reveals that the global topology of their active site is 
maintained (Fig. 3-5; 3-6). This observation can be further complemented by analysis of the 
distances between the Zn and the catalytic residues of these isopeptidases (Table 3-2). MD 
simulations were performed on CSN5 and AMSH-LP, where the dynamics of the side-chain 
of the zinc coordination implicated residues was analysed. For the simulations, here and 
thereafter, the dummy atom approach was used to mimic the tetrahedron-shaped zinc divalent 
cation. As such four peripheral dummy atoms are attached to the central zinc atom. This 
approach is expected to impose orientational constraints to the four zinc ligands (H138, H140, 
D151, and water). Using this approach, the position of the catalytic residues over the course 
of the 50 ns simulations was analysed, as a control ensuring that the zinc environment was 
maintained. The obtained values were coherent with those from the crystal structure (Table 3-
2; Fig. 3-6). Moreover, the stability of the zinc-coordinating site was analysed by choosing 
non-coordinating residues in the vicinity of the site, S148 and W146 for CSN5 and S357 and 
F355 for AMSH-LP. We observed that both pairs of residues selected are maintained at a 
steady distance from the Zn throughout the simulation (Fig. 3-6 E and F). These results 
highlight the conserved topology of their Zn-binding site and the neighbouring area. 
Interestingly, however, they do not all show catalytic activity, whilst AMSH-LP is active, 
CSN5 in the stand-alone form is void of catalytic activity (data shown in section 3.4). 
Comparison with the constitutively active AMSH-LP MPN domain dictates that the observed 
topology of the Zn-binding site in CSN5 and Rpn11 is likely to be in the optimal position and 
geometry for pursuing isopeptidase activity. This in itself indicates that the JAMM motif of 
CSN5 in isolation is catalytically competent and further suggests that other features contained 
in these proteins are implicated in regulating their activity. A striking difference observed for 
this region between CSN5 and AMSH-LP (and AMSH) structures is the presence, in the 
former, of a salt bridge formed between the R106 residue, belonging to its Ins-1 segment, and 
the Zn-coordinating D151 residue. Sequence conservation analysis of CSN5 orthologs 
revealed a highly conserved Ins-1 and a strictly conserved R106 residue. This type of 
electrostatic interaction is lacking in other MPN-domain containing proteins, suggesting a 
potential CSN5 unique regulatory mechanism. 
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Exploring the topology of the JAMM motif in other MPN enzymes, the model of BRCC36 
displays a canonical JAMM motif (Fig. 3-5 D). However, for the model produced for eIF3f, 
the JAMM motif appears highly divergent (Fig. 3-5 E). With the exception of the catalytic 
serine residue, the remaining JAMM motif residues, including the two histidines are replaced 
by an alanine and a glycine respectively, and the glutamate and the aspartate are replaced by 
an arginine and an isoleucine. Findings indicating that eIF3f lacks the canonical Zn-
coordinating residues had previously suggested that this subunit and thus the eIF3 complex 
lack DUB activity. More recently, however, it was reported that the eIF3 has an intrinsic DUB 
activity on activated Notch receptor [179]. Further structural and biochemical evidence is 
required to establish the DUB activity of the eIF3 complex and to understand the lack of 
JAMM motif residues. 
 
The zinc-binding site is a unique and conserved feature of the MPN+ members of the 
JAMM/MPN+ family. These proteins contain another two important features, as briefly 
previously presented, the Ins-1 and Ins-2, which are probably responsible for the important 
difference in regulation and in activity displayed by these enzymes. Although commonly 
present in MPN domain-containing proteins, these two structural elements exhibit a large 
variability showing highly divergent insertion sequences, structural composition, as well as 
potentially functional properties. 
 
Table 3-2. Distances between Zn and ligand atoms in the active site of the CSN5 JAMM motif. 
The comparison between CSN5 1-257 crystal structure, and the Zn-dependant DUB AMSH-LP (PDB 
code: 2ZNR; [186]) and their corresponding MD simulation are presented. The first four ligands 
belong to the tetrahedral coordination sphere. Residue numbers are indicated in bold for CSN5. 
Atom distance (Å) CSN5 1-257 AMSH-LP 
 X-ray model (A/B) MD X-ray model (A) MD 
Zn NE2 - H138/H347 2.07 / 2.10 2.03 ± 0.03 2.04 2.01 ± 0.02 
Zn NE2 - H140/H349 2.05 / 2.03 2.05 ± 0.03 2.02 1.98 ± 0.03 
Zn O - Wat 2.13 / 2.15 1.86 ± 0.02 1.92 1.63 ± 0.02 
Zn OD2 - D151/D360 2.06 / 2.02 2.02 ± 0.03 1.94 1.90 ± 0.03 
Zn CD - E76/E292 5.35 / 5.31 5.03 ± 0.25 4.71 4.50 ± 0.03 
Zn OG - S148/S357 3.49 / 3.71 3.87 ± 0.30 4.32 4.40 ± 0.02 
Zn CZ - R106 5.15 / 4.83 5.13 ± 0.20 - - 
Zn NE1 - W146 12.45 / 11.75 11.73 ± 
0.20 
- - 
Zn CZ - F355 - - 12.3 11.8 ± 0.06 
 
In both AMSH and AMSH-LP, their Ins-1 insertion forms a short two-stranded anti-parallel 
-hairpin and contributes to the catalytic site of the enzyme. Although structurally very 
different to the Ins-1 of AMSH-LP/AMSH, the Ins-1 regions of AMSH-LP/AMSH and of 
CSN5 are all in the immediate vicinity of the substrate binding site. Structurally, the Ins-1 of 
CSN5 is composed of a helical segment, 4, and a loop forming between 4 and 4. 
Superimposition with the Ins-1 segment of AMSH-LP, AMSH, and Rpn11 with the Ins-1 of 
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CSN5 reveals major differences in topology and occupancy within the active site. Most 
interestingly, CSN5 contains a crucial arginine residue (R106) located on its Ins-1 segment 
and which further projects to establish a salt bridge with the catalytic Asp151 residue. This 
feature of CSN5 has not previously been observed in other JAMM/MPN+ family members. 
Thus further characterisation of this salt bridge was required to understand its function and for 
questioning its presence in CSN5.     
 
 
Only the Ins-2 regions of AMSH-LP and AMSH have been structurally defined. The Ins-2 
region of AMSH-LP is composed of an -helical element followed by an extended loop 
harbouring the residues C402, H408 and H410, which, together with H362 (extending from 
the JAMM core), are implicated in the coordination of a second, non catalytic Zn2+. The 
substrate-bound crystal structure of AMSH-LP allowed to ascribe a function of its Ins-2 
region that was validated by enzymatic probing. It is implicated in recognising the proximal 
Ub of di-Ub moieties. Although not applicable for JAMM/MPN DUBs that do not bind di-Ub 
moieties, AMSH-LP Ins-2 contributes to catalysis, possibly by positioning correctly the 
substrate into the active site (mutations in the Ins-2 of AMSH-LP principally affect the kcat of 
the hydrolytic reaction) and by participating to the linkage specificity of AMSH-LP [186]. A 
similar conformation of Ins-2 is also observed in Prp8, although, in this case, it does not 
coordinate a second Zn2+. In CSN5 and Rpn11, these regions are disordered in the structures 
obtained. The reason for the lack of a definable conformation may be a result of the absence 
of a secondary Zn2+ coordinating site, which, in contrast, is present in the structures of both 
AMSH and AMSH-LP. The Zn2+ binding residues in these enzymes are implicated in the 
structuring of their Ins-2 loop, which in turn allows its interaction with the proximal Ub. For 
the Ins-2 insertion of Rpn11, a distinct role has been defined and is distinct to that of AMSH-
LP and AMSH’s. The unresolved Ins-2 segments in both the Rpn11 and CSN5 structures may 
additionally suggest that this region contains high flexibility and that its conformation may 
depend on its interaction with neighbouring partners within their complexes. This was shown, 
very recently, to be indeed the case for CSN5 in the context of the CSN complex [61]. 
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Figure 3-6. The catalytic MPN core domain. 
Close-up view of the JAMM motif of AMSH-LP (A), AMSH (B), Rpn11 (C) and CSN5 (D). Residues 
in the vicinity are shown in stick and ball representation. The Ins-1 region is indicated  in green. E. 
Fluctuations of CSN5 zinc biding site during MD simulations. Time dependence of the distance 
between the catalytic zinc, the side chains of the active site (H138, H140, D151, S148, R106, E76, 
W146) and water molecule during the MD simulations. F. Fluctuations of AMSH-LP zinc biding site 
during MD simulations. Time dependence of the distance between the catalytic zinc, the side chains of 
the active site (H347, H349, D360, S357, E292, F355) and water molecule during the MD simulations.
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Auto-inhibition has been an ascribed characteristic for various members of the JAMM/MPN+ 
family, however AMSH-LP and AMSH are key examples of isopeptidase enzymes that exist 
in a competent conformation even when unbound to their di-Lys63-Ub substrate. Examples of 
inactive MPN+ proteins include Rpn11, BRCC36 and CSN5. These three enzymes have been 
shown to require integration into their respective host complex(es) to express their catalytic 
activity. As described earlier, comparison of the conserved active site implicated residues 
between AMSH-LP with CSN5 or Rpn11 reveals that the catalytic residues align very well 
and contain a common overall topology. This suggests that, in the case of CSN5 and Rpn11, 
most probably, other factors are implicated in determining and forming a catalytically 
competent enzyme. Variation in the core MPN domain of these proteins has been highlighted 
and located mostly to their two insertions, Ins-1 and Ins-2, although additional variations 
beyond the construct borders used in structure determination could not be excluded, reflecting 
an important caveat in the structural biology of protein domains. As a result of its location in 
the active site of JAMM/MPN+ proteins, the Ins-1 region can be considered as a key 
participant. Across members of the family, this region reveals large diversity in composition, 
in their secondary structure composition and conformation and in their function.  
 
In AMSH-LP, the Ins-1 region composed of an antiparallel -sheet and a long -helix 
contributes to an extensive part of the substrate binding grove (Fig. 3-3). The structure of 
AMSH-LP bound to its di-Ub substrate allowed to define the function of this insertion in 
being implicated in interacting with the distal moiety of its substrate.  
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Here we report the investigation of the active site of CSN5 that allowed to gain insight in the 
regulation of its activation. CSN5 has been found in two different states of activity, one where 
it is integrated in the CSN complex and displays deneddylase active and the other one where 
it is not integrated in the CSN complex and is catalytically inactive. The conserved overall 
topology of MPN+ active site suggests that CSN5 and AMSH-LP bind their corresponding 
substrate (Nedd8 and Ub, respectively) in a similar orientation. This hypothesis is supported 
by the high residue conservation observed in the catalytic region between the two proteins and 
is further suggested by the high sequence identity (60%) between Nedd8 and Ub. 
 
To identify determinants that might explain the lack of activity of CSN5 in the stand-alone 
form, we assembled a crude model of CSN5 bound to Nedd8 in two steps. First, CSN5 
monomer structure (PDB code: 4F7O) was superimposed onto the structure of the DUB 
 DF
domain of AMSH-LP/di-Lys63-Ub (PDB code: 2ZNV). Second, the structure of Nedd8 (PDB 
code: 1NDD) was superimposed onto that of the distal Ub moiety from the AMSH-LP/di-
Lys63-Ub structure. The assembled CSN5-Nedd8 complex represented in Fig. 3-7A revealed 
that, in the conformation of the stand-alone form, CSN5 is unable to accommodate its 
substrate. Interestingly, the Ins-1 region of CSN5 containing a predominant helical character 
sits over the potential Nedd8-binding groove. The distance between side chains of residues 
located in the inner surface, including R106, V107, and T103, of the Ins-1 segment and the 
catalytic Zn atom identified values ranging from 4 Å for R106 to 9 Å for T103 and 11 Å for 
V107. As a result the topology and position of the Ins-1 insertion covering over the catalytic 
grove hinders the access for the Nedd8 C-terminus into the active site, highlighting for the 
first time a possible reason for CSN5 inactivity in the stand-alone form.  
 
Figure 3-7. CSN5 conformation in the stand-alone form is not compatible with Ubl binding. 
A. Superimposition of CSN5 structure (PDB code: 4F7O) with the structure of AMSH-LP (PDB code: 
2ZNR).  The conformation of their Ins-1 (in green) is compared. B. Superimposition of Rpn11 
structure (PDB code: 4O8X, in complex with Rpn8) with structure of AMSH-LP (PDB code: 2ZNR). 
The conformation of their Ins-1 (in green) is compared. 
 
The produced model of the complex CSN5 1-257/Nedd8 clearly depicts clashes between the 
C-terminus of Nedd8, residue 71-76, and regions of the Ins-1 segments. The tip comprising 
the residues 104-106 of the Ins-1 region and its following -helical element contribute to the 
observed hindrance. Solely based on this structural observation, one can suggest that, for 
CSN5 to be able to accommodate its substrate and thus be activated, its Ins-1 region requires 
substantial structural rearrangements. Given the different orientation of the long Ins-1 helix 
between AMSH-LP and CSN5, these conformational changes are likely not to be only local 
but probably engage profound distance rearrangements of this region. Moreover, the -helix 
located at the C-terminus of its Ins-1 segment would require flexibility in order to be able to 
relocate to a configuration more reminiscent to that of the Ins-1 of active AMSH-LP and 
therefore compatible with Nedd8 binding (Fig. 3-3; 3-7A).  
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Comparison between the Ins-1 region of Rpn11 with that of AMSH-LP and CSN5 suggests 
that the orientation of this region in Rpn11 is more closely related to the one observed in 
AMSH-LP (Fig. 3-7B; 4-8A). In a recent development in which the structure of Sc Rpn11, in 
complex with Rpn8 was determined, it was also shown that Rpn8-bound Rpn11 displays 
hydrolytic activity [158, 160]. Unexpectedly, Rpn11 Ins-1 region in that context adopts a 
rather different overall conformation that would be more closely described as a mixture 
between AMSH-LP and CSN5’s Ins-1 conformations. However, the segment 78 to 81 of 
Rpn11 Ins-1 is also sterically precluding the catalytic groove for substrate binding. On the 
basis of these observations, Martin and co-workers investigated the effect of deleting residues 
of the Ins-1 loop, abolishing hindrance of the active site. Their worked showed that the 
deletion results in the complete inhibition of Rpn11 DUB activity and they further 
hypothesised that, in fact, this region is of great importance for Rpn11/Rpn8 activity [160]. 
This study proposed that these residues are potentially important for catalysis and perhaps 
substrate positioning. However, further experimental proof would be required to claim that, in 
the conformation observed in crystal structures, this region is not acting in an inhibitory 
manor. More specifically, their -helical components superimpose to a better degree and 
occupy the same area, when compared to this element in CSN5 (Fig. 3-7; 4-8 A). Furthermore, 
the Ins-1 loop, specifically the side chains of residues V77 and S79 facing the vicinity of the 
zinc binding site of Rpn11 sit in average 6 Å away from the Zn, which when compared to the 
4.3 Å distance observed between R106 and the Zn in CSN5 can explain the slightly more 
relaxed conformation observed in Rpn11 in the context of Rpn8. This is further shown by the 
lower extend of steric hindrance observed with our model of Ub docked into the active site of 
Rpn11 (Fig. 3-7B). Whilst we see that the CSN5 residues 104 to 119 hinder the interaction 
with the C-terminus of Nedd8 and that the C-terminal helix of the Ins-1 requires to translocate 
in order to accommodate Nedd8, for Rpn11 this helix is in a compatible conformation and 
clashes are observed between the C-terminal Nedd8 tails and residues 79 to 81 of the Ins-1 
region.  
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In our work, the flexibility of the Ins-1 region of CSN5 was further exacerbated by focusing 
on a unique feature of this region in this enzyme, which includes the presence of the salt 
bridge between the Ins-1 residue R106 and the Zn-coordinating residue D151 (Fig. 3-6B). 
Sequence conservation amongst CSN5 orthologs identifies that this active site salt bridge is 
highly conserved. This may indicate a functional role of this feature corresponding to the 
activity regulation of CSN5. The strong anchorage of the Ins-1 insertion to the Zn-binding site 
is suggestive of a required activation step for which one of the switches is likely to correspond 
to the R106-D151 salt bridge, which would allow the Ins-1 insertion to undergo 
restructuration to form a substrate-binding groove in which the substrate would insert. To 
probe this hypothesis, in the next section we investigate the flexibility of the MPN domain 
 E>
and the dynamic nature of this insertion and try to characterise its role in the activity 
regulation of CSN5. 
Two MPN structural elements, namely the Ins-1 and Ins-2 regions appear as particularly 
flexible. We put forward the hypothesis that CSN5 inactive to active state transition, at least 
partially, rests on the necessity for Ins-1 to be intrinsically malleable. In our work, detailed 
structural comparison and MD simulations were used to gain insight in these flexible regions. 
Furthermore we address the potential functional importance of these regions mainly in the 
context of CSN5, but which could possibly apply to other JAMM/MPN+ family members. 
MD simulations were performed on CSN5 and AMSH-LP to allow comparison between a 
catalytically inactive and a catalytically active MPN domain containing protein. The presence 
unique to CSN5 of a salt bridge across the substrate binding site was investigated and its 
implication in the flexibility and function of the Ins-1 region was revealed. Our work allowed 
to determine an active site lock which could be essential for the activity regulation of the 
auto-inhibited CSN5. 
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In general, the wealth of conformations that, both the Ins-1 and Ins-2 regions, adopts across 
the MPN sub-family have been described in the various structures elucidated to date; thus 
suggesting the highly flexible nature of these insertions. In various studies, the Ins-1 region 
has been characterised both structurally and functionally in numerous members of MPN 
domain-containing proteins (Fig. 3-8A and B; [63, 158, 160, 186]). 
For the core MPN domain, an overall rigid structure, where in average residues show a 
difference in fluctuation of 1 to 2 Å (Fig. 3-8C and D), when compared to the initial crystal 
structure, can be depicted for both CSN5 and AMSH-LP. In general, the distribution of 
crystallographic B-factor values obtained for MPN domain-containing proteins would indicate 
a lower flexibility of their core domains compared to exposed regions. To identify the most 
flexible regions of both CSN5 and AMSH-LP, the root-mean-square fluctuation (rmsf) of the 
C atoms were calculated by fitting the backbone atoms of all snapshots obtained during the 
50 ns long MD simulations. This analysis allowed us to determine the intrinsic flexibility of 
the backbone of each protein. The rmsf value of each residue and the crystallographic B-
factors are displayed on Figure 3-8C. At a first look, CSN5 in general contains a more 
dynamic structure compared to that of AMSH-LP (Fig. 3-8C and D). For AMSH-LP, no 
distinct regions of major flexibility can be depicted. The large fluctuations observed in the N-
terminal end, observed frequently in MD simulations, are due to the unstructured component. 
In CSN5, the most flexible regions (i.e. rmsf above 2 Å) comprise residues at its N- and C-
terminal regions and also residues within its Ins-1 insertion and the complete Ins-2 insertion. 
The high crystallographic B-factor values, as well as the heterogeneity observed in the 
different conformations that the Ins-1 region adopts in the different MPN domain-containing 
proteins is coherent with this (Fig. 3-8A, C and D). Interestingly, the N- and C-terminals of 
CSN5 are helical elements, which in the crystal structure are stacked over each other, and the 
 E?
interface contains a tryptophan-rich region (Fig. 3-2A; 3-4A). Analyses from the simulations 
also indicate that these two helices are maintained in the same proximity to each other and, as 
described later in Chapter 4, could have some consequences on CSN5 regulation.  
 
The Ins-2 region, in the crystal structure of CSN5, is disordered, which could ultimately 
suggest a flexible segment. For the simulations, an initial molecular model of the Ins-2 region 
constituted of 24 residues, was built with Modeller 9v program (http://salilab.org/modeller). 
At the time where this work was performed, structural insight into the Ins-2 region of MPN+ 
proteins, specifically for those not implicated in the coordination of a second Zn, was largely 
lacking. The high flexibility observed by rmsf calculations may be a result of the 
conformation of this freely floating loop at the beginning of the simulation (Fig. 3-8C). At the 
end of the 50 ns long simulation runs, no tendency could be ascribed to the motion of the Ins-
2 region, however this potential event could not be completely ruled out for a longer 
simulation runs. Indeed, to observe such a drastic conformational rearrangement of this 
segment would require to overcome a large energy barrier. Additionally, it could also have 
been possible to presume that, similarly to the case with Rpn11, that the Ins-2 region of CSN5 
is also implicated in interactions within the CSN complex. Moreover, the low flexibility 
revealed for the Ins-2 region of AMSH-LP by our simulations, may indicate that the Ins-2 of 
CSN5 may actually be a less dynamics component than what is depicted in the simulations, as 
it may either be folded back towards the core of the protein or it may be implicated in protein-
protein interactions. This is further discussed in Chapter 6 in the light of recent structural data 
obtained in the laboratory of Dr. N. Thöma.  
 
Specifically for the Ins-1 region, the rmsf calculations depict flexible regions located at the N- 
terminal (residues 108-116) and C-terminal (residues 120-132) region of this insertion (Fig. 3-
8 C). These findings are coherent with our predictions from structural analysis, from which 
we hypothesised that the Ins-1 region requires conformational rearrangement to accommodate 
Nedd8. If the Ins-1 of CSN5 is to undergo a conformational change to adopt a conformation 
equivalent to Ins-1 in AMSH-LP, a displacement of the C-terminal helix would be foreseen, 
and is reflected here with the high degree of flexibility observed in the simulations.  
 
Interestingly for CSN5 we observe that, during the course of the simulation, the R106 residue 
is also remained at a constant distance around 5 Å from the Zn. This in interesting because, 
although rmsf analysis shows flexibility in the Ins-1 region, the R106 residue is stably 
anchored to the Zn-binding site during the entire simulation time. This is possibly a result of 
its interaction with D151 and the stable salt bridge formed between these two residues. The 
same helical component in AMSH-LP shows lack of such flexibility. However, this C-
terminal portion of the Ins-1 insertion is likely to play a role in CSN5 activation, as it adopts 
radically different position/orientation in CSN5 and in AMSH-LP, as well as in the Rpn8-
activated Rpn11 structure (Fig. 3-7A;B).  
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Figure 3-8. CSN5 MPN domain and specific extensions. 
A. Conformational heterogeneity of the Ins-1 region amongst MPN domain containing proteins. Our 
comparison, includes CSN5 (PDB code: 4F7O), CSN6 (PDB code: 4EOQ), Rpn8 (PDB code: 
2O95/2O96), Rpn11 (PDB code: 4O8X), AMSH-LP (PDB code: 2ZNR), AMSH (PDB code: 3RZU), 
Prp8p (PDB code: 2OG4), AfJAMM (PDB code: 1O10), and Rpn8 (PDB code: 2KCQ) Ins-1 
segments. B. Sequence alignment centered on the Ins-1 region of four human MPN+/JAMM 
representatives, CSN5, Rpn11, BRCC36, and AMSH-LP performed using ClustalW2. Conserved 
residues across the species are marked in red and a green box is used to highlight conservation of 
residues of strongly similar properties. Overall flexibility of MPN domain containing proteins 
analysed by MD simulations. The average C rmsf obtained over the 50 ns simulations for CSN5 (C) 
and AMSH-LP (D) are shown. 
AMSH-LP Rpn11 AfJAMM CSN5 AMSH 
A 
Rpn8 Mov34 Prp8 CSN6 
hRpn11         70  -AMPQSG-TGVSVEAVDPVFQ--AKMLDMLKQT-GRP- 101
hCSN5          97  -ALPVEG-TETRVNAQAAAYEYMAAYIENAKQV-GRLE 131
hBRCC36        78  IILRRSDKRKDRVEISPEQLSAASTEAERLAELTGRPM 116
hAMSH-LP       314 -PKQSAGPDYCDMENVEELFN-----VQDQHDL----- 339 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
0 50 100 150 200 250
0
5
10
0
50
100
150
200
Residue number
c
a
 r
m
s
f 
(Å
)
CSN5
1-257 
Rmsf
CSN5
1-257 
b-factors
A
v
e
ra
g
e
 B
-fa
c
to
rs
C 
300 350 400
0
2
4
6
8
10
0
10
20
30
Residue number
c
a
 r
m
s
f 
(Å
)
AMSH-LP Rmsf
AMSH-LP b-factor
 A
v
e
ra
g
e
 B
-fa
c
to
rs
D 
 EA

;3;3;#!$ #))+()!$ $=
 
To further question the role of the R106-D151 salt bridge in CSN5, in silico mutations were 
performed on the R106 residue to determine whether the disruption of the salt bridge triggers 
conformational changes of the Ins-1 segment compatible with CSN5 activation (i.e. substrate 
binding) and what the effect of this disruption is on the dynamics of the remaining structure. 
As such the arginine was substituted by different residues threonine, serine, glycine, and 
proline, consecutively forming various salt-bridge deficient variants of CSN5 to study. The 
rational behind the use of different R106 variants comes from the observation that, in AMSH-
LP, the Ins-1 is deeply involved in substrate binding and therefore sampling different physico-
chemical properties at this position was of interest. A good example of the dramatic role of 
these residues in enzymatic activity comes from the work in [160]. The simulations of each 
CSN5 variant were run for 50 ns and the trajectories were analysed by calculating their rmsf 
plots (Fig. 3-9. A). These results showed that the core elements maintain common dynamics 
in comparison with the wild type CSN5. Previously, we described the dynamics of the CSN5 
to be highly flexible in the regions including the Ins-1 and Ins-2 regions. Whilst this overall 
pattern was also observed for the CSN5 variants designed, variation in the extent of flexibility 
was observed. Our simulations clearly depict that, in the presence of the Ins-1 variants R106T 
and R106S, an increase in Ins-1 flexibility is displayed, as implied by an increase in the rmsf 
values of residues 99 to 104 (Fig. 3-9A). On average, the residues in these region show an 
increase of rmsf ranging from 1.5 to 5.0 Å difference compared to the wild-type simulation 
(Fig. 3-9A). Interestingly, these residues are located just before position 106. Indeed, analysis 
of the output trajectories from the simulations of CSN5 R106T and R106S reveals that Ins-1 
of these variant shows an equilibrium between forming a ‘open’ and the closed form observed 
in the crystal structure (Fig. 3-9D and E). Further analysis of the Ins-1 region of these variants 
reveals that in comparison to the wild type, flexibility on residues 105 to 113 is reduced for 
these variants, whilst the dynamic motion of the C-terminal end of the Ins-1 region previously 
identified is conserved for the variants as well. This approach allowed us to identify CSN5 
variants, namely R106T and R106S with the capacity to containing a higher flexibility in their 
Ins-1 region by disrupting the R106-D151 salt bridge. In the following section, we investigate 
the role of the CSN5 variants on the activity of CSN5. 
In the present section we have used structural and computational approaches to reach the 
conclusion that the rearrangement of the Ins-1 insertion is required for CSN5 to accommodate 
Nedd8. 
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Figure 3-9. Relaxation of the CSN5 Ins-1 conformation. 
A. Fluctuations of CSN5 in the wild type and Ins-1 variant forms during MD simulations. Ca rmsf 
fluctuations of monomeric CSN5 as a function of residue number during the 40 ns MD simulations are 
shown for the wild type (red), the R106T (blue), the R106G (orange), R106S (green) and R106P 
(violet) forms. Large fluctuations in the 190-220 correspond to the Ins-2 region that is disordered in 
the crystal structure and that has been modeled for the MD simulations. A snapshot after 20 ns 
simulations taken for each CSN5 variant, R106G (B), R106P (C), R106S (D), and R106T (E) is 
superimposed to the starting structure. Distinct changes in the conformation of the Ins-1 helix in 
variants R106T and R016S can be seen.  
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As suggested from our in silico study, mutations performed on R106, part of its Ins-1 segment, 
that disrupt the salt-bridge trigger conformational relaxation of the Ins-1 loop. This suggested 
that this portion is indeed implicated in the conformational changes required for CSN5 to 
accommodate its substrate. This is also suggested when superimposing the simulated CSN5 
R106 mutants with the active AMSH-LP crystal structure. To further validate these 
observations, the same mutations were performed in vitro, and their effect on CSN5 activity 
was evaluated by enzymatic measurements. In this work, the activity of CSN5 and its variants 
was tested against two synthetic substrates and was further verified using its physiological 
substrate, neddylated Cul1 in complex with Rbx1. Additionally, the binding affinity of the 
variants to Alexa488-labelled pro-Nedd8 was determined to allow the interpretation the 
activity results obtained.   
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With the objective being to gain functional understanding on the flexibility of the Ins-1 
segment of CSN5, enzymatic activity assays were performed. Synthetic fluorogenic substrates 
that mimic the isopeptide bond involving the C-terminus of Nedd8 have widely been used to 
investigate the hydrolytic and deneddylase activity of CSN5 [262, 263]. CSN5’s catalytic 
activity was evaluated on the two following substrates: LRGG-AMC and Nedd8-AMC. The 
LRGG-AMC probe represents a peptide chain corresponding to the last four C-terminal 
residues common to Ub and Nedd8, conjugated to AMC, whilst the Nedd8-AMC probe 
consists of the conjugation of the AMC with the C-terminal glycine of Nedd8. The 
fluorescence intensity (at the following wavelengths: 	excitation= 380 nm; 	emission= 460 nm) 
concomitant with the release of AMC, after cleavage of the amide bond between the AMC 
and its conjugate is proportional to the enzymatic activity. Therefore, the isopeptidase activity 
of CSN5 on this substrate was monitored by the measurement of the fluorescence intensity 
increase. 
 
As previously been reported, the activity assays ran on CSN5 1-257 WT, using both probes, 
confirmed that the WT form of CSN5 lacks isopeptidase activity (Fig. 3-10 A). Moreover, as 
expected from our structural and computational analyses, we detected that substitution of 
R106 with a threonine imposes a detectable basal activity on CSN5. Using Nedd8-AMC, we 
also considered the other variants of CSN5, including R106 substituted with an alanine or a 
glycine, which also confers an activated form to CSN5, compared to the WT. However, 
although the activatory effect of these substitutions on CSN5 is strong, the effects R106A and 
R106G on CSN5 activity are more modest compared to the R106T variant. Furthermore, the 
R106P variant is void of isopeptidase activity (Fig. 3-10 A). 
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To specifically ascribe catalytic activity of CSN5, we designed a dead-mutant variant of 
CSN5. To do so, comparison of AMSH-LP with CSN5 allowed to identify that the glutamate 
292 residue of AMSH-LP, which had been shown to lack DUB activity, aligns with the 
glutamate at position 76 of CSN5 [186]. The E292A variant of AMSH-LP was validated as a 
dead-mutant variant and used as negative control [186].This conserved glutamate residue 
(E292 and E76, in AMSH-LP and CSN5, respectively) is a key component in the catalytic 
mechanism of JAMM motif containing DUB, playing a significant role in contributing as a 
proton acceptor and donor, activating the water molecule. Based on this rational, the 
corresponding mutation was performed on the Glu76, substituting it with an alanine residue, 
for both CSN5 WT and its R106T variant. Comparison between the activity of the E76A 
variants with that of CSN5 WT and R106T, respectively, on the Nedd8-AMC substrate 
indicates a lack of activity (Fig. 3-10 A). The activity of the conformationally active R106 
variants of CSN5 can also be compared to the activity observed by the CSN holo-complex, 
which displays a significantly higher isopeptidase activity on Nedd8-AMC substrate. An 
apparent 79-fold difference in the activity between CSN5 R106T and the CSN complex can 
be observed (Fig. 3-10 A). Further kinetics characterisation of CSN5 R106T activity (i.e. kcat 
and KM) could unfortunately not be performed, because of the lack of substrate saturation 
over the concentration range used (in the case of CSN5 R106T). 
 
The activity data obtained is also in agreement with the results from the MD simulations 
performed on the different variants of CSN5 and support our hypothesis that CSN5 in the 
stand-alone state is maintained in an inactive state through the closed conformation of the Ins-
1 segment. The MD simulations suggested that the salt-bridge of CSN5 WT is maintained 
throughout the 50 ns of simulation, keeping the Ins-1 region in the proximity of the active site. 
This postulates a rigid conformation of the Ins-1 loop, which together with the activity data 
obtained, can explain the lack of activity observed by CSN5 WT. The simulations performed 
on the R106T variant of CSN5 demonstrated that disruption of the salt bridge lead to placing 
the Ins-1 insertion in a dynamic equilibrium between the opened and closed state of CSN5.  
 
;3<3:#.!)$#)+).$=
The most studied activity of the CSN complex is its ability to deneddylate neddylated Cul1 
which corresponds to the removal of the Nedd8 molecule from the Cullin subunit of CRLs 
(presented in Chapter 1). To probe whether the enhanced activity observed with the R106T 
variant of CSN5 on synthetic substrates extends to its physiological substrates, its activity was 
tested against neddylated Cul1 complexed with Rbx1 (Nedd8-Cul1-Rbx1). Previous studies 
investigating the deneddylation activity of the CSN complex have shown that this complex is 
very effective at deneddylating Cul1 [70, 72]. This was further confirmed in our work, where 
we followed the deneddylase activity on Nedd8-Cul1-Rbx1 by an anti-Nedd8 Western blot 
detection with the decrease in neddylated Cul1 and the consecutive increase in released free 
Nedd8. This was carried out by gel shift assay, as described in the Material and Methods 
 EE
Chapter. Interestingly the comparison of CSN5 WT and CSN5 R106T activity towards this 
substrate was coherent with our findings using the LRGG-AMC and Nedd8-AMC synthetic 
probes (described in section 3.4.1). CSN-independent CSN5 WT is unable to deneddylate 
neddylated Cul1, whilst the R106T variant shows a modest, however, significant, increase in 
the level of released Nedd8 (Fig. 3-10 B).  
 
These results further suggest that the conformational changes occurring on the Ins-1 region of 
CSN5 as a result of the disruption of the R106-D151 salt bridge result in an active CSN-
independent CSN5 variant. However, comparison of the activity of this variant with that 
observed for the CSN complex points out, as expected, that the CSN is a much better enzyme 
for the physiological Nedd8-Cul1-Rbx1 and the synthetic Nedd8-AMC substrate. This is not 
surprising and can be explained by the fact that the CSN is a complex molecular system 
consisting of eight subunits that are tailored for Cullin deneddylase activity. Indeed recent 
studies have contributed in understanding their individual roles. The EM study of the CSN 
complex both alone and in complex with SCF succeeded in giving insight into the topological 
organisation and structural arrangement of this complex [46]. Structural and biochemical 
analysis obtained from this work revealed that the interaction between the CSN and SCF 
predominantly involves the CSN subunits 1, 2, 3 and 5, although recent data also implicate 
CSN4 [61]. More specifically the C-terminus of the Cullin subunit was found to interact with 
CSN2 and CSN5 and the N-terminal conjugates of the Cullin contact CSN1 and CSN3. A 
general observation is that the SCF contains a broad interface which interacts with the CSN 
complex and which does not directly involve CSN5. Furthermore, it was shown that the 
presence of CSN5 is not a requisite for obtaining a CSN-SCF super-complex [46]. This 
implies that the interaction that CSN5 forms with Nedd8 is not dominant in the formation of 
the CSN-SCF super-complex. This data suggests that the contribution of Nedd8 in the affinity 
of SCF for the CSN is marginal, although work by the Deshaies’group suggests that Nedd8 is 
a mild inhibitor of CRL deneddylation [72]. The modest activity that we obtain when 
considering the R106T variant of CSN5 compared to that obtained by the CSN complex could 
stem from the weak affinity between CSN5 R106T and Nedd8, as the bulk of CSN-SCF 
affinity is likely to reside in interactions between other elements of these complexes. This was 
investigated further and is described in Section 3.3.3.1 of Chapter 3. Other factors, such as, 
the other CSN subunits, are therefore likely to contribute directly in the catalysis, either by 
increasing the affinity for the substrate, or by positioning the attached Nedd8 molecule 
correctly into the active site of CSN5, or both.  
 
Our work, including the release of the R106-D151 salt bridge and inducing a conformational 
relaxation on the Ins-1 region, allowed to unravel one layer of the activation mechanism 
involved in obtaining a catalytically competent CSN5 molecule. Together these data suggest 
that CSN5 within the CSN complex may undergo conformational changes, activating this 
enzyme. Although, with the CSN5 R106T variant, we identify that the relaxation of the Ins-1 
region is required for the CSN5 to be activated, it is likely not be the only requirement and 
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other factors may also play a role. These may include the other subunits neighbouring CSN5 
within the CSN complex. Taking a closer look to the EM map of the CSN complex suggests 
that, for example, CSN6 is in close proximity to CSN5 [46]. Furthermore, this is coherent 
with data obtained from analytical biochemistry studies showing that CSN5 and CSN6 
interact and with mass spectrometry, which identified the presence of CSN5 in a subcomplex 
containing CSN4, CSN6 and CSN7 [128, 259]. 
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Having shown that the Ins-1 region requires conformational relaxation for CSN5 activity, the 
underlying hypothesis to this was that the stand-alone conformation of Ins-1 prevents Nedd8 
binding. To probe this idea and complement the activity data obtained, fluorescence 
anisotropy assays were performed to gain further understanding in the mechanism by which 
the R106T variant of CSN5 has an increased ability to processes its substrates. The rational 
behind these experiments was to determine whether the R106T variant has an increased 
affinity or whether it is a better enzyme for its substrate. To investigate this, the affinities of 
CSN5 WT and R106T, for Alexa488-labelled pro-Nedd8, were compared (Fig. 3-10C). The 
use of pro-Nedd8 (i.e. Nedd8 precursor that contains a 5-amino acid extension in C-terminal) 
is down to the fact that it is easily recombinantly produced and can be mutagenised if 
necessary. More work that we have performed on pro-Nedd8 can be found in Chapters 5 and 
6. As suspected, CSN5 WT has a low affinity for Nedd8, displaying an apparent dissociation 
constant (KD) of around 320 ± 59 µM. In general, for DUBs, the values for their affinities for 
their mono-Ub substrates span a wide range, but are commonly characterised as weak 
interactions, ranging from 1 µM to several 100 µM [264]. More specifically for MPN domain 
containing proteins, Surface Plasmon Resonance (SPR) experiments showed that the pre-
mRNA splicing factor Prp8, an MPN- domain-containing protein, which lacks a 
JAMM/MPN+ motif, has a binding affinity to Ub of around 380 µM [265].  
 
Interestingly, for the CSN5 R106T variant, the KD value obtained is slightly lower than the 
WT form, around 202 ± 25 µM. Compared with CSN5 WT, these results indicate that the 
conformational relaxation induced on the Ins-1 segment via the disruption of the R106-
Asp151 salt bridge promotes Nedd8 binding. This is observed by the increase in affinity of 
CSN5 R106T for Nedd8. The fluorescence anisotropy results, together with the activity data 
(described in Sections 3.4.1 and 3.4.2) highlight the increase in the catalytic efficiency 
observed with the CSN5 R106T variant. From the MD simulations performed, the flexibility 
of the CSN5 variants was previously determined which seems to favour the binding of Nedd8 
to CSN5 (Fig. 3.10D). These results may indicate that, within the CSN complex, CSN5 
undergoes structural rearrangements, one which involves the restructuration of the Ins-1 loop, 
either via its neighbouring interacting partners or by the substrate itself, or both.   
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Figure. 3-10. Isopeptidase activity of CSN5. 
A. Activity of CSN5 and Ins-1 variants using the synthetic substrates LRGG-AMC (top) and Nedd8-
AMC (bottom). B. Deneddylase activity of CSN5 and the Ins-1 variant R106T. The R106T variant 
form of CSN5 is able to deneddylate Nedd8- Cullin 1. Upper band shows Nedd8 signal of the Nedd8-
Cullin 1 and the lower band is the Nedd8 released upon Nedd8-cullin1 isopeptide bond hydrolysis by 
CSN5 WT, CSN5 R106T and the CSN complex. (left to right). C. Fluorescence anisotropy assay 
showing the increased affinity of CSN5 R106T variant for Nedd8 substrate. The apparent dissociation 
constant (KD) for the active CSN5 variant was obtained at ± 200 µM. D. Molecular models of CSN5 
R106T variant recruiting Nedd8 substrate. The breakage of the R106-D151 salt bridge and relaxation 
of the Ins-1 is coherent with the increase in activity observed.
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Biochemical studies, as well as crystal structure determinations of some MPN domain-
containing proteins (Hs CSN5, Hs and Dm CSN6, Hs Rpn8, AfJAMM) have indicated their 
propensity to homodimerise. This is the case both for MPN+ and MPN- domain-containing 
proteins, where examples include CSN5 and CSN6, Rpn8, AfJAMM, respectively. However 
for others members, including AMSH, AMSH-LP and Prp8, there is no direct evidence of 
homodimerisation reported to date. For the members that display inclination to dimerise, these 
proteins assemble via different surfaces [67]. In relation to our work, the crystal structure of 
the human CSN5 is composed of two types of dimers, as briefly described in section 4.2.1.1 
of Chapter 3. 
 
Intriguingly, in addition to being a key component of the CSN complex, CSN5 is often found 
outside of this complex. Moreover, rather intriguingly, various cellular protagonists, some 
involved in the regulation of signal transduction and cell proliferation and survival, have been 
shown to interact with CSN5, as briefly described in Chapter 1 and section 3.1 of Chapter 3. 
This suggests that CSN5 may be involved, possibly in addition to CRL regulation, in other 
biochemical functions, including the specificity of transcription factors and the control of the 
distribution and turn-over of signalling proteins. The molecular organisation of CSN5 in its 
diverse functions remains unclear, however stand-alone species, as well as ones present in 
small CSN sub-complexes have been described [110, 126, 127]. The described ‘mini-CSN’ 
complexes containing a subset of CSN subunits, generally including CSN5, could hold 
specific physiological roles, as suggested in [127] in cell cycle control, but could also be mere 
stigma of CSN assembly and dissociation pathways. Additionally, these assemblies could be 
mediating protein-protein interactions with CSN5 partners or regulating CSN5 incorporation 
within the CSN complex. The fact that CSN5 organises into dimers in its crystal structure 
raises the question whether dimerisation of CSN5 might be observed in solution and in vivo 
and therefore potentially related to these functions.   
 
Furthermore, in the context of large protein complexes, MPN domain-containing proteins 
appear to have the tendency to associate in heterodimers. The MPN domain-containing 
proteins, MPN+ and MPN-, have previously been identified to interact. The interaction 
between these two proteins is thought to be mediated via their MPN domains. Evidence of 
their interaction was obtained from EM data on the 19S proteasome lid [174], the CSN 
complex [46, 266] and the eIF3 complex [267], where their respective MPN domain-
containing proteins were located in close proximity to each other.  
Taken together, these elements prompted us to further probe MPN dimerisation in the context 
of CSN5 self-association. Advanced understanding on the basis of MPN homo-dimerisation 
was investigated with the rational to shed light onto the molecular basis of heterodimer 
formation of MPN domain-containing proteins. We extended this study in cell extract, but in 
vivo experiments were beyond our reach. 
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In silico, biochemical and other biophysical techniques including analytical 
ultracentrifugation (AUC; in collaboration with Dr. Christine Ebel, Institut de Biologie 
Structurale, Grenoble) were used to study the dimerisation of CSN5. This work led to the 
identification of a preponderant dimeric arrangement. Co-immunoprecipitation experiments 
on mammalian cell extracts performed by our collaborator, Dr. Francois-Xavier Claret 
(Monroe Dunaway Anderson, University of Texas, Houston) has confirmed that CSN5 homo-
dimer is present in human cell extract and that the A-B dimer is the most likely one to exist.  
The presence of CSN5 dimeric or oligomeric assemblies in cellular extracts raises questions 
of the functional relevance of CSN5 dimeric assemblies. Moreover, the diverse interactions in 
which CSN5 is involved have implied that its activity could require tight regulation. It would 
thus be of great importance to investigate whether the dimerisation of CSN5 is part of its 
regulatory mechanism regarding its incorporation into the CSN complex, CSN5 dimerisation 
is involved in CSN-independent functions of CSN5 or the auto-association of CSN5 is related 
to its propensity to associate with another MPN domain containing protein, CSN6 (further 
discussed in Chapter 4). 
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In the crystal, the CSN5 1-257 fragment forms two types of dimers, providing two different 
dimerisation interfaces; the A-B interface within the asymmetric unit and the A-A’ interface 
between symmetrically related subunits (Fig. 3-11A). According to the PISA Server [210], 
the A-B and A-A’ dimers display similar estimated values for free energy of dissociation 
Gdiss (Table 3-3). Furthermore, analysis of the buried and accessible surface area (BSA and 
ASA, respectively) of the two dimers revealed also similar values (summarised in Table 3-3).  
 
In the A-B dimer, the CSN5 monomers are related by a local twofold axis running 
perpendicular to the crystallography dyad axis (Fig. 3-11A). The Ins-1 segment from each 
monomeric species is implicated in forming part of the interface of this dimeric arrangement. 
(Fig. 3-11B) Additionally, the C-terminal helix (residues 232 to 241) of the opposing 
monomer is packing against the helical portion (residues 119 to 126) of the Ins-1. As 
described previously, the investigation of the flexibility of the Ins-1 insertion, within our work, 
highlighted that the relaxation of this segment is a pre-requisite for the recruitment of Nedd8 
and to retrieve an active CSN5 subunit. With this in mind, the arrangement of the A-B dimer 
suggests that it could block the structural rearrangement of Ins-1 due to its contribution to the 
interface. The second A-A’ dimer contains an interface involving monomer A residues that 
are implicated in the active site together with some located on neighbouring loops (residues 
74, 141 to 143, 173, and 174) and the C-terminal extension, comprising the residues 248 to 
255 of monomer A’. The C-terminal tail of monomer A’ docks into the active site of the 
symmetry-related molecule A and adopts a conformation which would sterically hinder 
substrate binding (Fig. 3-11C). These two dimeric models A-B and A-A' thus stabilize the 
inactive form the CSN5 enzyme.  
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Table 3-3. CSN5 interface surface properties observed in the crystal structure. 
The average ASA and the BSA of each protomer are calculated with PISA [210] for each species: dimer A-B generated by local 2-fold 
symmetry axis (=179.7 deg, rmsd = 0.62 Å on 227 C atoms), dimer A-A’ generated by crystallographic dyad axis and the D2 tetramer 
constructed from these two dimers. The CSS interface score for dimer A-B is 0.183 and 0.136 for dimer A-A'. CSS ranges from 0 to 1 as 
interface relevance to complexation increases. Residues in bold play a major contribution to the interface (H-bonds, large buried surface area).
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 BSA 
and 
ASA 
(Å2) 
Number of 
interfacial 
residues 
Gint 
(kcal 
mol-1) 
Gdiss 
(kcal 
mol-1) 
Fraction of 
non-polar 
buried area 
(%) 
Number 
of H-
bond 
contacts 
Residues implicated in the interfaces 
dimer 
A-B 
1,056 
12,270 
34 -14.0 3.6 59 
 
4 L60; K64; M67; L82; K84; M93; D94; F96; P99; V100; E101; 
E104; T105; E115; Y116; M117; A118; A119; Y120; E122; 
N123; A124; Q126; V127; G128; R129; L130; E131; N132; 
L233; D234; K236; L237; L240; L241; N243 K244; V247; N248 
dimer 
A-A’ 
975 
12,270 
32 -10.9 2.2 28 11 R70; S71; G73; N74; L75; E76; G102; T103; R106; V107; H138; 
H140; P141; G142; Y143; W146; S148; I150; D151; D171; T173; 
R174; N248; L250; S251; S252; S253; S254; L255; T257 
tetrame
r A-A’-
B-B’ 
2,047 
12,270 
66 -51.3 15.8 48 15 S24; L60; K64; M67; R70; S71; G73; N74; L75; E76; L82; K84; 
M93; D94; F96; P99; V100; E101; G102; T103; E104; T105; 
R106; V107; E115; Y116; M117; A118; A119; Y120; E122; 
N123; A124; Q126; V127; G128; R129; L130; E131; N132; 
H138; H140; P141; G142; Y143; W146; S148; I150; D151; 
D171; T173; R174; L233; D234; K236; L237; L240; L241; N243 
K244; V247; N248; L250; S251; S252; S253; S254; L255; T257 
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Structural comparison between the A-A’ CSN5 dimer with the di-Ub bound AMSH-
LP structure may also suggest that the C-terminus positions in a similar manner to the 
isopeptide linkage present in the di-Lys63-Ub substrate, which is accommodated in 
the active site of AMSH-LP (Fig. 3-11C). Additionally, the packing of the C-terminus 
in the active site of CSN5 adopts a constrained horse-shoe-like conformation 
sterically compatible to position the remaining residues of the C-terminus, which are 
lacking in our crystal structure of CSN5. 
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Further to the identification of CSN5 homodimer in crystallo, biophysical 
characterisation of CSN5 dimerisation was initially investigated in solution. The 
approach used for this was sedimentation velocity analytical ultracentrifugation (SV-
AUC) that was carried out by Dr. Christine Ebel (IBS, Grenoble). Processed data 
were provided to us by our collaborator in Grenoble. This approach was used to 
separate CSN5 WT into its different oligomeric states in solution. Their sedimentation 
coefficient c(s) values, measured in Svedberg units, and the relative amounts of 
monomer/multimer components in the sample were determined. Data was obtained 
for different concentrations of CSN5 WT (333.0, 167.0, 67.0, and 33.0 µM) and the 
c(s) values were analysed. The most significant peaks appeared at 3.1 and 4.3 S which 
most likely correspond to the monomeric and dimeric species of CSN5 WT, 
respectively (Fig. 3-12. A). Thus the results obtained indicated that, in solution, CSN5 
WT is a mixture of monomeric and dimeric species. Larger oligomeric species than 
the dimeric state of CSN5 were not observed, ruling out the presence of stable 
tetrameric assemblies. At 333 µM, the equilibrium between monomer and dimer was 
almost entirely shifted towards dimeric species of CSN5 (Fig. 3-12. A). An evaluated 
KD value for CSN5 dimer (around 700 µM) reflects a weak association in the tested 
conditions. Addition of the C-terminal extension (residues 258-334) could affect this 
value, but the propensity of FL CSN5 to degrade prevented us to evaluate the effect of 
this region on CSN5 homodimerisation. 
 
As mentioned before, various studies have suggested that, in cells, CSN5 is present in 
different association states [256, 268]. An in vitro study where a mass spectrometry in 
native conditions approach was used also identified the formation of a total of 35 CSN 
subcomplexes [128], although it is presently unknown whether this reflects the 
distribution of CSN subcomplexes in cells. The existence, distribution and function of 
these different CSN-related species remain unclear. Although CSN5 within the CSN 
complex is active, its activity state within these potential ‘mini-CSN’ complexes has 
not probed in depth. Additionally, the sub-cellular distribution of CSN5 might hold a 
hint as to whether CSN5 has a CSN-independent function. Indeed, initial data had 
suggested that the CSN complex exists in the nucleus and that the CSN5 subunit was 
also found in the cytosol. However, recent data show evidence of presence of the CSN 
in the nucleus, in the cytosol and in chromatin-bound fractions [269]. Most 
predominantly, the CSN was observed in the cytosol. This study also confirms that, in 
the cytosol, CSN-free CSN5 form is observed, either in smaller CSN complexes or in 
the free form. Taken these data together, there is a strong hypothesis suggesting that 
CSN5 may have a function of its own which does not directly involve the catalytic-
related function of the CSN complex. With this in mind, and with our 
homodimerisation data on CSN5 both in the crystal structure and in solution, the 
 KH
presence of oligomeric species of CSN5 in human cell extracts was further 
investigated.  
 
To gain evidence on the presence of CSN5 homodimerisation in human cell extract, 
co-immunoprecipitation experiments on mammalian cell extracts were performed by 
our collaborator, Dr. F.-X. Claret. These experiments were performed on the 293T 
cell line (embryonic kidney cell line), which were transfected with plasmids coding 
for either Flag- or His-tagged CSN5 or both and incubated for 48 hours. Either anti-
Flag or anti-His tag antibodies were used to immunoprecipitate the cell lysate and 
detection was performed by immunoblotting with anti-His or anti-Flag tag antibodies. 
Corresponding expression control of Flag- and His-tagged CSN5 was checked by 
immunoblotting with anti-Flag and anti-His antibodies, respectively. As presented in 
Figure 3-12B, both His- or Flag tagged FL CSN5 can efficiently immunoprecipitate 
the alternatively tagged CSN5 subunits, indicating that FL CSN5 forms oligomeric 
assemblies in cells. These experiments confirmed that the homo-oligomeric 
arrangement of CSN5 could be observed in a cell extract context, coherently with the 
crystallographic and biophysical data. 
 
The general tendency of MPN domains to dimerise was highlighted by the fact that 
many members display dimeric assemblies in crystallo, as observed in the MPN 
domain crystal structures, of Hs Rpn8, Hs and Dm CSN6 and AfJAMM. However, in 
all these cases, only fragments containing the MPN domain were investigated, 
probably due to difficulty encountered in the purification of FL proteins, as 
experienced in the case of CSN5. To overcome this, the approach of co-
immunoprecipitation of FL CSN5 was used as a method to decipher the argument 
whether the dimerisation of CSN5 in its FL form can be observed or is a result of the 
fragment-based approach taken. This allowed, in the context of CSN5, to determine 
that the dimerisation of CSN5 observed for the fragment 1-257, is unlikely to be a 
crystallographic artefact formed by the fragment of CSN5 used. Indeed, evidence of 
oligomerisation was obtained for the FL CSN5 in cell extracts. However, the cellular 
function of these arrangements of CSN5 was not addressed in our work and remains 
an interesting aspect to investigate.  
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Figure 3-12. Oligomeric arrangement of CSN5. 
A. Sedimentation velocity experiments of the WT form of CSN51-257, showing the results of 
the c(s) analysis for the protein at 333.0, 167.0, 67.0 and 33.0 µM. The dominant peaks at 3.1 
and 4.3 Svedberg units correspond to monomeric and dimeric species, respectively. B. Co-
immunoprecipitation experiments used to biochemically identify CSN5 dimers in cell extracts. 
Biochemical identification of CSN5 dimer in vivo by coimmunoprecipitation experiments. 
293T cells were transfected with either Flag- or His-tagged CSN5 or both for 48 h, and then 
cell lysates were immunoprecipitated (IP) with either anti- Flag (Upper) or anti-His (Lower) 
tag antibodies and immunoblotted (IB) with anti-His or anti-Flag tag antibodies (Left). The 
expression of the corresponding pairs of Flag- and His-tagged CSN5 was confirmed by IB 
using anti- Flag and anti-His antibodies, respectively (Right). IgG heavy chain (HC) and light 
chain (LC) are indicated.

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Intriguing results obtained from our investigation of CSN5 homodimerisation guided 
us to further understand the dynamics of CSN5 homodimer and compare it to its 
previously studied monomeric state. In silico, MD simulations were employed to 
study the dimerisation of CSN5. The aim of this study was to investigate the 
dimerisation interfaces of the two CSN5 dimeric forms in further atomic detail, with 
A 
B 






                   
333.0 µM 
167.0 µM 
67.0 µM 
33.0 µM 
16.5 µM 


 
 
 
 
333.0 µM 
 
 
167.0 µM 
 
 
67.0 µM 
 
33.0 µM 
 
 
16.5 µM 
 KJ
the aim to evaluate whether one of these two assemblies is more likely than the other. 
As described in earlier sections, the crystal structure of CSN5 contains two types of 
dimers which have a interface surface of comparable properties. As such, the 
approach described hereafter was used to identify the CSN5 dimer which represent 
the predominant form in solution and may be of potential biological relevance.  
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For each dimer, A-B and A-A’, 50 ns long MD simulations were ran and the outcome 
trajectories were analysed. A detailed investigation of the behaviour of individual 
subunits at the atomic level during simulations of the different dimers was carried out. 
The overall stability of the dimers was measured by estimating the rmsd deviations of 
each assembly with respect to the initial structures, evaluating changes in hydrogen 
bonding pattern over the simulations and following the evolution of BSA and ASA 
values over the course of the simulations. As shown in Fig. 3-13A. the comparative 
rmsd profiles indicate that each dimer tends to stabilize after 20-30 ns of MD 
simulation, around a value of ~2.7 Å. Analysis of the rmsf of each monomer of CSN5 
from the two dimers are compared to the rmsf values obtained previously from our 
simulation of the monomeric CSN5 (Fig. 3-13B). Overall the expected high 
fluctuation regions located on the Ins-2 insertion is also observed in both dimers. 
However the N- and C- terminal regions, which we had previously classified as highly 
flexible regions, do not display the same behaviours. A difference is seen for dimer A-
A’, for which the C-terminal part experiences lower rmsf values, reflecting restricted 
flexibility. This is directly linked to the position of this segment: indeed, the C-
terminal region of monomer A is anchored in the active site of monomer A’ in A-A' 
dimer and partially stacked on the monomer B in A-B dimer. Additionally, a common 
pattern which differs from the monomeric CSN5 is observed in the Ins-1 region of 
both CSN5 dimers. Whilst, in monomeric CSN5, residues 108 to 113 are highly 
flexible, in both dimers, the fluctuations in this region are significantly dropped, 
although the flexibility on the C-terminal helix of the Ins-1 (residues 122 to 130) is 
maintained in the CSN5 dimers (Fig. 3-13C).   
 
An another way of analysing these dimers is to calculate their interface areas. BSA 
and ASA analysis over the 50 ns of simulation were plotted to analyse the stability of 
the dimers (Fig. 3-13. C and D, respectively). Our aim was to use BSA as a criterion 
to assess protein surface that is not exposed to water and, as such, an increase in the 
BSA would indicate an increase in the ‘compactness’ of the binary complex. Results 
of the analysis indicate that the dimer A-B displays a more extensive buried interface 
between the 2 subunits, as compared to the A-A’ dimer giving an average difference 
of approximately 400 Å2 in BSA. Moreover, whilst the dimer A-A’ reaches an 
equilibrium, with its BSA reaching approximately 1200 Å2 in the final 10 ns of the 
simulation, the BSA of the A-B dimer shows a gradual increase throughout the 
simulation, starting at values of around 1400 Å2 and rising to 1700 Å2, thus indicating 
 KK
in gain of stability. ASA can be used as a way to validate what we see with BSA 
calculations, the dimer showing an increase in BSA is expected to have a reduced 
ASA. Our results clearly show that ASA of dimer A-B is decreasing over the course 
of the simulation, whilst dimer A-A’ remains steady, with a slight tendency to higher 
ASA values compared to starting values, potentially losing its compactness. Taken 
together this analysis of the A-B and A-A’ CSN5 dimers suggest that the A-B dimer 
behaves better during the course of the simulations and is more likely to be the stable 
oligomeric state in solution. 
Accurate estimate of thermodynamic properties, for example binding free energy 
calculations require even more extensive simulations on both dimeric species and thus 
were not attempted in this work. We used an experimental approach based on the 
rational mutagenesis of interfacial hydrophobic residues governing the dimer stability 
to identify the CSN5 dimer which represents the predominant form in solution. 

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 . Dynamics of CSN5 
homodimers. 
A. R.m.s. deviations from the 
minimized crystal structure of the 
two CSN5 homodimers during the 
50 ns MD simulations. B.  
Fluctuations of each CSN5 monomer 
from the CSN5 homodimers during 
MD simulations. C atom r.m.s. 
fluctuations of monomeric CSN5 as 
a function of residue number during 
the 50 ns MD simulations are 
shown. C. Calculated buried surface 
area of CSN5 dimers A-B and A-A’ 
over the course of 50 ns simulations.
D. Calculated accessible surface area 
of CSN5 dimers A-B and A-A’ over 
the course of 50 ns simulations.
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Interfacial mutations were introduced to investigate the disruption of CSN5 dimeric 
interfaces and to identify a monomeric CSN5 variant. The design of these mutations 
was guided by data obtained from structural analysis and the MD simulations 
performed (described in the section above). Targeting the disruption of the A-B dimer, 
mutations performed include two leucine residues (Leu237 and Leu240) located on 
the C-terminal helix 6, facing the helix 4 of the second monomer (Fig. 3-11B). The 
effects of these mutations were evaluated both in vitro and in cell extracts using SV-
AUC and co-IP, respectively. The CSN5 L237Q/L240K variant was subjected to SV-
AUC experiments. Analysis of the sedimentation coefficient at differing protein 
concentrations of 333.0, 167.0, 67.0, 33.0 and 16.5 µM allows to determine a 
dominate peaks at 2.95 S (Fig. 3-14A; 4-12A for WT CSN5). Analysis of the AUC 
data on the CSN5 L237Q/L240K variant clearly depicted a drastic decrease in dimeric 
species of CSN5 in solution. These results confirm the disruption of the A-B dimer in 
solution and that introduction of the L237Q/L240K substitutions in CSN5 destabilises 
CSN5 dimerisation, yielding a mostly monomeric protein. Equilibrium displacement 
towards monomer for the CSN5 L237Q/L240K variant was also clearly visible in the 
quality of 
15
N-CSN5 L237Q/L240K HSQC (data not shown; collected, processed and 
evaluated by Dr. Y. Yang). These results suggest that in solution the variant 
specifically designed to weaken the A-B dimer assembly displays reduced propensity 
to dimerise, and thus further supports that the A-B dimer is the predominant assembly 
in solution, as suggested by our MD simulations analysis.  
 
Results obtained from the investigation of the dimeric interface of CSN5 in solution 
highlighted that CSN5 in solution consists of a mixture of monomeric and A-B-type 
dimeric species. This prompted us to confirm the predominance of CSN5 A-B-type 
dimers in cell extracts. In addition to investigating the CSN5 L237Q/L240K variant, 
an additional substitution of R129 to an alanine, located on the loop between the helix 
4 and the strand 5 was probed by Dr F.-X. Claret’s team. Following the same 
protocol as previously outlined, mammalian 293T cells were transfected with 
plasmids with Flag-tag or His-tag sequence, coding for CSN5 L237Q/L240K variant, 
CSN5 R129 A variant, or CSN5 WT. Cell lysates were subjected to co-IP and IB with 
anti-Flag and anti-His antibodies, respectively. Comparing the IP of CSN5 WT with 
the CSN5 interfacial variants indicates that, for both CSN5 L237Q/L240K and CSN5 
R129A, there is a decrease in oligomeric assemblies of CSN5 (Fig. 3-14B). 
Quantification of the bands obtained highlights a significant, 70-80%, reduction in 
dimer formation. These results confirm the CSN5 A-B dimer is also the preponderant 
assembly in cell extracts and therefore possibly in vivo. On the basis of these results, a 
study addressing the presence and role of CSN5 homo-dimer in cells would be 
required.  
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Figure 3-14. Disrupting the oligomeric state of CSN5. 
A. Sedimentation velocity experiments of the L237QL240K (LL/QK) variant form of CSN5 
1-257, showing the results of the c(s) analysis for the protein at 333.0, 167.0, 67.0 and 33.0 
µM. The dominant peaks at 2.95 and 5.0 Svedberg units correspond to monomeric and, 
probably, dimeric species, respectively. B. CSN5 homodimers are disrupted by the LL/QK 
and R129A (R/A) mutations. 293T cells were transfected with the CSN5 LL/QK mutation, 
R/A mutation, or wild type CSN5 for 48 hours and cell lysates were IP with an anti-Flag 
antibodies and IB with and anti-His antibodies. Cell lysates immunoblotted are shown in the 
bottom panel. Signal intensities were quantified using ImageJ software. 
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As described in section 1.4 of the Chapter 1, members of the JAMM/MPN+ family 
have been found either as single stand-alone multidomain proteins containing 
deubiquitinating activity or as isopeptidases which are associated in more complex 
organisations. Interestingly, for the JAMM/MPN+ protein, Rpn11, CSN5, and 
BRCC36, the incorporation into their corresponding protein complexes is required for 
their activation, whilst this does not appear to be the case for AMSH and AMSH-LP 
[63, 70, 159, 160, 168, 186]. It has been shown in the case of Rpn11 and of BRCC36 
that the protein context in which these enzymes are placed influences their activation 
state. One element that seems to be of particular importance is the presence of a 
MPN- subunit [183]. Indeed in both cases for Rpn11 and BRCC36 and, as we also 
present here for CSN5, the presence of their respective MPN- is sufficient to activate 
them, as detailed in section 1.4 of Chapter 1. Furthermore, in vivo knockdown 
experiments of MPN- subunits give rise to abrogated isopeptidase activity of their 
corresponding complexes [168]. Whilst the catalytic capacity for MPN- subunits in 
itself has been excluded and their role in MPN+/JAMM activation has been 
established, little was known about how this domain contributes to the enzymatic 
activity of the complexes. Recent structural and biochemical evidence have suggested 
that the MPN proteins of these complexes interact directly, forming MPN+/MPN- 
heterodimers, within their complexes [67, 158, 160, 168, 259]. 
 
In the context of the CSN, the crystal structures of the CSN MPN domain-containing 
subunits have individually been elucidated. Initially the structure of CSN6 MPN 
domain, fragment 51-187, from Dm at a resolution of 2.5 Å was solved by molecular 
replacement (PDB code: 4E0Q). This study recapitulated the classical MPN fold 
commonly described in other proteins containing this domain and further identified 
the lack of metal binding ability (Fig. 3-1) [64]. However the length of the CSN6 
fragment (residues 51 to 184) limited the insight that could be gained regarding its 
function in the CSN complex. The role of the CSN6 subunit has been heavily 
accounted for mediating protein-protein interactions. The main reason for this being a 
general trend of MPN- domain-containing proteins which has been depicted in the 
case of Prp8 and Rpn8 [176]. The importance of protein-protein interactions in CSN6 
function was subsequently confirmed, with the N-terminal MPN domain of CSN6 
responsible for the interaction with CSN5, whilst C-terminal half involved in its 
association with the subunits CSN4 and CSN7 [259]. This study suggested that within 
the CSN complex, the role of CSN6 in keeping the integrity of the holo-complex is 
essential. Moreover, in At, knockout of csn6 resulted in a global destabilisation of the 
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CSN complex, accounting for CSN6 essential role in complex assembly [136]. 
Besides the contribution of CSN6 in the assembly of the CSN complex, it has also 
been shown that this subunit also contributes to the association of the complex with 
E3 ligases [47, 70]. However the precise mechanism underlining the function of 
CSN6 within the CSN complex and its involvement in E3 ligases remain to be fully 
elucidated.  
 
As described in Chapter 3, molecular determinants of CSN5 activation was 
established through its active site lock mediated by the salt bridge established between 
residue R106 and D151 [63]. Here we questioned the activation mechanism of CSN5 
within the CSN complex and probed the role of CSN6 in CSN5 activation. Although 
cryo-EM data of the CSN complex provided evidence that these two subunits are 
located in close proximity, biochemical confirmation and biophysical characterisation 
of this binary complex had been lacking [46]. In this Chapter, we investigated the 
association between the CSN5 and CSN6 subunits and identified that CSN6 is able to 
activate CSN5, extending the role of CSN6 beyond CSN assembly. Different 
substrate probes were used to identify the contribution of CSN6 in the activation of 
CSN5. Moreover the crystal structure elucidation of a human CSN6 fragment 
(residues 31 to 220) provides further insight to the molecular architecture and aids the 
understanding of its interaction with CSN5. In addition, the structural information 
about this subunit helped explain its proposed multi-functional nature. A range of 
biophysical techniques, used in conjunction with mutational studies was utilised to 
acquire experimental constraints for the mapping of the interface between the two 
MPN proteins. Here we provide a reconstructed model of the CSN5-CSN6 
heterodimer and characterise its interaction with the Nedd8 part of its substrate. Lastly, 
given the latest development in the CSN literature, we compare the activation 
mechanism of the CSN5-CSN6 heterodimer determined with that proposed from the 
crystal structure of the CSN complex [61].
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The existence in multi-protein complexes of pair of MPN domain-containing proteins, 
as well as various reports based on yeast two-hybrid, proteomic, non-denaturing 
mass-spectrometry or electron microscopy studies have brought insights into their 
dimerisation. To confirm this hypothesis, the association between these two CSN 
MPN proteins was investigated initially by analytical gel filtration and chemical 
cross-linking experiments.  
 
An analytical gel filtration assay was designed as a convenient method to check the 
interaction between the two MPN subunits of the CSN complex. Although several 
reports had indicated that CSN5 and CSN6 interact, a mass spectrometry-based model 
of the CSN complex did not support this association [128]. To determine whether 
these subunits directly associate, CSN6 was titrated into CSN5 to obtain varying 
ratios of CSN5 R106T:CSN6. As seen in Fig. 4-1A. and B., CSN5 and CSN6 interact 
and form a gel-filtration stable binary complex. The ratio 1:1 results in a sample that 
is mostly dimeric.   
 
Although the heterodimerisation is clear from the analytical gel filtration experiments, 
the association between CSN5 and CSN6 was further investigated by chemical cross-
linking experiments. The cross-linking agent bis-(sulfosuccinimidyl)suberate (BS3), a 
bifunctional reagent popular in protein-protein interaction studies, selective for the N-
terminal amino group and lysine side chains was used. Denaturing gel electrophoresis 
of samples after chemical cross-linking showed that the reaction resulted in the 
production of covalently linked species of different electrophoretic mobility (Fig. 4-
1C). In the presence of the cross-linker, the sample containing CSN5 and CSN6, 
generated three additional protein bands at molecular weights corresponding to the 
CSN5-CSN6 heterodimer, to the CSN5 homo-dimer and -trimer complexes. The 
dimeric arrangement of CSN5 in solution was previously discussed in Chapter 3. As 
controls, CSN5 and CSN6 were individually subjected to the BS3 agent and yielded 
dimeric, trimeric and higher order CSN5 species, whilst a small band corresponding 
to the dimeric species of CSN6 was visible. 
 
The results obtained here indicate that the MPN domains of CSN5 and CSN6 form a 
stable heterodimer complex. The results obtained are also in agreement with reports 
on the interaction between the MPN proteins Rpn11 and Rpn8 of the proteasome lid, 
in which the two co-expressed MPN domains form a stable binary complex [158, 160].  
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The interaction between the MPN domains of CSN5 and CSN6 was further quantified 
using ITC experiments. Sequential titrations of CSN6 at 1 mM were performed on 
100 M of CSN5. Besides confirming the CSN5-CSN6 binary formation, these 
experiments also revealed a heterodimer KD of 6 ± 1 M (Fig. 4-1D). Consistent 
values regarding the binding properties to CSN6 to the CSN5 constitutively active 
variant R106T were also obtained, indicating a similar affinity of CSN5 R106T to 
CSN6 when compared to that of the WT CSN5 (Fig. 4-1D). Our data reveal a 
comparable affinity of CSN6 for both CSN5 wild type and its conformationally-
relaxed variant, indicating that this mutation does not affect CSN5 ability to associate 
with CSN6.  
Here we present the first quantitative analysis of the MPN+/MPN- direct interaction. 
Previously characterisation of this association has been limited due to challenges 
associated with the purification of these proteins individually or the co-purification of 
the two partners [158, 160]. 
 
 
Figure 4-1. CSN5 and 
CSN6 form a binary 
complex. 
A. The interaction of 
CSN5 with CSN6 was 
monitored by analytical 
gel filtration. Varying 
ratios of CSN5 
R106T:CSN6 were run on 
a Superdex 75 10/300 
column. B. SDS-Page of 
fractions eluted from the 
analytical gel filtration 
column for a ratio 1:1 of 
CSN5 R106T:CSN6. C. 
Chemical cross-linking 
experiments using BS3 
cross-linker. D. The 
interaction between CSN5 
and CSN6 was quantified 
in ITC titration 
experiments. The 
isothermograms represent 
the binding of CSN5 (left) 
and CSN5 R106T variant 
(right) to CSN6 at 305 K. 
The KD is 6 ± 1 µM. 
Titration raw data: upper 
panel; integrated data 
obtained after subtracting 
the heat of dilution: lower 
panel. Titration buffer: 20 
mM Tris-HCl pH7.5, 50 
mM NaCl. Titration: 
sequential addition of 
CSN6 (at 1 mM) to CSN5 
and CSN5 R106T (at 100 
µM).
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The catalytic MPN+ domain-containing proteins that, form part of larger complexes, 
including the CSN, are known to lack significant enzymatic activity, in their stand-
alone form. Various studies on the 19S proteasome lid and the BRCC36 complexes 
have shown that their MPN- domain-containing proteins are required for expressing 
the activity of the catalytic subunits. Most recently, the structural studies on Sc 
Rpn11-Rpn8 complex addressed the activity of this heterodimer and showed that this 
construct, including the MPN domains of these proteins, is in a catalytically active 
conformation, albeit revealing lower activity compared to the holo-proteasome [158, 
160]. It is noteworthy that the specific contribution of Rpn8 in Rpn11 activation was 
not established in these studies. 
 
Previously we addressed, at the molecular level, the activation mechanism of CSN5 in 
its stand-alone state (Chapter 3). We showed that CSN5 could be partially activated 
by the disruption of the active site located salt-bridge between residues R106 and 
D151. This work highlighted a low affinity of CSN5 for Nedd8 and in particular 
indicated that its Ins-1 region requires undergoing conformational changes to form a 
competent recruitment site groove for its substrate [63]. Although insights into the 
activation of CSN5 had been gained at the atomic level, the activation determinant of 
CSN5 within the CSN complex remained unknown, i.e. which factors contributes to 
the structural changes necessary for CSN5 to be in a catalytically primed 
conformation. The first ‘suspect’ considered was CSN6. We based our work on the 
three following mechanistic hypothesis: (i) Together with previous literature of MPN- 
proteins activating MPN+ domain containing enzymes, the direct interaction between 
CSN5 and CSN6, allowed us to speculate that CSN6 activates CSN5. (ii) The 
contribution of the substrate could not be neglected, nor could the association of the 
substrate with other CSN subunits. (iii) It was thus unclear whether the activation of 
CSN5 is regulated by its incorporation into the CSN or if it is subjected to a substrate 
induced activation mechanism. Moreover the contributions of the two proposed 
mechanisms may not be exclusive. We have shown that CSN5 and CSN6 directly 
interact. Here, we addressed the impact of CSN6 on the isopeptidase activity of CSN5. 
To do so, we employed the use of different synthetic substrates to conduct enzymatic 
assays and further characterise the activity using the more complex, physiological 
neddylated Cul1-Rbx1 substrate. 
 
Initially the activity of CSN5 as a heterodimer with CSN6 was measured against the 
synthetic substrate, LRGG-AMC. Our results in Chapter 3, revealed that both CSN5 
lacks detectable activity on this substrate but its R106T variant displays increased 
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hydrolytic ability in the tested conditions. In our studies, the addition of CSN6 to the 
WT and variant forms of CSN5 triggers an unprecedented increase in fluorescence 
intensity and therefore in catalytic activity for both (Fig. 4-2A). At the highest 
substrate concentration tested (400 µM), saturation was not reached. Because of that, 
full kinetic characterisation could not be obtained and the kapp values were 
extrapolated from the slope of the plot kobs (v0/E) versus substrate concentration. 
Comparison of the results obtained reveals a higher catalytic efficiency, of 0.056 M
-
1
s-
1
, for the CSN5 R106T variant in the presence of CSN6, compared to the CSN5-
CSN6, showing 3-fold lower efficiency (Fig. 4-2A). Our results indicate that the loss 
of the salt bridge between R106 and D151 appears to help the activation mechanism 
and further a synergetic effect of the presence of CSN6 and of the conformational 
relaxation of the Ins-1 insertion can be assumed. For comparison, the activity of 
NEDP1, which contains both deneddylation and pro-Nedd8 processing functions, 
against LRGG-AMC substrate was investigated. In the cell, the Nedd8 substrate is 
synthesised as a precursor protein (pro-Nedd8; 81 residues) containing a C-terminal 
extension, -G
75
G
76
GGLRQ, which is later converted into the mature form (76 
residues) via a C-terminal hydrolytic activity resulting in a functional -G
75
G
76
 C-
terminus [38]. The processed Nedd8 is then able to be conjugated to Cullin molecules, 
which results in active CRLs. In mammals, NEDP1 (also known as DEN1), a 211-
residue Nedd8-specific protease, has been shown to be responsible for Nedd8 
maturation [53]. This enzyme displays kapp values of approximately 4 M
-1
s
-1
, 
revealing appreciably more efficient activity compared to the MPN heterodimer 
investigated (Fig 4-2A). 
 
The activity of CSN5 in the presence of CSN6 was also investigated using the 
synthetic, AMC-derived substrate, Nedd8-AMC. Previously, in our work, we revealed 
that, although stand-alone CSN5 lacks catalytic activity, the CSN5 R106T variant is 
able to hydrolyse the Nedd8-AMC substrate. Comparison of these results with those 
obtained in the presence of CSN6 highlighted that the activity of both CSN5 and 
CSN5 R106T are significantly enhanced in the case of the Nedd8 substrate. In these 
experiments, the saturating concentrations of substrate were not reached. 
Consequently, full kinetic characterisation could not be carried out and the kapp was 
determined to obtain a quantifiable comparison of enzyme efficiency. For the 4 nM 
CSN5 R106T-CSN6 complex (the concentration of binary complex was calculated 
using the apparent KD values determined by ITC), a strong activity on Nedd8-AMC 
was detected, giving estimated KM and kcat values of 18 µM and 4.3 s
-1
, respectively 
(Fig 4-2B). The same concentration of CSN5 WT-CSN6 complex is unable to be 
saturated with 6 µM substrate concentration, potentially suggesting a reduced affinity 
of CSN5 WT/CSN6 for Nedd8. Moreover, comparison of kapp between these two 
complexes highlighted that the CSN5 R106T-CSN6 is approximately 4-fold more 
efficient at hydrolysing Nedd8-AMC, than the CSN5 WT-CSN6 one. The catalytic 
efficiency of the MPN heterodimer of the CSN can be further compared to data 
reported on the hydrolysis of Nedd8-AMC by NEDP1. This study showed that this 
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enzyme contains a significantly stronger catalytic efficiency of about 41.10
6
 M
-1
s
-1
 for 
the substrate [270]. These results are coherent with ours presented on the hydrolysis 
of LRGG-AMC substrate by NEDP1, which commonly shows higher efficiency for 
both Nedd8 and LRGG-AMC substrates. 
 
Furthermore, our results obtained on the enzymatic activity of the CSN5-CSN6 
heterodimer are coherent with recent data determined on the kinetic parameters of the 
19S proteasome lid Rpn11-Rpn8 dimer. In this work the cleavage of di-Ub was 
measured determining KM and kcat values ranging from 120 to 299 µM and 4.8 x 10
-3
 
to 1.2 x 10
-2
 s
-1
, respectively, depending in the type of Ub linkage. The high KM 
values obtained in this work were reasoned as a result of steric hindrance caused by 
the proximal moiety of the di-Ub. This value is consistent with the KM value obtained 
for the CSN5-CSN6 heterodimer cleavage of NEDD8-AMC in our experiments.  
 
To determine whether the catalytic efficiency determined for these heterodimer 
complexes is comparable to that observed with the CSN complex, the ability of the 
holo-enzyme to hydrolyse Nedd8-AMC was investigated. These results revealed KM 
values of 3 µM and kcat values of 0.05 s
-1
 for the CSN (Fig 4-2B). These values 
suggest at first approximation that the holo-complex could have a higher affinity for 
the substrate and thus requiring a lower substrate concentration for effective catalysis 
compared to the CSN5 R106T-CSN6 complex. However the lower kcat value obtained 
with the CSN complex dictates that a reduced amount of substrate molecules are 
turned over per enzyme molecule per second when compared to the CSN5 R106T-
CSN6 heterodimer. This indicates a lower overall catalytic efficiency for the CSN 
complex. These values obtained for the CSN complex suggest that, although its 
affinity to the Nedd8-AMC substrate is significant, its ability to hydrolyse the 
substrate is not optimal. The kcat value of the CSN on Nedd8-AMC is significantly 
lower than on neddylated Cul1 substrate, as measured by Deshaies and co-workers 
[72]. This study yielded values of KM and kcat at 212 nM and 1.1 s
-1
, respectively, for 
CSN on its natural substrate [72], highlighting the contribution of the nature of the 
substrate to these values. In other terms, these results indicate that neddylated Cul1-
Rbx1 is a better substrate for the CSN complex, consistent with various studies [72]. 
This is likely to result from a stronger affinity between the holo-CSN complex and its 
natural substrate. Moreover it is possible that neddylated Cullin substrates contribute 
to the correct positioning of Nedd8-cullin isopeptide bond within CSN5 active site, 
through extensive interactions between the neddylated CRL substrate and different 
CSN subunits. In the following section, we further addressed the activity of the 
CSN5-CSN6 heterodimer on one of its natural substrates and compare it with that of 
the CSN. 
 
The results presented here in this section clearly demonstrate that CSN6 is able to 
activate CSN5 from its inactive, stand-alone state, making it a competent enzyme for 
the hydrolysis of both the LRGG-AMC and Nedd8-AMC substrates. Previous to our 
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work, whilst the activation of MPN+ domain-containing proteins via their association 
with their corresponding MPN- domain-containing proteins was reported for both 
Rpn11 and BRCC36, contradicting data was reported for the relationship between the 
MPN proteins of the CSN complex. The referred study [143] investigated the 
significance of the MPN- domain of human CSN6 and a yeast homolog, namely Csi1. 
Despite sharing substantial sequence homology with the C-terminal domain of human 
CSN6, the yeast homolog lacks the characteristic MPN- domain. This study suggested 
that the C-terminus of human CSN6, and not its MPN- domain, is sufficient for the 
assembly of the holo-complex, forming a fully active organisation. Moreover the 
absence of the MPN- domain in yeast further encouraged to conclude that the MPN- 
domain is not a prerequisite for the deneddylase activity of the CSN complex [143]. 
In addition to lacking a fully corresponding CSN6, subunits CSN3 and CSN8 are also 
absent in yeast (Table 1-1.) [143]. Furthermore little structural and functional 
informational is available on the activation state of CSN5 in yeast.  
 
Additionally, within our work, using a variety of substrates, we were able to 
discriminate Nedd8-AMC as a better substrate for the CSN5/CSN6 heterodimer over 
the minimal LRGG-AMC substrate. Higher affinity for Nedd8 and further interactions 
with the full Nedd8 substrate may be required for the correct orientation of the 
isopeptide bond for optimum activity. The similar range of kinetic values obtained for 
both the CSN and the MPN heterodimer complex, allows us to propose the CSN5-
CSN6 complex as the core CSN deneddylase. A major contributor in the activation of 
the CSN5 subunit appears to be its interaction with CSN6. That being said, the 
contribution of other subunits has not been addressed here. Previous studies have 
shown that the CSN5-CSN6 heterodimer forms a distinct appendix, flexibly anchored 
to the CSN PCI core through their C-terminal regions [46, 61]. As such it is likely that 
this heterodimer is mostly directly responsible for the catalytic reaction, although 
other CSN subunits are known to contribute to substrate recruitment in the context of 
neddylated CRLs. 
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. CSN6 activates CSN5 to form the catalytic core of the CSN complex. 
A. The isopeptidase activity of the CSN5-CSN6 complex was tested against the LRGG-AMC 
substrate. B. Kinetic parameters of the isopeptidase activity of the CSN5-CSN6 complex on 
Nedd8-AMC substrate were determined. Kinetic data for NEDP1 was obtained from [270]. 
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Having both shown that CSN5 in the stand-alone state was not competent for Nedd8 
binding and that CSN6 binding to CSN5 triggers its activation, this prompted us to 
address whether the role of CSN6 in the activation of CSN5 is correlated with an 
increase in Nedd8 affinity. To explore this, we studied the effect of CSN6 on the 
interaction of CSN5 with Alexa Fluor 488-labeled Nedd8 by fluorescence anisotropy 
(Fig. 4-3A). Our results correspond to the binding affinity of the CSN5 WT-CSN6 
complex or of the complex containing CSN5 R106T variant, to the Nedd8 substrate. 
By fitting the data to the Hill equation, apparent KD values were determined for each 
case. Previously we had shown that the conformational relaxation introduced to the 
Ins-1 region of CSN5 by the R106T variant increases the affinity for Nedd8, as 
presented in Chapter 3.  
 
Addition of CSN6 to CSN5 WT or to the CSN5 conformational variant R106T 
revealed in both cases that the presence of CSN6 increases the affinity of the 
complexes for Alexa Fluor 488-Nedd8 (Fig. 4-3). To clarify whether the increase in 
affinity observed in the presence of CSN6 is a consequence of CSN6 interacting with 
Nedd8, its interaction with Alexa Fluor 488-Nedd8 was measured (Fig. 4-3). Here we 
showed that CSN6 is not interacting with the substrate, although some evidences of 
very weak interaction had been recorded using NMR (data not shown). The increase 
in affinity was more pronounced in the case of the CSN5 WT-CSN6 complex where a 
nearly 2-fold decrease in KD was observed, whilst for the CSN5 R106T-CSN6 
complex a less significant drop in KD was obtained (Fig. 4-3). The same range of 
affinity observed for the CSN5 R106T stand-alone and, when in complex with CSN6, 
further suggests that the opening of the Ins-1 region is part of the mechanism involved 
in forming a competent active site groove that can accommodate Nedd8. Our results 
indicate that these conformational changes, among which the reorganisation of the 
Ins-1 region, in the case of CSN5 WT and possibly of CSN5 R106T are promoted, at 
least in part, by the association with CSN6. 
 
Figure 4-3. Determination of the dissociation constant of the CSN5-CSN6 interaction 
with Nedd8. 
The normalised anisotropy of Alexa 488-labelled Nedd8 (4 nM) is plotted as a function of 
CSN5-CSN6 complex concentration. The K
D
 was determined for the CSN5-CSN6 and CSN5 
R106T-CSN6 complexes; the binding constant for CSN6 was too low to be determined. 
 CCD
For context, the affinity of NEDP1 for Alexa Fluor 488-Nedd8 was also measured 
giving values of a similar range to that obtained by the CSN5-CSN6 heterodimer (Fig. 
4.3). As a crude generalisation, for proteins containing Ub-binding domains, their 
association with single Ub or Ub-like proteins has been classified as moderate to 
weak interactions, typically containing KD values ranging from 1-500 µM. In 
biological systems, low range protein-protein interactions are commonly 
physiologically relevant [264, 271]. Thus the weak binding affinities of Ub-binding 
domain-containing proteins have been suggested to prevent promiscuous binding of 
free Ub, which in mammalian cells, exists at a high concentration of approximately 6 
µM [272]. Examples of affinity studies on MPN domain-containing proteins include 
that of the pre-mRNA splicing factor, Prp8p, which binds Ub with an affinity of ~380 
µM, although the relevance of this interaction is presently unknown [265]. More 
specific for JAMM/MPN+ domain-containing protein, low affinity for the substrate 
may be considered part of the mechanism of preventing premature activation of their 
isopeptidase activity. For the heterodimer Rpn11-Rpn8, a tryptophan fluorescence-
based assay was reported for its interaction with K48-linked di-Ub revealing a KD of 
~67 µM [160]. We have shown that the affinity of the CSN5-CSN6 dimer is in the 
reach with KD values of other MPN domain containing proteins reported in literature, 
to date. Inevitably the affinity of CSN5 within the CSN complex for Nedd8 may be 
stronger, and more so for neddylated Cul1-Rbx1. Factors that may influence the 
affinity may include the C-terminal helical bundle of the MPN proteins (which are 
absent in our experimental setup) or further subunit contacts either with CSN5 itself 
or with the substrate. However correlating with our activity results, the CSN5-CSN6 
dimer is in a competent state that can bind and hydrolysis Nedd8-based substrate.   
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Determining that the CSN5-CSN6 heterodimer is a catalytically active complex 
towards the synthetic substrates, LRGG-AMC and Nedd8-AMC encouraged us to 
measure its deneddylase activity towards its physiological neddylated Cul1-Rbx1 
substrate. To date, the major function of the 8-subunit CSN constitutes the cleavage of 
the isopeptide bond between the Nedd8 and Cullin proteins [47, 163].  
 
We thus set ourselves to characterise the CSN5-CSN6 deneddylating activity by 
developing an in vitro assay in which the conversion of neddylated Cul1-Rbx1 to 
Cul1-Rbx1 could be detected and quantitatively measured (Fig. 4-4A). Our results 
here indicated that, as expected, the CSN at a concentration of 4 nM contains robust 
activity towards 1 M neddylated Cul1-Rbx1 complex. As previously discussed, the 
high affinity of CSN towards its physiological substrate was reported in earlier studies 
where in comparison with our work coherent rates were determined. In both studies 
the CSN complex hydrolysis more than 80% of its substrate after 10 minutes 
incubation. In Chapter 3 (Fig. 3-10), we confirmed the lack of deneddylase activity of 
CSN5 on neddylated Cul1-Rbx1, whilst after 3 hours incubation, the conformational 
 CCE
variant CSN5 R106T showed a modest but significant deneddylase activity. Here in 
the presence of CSN6, we determined that for both CSN5 WT and its R106T variant 
(at a 4 nM concentration of the binary complex) against 1 M substrate, 
approximately 40% and 60%, respectively, of the activity observed for the holo-CSN 
complex is retrieved (Fig 4-4). Additionally the activity of CSN5 R106T alone on 
neddylated Cul1-Rbx1 was measured using 900 nM of enzyme and 1 µM of substrate, 
showing a reduced capacity for hydrolysis after 120 min incubation, compared to both 
CSN5 WT-CSN6 and CSN5 R106T-CSN6 complexes.  
 
Comparison of our results obtained on the hydrolytic activity of the CSN on the 
synthetic Nedd8-AMC and the physiological neddylated Cul1-Rbx1 substrates further 
reinforces the already documented contribution of the holo-CSN complex in the 
efficient binding of neddylated CRLs [46]. A recent electron microscopy study on the 
CSN in complex with the SCF substrate has shown that the CSN localises to both the 
functional N- and C- terminal sites of the SCF. In the model proposed, interactions 
primarily involve the CSN2/CSN5 region forming contacts with Cul1 C-terminus and 
the CSN1/CSN3 region with the N-terminal substrate receptor module. This indicates 
a large interaction surface governed on the CSN complex, which can accommodate 
the SCF. In fact the contribution of CSN5 in this interaction is suggested to be 
minimal, as this subunit has been shown to be dispensable for the assembly of the 
remaining seven subunits. This is coherent with the peripheral location of CSN5 
within the complex. Moreover, even in the absence of CSN5 it was shown that the 
remaining subunits could still form a stable complex with SCF, actually suggesting 
that a CSN5-Nedd8 contact is not required for the CSN-SCF complex formation. This 
study highly suggested that, although CSN5 harbours the catalytic centre of the CSN, 
it is itself not fully competent at recognising neddylated SCF substrates in their whole, 
but requires CSN2 and potentially other CSN subunits to correctly position the Nedd8 
moiety in its active site [46]. 
 CCF


Figure 4-4. Deneddylase activity of the CSN5-CSN6 heterodimer. 
A. The experiments were performed at 37
°
C, in the time intervals indicated on the figure. For 
comparison CSN (at 5 nM) and CSN5-CSN6 complex (at 4 nM) were incubated with 1 µM 
substrate. The activity of the heterodimer complex was tested against neddylated Cul1 substrate 
using a gel shift assay. The bands of neddylated-Cul1 and Cul1 after the experimental run were 
visualised and quantified. B. Plot of deneddylase activity of CSN5-CSN6 binary complex. To 
obtain a quantifiable value for the deneddylase activity of CSN5 R106T variant, 900 nM of 
enzyme was incubated with 9 µM substrate for 2 hours at 37
o
C.
 CCG

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The recently determined crystal structure of Dm CSN6 MPN domain (PDB code: 
4E0Q) fragment (comprising residues 51 to 184) corresponds to a portion of the MPN 
core domain, with various missing fragments difficult to model and lacking its C-
terminal region [64]. As a result of this limited structure, our work has aimed to 
obtain the structure of the human counterpart, preferably of a longer fragment. Three 
C-terminal truncated constructs of CSN6 were designed on the basis of secondary 
structure prediction calculated by the server JPred [273]. These three constructs 
produced protein in expression trials, although the longest fragment was susceptible to 
protein degradation and the shorter fragment comprising the residues 31 to 220 
yielding most robust expression was selected for crystallisation. Additional insights 
were gained by elucidating the crystal structure of the MPN- core domain (fragment 
31 to 220) of human CSN6 by molecular replacement at a resolution of 1.76 Å, where 
HsRpn8 was used as the search model (PDB code: 2095; Table 4-1). The crystal 
belongs to the space group P3121 and contains a single molecule per asymmetric unit. 
The crystallised human CSN6 MPN structure displays a typical MPN domain 
arrangement comprising of a central -sheet made of seven strands decorated with 
three -helices (Fig. 4-5A and B). The human CSN6 core is tightly folded and forms 
an anti-parallel -sheet (made of the 1, 2, 3 and 6 strands) surrounded by the 1, 
2, and 3 -helices. The small anti-parallel -sheet, consisting of the 4 and 5 
strands, followed by the 2 helix forms the Ins-1 region of human CSN6. The second 
insertion, Ins-2, in this structure is composed of a -sheet made of the 8 and 9 
strands. A C-terminal appendix (comprising the residues 192 to 208) includes a small 
helical part (4 helix composed on the residues 201 to 207; Fig. 4-5A) that displays 
signs of flexibility (high B-factor values).  
  
 CCH

 . Data collection and structure refinement statistics of human CSN6 MPN 
domain. 
Data collection CSN6 
(residues 31-211) 
PDB code 4QFT 
Space group P3121 
Cell dimensions (Å)  
a 96.84 
b 96.84 
c 48.33 
Maximal resolution (Å) 1.76 
Observed reflections 263.696 
Unique reflections 26.172 
Completeness (%) 100 
Rmerge
a
 0.104 
Mean I/ (I) 14.4 
Highest resolution bin (Å) 1.86-1.76 
Completeness (%) 100 
Rmerge
a
 0.492 
Mean I/ (I) 4.9 
  
Refinement  
Protein atoms 1474 
Waters 181 
Resolution range (Å) 48.00-1.76 
Rconv
b (%) 15.5 
Rfree
c (%) 20.6 
Mean protein B factor (Å2) 25.3 
Mean solvent B factor (Å2) 39.1 
Rms deviation bond angles () 1.164 
Rms deviation bond length (Å) 0.007 
Estimated coordinate error (Å) 0.112 
 
aRmerge = hj |Ih,j – h|/hj|Ih,j|, where Ih,j is the jth observation of reflection h.  
bRconv = h||Foh| - |Fch||/h|Foh|, where Foh and Fch are the observed and calculated 
structure factor amplitudes respectively for the reflection h.  
cRfree is equivalent to Rconv for a 5% subset of reflections not used in the refinement 
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Figure 4-5. Crystal structure of human CSN6. 
A. Crystal structure of human CSN6 (fragment 31 to 220) revealing its core MPN domain 
(magenta) decorated with a peripheral C-terminal extension (yellow). Secondary structure 
elements are numbered as indicated. The Ins-1 and Ins-2 insertion have been highlighted. 
Right panel: 180° rotated view of left panel. B. Schematic representation of the CSN6 domain 
organisation. The MPN domain is delineated in magenta; the N- and C-terminal extensions 
are yellow. The Ins-1 and Ins-2 insertions are placed with respect to their location in the 
sequence. The secondary structure elements are indicated. Regions that are either not ordered 
in the crystal structure or not included in the crystallised fragment are indicated by a black 
dotted line.  
 
Although a single CSN6 molecule is present in the asymmetric unit, the 
crystallographic 2-fold symmetry operator generates a dimer stabilised by an -helix 
swapping, via the C-terminal 4 helix from each of the molecules (Fig. 4-6A). The 
homodimer interface involves the following secondary structure elements: 1, a2, 4 
on both subunits. According to the PISA Server [210], the interface area for this 
crystallographic dimer of human CSN6 is 2478 Å2. Various other structural examples 
of MPN domain homodimerisation have previously been demonstrated including the 
DmCSN6 and the HsRpn8 dimers [64, 176], illustrated in Fig. 4-6B and C, 
respectively. However until recently, all the MPN homodimers structurally 
documented were involving different interfaces.  
 
The DmCSN6 structure identified two dimeric arrangements where the asymmetric 
unit comprises of the A:B type of dimer with non-crystallographic 2-fold axis, whilst 
the second B:B type dimer identified is created by crystal packing. The crystal 
structure of Hs Rpn8 also identified two possible dimeric assemblies showing 
different kinds of dimerisation interfaces: the A:B interface that is contained within 
the asymmetric unit related by a non-crystallographic 2-fold axis and the A:A dimer 
representing an interface between symmetrically related subunits. In both structural 
 CCJ
studies a biologically relevant dimerisation interface was proposed accounting to the 
A:B dimer in DmCSN6 and the A:A dimer in Rpn8/Mov34. As shown in Fig. 4-6B 
and C, the interface of the non-crystallographic dimers of these two subunits differs 
vastly, however the interface observed in human CSN6 is reminiscent of that 
described in the A:A dimer of Rpn8/Mov34 crystal structure (Fig. 4-6A and C). The 
C-terminal helix swapping observed in these two homodimers is a prominent feature. 
Interestingly, the human CSN6 homodimeric organisation differs to those observed in 
the Dm crystal structure (Fig. 4-6A and B). The difference in the interaction surface 
observed between human and Dm CSN6 structures may be a consequence of the use 
of a smaller fragment in the case of Dm CSN6, resulting in an atypical dimeric 
arrangement.   
 
The elucidation of the human CSN6 structure allowed us to obtain a more 
comprehensive view of CSN6 architecture, in particular, regarding the C-terminal part 
of CSN6 MPN domain and its potential role. Moreover the shared dimeric interface 
with Hs Rpn8 may provide the basis for the JAMM/MPN+ interaction surface with 
MPN- subunits.  
 
 
 
 
 
Figure 4-6. Homodimerisation 
of MPN- domain containing 
proteins. 
The crystal structures 
represented here depict the core 
MPN domain in magenta 
decorated with peripheral the C-
terminal extension in yellow and 
are placed in the same 
orientation. The symmetry-
related molecule is shown in 
gray by transparent surface 
representation. A. Dimer of 
human CSN6
 
(fragment 31 to 
220; PDB code: 4QFT)
 
 
generated by the crystallographic 
2-fold operator. Right panel: 
180° rotated view of left panel. 
B. Structural comparison 
performed with the potential 
biologically relevant dimer of 
Dm CSN6
 
(fragment 51 to 185; 
PDB code: 4E0Q). Right panel: 
180° rotated view of left panel. 
C. The crystal structure of 
human Rpn8 (fragment 1 to 177) 
PDB code: 2096). The 
dimerisation mode of human 
CSN6 and of Rpn8 reveals a 
common dimeric arrangement. 
Right panel: 180° rotated view of 
left panel.
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A multiple sequence alignment of human CSN6 MPN domain with its homologues 
depicts a high degree of identity (Fig. 4-7A and B). Mapping the sequence 
conservation onto our structure of human CSN6 results in a highly dispatched profile. 
Small conserved patches can be found on the solvent-exposed area, however a large 
conserved region is identified that is involved in making up the dimer interface. This 
is suggestive of a potentially important role in CSN6 functions and associations.   
 
Electrostatic surface potential analysis was performed on our structure of human 
CSN6 revealing that the fragment crystallised preponderantly displays electronegative 
residues at its surface which is in agreement with its theoretical isoelectric point of 5 
(Fig. 4-7C). Regions of strong positive electrostatic potential are located on the C-
terminal end of the 2 helix and the loop between the 7 and 8 strands that together 
form a solvent exposed groove. The grove corresponds to the site where the canonical 
JAMM motif is located for JAMM/MPN+ proteins. In addition to the positive charge 
observed in this region, the groove is also well conserved which could potentially 
indicate a functional importance associated to protein interactions. Furthermore, the 
4 helix also contains regions of positively charged residues, whilst the Ins-1 and Ins-
2 insertions are highly negatively charged.  
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As observed with other MPN- domain-containing proteins [64, 176, 274], the human 
CSN6 structure is void of a canonical JAMM motif and thus lacks a metal or water 
molecule in the corresponding region. However, comparison of the zinc-binding site 
of human CSN5 with the equivalent region on CSN6 reveals that several residues 
forming the JAMM motif in CSN5 are also contained similar in CSN6, suggesting a 
pseudo metal-binding site. Superimposition of the two subunits identifies that the 
CSN5 active-site residues, E76, S148, and D151 structurally correspond to residues 
Q67, D132, and D135, respectively, in CSN6 (Fig 4-7D). The major difference 
observed is the replacement of the two catalytic histidine residues, H138 and H140, in 
CSN5 by T126 and G128 in CSN6. This disrupts the zinc coordination site and thus 
explains the lack of metal-binding ability of CSN6. In CSN6, K153 is seen to occupy 
the side chain position of H140 present in CSN5 and can potentially restore the 
negative charge missing from the absence of a histidine, however it is not sufficient 
for establishing an active catalytic site. 
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Figure 4-7. Biochemical 
and structural 
properties of human 
CSN6. 
A. Sequence alignment of 
CSN6 from eight diverse 
organisms. CSN6 
sequences were retrieved 
using Blastp with human 
CSN6 as the search 
sequence. Subsequent 
alignment of the nine 
sequences was performed 
by Clustal Omega server 
(default parameters). Dm: 
Uniprot entry: Q9VCY3; 
Hs: Uniprot entry: 
Q7L5N1); Mm: Uniprot 
entry: Q3UIT2; Xl 
(Xenopus laevis): Uniprot 
entry: Q6NUC2; Dm: 
Uniprot entry: Q9VCY3; 
Sm: (Schistosoma 
mansoni): Uniprot entry: 
G4V7G0; Os (Oryza 
sativa): Uniprot entry: 
Q6ZKM2; Bm (Bombyx 
mori): Uniprot entry: 
Q2F614. Strictly 
conserved residues are 
shown in red. Residues 
that form the pseudo 
metal-binding site of 
CSN6 are indicated with 
a ‘*’ sign, in black for 
residues similar to and in 
green for those diverging 
from the canonical 
JAMM motif. Residues 
H44, N85, E88 and V115 
discussed in the text are 
in green. The Ins-1 and 
Ins-2 regions were 
highlighted in blue boxes, 
whilst CSN6 residues 
involved in forming the 
interface with CSN5 are 
shown in yellow boxes.
HsCSN6        ------MAAAAAAAAATNGTGGSSGMEVDAAV------VPSVMACG-VTG 37
MmCSN6        --------MAAAAAAGANGSGGSSGMEVDAA-------VPSVMASG-VTG 34
XlCSN6        -----------MAAAASNG----NGMEVDVAA------LPSVMAQG-VTG 28
DmCSN6        MEQMEVDVDMSAKPSTSSSAAAGSSMAVDKTADQNPQPQGNIMAAAGTSG 50
SmCSN6        ------------------------------MS---------------SSS 5
OsCSN6        ----------MSAPSDPAVATHPQAGAAAAAS---------------SSS 25
DdCSN6        -----------MTDTTTTTTTDANKLVLEKSA---------------NSS 24
BmCSN6        -----------MTEDDSKLAG-------HSEP----------------IS 16
                                                             
HsCSN6        SVSVALHPLVILNISDHWIRMRSQEGRPV-------------QVIGALIG 74
MmCSN6        SVSVALHPLVILNISDHWIRMRSQEGRPM-------------QVIGALIG 71
XlCSN6        SVTVALHPLVILNISDHWIRMRSQEGRPM-------------QVIGALIG 65
DmCSN6        SVTISLHPLVIMNISEHWTRFRAQHGEPR-------------QVYGALIG 87
SmCSN6        GLTFKLHPLVIVNISDHYTRLMAQAAATG-----SAGIPPPLRVFGCVIG 50
OsCSN6        GLTFKLHPLVIVNVSDHHTRVKAQAACSGDGASSAAAGGQPPRVFGCVIG 75
DdCSN6        GLEVDLHPLVLINISDHFTRTKVQSNYQDN-----------CRVIGVILG 63
BmCSN6        AIAVSLHPLVIMNISEHVTRISAQRNDGKP-----------FEVFGAILG 55
                                                        *  
HsCSN6        KQEGRNIEVMNSFELLS-HTVEEKIIIDKEYYYTKEEQFKQVFKELEFLG 123
MmCSN6        KQEGRNIEVMNSFELLS-HTVEEKIIIDKEYYYTKEEQFKQVFKELEFLG 120
XlCSN6        KQEGRNIEVMNSFELLS-QINDEKITINKEYYYTKEEQFKQVFKDMEFLG 114
DmCSN6        KQKGRNIEIMNSFELKT-DVIGDETVINKDYYNKKEQQYKQVFSDLDFIG 136
SmCSN6        VQAGRNVEIFNSFELKH-DAATD--SLDRPFLETKQEQYKKVFPKYDVLG 97
OsCSN6        VQRGRTVEIFNSFELVL-DPVSG--TLDRAFLEKKQELYKKVFPDFYVLG 122
DdCSN6        VQNGRNVEICNSFEMVY-ATVDKQLVLDIEYLRKK---YEQLFPLYDLLG 109
BmCSN6        KQSGRHIEMMNSFEVKWNNEGKGYAVIDADFLSTREQQYQEVFQDLDYVG 105
            
HsCSN6        WYTTGGPP-DPSDIHVHKQVCEIIESPLFLKLNPMT-KHTD-LPVSVFES 170
MmCSN6        WYTTGGPP-DPSDIHVHKQVCEIIESPLFLKLNPMT-KHTD-LPVSVFES 167
XlCSN6        WYTTGGTP-DPSDIHVHKQVCEIIESPLFLKLNPMT-KHTD-LPVSVYES 161
DmCSN6        WYTTGDNP-TADDIKIQRQIAAINECPIMLQLNPLS-RSVDHLPLKLFES 184
SmCSN6        WYSIGADI-RESDMVIHKALMDINESPVYLLLNPAINPARKELPLSIYES 146
OsCSN6        WYSTGSDV-RDTDMQIHKALMDINESPVYLLLNPAINLSQKDLPVTIYES 171
DdCSN6        WYSTGSQV-SKDDILLHKQISEHNESPLYLMLDTDS-PKSKDLPVIIYES 157
BmCSN6        WYTIGDTTPTQADWEVHQQFSVMHESPIMVKLDPKAPPGNK-LPVAIYES 154
                * *    *  * 
HsCSN6        VIDI---INGEATMLFAELTYTLATEEAERIGVDHVARMTAT-GSGENST 216
MmCSN6        VIDI---INGEATMLFAELTYTLATEEAERIGVDHVARMTAT-GSGENST 213
XlCSN6        VIDI---VNGEATMLLAELSYTLATEEAERIGVDHVARMTAT-GSGENST 207
DmCSN6        LIDL---VDGEATMLFVPLTYTLATEEAERIGVDHVARMTSN-ESGEKSV 230
SmCSN6        ELHV---IDGVPSLIFVKASYTIETVEAERISVDHVAHIKPSDGSSAATQ 193
OsCSN6        ELHV---IDGSPQLIFVRANYTIETVEAERISVDHVAHLKPSDGGSAATQ 218
DdCSN6        ELHI---VNDEPTTIFVKTPYKIQTGEAERIGVNHIAKVTPS--GSEGSG 202
BmCSN6        VCTTGLSASSPSSVVWHSVNWSLASEQAERIGIEHVAQISTV-STNTVSS 203
           
HsCSN6        VAEHLIAQHSAIKMLHSRVKLILEYVKASEAGEVPFNHEILREAYALCHC 266
MmCSN6        VAEHLIAQHSAIKMLHSRVKLILEYVKASEAGEVPFNHEILREAYALCHC 263
XlCSN6        VAEHLIAQHSAIKMLHSRVRLILEYVRAAEGGEVPFNHEILREASALCHC 257
DmCSN6        VAEHLVAQDSAIKMLNTRIKIVLQYIRDVEAGKLRANQEILREAYALCHR 280
SmCSN6        LAAHLTGMHSAIKMLHSRIKVLHHLLAAIQKGDAPPEHALLRQVSSLVRR 243
OsCSN6        LAAHLTGIHSAIKMLNSRVRVIHQYLVSMQKGDMPLDNSLLRQVSSLVRR 268
DdCSN6        LTSHLFTMHNAISMLNIRVKALSDYLQAVKEKRLPYEQNILRKASSLCNQ 252
BmCSN6        TNKQIAGQLGAINMLQSRLELIYDYLVAVRKGELPRDEAIIREIAQLVRR 253
               
HsCSN6        LPVLSTDKFKTDFYDQCNDVGLMAYLGTITKTCNTMNQFVNKFNVLYDRQ 316
MmCSN6        LPVLSTDKFKTDFYDQCNDVGLMAYLGTITKTCNTMNQFVNKFNVLYDRQ 313
XlCSN6        LPVLSTDKFKTDFYDQCNDVGLMSYLGTITKTCNTMNQFVNKFNILYDRQ 307
DmCSN6        LPVMQVPAFQEEFYTQCNDVGLISYLGTLTKGCNDMHHFVNKFNMLYDRQ 330
SmCSN6        LPAIDSPKFQDDFLMEYNDTLLMTYLATITKCSNTMNEFVEKFTTAYDK- 292
OsCSN6        LPAMESEKFQDDFLMEYNDTLLMTYLAMFTNCSSTMNELVEKFNATYERS 318
DdCSN6        LPTIDTHDFKKSYLQEYNDVLLVTYLASITKTSASLNDTIDKYLVSNEKQ 302
BmCSN6        VPVMSSDKFLQQYKNQCLEVKMTSLVAVLTKTCGTLNDLVTKMNVMSVER 303
            
HsCSN6        GIGRRMRGLFF------ 327
MmCSN6        GIGRRMRGLFF------ 324
XlCSN6        GIGRRMRGLFF------ 318
DmCSN6        GSARRMRGLYY------ 341
SmCSN6        QSRRGGRTVFV------ 303
OsCSN6        TARRGGRGAFM------ 329
DdCSN6        SKRRFYQ---------- 309
BmCSN6        QTWLLASGRRARPFPAM 320
A 
 CDC

B. Mapping sequence 
conservation on the 
molecular surface of 
HsCSN6. The sequence 
conservation was 
calculated using the 
ConSurf software and 
visualized by surface-
transparent view. C. 
Electrostatic surface 
potential of human CSN6 
(fragment 31 to 220). 
Blue and red are 
positively and negatively 
charged, respectively. 
White represents neutral 
potential. D. 
Superimposition of the 
human CSN6 (fragment 
31 to 220; PDB code: 
4QFT)
 
 and human CSN5 
(fragment 1 to 257 PDB 
code: 47F0) structures. 
The Ins-1 and Ins-2 
regions are labelled. A 
close-up representing 
CSN5 JAMM motif of 
CSN5 superimposed with 
the pseudo metal-binding 
of CSN6. Residues in 
violet are belonging to 
CSN5, whilst those in 
magenta are CSN6 
residues.
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The heterodimerisation of MPN domain-containing proteins have long been 
anticipated with evidence coming from their X-ray structures and from EM data both 
for the CSN complex and the 19S proteasome lid. Among the crystal structures of 
MPN domains, characterised to date, including those of AfJAMM [65], AMSH-LP 
[186]; AMSH [275]; HsRpn8 [158, 160, 176], DmCSN6 [64], HsCSN6 [276], Prp8 
[274] and CSN5 [63], available to date, only few (AMSH; AMSH-LP; Prp8) do not 
display evidence of dimerisation (Table 4-2). For most, excluding AfJAMM, dimeric 
species of MPN domain-containing proteins was also identified in solution. 
Interestingly, many of these MPN proteins display in their crystal structure two 
different kinds of dimers, one within the asymmetric unit and the other created by 
symmetry operators. Relying on differences in solvation free energies for interface 
formation between the two dimer interfaces, calculated by PISA [210], detected in Hs 
Rpn8 and DmCSN6, allowed to distinguish the biologically relevant dimerisation 
interface. For Hs Rpn8, the biological dimer was suggested to be the dimer resulting 
from crystal packing, as it is also the case for human CSN6, whilst the asymmetric 
unit potentially forms the physiologically relevant dimer of DmCSN6.  
 
Table 4-2 Summary of the MPN-MPN contacts (in the context of homo- or hetero-
dimers) in MPN crystal structures. 
Interface surface areas were computed by the PISA server [210]. (?): no additional 
experiments have been reported to establish the oligomeric state. (*): although it has been 
shown in cellular context that the full-length protein does not homo-dimerise. 
Protein PDB code Surface area (Å2) Potential homo-dimer 
AfJAMM 1OI0 720 X (?) 
 1R5X 730  
AMSH 3RZU 700  
 3RZV 615  
AMSH-LP 2ZNR 550  
 2ZNV 260  
HsCSN5 4F7O 1055 
974 
X 
HsCSN6 4D18 
4QFT 3798 (with CSN5) 
2478 
heterodimer 
? 
DmCSN6 4EQ0 965 
694 
X (*) 
HsRpn8 2O95 2300/600 X (?) 
 2O96 1100/750 X (?) 
ScRpn8/ScRpn11 
4O8X 1981 heterodimer 
 
4OCL 1938 heterodimer 
Prp8 2P87 600  
 
As detailed in Chapter 3, the two types of homodimers observed in the crystal 
structure of CSN5 showed comparable values for interface analysis making their 
 CDE
differentiation more challenging. In our work, we determined that the A-B dimer 
within the asymmetric unit, involving the helices 4 and 6 secondary structure 
elements, represents the most probable biological interface of CSN5. The particular 
interest in the studies of MPN homodimer interfaces is that it may provide the basis 
for the MPN+-MPN- heterodimer complexes. Although dimerisation seems to be a 
recurrent principle of MPN domain containing proteins, a considerable variation in 
the mode of dimerisation is exhibited. As the time at which we started investigating 
the interaction between CSN5 and CSN6, it had remained unclear which of the 
observed interactions, if any, were biologically relevant.  
 
To date EM studies of the 19S proteasome lid [175, 258], the CSN complex [46, 266, 
277] and of the eIF3 complex [267] have been reported. The general similarity of the 
organisation of these three complexes suggested that their MPN domain-containing 
subunits would display alike assemblies. In these three complexes, the MPN domain-
containing proteins are found in close proximity. The dimeric nature of the MPN 
domains of these proteins and their location within their complexes, together, suggest 
that these pairs of subunits could interact through their MPN domains. This is 
supported by our findings that CSN5 and CSN6 associate directly. Furthermore, 
recently, whilst our work was in progress, the first heterodimer arrangement of an 
MPN+ with an MPN- domain-containing protein was reported in the crystal structure 
of the yeast Rpn11-Rpn8 binary complex of the 19S proteasome lid [158, 160]. These 
two studies, confirming our at-the-time-unpublished findings reported that this 
heterodimer adopts a dimeric arrangement oriented in a manner reminiscent of the 
HsRpn8 homodimer structure and of our HsCSN6 homodimer structure [158, 160].  
 
The identification that CSN5 and CSN6 directly interact encouraged us to investigate 
the interface between these two subunits that mediates their heterodimer arrangement. 
And we therefore aimed to obtain high-resolution structural and mechanistic insights 
on this binary complex, which could help to unravel the unknown activation of CSN5 
within the CSN complex. Here we present the two approaches taken to accomplish 
this; interface investigation by NMR followed by sequence conservation analysis and 
mutagenesis studies, and high-resolution structure of the binary complex by X-ray 
crystallography. 
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Following our findings that CSN5 and CSN6 form a gel filtration stable binary 
complex and further determining a KD of 6 µM prompted us to employ X-ray 
crystallography to gather structural information on the CSN heterodimer complex. 
Each subunit (CSN5 fragment 1-257; CSN6 fragment 31-220) was expressed and 
purified individually and were then incubated together in a mixture on ice for one 
hour before being concentrated. Initial commercial crystallisation plates (Classic I, 
PACT) were set up to determine an optimum concentration of 7 mg/mL for the 
 CDF
complex. We then used this concentration to screen several other conditions. Despite 
the vast number of conditions screened both at 18
o
C and 4
o
C, only one hit was found 
in the Pro-complex screen (composition: 0.1 M MgCl2, 0.1 M HEPES pH7, 15% PEG 
4000) at 18
o
C after one week producing small bi-pyramidal-shaped crystals. 
Extensive refinement of these small crystals was carried out, to obtain sufficient sized 
crystals for mounting and collecting diffraction data, by screening around the hit 
conditions. Manually prepared screens were set up ranging in pH, from 5 to 8, and in 
concentration of precipitating agent, from 5% to 30%. Regardless our efforts to 
reproduce and optimise the crystals obtained from the commercial screen, further 
crystals were not obtained. We thus employed microseeding technique to improve our 
crystal quality and size. The principle of microseeding is to control crystallisation by 
avoiding the nucleation zone. The small crystals obtained in the hit solution were 
fished, crushed and suspended in a slurry of mother liquor. The microcrystals created 
were then used to set up crystallisation screens. This approach identified one hit 
condition in the JSCG+ screen. The resulting crystal was mounted for data collection, 
but did not show signs of diffraction on the ESRF ID29 beamline.  
 
Although difficult to rationalise, another often mentioned prerequisite for successful 
crystallisation is the absence of unstructured, highly flexible regions within a protein, 
including extended loops or tails. Specifically for CSN5, although previously the 
crystal structure was obtained, we identified the highly mobile Ins-2 region for 
instance that is disordered in the crystal. We thus removed such regions from the 
CSN5-CSN6 complex by carrying out limited proteolysis (using the limited 
proteolysis kit implemented by Dr. François Hoh) in order to search for a stable 
fragment. Three dilutions of each protease were tested and we found that trypsin 
(1000:1 protein:trypsin ratio) gave most promising results by producing one major 
protein band corresponding to a smaller sized CSN5-CSN6 complex. We further used 
these conditions to perform in situ limited proteolysis for crystallisation. Trypsin 
solution was incubated with the protein complex mixture for thirty minutes prior to 
setting up the crystallisation plates at 18
o
C. Despite identifying two hit conditions 
giving small protein crystals, they were not reproducible in subsequent refinement 
screens. However, the initial crystals obtained from the commercial screen were 
mounted and exposed to X-ray. The crystal was unable to provide a diffraction pattern 
of the complex, further confirming the protein nature of these poorly ordered crystals. 
 
In spite of extensive trials, the crystallisation of human CSN5-CSN6 heterodimer was 
not successful. Within our work, the poor solubility, highlighted by the heavy 
precipitation of the protein complex solution in many conditions and the high 
flexibility of the CSN5-CSN6 were evident observations. These two physical 
principles are also major factors that may influence crystallisation. However, by 
performing limited proteolysis and still not obtaining crystals may suggest that it is 
not a matter of flexibility but rather the poor solubility and/or overall dynamic of the 
complex that accounts to the limited crystals obtained. Whilst crystallisation trials 
 CDG
were in progress, in parallel other biophysical techniques were employed to 
investigate the biochemical characterisation of the CSN5-CSN6 complex.  

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MPN domains tend to form homodimers through various interfaces and this may 
reflect the interface of the MPN heterodimer arrangement. Moreover, reports of the 
crystal structure of the Rpn11-Rpn8 binary complex from yeast provided a model 
system to compare these MPN heterodimers. It is important to stress that virtually all 
the work described here was carried out before the publication of the Rpn11-Rpn8 
structural studies. As CSN5-CSN6 failed to crystallise readily, we employed NMR 
spectroscopy, under the direction of Dr. A. Padilla together with other biophysical 
methods, as well as mutagenesis experiments to identify the mode of interaction 
present in the CSN5-CSN6 heterodimer.  
 
NMR chemical shifts of protein residues (through 
15
N and 
1
H signals) are highly 
sensitive to changes in the local environment. Therefore chemical shift perturbations 
can used to map intermolecular interfaces of protein complexes [278]. NMR HSQC 
titration experiments of CSN5 with 
15
N-uniformly labelled CSN6 were performed. 
Prior to performing titration experiments, a 3D 
1
H-
15
N-NOESY-HSQC spectrum of 
CSN6 (600 M) was acquired for the assignment of the side chains of this subunit by 
Dr. Yinshan Yang. Assignments were obtained for 
15
N, HN and Ha atoms producing 
an overall assignment completeness for 
1
H resonances at 79 % (Fig. 4-8A). Proline 
residues, as well as the G40-L42/L59-L60 stretches and the residues D71 and H130 
were not assigned. Additionally, a temperature screen was performed to determine an 
optimum temperature to conduct HSQC experiments of CSN6. Indeed this was 
important to obtain exploitable data as the heterodimer complex reaches a size of 50 
kDa. We determined that at 308K the most useful spectrum was obtained and this 
temperature was used in the following experiments.  
 
Titration of 
15
N-labeled CSN6 at 100 M with increased concentration of unlabeled 
of CSN5 (up to 200 M) caused large shift changes of both amide proton and nitrogen 
resonances of several CSN6 residues (Fig 4-8B). The vast amounts of chemical shifts 
indicate potential residues involved in the interaction between the two proteins 
(although it could also be due to conformational changes), whilst the peak broadening 
and disappearance could suggest conformational changes occurring on CSN6 upon 
binding to CSN5. Additionally, the size of the CSN5-CSN6 complex of calculated 
mass at 50 kDa is on the large size front of proteins that can be investigated by NMR. 
This resulted in a substantial broadening of the peaks and introduced a further 
difficulty to unambiguously ascribe the CSN6 residues perturbed as a result of the 
interaction with CSN5. Upon addition of CSN5, the observed gradual loss in intensity 
of the signals in the CSN6 spectrum is suggestive of a large complex formation and of 
an intermediate chemical exchange binding, coherent with the lower M dissociation 
 CDH
constant determined by ITC (6 ± 1 M). From the spectrum obtained we can clearly 
depict an interaction occurring but we could also hypothesis that the drastic changes, 
including a large number of resonances shifting or reducing in intensity, and several 
being entirely absent, observed may be a result of conformational changes induced on 
CSN6, upon CSN5 binding.  
 
Moreover, the HSQC experiments highlighted the fact that the CSN5-CSN6 complex 
has limited solubility in the tested conditions, as suggested by the precipitation of the 
sample after overnight data collection, although this is not an atypical sample 
behaviour. This observation is coherent with the crystallization trials and explains the 
reaon why we were not able to carry out a full HSQC titration of CSN5. Attempts to 
troubleshoot this physical limitation of solubility was investigated by applying 
changes in temperature, pH and protein concentration, however these changes 
affected the spectrum recorded for CSN6 alone and better conditions were not 
determined. In summary at this stage, we were confronted to a situation in which, 
although HSQC spectrum changes could be observed, we could not absolutely 
confident that all the changes were due to short range residue-residue interaction, and 
we could not exclude long range effects. Consequently, as a result of the challenges 
encountered to specifically assigning chemical shifts occurring upon addition of 
CSN5 to 
15
N-CSN6, a reverse approach was taken where the 
15
N-CSN6 HSQC was 
analysed by extracting the residues that remained unperturbed upon addition of CSN5. 
Data from this approach highlighted residues that are not primarily involved in the 
interaction (Table 4-3; Fig. 4-8C). Some of these residues mapped on non-exposed 
regions and are located in the core of CSN6, while others mapped on the outer surface. 
Highlighting these residues on our human CSN6 structure molecular surface defined 
two exposed regions, one which groups most of the unperturbed residues and the 
other which mostly lacks unperturbed residues. Solely from our NMR data however, 
this later surface could not be defined as the surface implicated in the interaction with 
CSN5. Further data were needed to confirm the involvement of this surface in the 
CSN5/CSN6 association. 
 
To further validate our NMR data, the sequence conservation pattern of CSN6 was 
analysed. Various studies have determined that functionally important surfaces were 
enriched in conserved residues, in comparison with the remaining accessible surface 
[279, 280]. Our rational was to determine whether the CSN6 surface identified by 
NMR which, may be the CSN5 binding interface, contains a larger population of 
conserved residues. However, CSN6 has been attributed to contain various interaction 
partners and thus conserved regions outside of its interaction interface with CSN5 
were expected. Indeed mapping sequence conservation on the human CSN6 structure 
highlighted a surface of highly conserved surface residues corresponding to the same 
region accommodating the residues which according to our NMR data may 
potentially be implicated in the interaction with CSN5 (Fig. 4-8C). In addition the 
surface containing unperturbed residues contains low sequence conservation whilst 
 CDI
other conserved patched were determined possibly accounting for the interaction of 
CSN6 with other binding partners (Fig. 4-7B). 
Table 4-3. CSN6 residues found unperturbed, upon binding with CSN5 as evaluated by 
NMR HSQC. 
Residues marked with an asterisk (*) are not present in human CSN6 crystal structure. 
C33* M84 V171 L182 
G34* L90 I172 L186 
V35* K97 D173 T187 
T36* E109 I174 T189 
G37* L119 I175 E196 
S40 H139 N176 G199 
G78 K140 G177 V200 
R79 F151 A179 H202 
N80 K159 T180 T209* 
 
Moreover, structural analysis depicted that the surface highlighted both by NMR and 
sequence conservation analysis is also the one governing the homodimerisation of 
both HsRpn8 and HsCSN6 structures. It is noteworthy that this also meant that we 
could possibly deduce the interaction surface of CSN5 with CSN6. The data presented 
here suggests that the surface of CSN6, which is engaged in the binding to CSN5, is 
mostly likely to be comprised of interactions mediated from helices 1 and 2 and 
the surface in between these two (Fig. 4-5A; 4-6A). Our findings were further 
validated by the crystal structure of the CSN5-CSN6 homolog complex, Rpn11-Rpn8, 
where the corresponding helices on Rpn8 (also 1 and 2) are directly implicated in 
forming two distinct parts of the complex interface. Next, using the binding surface of 
CSN6 determined, specific variants of CSN6 were designed to probe the interaction 
with CSN5. The functional relevance of these interactions was validated by activity 
and binding assays. 
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Figure 4-8. Elucidation of the 
interface between the CSN5-
CSN6 heterodimer. 
A. The assigned 
1
H-
15
N HSQC 
spectra of human CSN6. B. 
The overlaid 2D 
1
H-
15
N HSQC 
spectra highlighting the 
difference between free human 
CSN6 (magenta) and CSN5 
bound CSN6 (black). C. 
Mapping interfacial data 
obtained from NMR on the 
structure of human CSN6. 
Residues of CSN6 which have 
not been perturbed after the 
addition of CSN5 are 
highlighted in red and 
illustrated with a surface-
transparent view. Helices 1 
and 2 are highlighted as 
potentially forming the 
interface between the CSN5-
CSN6 complex. Right panel: 
180° rotated view of left Panel.
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Further validation of the interaction surface of CSN6 in the complex that it forms with 
CSN5 was addressed by conceiving and obtaining interfacial variants of CSN6 by 
site-directed mutagenesis. Here we aimed to probe the potential interaction surface 
and to confirm the binding interface identified. Chosen due to their high conservation 
across CSN6 orthologues and their location on the presumptive interaction surface, 
two CSN6 variants were designed. The nature of the substituting amino-acid was 
chosen to be different from the original position: for H44 located on the helix 1, 
from a bulky and polar histidine amino-acid to a small and hydrophobic amino-acid, 
alanine (H44A) and for Val115 located on the helix 2, from a small and hydrophobic 
to a large and charged amino acid, glutamic acid (V115E) (Fig. 4-9A).  


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Figure 4-9. Mutations performed to 
validate the CSN5-CSN6 
heterodimer interface. 
A. The putative interfacial residues 
mutated mapped on the structure of 
human CSN6. B. The effect of the 
interfacial mutants, CSN6 H44A and 
CSN6 V115E were evaluated by ITC 
titration experiments. The 
isothermogram represents the binding 
of CSN5 R106T variant to CSN6 
H44A (left panel) and CSN6 V115E 
(right panel) at 305K. The raw data of 
the titration of CSN5 R106T with the 
CSN6 variants are shown in the upper 
panel and the integrated data obtained 
after subtracting the heat of dilution 
are shown in the lower panel. The 
titrations were performed in 20 mM 
Tris-HCl pH 7.5, 50 mM NaCl. C. 
The effect of the CSN6 interfacial 
mutants on the pro-Nedd8 processing 
activity of the complex was tested 
and compared to the WT activity. The 
pro-Nedd8 variants by their ability to 
be able to be processed by CSN5 
R106T-CSN6 complex. The plots 
show the percentage of pro-Nedd8 
processed after 90 mins incubation at 
37
o
C. D. The Ins-1 segment of CSN5 
with the residues that have been 
mutated shown in ball-and-stick 
mode. E. The CSN5 R106T variants 
are evaluated by pro-Nedd8 
processing activity. The plots show 
the percentage of pro-Nedd8 
processed after 90 mins incubation at 
37
o
C.  
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The effect of these mutations on the association with CSN5 was monitored by ITC 
experiments on CSN5 and the H44A and V115E variants of CSN6. Both CSN6 
variants bind to CSN5 with a moderately lower affinity with a KD of 9.2 ± 1.0 M for 
H44A and 29.0 ± 2.1 M for V115E (Fig. 4-9B). Compared to the WT CSN6 
showing a KD of 6 ± 1 M (Fig. 4-1D), admittedly but also not surprisingly, the effect 
impaired by the variants is modest. Following our experimentally-based hypothesis 
that the CSN5-CSN6 complex is mediated in a similar manner as that of the HsRpn8 
homodimer and the ScRpn11-Rpn8 heterodimer, it is perhaps not surprising that a 
large interface is not entirely disrupted by one amino-acid substitution. The interfacial 
surface area reported for the physiologically relevant Hs Rpn8 homodimer is 
approximately 2,300 Å2 [176] and for the Rpn11-Rpn8 heterodimer around 2,000 Å2 
[160] (Table 4-2). These values predict an equivalently large buried area for the 
CSN5-CSN6 complex, which within our molecular docking experiments (detailed in 
section 4.6) all the models obtained, had a buried surface area in the range of 1,430 to 
1,695 Å2. It must be noted that conceiving an interfacial variant which has a larger 
effect in disrupting the interface of the CSN5-CSN6 complex, and which in addition, 
is not effecting the potential activating property of CSN6 on CSN5 was a great 
challenge. More specifically, if the mode of interaction for the CSN5-CSN6 
heterodimer is as we suggest, the surface largely implicates the Ins-1 segment of 
CSN5, which from our previous work in Chapter 3, is likely to undergo 
conformational changes to form an active enzyme. As such targeting further 
mutations in this region would inevitably have a consequence in the conformation of 
this segment that is difficult to predict at the atomic level and thus in the activity of 
CSN5. Nevertheless predicting further conformational changes is also challenging, 
residues in the interface may be implicated in the interaction and/or in inducing a 
conformationally active enzyme.    
 
Further to looking into the effect of interfacial mutations on the association of CSN5 
and CSN6, we probed their effect on the CSN6-mediated CSN5 activation. Our work 
has established that in vitro the CSN5-CSN6 complex can pursue peptidase activity to 
process pro-Nedd8 and we have employed this activity as a convenient enzymatic tool. 
 
Pro-Nedd8 processing assays were employed to address the effect of the CSN6 
variants in the hydrolytic activity of the CSN5 R106T-CSN6 complex. In addition to 
the H44A and V115E variants of CSN6, further mutations of residues N85 and E88 to 
lysine and alanine, respectively, were performed. Both CSN6 N85 and E88 located on 
the -sheet 3 are highly conserved residues (Fig. 4-9A) and are on the surface of 
CSN6 which we propose to mediate the CSN5-CSN6 complex. Our data here show 
that the hydrolytic activity of the complex is completely suppressed in the presence of 
the H44A and V115E variants of CSN6 (Fig. 4-9C). Whilst a slight decrease in 
activity was observed in the case of N85K variant, for the E88A variant, a WT level 
of activity was observed. These results indicate that, in agreement with the ITC data 
(ITC experiments were not performed for the N85K and E88A mutants due to the low 
effect in activity detected), the disruption of the heterodimer interface influences the 
 CED
catalytic activity. Moreover the strong effect observed from the variants located on 
helices 1 and 2, compared to those on the 3 strand can suggest that the helices are 
key in the binding interface of the complex whilst the  strands may be involved in 
forming hydrophobic patches.  
 
We further utilised pro-Nedd8 processing activity to investigate the contribution of 
the Ins-1 segment of CSN5 in the interface with CSN6. Mutations were performed on 
this segment of CSN5 R106T to form the variants Y120D, E122A, Y116D and 
E115A. Whilst E115A and E122A face the inner catalytic grove, the remaining two 
variants face the out side (Fig. 4-9D). Pro-Nedd8 processing ability of these variant 
showed that they were all negatively affected, however to different extents. The 
activity with CSN5 R106T Y120D and E115A variants resulted in a 30% drop in 
activity, whilst the E122A and Y116D showed complete inhibition of pro-Nedd8 
processing activity (Fig. 4-9E). Although the results here clearly indicate that the Ins-
1 region plays a key role in the CSN5-CSN6-Nedd8 ternary complex and we 
previously showed that it is important to form a catalytically competent CSN5. As 
such, differentiation between residues implicated in the interaction with CSN6 and 
those with Nedd8 was proved challenging. However comparison with data presented 
in section 4.6.1, Fig. 4.10, where we test pro-Nedd8 processing activity of the CSN5 
variants in the absence of CSN6, we see that variants, E115A, Y116D and Y120D 
show approximately 50 % drop in activity, whilst E122A shows WT activity. 
Together with the results presented in this section, we can conclude that whilst the 
activity of E115A and Y116D is rescued in the presence of CSN6, the activity of 
variant Y116D is not and nor can we detect any activity for E122A. The reason we do 
not detect any activity for E122A is because of concentration differences. Whilst in 
the absence of CSN6 we use 900 µM of enzyme, in the presence of CSN6 we are 
nanomolar range to obtain 4 nM of CSN5-CSN6 complex. These results thus indicate 
that residues Y116D and E122A are likely to affect the binding to CSN6 (as CSN6 
was also shown not to interact significantly directly with Nedd8).   
   
In this work, we have gathered evidence to propose that the CSN5-CSN6 heterodimer 
is mediated by a surface delineated by the helices 1 and 2 and previously observed 
in the structures of the Rpn8 homodimer and the Rpn11-Rpn8 heterodimer. We were 
further able to determine that residues H44 and V115 of CSN6 and residues, Y116 
and E122 of CSN5 are likely to be involved in the interaction mediating the CSN5-
CSN6 interface. Here we have obtained experimental proof that we further exploited 
to reconstruct a molecular model of the CSN5-CSN6 complex. 

4*6 !"!!!&5+6+7%)  
 
The experimental data obtained from characterising the interaction interface for CSN5 
with Nedd8 and CSN5 with CSN6 individually prompted us to build a model of this 
 CEE
complex using a molecular docking approach with experimental constraints to 
reconstitute the CSN5-CSN6 binary complex. By performing molecular docking, we 
aim to predict the three-dimensional structure of the intermolecular complex formed 
between two or more individual proteins in aqueous solution. Prior to exploring this 
approach certain challenges and pose limitations of protein-protein docking had to be 
considered. The difficult cases for docking involve: (i) large-scale conformational 
movements upon binding; (ii) weak or transient binding; (iii) unavailability of X-ray 
structure for proteins implicated. Expectedly, such difficulties lead to a considerable 
drop in the reliability of the predictions obtained.   
 
When employing molecular docking to obtain a putative model corresponding to the 
CSN5-CSN6 hetero-complex, we thought critically about the highly probable 
conformational changes occurring upon the interaction between the two protein 
subunits. In Chapter 3, we showed via MD simulations and structural analysis that the 
CSN5 subunit contains highly flexible regions, including its Ins-1 and Ins-2 regions. 
Earlier in this chapter we demonstrated that auto-inhibited CSN5 is activated upon its 
interaction with CSN6. This finding is suggestive that at least the Ins-1 region of 
CSN5 would have changed conformation upon the interaction and further 
conformational changes cannot be excluded. Moreover potential flexibility may also 
be present in CSN6. The NMR HSQC spectrum of 
15
N-uniformly labelled CSN6 
indicated conformational changes occurring upon titration of CSN5. Taken together, 
these results guided us to design an approach where in addition to providing 
experimental constraints from the experimental methods discussed previously, we 
strongly consider the conformational changes potentially occurring upon binding. The 
following sections detail the consecutive steps taken to obtain a molecular model of 
the CSN5-CSN6 complex.    

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The first step in this process was to build a CSN5-Nedd8 complex. To do so, we first 
determined whether Nedd8 associates with CSN5 in the same way as the distal Ub 
does with AMSH-LP. The co-crystal structure of AMSH-LP with a di-K63-Ub moiety 
brought important insights into Ub binding to JAMM/MPN+ proteins (PDB code: 
2ZNV). This indicated how specific recognition of Ub and of K63-linked di-ubiquitin 
is achieved by the direct contact formed between the DUB domain and all the residues 
involved in the K63 linkage, including K63 itself [186]. This structure allowed the 
identification of a substrate-binding mode potentially common to other JAMM/MPN+ 
DUBs. In general, Ub-binding DUBs contain a substrate-binding site that 
encompasses an extensive interaction network. The foremost interactions are 
established through the Ub I44 patch, an Ub canonical protein interaction site [264], 
and additional surfaces specific for this DUB family. Commonly in interactions with 
DUBs, approximately 20-40% of the total Ub surface can be occupied [217]. The C-
terminus of the distal Ub moiety extends from its binding groove and inserts into the 
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DUB catalytic centre, positioning firmly for catalysis (Chapter 3, Fig. 3-3B). 
Moreover it is this C-terminal amino acid extension that allows to distinguish between 
different substrates, including between Ub and Ubl molecules. The C-terminal tail of 
Ub contains the sequence L71-R72-L73-R74-G75-G76, which differs to that of 
Nedd8, L-A-L-R-G-G, and to that of SUMO, Q-Q/E-Q-T-G-G. Biochemical studies 
have demonstrated that the composition of the five last C-terminal residues 
determines the specificity for the recognition by individual DUB families. For 
example, AMSH-LP and Rpn11 specifically recognise Ub, whilst CSN5 shows 
specificity for Nedd8. To date, Nedd8 has only been co-crystallised with NEDP1 
[281], however limited information is generally available on Nedd8-bound DUBs. 
 

. Nedd8 binding to CSN5. 
A. The structure of pro-Nedd8 (PDB code: 2BKR) was extended at the C-terminus to form 
pro-Nedd8. The model was built in Chimera. Residues that have been mutated in our work 
have been highlighted and shown in stick mode. B. Pro-Nedd8 processing activity assays 
were employed to characterise the interaction between CSN5 and Nedd8. The Nedd8 variants 
were tested for pro-Nedd8 processing activity. The plotted bar charts show the percentage of 
Nedd8 processed after 90 minutes incubation at 37
°
C. C. Model of CSN5 and Nedd8 
interactions. Residues that have been mutated both in pro-Nedd8 and CSN5 R106T are shown 
in stick mode. D. Pro-Nedd8 activity tested with the variants of CSN5 R106T. The Ins-1 
located CSN5 R106T variants in complex with CSN6 were tested for pro-Nedd8 processing 
activity. The plotted bar charts show the percentage of Nedd8 processed after 90 minutes 
incubation at 37
o
C. 
 
We thus sought to characterise the CSN5 mode of Nedd8 binding in more detail. High 
KD values of CSN5 for Nedd8 (as determined by fluorescence anisotropy) deterred us 
from attempting CSN5/Nedd8 co-crystallisation. Instead, we used mutagenesis 
A 
B 
C 
D 
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analysis coupled to activity assays. As highly expected, if CSN5 binds to Nedd8 in a 
similar orientation as does AMSH-LP to Ub, investigation of an AMSH-LP-like 
binding surface in CSN5 would be expected to have an effect on the binding and 
potentially in its activity. To test this hypothesis, we generated the variants on pro-
Nedd8 including, T9M, R42D, K48D, V70D (Fig. 4-10A and B). The use of pro-
Nedd8 here is explained by the fact that it is readily expressed in bacteria (unlike 
Nedd8 which recombinant expression is notoriously difficult), that it can be easily 
mutagenised and that we have found that pro-Nedd8 is an in vitro substrate for CSN5. 
These mutations were designed after structural analysis was performed using the 
structure of di-Ub bound AMSH-LP and their effect was investigated by the pro-
Nedd8 processing activity of the active R106T variant of CSN5 (in the absence of 
CSN6). The rational behind this approach was also to obtain biochemical evidence 
that could guide the mapping of Nedd8 binding in the active site of CSN5. The 
quantification of the bands from our activity assays indicated that all four variants of 
pro-Nedd8 have decreased catalytic activity. This reduced activity is most evident for 
the K48D and V70D variants of pro-Nedd8, which completely inhibit the processing 
activity of CSN5 R106T (Fig. 4-10B). These results confirm our hypothesis that 
Nedd8 binds to CSN5 in similar manner to Ub binding to AMSH-LP (Fig. 4-10C). 
 
Moreover the CSN5 variants located on the Ins-1 segment, previously designed to 
detect the implication of this region in the interaction with CSN6, were used to 
determine whether the Ins-1 region is also involved in the interaction with the 
substrate. To unravel this, the effect of the following CSN5 R106T variants on the 
pro-Nedd8 processing activity - E115A, Y116D, Y120D and E122A was tested (Fig 
4-9D; 4-10D). The E115A, Y116D, and Y120D variants revealed a significant drop in 
pro-Nedd8 processing ability compared to CSN5 R106T tested in the same conditions 
(Fig. 4.10D). However, the CSN5 R106T E122A variant does not affect pro-Nedd8 
hydrolysis and this confirmed that E122 does not significantly contribute to substrate 
binding or catalysis (Fig. 4-10D), but is implicated in the interaction with CSN6 (Fig. 
4-9E). Together these results allow to conclude that the Ins-1 segment and more 
specifically the start of its C-terminal helix and the face locating residues Y116 and 
Y120 are implicated in the recruitment of substrate or its correct positioning (Fig. 4-
9D). The effect observed may be a result of either the inhibition of enzyme-substrate 
contact or potentially an impact on the flexibility of the Ins-1 segment of CSN5. As 
we discuss in Chapter 3, the conformation and the dynamic nature of the Ins-1 region 
is important for the activity of the enzyme.  
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In Chapter 3, we identified that the auto-inhibited CSN5 structure is unable to 
accommodate Nedd8 accounting for its lack of isopeptidase activity. Detailed 
structural analysis together with insights from MD simulations allowed us to design 
the R106T variant of CSN5 exhibiting a conformationally relaxed Ins-1 region. We 
further showed that this variant is able to bind to Nedd8 and displays significant 
catalytic activity. Earlier in this chapter we verified our hypothesis that Nedd8 binds 
to CSN5 in similar manner to Ub binding to AMSH-LP. These findings highlight the 
challenges that could be faced in using CSN5 for our docking experiments regarding 
the likelihood that it undergoes conformational changes and most certainly at its Ins-1 
region. To aid the docking procedure we thus chose to assemble a complex composed 
of CSN5 harbouring an Ins-1 conformation similar to that of AMSH-LP, and Nedd8 
occupying the same surface to that of AMSH-LP-bound distal Ub. An interesting 
observation encountered from the modelling of the CSN5 Ins-1 insertion was its 
remarkable resemblance a posteriori to the Ins-1 segment of Rpn11 when in a binary 
complex with Rpn8.  
 
The generated CSN5-Nedd8 model was the starting complex structure used to 
perform the molecular docking with CSN6 (described in the next section). This rather 
provided an extra layer of constraints for the docking approach.   
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In eukaryotes, the heterodimerisation of JAMM/MPN+ and MPN- subunits appears to 
be an important principle in the regulation of several multiprotein complexes, 
including the 19S proteasome lid, the BRCA1-RAP80 complex, the BRISC complex 
and within our work this aspect was demonstrated for the CSN complex. The crystal 
structures of MPN domain-containing proteins depicted their propensity to form 
homodimers. As we discussed however, the different MPN-containing domains 
engage through unique dimerisation interfaces, making the elucidation of which 
interface corresponds to that observed in heterodimers of JAMM/MPN+ with MPN- 
subunits challenging to decipher. The elucidation of the human CSN6 structure 
showing a homodimerisation interface reminiscent to that observed in HsRpn8 crystal 
structure hinted a common MPN dimerisation interface. More recently, the structure 
of the CSN5-CSN6 paralog dimer, Rpn11-Rpn8, from yeast, further depicted an 
organisation following the mode of dimerisation originally described in the Rpn8 
homodimer.  
 
Our initial attempt to investigate the CSN5-CSN6 heterodimerisation by ab initio 
molecular docking using experimental constraints corresponded to the use of the 
CSN5-Nedd8 model generated and the human CSN6 crystal structure. The molecular 
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docking was preformed using ZDOCK which utilises a fast Fourier transform to 
search for all possible binding modes for the proteins. Evaluation of the models 
generated is based on shape complementarity (defining the match of the convex 
surface and concave surface of the proteins), desolvation energy, and electrostatics, 
giving an output of the top 2000 predictions. The predictions of the models generated 
by ZDOCK were further enhanced by a tailored post-docking scoring strategy 
resulting in several convincing solutions. The putative solutions were further 
evaluated by our experimental constraints, resulting in a few assemblies which 
satisfied data obtained from the NMR and mutagenesis analysis performed previously 
(Fig. 4-11A).  
 
Interestingly, comparison between the crystal structure of the Rpn11-Rpn8 complex 
and the selected docking complex for CSN5-CSN6 revealed to be highly similar. 
Although occupying the same protein-protein interaction surface the main difference 
was depicted in the topology of the CSN6 subunit in comparison to that of Rpn8. 
Relative to the position of Rpn8 on Rpn11, the CSN6 subunit in our selected model 
shows a rotation of 25o and is translated relative to the Rpn8 position (Fig 4-11B). 
This observation indicates a deviation from the two-fold symmetry observed in the 
structure of Rpn11-Rpn8, but also of the Rpn8 and human CSN6 homodimers. 
Structural analysis identified that the cause for this difference in the CSN6 topology 
accounted to the presence of the N- and C-terminal helical appendices corresponding 
to residues, 6 to 71 and 235 to 251, respectively, in CSN5. As previously mentioned 
in Chapter 3 (section 3.2.1.2, Fig. 3-4A) in the CSN5 structure these two helices are 
stapled together via a hydrophobic core. We had investigated the flexibility of the N- 
and C-terminal extensions of CSN5 by MD simulations and had identified these 
regions as highly flexible (referring to Chapter 3, Fig. 3-8C). This data was suggestive 
of potential conformational changes occurring at this region of the N- and C-terminal 
helices. Additionally compared to the N-terminal helix of Rpn11, this helix is slightly 
longer in CSN5 and in particular carries the characteristic of wrapping around the 
MPN core of CSN5. Taken together we thus hypothesised that the reason for the 
deviation observed between the structural topology of the Rpn11-Rpn8 and that of the 
modelled CSN5-CSN6 complex is likely owed to the N- and C-terminal appendices of 
CSN5 preventing CSN6 to be placed in the exact same position as Rpn8 on Rpn11. 
 
We furthered our molecular docking simulations to investigate the importance of the 
N- and C-terminal regions of CSN5 in the assembly of the heterodimer complex (Fig 
4-11C). We thus repeated the procedure with ZDOCK using a CSN5 variant lacking 
the N- and C-terminal helices. Following our post-docking scoring strategy and 
further validation with our experimental constraints, the top scoring solution 
generated a model of the CSN5-CSN6 complex strongly superimposable to that of the 
Rpn11-Rpn8 complex. An rmsd value of 2.5 Å was obtained for these two complexes. 
Most interestingly, upon the report of the CSN structure, superimposition of our 
putative CSN5-CSN6 model with the CSN5-CSN6 structure of the CSN (Fig 4-11D), 
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identified highly coherent fit, giving an rmsd value of 1.8 Å for the superimposition of 
the CSN6 subunits within their heterodimer complex. 
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Figure 4-11. JAMM/MPN+-
MPN- heterodimer assembly.  
Residues discussed in the text are 
shown in stick mode. A. The best 
docking pose model of CSN5-
Nedd8-CSN6 obtained by data-
driven docking. Right panel: 180° 
rotated view of left panel. B. 
Topology of CSN5-CSN6 docking 
model and Rpn11-Rpn8-like CSN5-
CSN6. The best CSN5-Nedd8-
CSN6 pose obtained from filtering 
ZDOCK solutions is presented here. 
To this model, the CSN5-Nedd8-
CSN6 model built following the 
Rpn11-Rpn8 (PDB code: 4O8X) 
structure has been superimposed. 
The CSN6 structure superimposed 
on Rpn8 is shown in light pink to 
distinguish it from the position in 
our docking solution. Right panel: 
180° rotated view of left panel. C. 
Removal of N- and C- terminal 
extensions and the resulting 
docking pose. The best docking 
pose using a CSN5
C
 model in 
which the N- and C-terminal 
extensions were deleted is shown. 
Right panel: 180° rotated view of 
left panel. D. Comparison with the 
CSN5-CSN6 heterodimer in the 
CSN complex. The docking pose 
obtained for the CSN5-CSN6 
heterodimer using the CSN5
C
 
model is superimposed with the 
CSN5-CSN6 from the crystal 
structure of the CSN complex (PDB 
code: 4D18). Right panel: 180° 
rotated view of left panel.
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Here we have constructed a putative model of the CSN5-CSN6 heterodimer showing 
a protein-protein interaction surface that is also found in the Rpn11-Rpn8, Rpn8, and 
human CSN6 dimers, and is also in good agreement with the CSN5-CSN6 crystal 
structure from the CSN complex recently published. Our findings emphasise the 
determinant role of the position of the N- and C-terminal helices of CSN5, where their 
dissociation is required for CSN5 and CSN6 to interact through an architecture 
reminiscent of Rpn11-Rpn8. Following our hypothesis that Nedd8 interacts with 
CSN5 in a similar manner as distal Ub associates with AMSH-LP, we constructed a 
putative model of the CSN5-CSN6-Nedd8 ternary complex.   
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In the light of our work, we have compared the CSN complex and, more specifically, 
its catalytic subunit, CSN5, with various model systems. The crystal structure of the 
inactive CSN5 (fragment 1-257) subunit was initially solved by the group and, at the 
time, was the only JAMM/MPN+ protein crystallised from the ‘Zomes’ family. Our 
work initially encompassed the biophysical characterisation of the catalytic subunit 
(Fig. 5-1A). Sequence alignment of CSN5 from different organisms reveals highly 
conserved features, identifying key components of its catalytic function within the 
CSN complex. A number of studies have proposed the presence of CSN5 distributed 
between the CSN complex, different CSN sub-complexes and in a CSN-independent 
form. Although this distribution may contribute to a major regulatory element, little in 
known about the function and regulation of these CSN5-containing complexes – even 
their physiological significance requires firmer investigations. Clearly for a number of 
years now, the best understood function of CSN5 and thus of the CSN complex 
resides in the deneddylation of Cullins. This is this catalytic aspect that we mainly 
focused on. 
 
Besides its catalytic function within the CSN complex, the CSN5 subunit was 
suggested to mediate other biochemical purposes, which have not been clearly 
comprehended. Suggestions of roles of CSN5 include, specificity determination of 
transcription factors (such as AP-1 (for Activator Protein-1) and E2F-1) [123, 292], 
regulation of intracellular distribution and turn-over of signalling molecules (p27, 
COP1, and p53) [107, 293], and promoting c-Jun, NFB, and p53 phosphorylation 
[88, 119]. Our work has identified that in vitro CSN5 can be found in different 
oligomeric assemblies and that, in cells, CSN5 is found to be in equilibrium between 
monomeric and dimeric species. Although CSN5 has been found to interact with 
various partners as mentioned earlier, the studies that have investigated these 
interactions have relied solely on a monomeric form of CSN5 being implicated and 
should be revisited taking into account the ability of CSN5 to auto-associate. Indeed, 
in our work, our findings led us to propose that the dimeric assembly of this subunit 
could be relevant in mediating protein-protein interactions. We have further utilised 
various approaches, ranging from cellular, solution, and in silico techniques, to 
determine structural information regarding the dimeric arrangements and we were 
able to propose the most probable, physiologically relevant, dimeric interaction 
interface. Contrary to the homodimeric assembly of CSN6 observed in the crystal, this 
homodimeric CSN5 interface does not mimic the CSN5-CSN6 heterodimer.  
 
Early on in this work, we have mainly presented our findings on CSN5 activity, 
mainly focusing on its activation state in the CSN-independent state. The 
complementary use of structural biology and MD simulations allowed the detailed 
characterisation of CSN5 activity regulation at the molecular level. Our work 
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encompassed a detailed comparison of the inactive CSN5 with the catalytically active 
structure of AMSH-LP/K63-Ub2, where distinctively the catalytic zinc-binding site of 
both proteins adopts a common geometry. This observation had suggested that, as 
AMSH-LP, CSN5 active site is competent to perform isopeptidase activity and to 
hydrolyse an isopeptide bond. CSN5 crystal structure and the investigation of the 
recruitment of Nedd8 substrate by CSN5 identified that, unlike the AMSH-LP, part of 
substrate-binding site of CSN5 delineated by the Ins-1 segment would not be 
sterically able to accommodate its substrate, in particular the LRGG C-terminus 
segment. This observation led us to suggest that this Ins-1 insertion of the CSN5 
would require substantial conformational rearrangement to be primed to recruit Nedd8. 
This hypothesis is based on the ability of the Ins-1 segment to display a large degree 
of flexibly. The use of MD simulations allowed to investigate the plasticity of this 
segment and identified a functional role of the conserved R106 residue. We identified 
that the R106 residue is implicated in forming a salt bridge with the zinc-chelating 
D151 residue and by mutational studies, both in silico and in vitro, we revealed that 
the breakage of the salt bridge is required for the rearrangement of the Ins-1 region 
and for restoring some ‘basal’ isopeptidase activity on the CSN5 subunit. The use of 
two synthetic substrates, LRGG-AMC and Nedd8-AMC, confirmed that the 
substitution of R106 to a threonine and, to a lesser extent, to an alanine and glycine 
(but not proline) imposes constitutive activity to CSN5 in the stand-alone form. 
Together these results allowed to identify that the strictly conserved R106 residue is a 
key component in the activation switch of the isolated form of CSN5 (Fig. 5-1C). 
Comparison between the binding affinity of wild type CSN5 and CSN5 R106T to 
Nedd8 showed that the increase in flexibility of the Ins-1 insertion segment is indeed 
associated with a significant enhancement of the binding affinity for the Nedd8 
substrate and thus contributes to form a catalytically more efficient enzyme. 
Furthermore, our work also identified that the R106T variant is also able to 
deneddylate neddylated Cul1, although at a modest level compared to the CSN 
activity. However, these results confirmed those obtained using synthetic substrates. 
 
Our work and those of others have suggested that CSN5 activation is highly regulated, 
keeping CSN5 under tight control. We have shown that CSN5 activation requires an 
activation step and one such step corresponds to the ‘unhooking’ of the R106 residue 
from the zinc-binding site, which in turn promotes the opened conformation of the 
enzyme and reveals its isopeptidase activity. The integration of CSN5 into the CSN 
complex and the consequent protein-protein interactions with other CSN subunits 
were speculated from various studies to play a role in both CSN5 activation as well as 
substrate recruitment. Most recently, Lingaraju et al. characterised the activation of 
CSN5 within the crystal structure of the CSN complex. However, it was indeed a 
surprise that CSN5 was found in an inactive conformation in the CSN crystal. 
Interestingly whereas the histidine and aspartate residues in the active site of CSN5 
are positioned as expected, the catalytic water molecule is replaced by another amino 
acid, E104. The role of this residue in CSN regulation was tested and findings 
indicated that E104-Zn binding might serve to keep the CSN in an inactive state when 
 CFD
it is not conjugating to CRLs. These findings together with our work suggest that 
CSN5 is inhibited by distinct mechanisms depending on whether the subunit is on its 
own or integrated into the CSN. 
 
Given the evidence from studies on the CSN complex, but also from JAMM/MPN+ 
subunit-containing complexes, such as the 26S proteasome lid and the BRCC36-
containing complexes, we furthered our investigation of CSN5 activation by probing 
its interaction with the MPN- subunit, CSN6. Although previously highly speculated, 
we provided supporting evidence that the two subunits interact directly via their MPN 
domains. We further structurally, biophysically and functionally characterised the 
interaction in vitro. Upon near completion of this work two recent reports on the 
paralog MPN+-MPN- heterodimer of Rpn11-Rpn8 were conveyed with data on the 
crystal structure of the complex and on its activity. The design of these studies 
prevented the quantification of the interaction affinity of the MPN domain proteins, as 
they were either co-expressed or expressed as a single polypeptide chain, because of 
the poor stability of Rpn11 when expressed alone. In our work, we were therefore 
able to go further and quantify the interaction of CSN5 and CSN6 MPN domains to a 
KD of ~6 M, although the C-terminal extensions of the two proteins, absent in our 
constructs, could play a role in the subunit interaction affinity. The association of 
CSN6 to CSN5 was shown to markedly enhance its hydrolytic activity on a variety of 
substrates and to increase the affinity for Nedd8 (Fig. 5-1D). Quantification of the 
kinetic parameters describing the activity of the CSN5-CSN6 complex and 
comparison with other isopeptidases, including the CSN complex suggest that the 
MPN heterodimer could contribute significantly to the catalytic activity of the human 
CSN, potentially forming the core catalytic domain of this complex. Although, for 
Rpn11 and BRCC36, it had previously been shown that their isopeptidase activity 
requires with the presence of their corresponding MPN- domain-containing subunits 
[168], contradictory data for CSN5 was reported [143]. In this work, the function of 
CSN6/Csi1 in human and in budding yeast, respectively was probed and conclusions 
derived suggested that only the C-terminal region of CSN6 is necessary for the 
deneddylation activity. Although highly confident in our results obtained as various 
different substrates were used to detect the activity in the presence of CSN6, further 
investigation may be required to reconcile the different results obtained in these two 
studies. 
 
Although attempts to characterise the CSN5-CSN6 interaction by X-ray 
crystallography were undertaken within our work as well, whilst this approach 
claimed unsuccessful, we also investigated the interaction by means of an integrated 
approach comprising of interface mapping by NMR, sequence conservation analysis, 
site-directed mutagenesis combined with enzymatic activity assays. These 
experimental approaches provided experimental constraints which were further used 
to reconstitute the CSN5-CSN6 heterodimer complex by molecular docking. 
Interestingly, the surfaces engaged in the CSN5-CSN6 model produced are highly 
similar to those observed in the Rpn11-Rpn8 complex although differences in the C-
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terminal region were detected. This probed us to identify and characterise the 
flexibility of the N- and C-terminal regions of CSN5. We thereby showed that the N- 
and C-terminal regions of CSN5, adopting a stapled conformation in the crystal 
structure, has the ability to undergo conformational changes. In that case, the resulting 
CSN5-CSN6 heterodimer model obtained is reminiscent to that of the yeast Rpn11-
Rpn8 heterodimer, and human Rpn8 and CSN6 homodimers mode of interaction. 
 
Our work provided an updated model of the CSN5-CSN6 complex and overall 
highlighted the importance of the MPN domain interaction in the catalytic activity. 
This could further suggest that the C-terminal regions of full length CSN5 and CSN6 
may contribute to anchoring and optimal positioning of these subunits within the CSN 
complex. Whilst we were in the processing of submitting our work, a manuscript 
reporting the crystal structure of human CSN complex at 3.8 Å resolution was 
published [61]. Findings described in this study are in good agreement and support 
conclusions reached in our study.  
 
Within the thesis occasionally we have briefly mentioned and compared the work 
presented in this study to ours. However detailed investigation in this manuscript was 
limited as a result of the timing of this paper barely coincided with our work. 
Nevertheless this study, together with others which we have detailed earlier in our 
work, and of course with our present studies, have contributed in the blossom of 
information regarding the activity and activity regulation of this protein complex. The 
structure of the CSN complex depicted some anticipated features coming from 
previous work on related proteins. However the inactive configuration of the CSN in 
the crystal structure was a surprise for many (Fig. 5-1B). A further difference was 
observed in the Zn coordination site, where the activated water molecule is replaced 
by another amino acid, E104 from the Ins-1 insertion segment. Interestingly, 
Lingaraju et al. proposed that the E104-Zn2+ binding might be responsible for keeping 
the CSN in an inactive state when free from CRLs (Fig. 5-1E). These findings 
together with ours, would suggest that the CSN5 subunit is inhibited by distinct 
mechanisms depending on whether the subunit is in its stand-alone state or whether 
within the CSN complex. These findings reveal that, although some generalisations 
could be made across the JAMM/MPN+ family, they all seem to have unique and 
distinctive features. These findings not only contribute to answering a number of 
questions which have been awaiting for many years, but also open further doors in the 
field of JAMM/MPN+ family proteins, and much more exciting work remains to be 
done to grasp the intricate regulatory mechanisms responsible for the controlled 
functions of the CRLs and more globally, of the UPS.  
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Figure 5-1. Modes of activity regulation of CSN5 and the CSN complex. 
A. CSN5 alone is inactive, the Ins-1 segment is in a closed conformation, blocking the site for 
Nedd8 binding. B. Ins-1 of CSN5 within the CSN complex, is in a partially closed 
conformation. C. A molecular model of CSN5 where the Ins-1 is in an open conformation, 
due to breaking of R106-D151 salt bridge, allowing for substrate accommodation. D. CSN5 is 
activated by CSN6, the Ins-1 is speculated to be in an open conformation. E. The E104-Zn
2+
 
binding is responsible for keeping the CSN in an inactive state when free from CRLs. Upon 
CRL binding, the CSN is activated. 
 
Even from the structural point of view, there still remains work ahead including for 
example the examination of the structure of different functional mutants of the CSN, 
which could help unravel the mechanism by which binding of the CRLs induces 
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conformational changes. Even more intriguing would be to investigate the CSN-
Nedd8-CRL complex and determine the CSN-CRL interface and the influence of 
Nedd8 in the activation of the CSN. Moreover, the structural studies of CSN5, CSN5-
CSN6 and the CSN complex, now provide templates for the design of drugs that act 
on the CSN, which could be an attractive target for various cancers.
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The COP9 (Constitutive photomorphogenesis 9) signalosome (CSN),
a large multiprotein complex that resembles the 19S lid of the
26S proteasome, plays a central role in the regulation of the E3-
cullin RING ubiquitin ligases (CRLs). The catalytic activity of the
CSN complex, carried by subunit 5 (CSN5/Jab1), resides in the
deneddylation of the CRLs that is the hydrolysis of the cullin-neural
precursor cell expressed developmentally downregulated gene 8
(Nedd8)isopeptide bond. Whereas CSN-dependent CSN5 displays
isopeptidase activity, it is intrinsically inactive in other physiologi-
cally relevant forms. Here we analyze the crystal structure of CSN5
in its catalytically inactive form to illuminate the molecular basis for
its activation state. We show that CSN5 presents a catalytic domain
that brings essential elements to understand its activity control.
Although the CSN5 active site is catalytically competent and
compatible with di-isopeptide binding, the Ins-1 segment obstructs
access to its substrate-binding site, and structural rearrangements
are necessary for the Nedd8-binding pocket formation. Detailed
study of CSN5 by molecular dynamics unveils signs of ﬂexibility and
plasticity of the Ins-1 segment. These analyses led to the identiﬁ-
cation of a molecular trigger implicated in the active/inactive switch
that is sufﬁcient to impose on CSN5 an active isopeptidase state.
We show that a single mutation in the Ins-1 segment restores
biologically relevant deneddylase activity. This study presents de-
tailed insights into CSN5 regulation. Additionally, a dynamic mono-
mer-dimer equilibrium exists both in vitro and in vivo and may be
functionally relevant.
cullin regulation | protein degradation | MPN | Rpn11
Cell signaling processes mediated by ubiquitinylation, theposttranslational covalent conjugation of ubiquitin molecules,
are of prime importance for cellular activity and particularly for
protein turnover. Ubiquitin-ligase enzymes (E3s) are responsible
for the last step of the ubiquitinylation reaction, and the multi-
subunit cullin–RING E3 ubiquitin ligases (CRLs) represent the
most prominent of E3 enzymes. Among the several factors that
regulate CRL activity, cullin neddylation/deneddylation cycles
are central (1).
The Cop9 signalosome (CSN), which is an eight-subunit com-
plex largely conserved through evolution, deneddylates CRLs and
thereby regulates CRL activity. As a large number of proteins are
ubiquitinylated by CRLs, the CSN complex is implicated in the
control of a signiﬁcant proportion of the proteome, including
prooncogenes, tumor suppressors, and other important cellular
protagonists (1). Not surprisingly, the CSN has been implicated in
various cellular functions, ranging from cell cycles to circadian
rhythm and to immunity in various organisms. Furthermore, many
studies have found a strong link between the CSN and cancers (2).
The CSN, a multi-protein complex of about 320 kDa, contains
six proteasome Cop9 eIF3 (PCI)-based subunits and two MPR1-
Pad1-N-terminal (MPN)-based subunits. The subunit 5 [CSN5;
also known as c-Jun activation domain-binding protein-1 (Jab1)]
(3) , one of the two MPN-containing subunits, carries a zinc-
dependent isopeptidase catalytic center that contains a Jab1/
MPN/Mov34 (JAMM) motif (also known as MPN+ motif) (4).
Several detailed studies suggested that the organization of the
CSN complex resembles that of the 26S proteasome lid (5), with
the deubiquitinase enzyme Rpn11 being the equivalent of the
deneddylating subunit CSN5 (4, 6). The physiology of the CSN
has been well researched (2). Intriguingly, the CSN cancer im-
plication is attributable mainly to CSN5, which is located on
human chromosome 8q.
Smaller forms of the holo-CSN complex, with variable com-
positions, have been found in vivo (7–11). Although possibly
important in cell cycle progression, these sub-CSN complexes
have not yet been fully functionally characterized (12). It is in-
teresting that, as alluded to for Rpn11 in several reports (6, 13),
CSN5 is found in two forms: a holo-CSN–associated form that is
catalytically active and a stand-alone state void of isopeptidase
activity (4, 5). The modularity and topology of the CSN complex
have been explored in vitro by nondenaturing mass spectrometry
(MS), which revealed that CSN5 is a peripheral subunit that can
homo-dimerize outside of the CSN complex and interacts mostly
with the other MPN-containing subunit, CSN6, in the context of
the CSN complex (5). The potential interactions of CSN5 with
other CSN subunits, namely CSN1, CSN2, CSN4, and CSN7,
have also been highlighted (1, 8, 14, 15).
To elucidate the molecular regulation of CSN5 activity, we
structurally and functionally characterized it in its CSN-in-
dependent form by X-ray crystallography, molecular dynamics
(MD) simulations, and in vitro and in vivo studies. Our struc-
tural work uncovered a potential molecular trigger that regu-
lates the active/inactive transition of CSN5. These experiments
contributed to the design of a constitutively active form of iso-
lated CSN5, shedding lights on its activation control mechanism
at a molecular level.
Results
Overall Structure and Oligomeric Arrangement. A stable form of
human CSN5 comprising residues 1–257 (CSN51–257), identiﬁed
by MS and N-terminal sequencing, was isolated and crystallized.
The crystal structure was solved by selenium– single-wavelength
anomalous dispersion (SAD) using diffraction data to 2.6 Å (SI
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Appendix, Table S1). CSN5, which consists of 334 residues, is
a Jab1/MPN superfamily member with a conserved core MPN
domain (51–230) and a JAMM motif (Glu76, His138, His140,
and Asp151) (Fig. 1 A and B). In addition to the MPN cata-
lytic domain, CSN5 possesses N- and C-terminal regions that
tightly pack against the MPN fold and form an extended
catalytic domain.
The asymmetric unit of CSN51–257 crystal contains a dimer,
related by a local twofold axis perpendicular to the crystallo-
graphic dyad axis, also generating a second dimeric arrangement
(SI Appendix; SI Appendix, Fig. S1A). The evidence that CSN5
could adopt a homo-oligomeric arrangement in vivo could be of
substantial interest and was further investigated.
CSN5 Can Form Homo-Dimers Both In Vitro and In Vivo. To in-
vestigate the presence of the oligomeric species, our experi-
mental approach was based on chemical cross-linking (SI
Appendix, Fig. S1B), dynamic light scattering (DLS; SI Appendix,
Table S3), and analytical ultracentrifugation (AUC; SI Appendix,
Table S4 and Fig. S1 C and D). The results showed that mono-
mers and dimers were the major species of CSN5 detected in
solution. Investigation of the presence of CSN5 oligomers in vivo
carried out by coimmunoprecipitation experiments on mammalian
cell extracts conﬁrmed that CSN5 assembles in dimer (Fig. 1C).
Supported by both in vitro and in vivo data, these observations
suggest that a CSN5 dimeric assembly could be present in solu-
tion in equilibrium with monomeric species (SI Appendix, Tables
S3 and S4). It is noteworthy that other MPN-containing proteins
were found to assemble in dimers in the crystals and that each of
the described dimers proceeds via totally different interfaces (16,
17), preventing further comparison. Moreover, the question of
the physiological relevance of these dimers has not yet been
addressed in vivo.
In addition to these experiments and on the basis of the A–B
and A–A′ dimer interface analysis, mutations or deletions were
designed to selectively weaken these two intersubunit interactions.
These data conﬁrmed that CSN5 dimers proceed both in vitro and
in vivo predominantly via the A–B interface (SI Appendix; SI
Appendix, Fig. S1, E–G) where more than 50% of the contributing
residues are highly conserved among the 170 available sequences
(SI Appendix, Fig. S2), further suggesting that this assembly may
be physiologically relevant. Taken together, these results suggest
that CSN5 could form dimers, unveiling a potential new level of
regulation in the biology of CSN5. Additional studies will be
needed to understand the biological role and the distribution of
the CSN5 dimeric form in cells.
Conserved Rigid MPN Domain Is Decorated by CSN5-Speciﬁc N- and C-
Terminal Extensions. The CSN51–257 structure reveals a fold typi-
cal to the Jab1/MPN superfamily that has been described in
a number of structures (Fig. 1A; SI Appendix; SI Appendix, Fig.
S3) (16–21). Interestingly structural comparison between MPN
members revealed that the region spanning from residues 97–131
(referred to as Ins-1) displays an array of conformations in the
various MPN members (Fig. 2A). A sequence alignment focused
on the Ins-1 segment of four representatives of the MPN+
/JAMM family is presented in Fig. 2B. It is noteworthy that the
lack of electron density for the CSN5 portion consisting of res-
idues 197–219 [corresponding to Ins-2 in the structure of asso-
ciated molecule with the SH3 domain of STAM (signal
transducing adapter molecule) deubiquitinase (AMSH-LP) (20)]
prevented accurate modeling and analysis of this segment.
The ensemble of the CSN5-speciﬁc N- and C-terminal seg-
ments wraps around and makes extensive contacts with the
conserved MPN domain core (Fig. 1A; SI Appendix, Fig. S3).
Most MPN protein structures solved to date display reduced or
are lacking N- and C-terminal additions, with the exception of
Prp8p structure that has extensions of similar size to that of
CSN5 (19). However, in CSN5 and in the Prp8p scaffolding
protein, these regions adopt very different positions and con-
formations with respect to the core MPN domain.
To extend and complement the structural insights obtained
from crystallography, we carried out a series of MD simulations.
The CSN5 crystal structure suggests that the central core domain
is stable and that some  anking α-helices and loops displaying
higher B-factors could be locked into the structure due to the
crystal packing. MD simulations of the solvated CSN5 monomer
at 300 K for 40 ns conﬁrmed that the core domain is stable (SI
Appendix, Fig. S4A) and that the residues forming the Ins-2
segment, the loops, and the N- and C-terminal ends display the
maximum  uctuation compared with the central core domain (SI
Appendix, Fig. S4B).
CSN5 Zinc-Binding Site Is Catalytically Competent, Similar to Other
JAMM-Containing Motifs. As we anticipated from other MPN+
/JAMM proteases, the CSN5 structure contains one zinc atom
(Fig. 3A). The strictly conserved zinc coordination site (Fig. 2B)
is composed of residues from helix α5 and a subset of the central
β-sheet (β5, β5-α5, β6, and β7). The zinc is tetrahedrally co-
ordinated to two His residues (His138 and His140), one Asp
residue (Asp151), and a catalytic water molecule hydrogen
bonded to Glu76 and Ser148. The importance of the active site
zinc-coordinating residues in catalysis was previously tested by
mutagenesis (4).
To date, AMSH-LP is the only structural example of an ac-
tive MPN+/JAMM isopeptidase enzyme that exists in an
Fig. 1. CSN5 overall structure and oligomeric arrangement. (A) Overall
monomeric structure of CSN51–257 reveals a central MPN core domain (light
brown) and peripheral N- and C-terminal extensions (green). The Ins-1 re-
gion (residues 97–131) is yellow. Secondary structure elements are num-
bered, and the catalytic center is shown in ball-and-stick representation. (B)
Schematic representation of the CSN5 domain organization. The MPN do-
main is delineated in orange; the N- and C-terminal extensions are green.
The ﬁve residues of the JAMM motif, namely E76, H138, H140, S148, and
D151, are indicated by red dotted lines. The Ins-1 and Ins-2 insertions are
placed with respect to their positions in the sequence. The secondary
structure elements are shown in red for α-helices and in blue for β-strands.
Regions that are either not ordered in the crystal structure or not included in
the crystallized fragment are indicated by a gray dotted line. (C) Biochemical
identiﬁcation of CSN5 dimer in vivo by coimmunoprecipitation experiments.
293T cells were transfected with either Flag- or His-tagged CSN5 or both for
48 h, and then cell lysates were immunoprecipitated (IP) with either anti-
Flag (Upper) or anti-His (Lower) tag antibodies and immunoblotted (IB) with
anti-His or anti-Flag tag antibodies (Left). The expression of the corre-
sponding pairs of Flag- and His-tagged CSN5 was conﬁrmed by IB using anti-
Flag and anti-His antibodies, respectively (Right). IgG heavy chain (HC) and
light chain (LC) are indicated.
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unbound form or in complex with its K63-Ub2 substrate (20).
Therefore, it provides for this enzyme family a model for
a catalytically competent active site and for substrate inter-
actions. Comparison of the zinc-binding sites of CSN5 and
AMSH-LP revealed that the overall topology of their active
sites is well conserved (Fig. 3A; SI Appendix, Table S5). In ad-
dition, the position and environment of the Gly76-Lys63 iso-
peptide, inferred from the AMSH-LP/K63-Ub2 complex and
straightforwardly placed in the CSN5 active site conﬁrmed that
CSN5 adopts a catalytically competent geometry (Fig. 3B). The
Gly76-Lys63 isopeptide bond, placed in the CSN5 zinc-binding
site, is maintained via a hydrogen bond between the Gly76
carbonyl group and the Ser148 hydroxyl group and between the
Lys63 e-amino group and the Glu76 carboxylate. Moreover,
analysis of the crystal packing showed that the C-terminal
segment (residues 248–257) of a monomer docks into the active
site of the neighboring molecule (SI Appendix, Fig. S4C). In-
terestingly, a close inspection revealed that this C-terminal
portion interacts with the neighboring molecule  s active site in
a manner that is reminiscent of the K63-Ub2 isopeptide bond in
the AMSH-LP/K63-Ub2 structure (Fig. 3B). Moreover, the
CSN5 Ser254 hydroxyl group is hydrogen bonded to Ser148 and
occupies a position similar to the distal ubiquitin Gly76 car-
bonyl in the AMSH-LP active site.
We also investigated the role played by the catalytic zinc ion
on the structure and stability of the active site. The side-chain
motions of the zinc catalytic site amino acids were analyzed.
Their positions were stable over the course of the MD simu-
lations (SI Appendix, Fig. S4D), and their averaged interatomic
distances from Zn2+ were in good agreement with those mea-
sured from the CSN51–257 and AMSH-LP crystal structures (SI
Appendix, Table S5).
Taken together, these observations suggest that, as in AMSH-
LP, the zinc-binding site catalytic residues of CSN5 are in a po-
sition and are geometry compatible with isopeptidase activity,
and therefore the zinc active site conformation of this enzyme in
its isolated form is catalytically competent.
Although the CSN5 zinc-binding site and its catalytic residues
are very similar to those of AMSH-LP, their spatial environment
and accessibility have several signiﬁcant differentiating features.
In particular, the CSN5 Ins-1 region shielding the active site
adopts a radically different topology (loop β4-α4 and α4 helix)
compared with AMSH-LP characterized by two antiparallel
β-strands followed by a short α-helix (Fig. 4A). An additional
crucial feature of CSN5 is the presence of the Arg106 residue
projecting out of the Ins-1 segment and establishing a salt bridge
with the Asp151 (Fig. 3A).
Surroundings of the CSN5 Zinc Catalytic Site Is Not Competent for
Nedd8 Recruitment, Without Conformational Rearrangements. Two
different activation states of CSN5 are described in the literature
(4, 5): an active deneddylase in the context of the holo-CSN
complex and a stand-alone inactive form in the isolated subunit.
Because our data suggest that the CSN5 active site is poised for
catalysis, it seemed logical to explore substrate binding and re-
cruitment by this enzyme.
In the crystal structure of theAMSH-LP/K63-Ub2 complex, the
two ubiquitin molecules, referred to as proximal and distal, in-
teract with AMSH-LP via numerous electrostatic and hydropho-
bic interactions (SI Appendix, Fig. S2) (20). The directionality of
the isopeptide bond implies that neural precursor cell expressed
developmentally downregulated gene 8 (Nedd8) would occupy
the site corresponding to the distal ubiquitin in the AMSH-LP/
K63-Ub2 structure. The distal ubiquitin molecule mediates the
largest interaction surface area and contributes the most to the
binding afﬁnity of K63-Ub2 for AMSH-LP. Correct positioning of
the K63-Ub2 isopeptide bond in the long recognition groove of
AMSH-LP is ensured by interactions between AMSH-LP [in
particular, the Ins-1 region, the Ins-2 loop (disordered in CSN5),
and the segment between these two insertions) and the proximal
and distal ubiquitins (SI Appendix, Fig. S2)]. The C-terminal
portion of the distal ubiquitin adopts an extended conformation
that ﬁts in the substrate-binding groove delimitated by two α-he-
lices and a β-hairpin. Ubiquitin and Nedd8 molecules are 58%
Fig. 2. CSN5 MPN domain and speciﬁc extensions. (A) Conformational het-
erogeneity of the Ins-1 region in CSN5 (residues 97–131; brown), CSN6 (yel-
low; PDB code: 4E0Q), Mov34 (cyan; PDB code: 2O95), Prp8p (magenta; PDB
code: 2OG4), AfJAMM (green; PDB code: 1OI0), and SRU-2040 (purple; PDB
code: 2KCQ). Secondary structure elements around CSN5 Ins-1 are shown for
context in white. (B) Sequence alignment focused on the residues 97–171
(CSN5 numbering) of four humanMPN+/JAMM representatives. Residues that
correspond to the JAMMmotif (with the exception of E76) are indicated with
a black *. In addition to each of the proteins, conservation of the residues
across the species are illustrated by a color code ranging from red for strictly
conserved residues to light gray for residues that are highly variable.
Fig. 3. Geometry of CSN5 zinc-binding site is compatible with catalysis. Zinc
and catalytic water are represented by green and red spheres, respectively.
(A) CSN5 active site residues are poised for catalysis. Active site residues and
their associated secondary structure are presented for CSN5 (light brown)
and AMSH-LP (pink). (B) Model of AMSH-LP Gly-Lys isopeptide in CSN5
conﬁrms that its zinc-binding site geometry is similar to that of AMSH-LP and
is therefore competent for isopeptidase activity. The residues of the CSN5
and AMSH-LP zinc-binding sites and of the Gly-Lys isopeptide are shown in
ball-and-stick format (light brown, light pink, and dark gray, respectively).
The positions of the AMSH-LP residue Glu292, marked by an asterisk, as well
as its zinc and catalytic water, were extrapolated from the AMSH-LP struc-
ture (PDB code: 2ZNR); the rest is from the structure of the AMSH-LP/K63-
Ub2 complex (PDB code: 2ZNV).
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identical over 76 residues and adopt the same fold (22, 23). The
interactions with the last four residues of ubiquitin/Nedd8 pre-
ceding the isopeptide bond are likely to be preserved in CSN5.
Only one residue at position 72 (arginine and alanine in ubiquitin
and Nedd8, respectively) differentiates ubiquitin from Nedd8 in
the last 10 residues. Analysis of the AMSH-LP residues impli-
cated in the distal ubiquitin recognition site revealed that more
than 65%of them are highly conserved in CSN5 (SI Appendix, Fig.
S2). However, most of the residues for which no equivalent could
be found in CSN5 belong to the highly divergent Ins-1 region that
has a very different sequence (Fig. 2B) and conformation in CSN5
and AMSH-LP. Consequently, without the structure of CSN5 in
its active state, detailed analysis of the substrate-binding site in
CSN5 is prevented.
Despite the high conservation of the interaction site in CSN5
(SI Appendix, Fig. S2), the conformation of the Ins-1 segment
observed here sterically precludes Nedd8 binding (Fig. 4A).
Extensive structural changes of this segment, which probably
confers some of the speciﬁcity for Nedd8 ligand, would be re-
quired to create a fully competent binding site.
Arginine Residue Contributes to the Control of CSN5 Isopeptidase
Activation State. The major difference at the active site level
between CSN5 and AMSH-LP corresponds to the conformation
of the Ins-1 segment. It is therefore most interesting to note
that the Ins-1 segment of CSN5 shows signs of  exibility, as
indicated by high crystallographic B-factor values and the fact
that it exhibits signiﬁcant conformational variability within
representatives of the MPN family (Fig. 2A). Moreover, MD
simulations  agged portions of the Ins-1 region as highly  exi-
ble (residues 101–104, 108–112, and 123–131), with a pro-
pensity to adopt different conformations during the course of
the simulations (SI Appendix, Fig. S4B). These CSN5 segments,
bracketing the residue Arg106, display pronounced movements
opening onto the solvent in MD simulations, whereas Arg106
contributes signiﬁcantly to the anchoring of the Ins-1 segment
to the zinc-binding site via its salt bridge with Asp151 (SI Ap-
pendix, Fig. S5A). Our MD studies conﬁrmed the potential
importance of Arg106 with this salt bridge being maintained in
the 40-ns trajectory. The observations that Arg106 plays a role
in CSN5 plasticity were further probed and conﬁrmed by
rotamerically induced perturbation (RIP) simulations (SI Ap-
pendix, Fig. S5B) (24). These data suggest that the intrinsic
 exibility and plasticity of the Ins-1 region could allow major
conformational rearrangements to accommodate Nedd8 bind-
ing and that Arg106 could have here a triggering function for
structural rearrangement of the Ins-1 segment.
To evaluate the role of Arg106 as a potentially important
protagonist in CSN5 activation switch, we tested the effect of
Arg106 substitution on CSN5 isopeptidase activity. In agreement
with published data in the literature (4, 5), we conﬁrmed that the
CSN51–257 WT form is void of isopeptidase activity and showed
that the R106 substitution to threonine is sufﬁcient to restore
robust constitutive isopeptidase activity against two synthetic
substrates: LRGG–7-amido-4-methylcoumarin (AMC) and
Nedd8-AMC (Fig. 4B; SI Appendix, Fig. S6). Substitution of the
arginine residue by alanine and glycine similarly confers iso-
peptidase activity to CSN5, albeit to a slightly reduced level
compared with the R106T variant, whereas the R106P variant is
void of activity (Fig. 4B). Analysis of the zinc binding site topology
in CSN5 and AMSH-LP revealed that the glutamate residue
corresponding to the position 292 in AMSH-LP is the glutamate
76 in CSN5. The position 76 was consequently mutated to an al-
anine residue. As expected and in comparison with the WT and
R106T variants, the E76A and E76A/R106T variants do not dis-
play isopeptidase activity on Nedd8-AMC (Fig. 4B). Comparison
of the rescued activity of CSN5 R106T with that of the holo-CSN
complex using Nedd8-AMC as a substrate highlighted that the
multiprotein complex is about 79-fold more active than the stand-
alone protein (Fig. 4B). To complement these activity data, pull-
down experiments, usingGST-CSN51–257 as the bait andNedd8 as
the target, showed that the R106T form was much more efﬁcient
at binding Nedd8 than theWT counterpart (SI Appendix, Fig. S7).
Furthermore, MD simulations on the R106T variant conﬁrm that
the Ins-1 segment is released from the vicinity of the zinc-binding
site; similar results were obtained for R106G and R106P (SI
Appendix, Figs. S4B and S5C). These observations conﬁrm that
releasing the Ins-1 segment from its anchoring point could favor
a conformation that is compatible with Nedd8 binding. Taken
together, these data strongly suggest the implication of Arg106 in
the active/inactive switch of CSN5. The importance of R106 is
Fig. 4. CSN5 adopts a conformation incompatible with Nedd8 recruitment
and requires conformational relaxation to perform catalysis. (A) CSN5 Ins-1
masks the putative binding site for Nedd8. (Top) CSN5 surface and a close-up
view of the Ins-1 region. (Middle) AMSH-LP surface and a close-up view of
the Ins-1 region. (Bottom) Surface of AMSH-LP bound to K63-Ub2 and
a close-up view of the groove that accommodates the isopeptide. (B) R106T
(or R106A,G) substitution constitutively activates CSN5 against Nedd8 sub-
strate. Isopeptidase activity of CSN5 or of the CSN on Nedd8-AMC was
measured by the increase of ﬂuorescence intensity at 460 nm (λexcitation = 380
nm) after 50 min at 28 °C. The concentration of CSN5 used in these experi-
ments is 210-fold more than that of the CSN complex, as indicated by an
asterisk. Taking into account this dilution factor, the CSN complex appears
79-fold more active than the most active R106 variant, R106T. (C) The R106T
variant form of CSN51–257 is able to deneddylate Nedd8-cullin 1. (Upper)
Nedd8 signal of the Nedd8-cullin 1 and (Lower) Nedd8 released on Nedd8-
cullin 1 isopeptide bond hydrolysis for CSN5 WT, CSN5 R106T, and the CSN
complex (from left to right).
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further supported by its strict conservation in CSN5 across eu-
karyote species (Fig. 2B; SI Appendix, Fig. S2). These results
would indicate that the conformational relaxation of the Ins-1
region allows substrate binding and additionally corroborates our
analysis on the intrinsic topological competence of the zinc
binding site for catalysis but also point out that the CSN complex
brings further activation and/or activity determinants that makes
CSN-associated CSN5 more active than its stand-alone form.
To extend our analysis to a physiological substrate, we asked
whether R106T also supports deneddylation of neddylated cullin
1, in complex with Rbx1 in vitro. As expected, the CSN complex
is very effective at deneddylating cullin 1, as visualized by the
important decrease of neddylated forms of cullin 1 and con-
comitant release of free forms of Nedd8, detected with Nedd8
antibodies. Importantly, although the stand-alone CSN5 WT
was unable to deneddylate cullin 1, a modest but signiﬁcant level
of free Nedd8 was released when using the R106T variant (Fig.
4C). Conﬁrming our results using Nedd8-AMC, these observa-
tions show that the WT-isolated form of CSN5 is indeed void of
deneddylase activity, that the loss of the R106-D151 salt bridge
contributes to unveiling its deneddylase activity, and that the
integral CSN is much more efﬁcient at deneddylating cullin 1.
Discussion
Mediated most likely through its deneddylase activity, the func-
tion of the CSN complex is important for cellular homeostasis, as
highlighted by its implication in proliferative diseases (25). The
sequence alignment of the CSN catalytic subunit, CSN5, from
different organisms reveals highly conserved features throughout
the sequence in agreement with its catalytic function within the
CSN complex. The distribution of CSN5 between the holo-CSN,
different sub-CSN complexes, and CSN-independent forms ob-
served in a number of studies could play a role in CSN5 regu-
lation, but clearly the critical and best understood function
resides in the deneddylation of cullins.
Our work reveals that CSN5 can be found in different oligo-
meric states in vitro and in cell lysates and may predominantly
follow a monomer-dimer equilibrium. The interaction between
CSN5 and various partners has been investigated in previous
studies, but only in its monomeric form (2). Its assembly in
dimers could be relevant in mediating protein-protein inter-
actions and subcellular localization of CSN5.
The main aspect in CSN5 biology that is addressed in this work
is its activation state in the CSN-independent context. To glean
insights into CSN5 isopeptidase activity regulation, we used
structural biology and in silico MD simulations, which together
created a detailed picture of CSN5 activity control. The crystal
structure of CSN5 in a CSN-independent form displays an ex-
tended catalytic domain that revealed a number of features,
contributing to our understanding of the enzyme s activation and
substrate recruitment. In analogy to the structure of AMSH-LP
(20), the stand-alone form of CSN5 adopts a zinc-binding site
geometry that appears compatible with isopeptidase activity and
potentially with binding of the Gly76-Lys63 isopeptide, as extrap-
olated from the cocrystal structure of AMSH-LP/K63-Ub2 to the
CSN5 zinc-binding site (Fig. 3B). Unlike AMSH-LP/K63-Ub2,
however, investigation of the recruitment of Nedd8 by CSN5
revealed that the substrate-binding site is not formed in CSN5 and
that the Ins-1 segment would require substantial structural rear-
rangement for Nedd8 to bind. These observations were conﬁrmed
by analysis of Ins-1  exibility and plasticity by in silico simulations.
Our work also helped understanding one of the molecular events
that may trigger these conformational changes in CSN5. MD and
RIP calculations pointed to a role for the strictly conserved Arg106
in keeping this segment in a conformation not competent for
Nedd8 binding. The implication of this residue, validated by in vitro
experiments, led to the conﬁrmation that Arg106 is an important
protagonist in CSN5 activation switch. Indeed, substitution of this
residue by a threonine and to a lesser extent, alanine and glycine
(but not proline), restores a constitutive isopeptidase activity
against two synthetic substrates: LRGG-AMC and Nedd8-AMC
(Fig. 4B). This work was extended by testing isopeptidase activity of
the R106T variant on a physiological substrate, neddylated cullin 1.
The CSN5 R106T variant shows modest but signiﬁcant iso-
peptidase activity, conﬁrming results obtained on synthetic sub-
strates (Fig. 4C). However, comparison of this activity with that of
the CSN complex reveals, as observed for Nedd8-AMC, that the
CSN complex is a more efﬁcient deneddylase than CSN5 R106T. It
is noteworthy that, although we observed robust isopeptidase ac-
tivity on Nedd8-AMC by the CSN complex, this is in contrast with
the observations reported by the Dubiel s group (26, 27), in which
no activity was found. Even though the CSN isopeptidase activity
measured in our experiments corresponds to a weaker level than
the activity recorded on a physiological substrate reported in ref. 28,
probably re ecting the higher efﬁciency of the CSN complex on the
physiological substrate, this activity was readily measured in our
 uorescence-based assay. Additionally Pan s group reported that
the CSN complex was unable to process another linear substrate,
pro-Nedd8 (29), using a gel-shift assay. These discrepancies,
probably re ecting on the complexity of the studied system, would
need further investigation to be resolved.
These observations relative to CSN5 activation shed some
light onto different regulatory levels that keep CSN5 under
control. CSN5 appears to require an activation step for which
one of the switches is likely to correspond to the Arg106–Asp151
salt bridge: loss of this strong interaction promotes the existence
of an open form of the enzyme that unveils deneddylase activity
on both synthetic and physiological substrates. Coming in addi-
tion to the Ins-1 release is its restructuration to form the second
ridge of the substrate-binding groove in which the isopeptide
would insert. Integration of CSN5 into the CSN complex and the
consequent protein–protein interactions with CSN subunits such
as CSN6, as highlighted by nondenaturing MS experiments (5),
are likely to play a part in both CSN5 activation and substrate
recruitment. Given the body of evidence (30–33) that supports
the involvement of multiple CSN subunits in substrate re-
cruitment (e.g., the interaction between CSN2 and cullin 1), the
observed difference in activity between the CSN complex and the
stand-alone R106T CSN5 could be directly linked to the pres-
ence of substrate recruitment exosites remote from CSN5 cata-
lytic site, achieving optimal activation and contributing to
productive binding of Nedd8-cullin isopeptide bond. Supported
by our work, CSN5 incorporation into the CSN complex prob-
ably does not lead to global structural reshaping of the enzyme.
Instead, the structural changes are likely to be limited to the
conserved Ins-1 segment (identiﬁed as malleable in our MD
calculations), the Ins-2 region (disordered in the crystal), and
possibly the C-terminal domain (residues 258–334) to prime the
deneddylating molecule for catalysis. Integration of CSN5 in the
CSN complex is probably providing the conformational energy
necessary for the activation switch.
In addition to addressing CSN5 activity regulation, our work
generates insights into the development of CSN5-speciﬁc inhib-
itors. Essentially, the C-terminal tail of one molecule docks in
the active site of another one. This association could be exploited
to build potent peptidomimetic antagonists that would be of
possible interest in the context of breast cancers (2).
Taken together, our study suggests that CSN5 in its CSN-in-
dependent form is deﬁcient in substrate recruitment and that
a single residue contributes signiﬁcantly to the activation switch.
This discovery provides the framework for conducting bio-
chemical and functional investigations to elucidate the regula-
tory mechanisms that control CSN5 function.
Materials and Methods
Construct Design. For detailed construct design, cloning, mutagenesis, protein
expression, and puriﬁcation procedures, see SI Appendix.
Crystallization, Data Collection, Structure Determination, and Molecular Dynamics
Simulations. Puriﬁed CSN51–257 formed crystals using the sitting drop vapor
diffusion method. A dataset, collected at 2.6-Å resolution from a SeMet-la-
beled CSN51–257 crystal, was used to determine the structure using the SAD
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method. The Se substructure was solved using the Charge Flipping method (34)
and used for phasing with the PHASER program (35). Details are provided in SI
Appendix and SI Appendix, Table S1. The A chain from the CSN51–257 crystal
structure was used as the initial structure for MD simulations. Detailed
procedures and references are provided in SI Appendix.
Coimmunoprecipitation Experiments and Isopeptidase Assay.Details regarding
cell culture, reagents, transfection, and coimmunoprecipitation experiments
are provided in SI Appendix. Different types of AMC-derived substrates,
LRGG-AMC, and Nedd8-AMC, as well as neddylated cullin 1, were used to
assess CSN5 activity. Details are provided in SI Appendix.
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Abstract
The Cop9 signalosome complex (CSN) regulates the functional cycle of the major E3 ubiquitin ligase family, the cullin RING
E3 ubiquitin ligases (CRLs). Activated CRLs are covalently modified by the ubiquitin-like protein Nedd8 (neural precursor cell
expressed developmentally down-regulated protein 8). CSN serves an essential role in myriad cellular processes by reversing
this modification through the isopeptidase activity of its CSN5 subunit. CSN5 alone is inactive due to an auto-inhibited
conformation of its catalytic domain. Here we report the molecular basis of CSN5 catalytic domain activation and unravel a
molecular hierarchy in CSN deneddylation activity. The association of CSN5 and CSN6 MPN (for Mpr1/Pad1 N-terminal)
domains activates its isopeptidase activity. The CSN5/CSN6 module, however, is inefficient in CRL deneddylation, indicating
a requirement of further elements in this reaction such as other CSN subunits. A hybrid molecular model of CSN5/CSN6
provides a structural framework to explain these functional observations. Docking this model into a published CSN electron
density map and using distance constraints obtained from cross-linking coupled to mass-spectrometry, we find that the C-
termini of the CSN subunits could form a helical bundle in the centre of the structure. They likely play a key scaffolding role
in the spatial organization of CSN and precise positioning of the dimeric MPN catalytic core.
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Introduction
The ubiquitin-proteasome system is implicated in virtually all
functions of eukaryotic living cells. The covalent attachment of
ubiquitin molecules, ubiquitylation, requires the concerted inter-
vention of the distinct E1, E2 and E3 enzymes. The most
prominent E3 ubiquitin ligase family comprises the cullin RING
E3 ubiquitin ligases (CRLs). CRLs are important regulators of
cellular homeostasis, division, and responses to various cellular
insults [1]. Their significance is further highlighted by the
deregulation of some CRL elements in human diseases and, in
particular, in cancers [2,3].
CRLs are built around a cullin scaffold, which associates with a
substrate-specific adaptor and a RING finger protein [4]. CRL
activity is tightly regulated to ensure the timely and specific
substrate ubiquitylation [1]. The covalent attachment of the
ubiquitin-like (UBL) molecule Nedd8 (neural precursor cell
expressed developmentally down-regulated protein 8) to cullins,
termed neddylation, activates their ubiquitylation activity by
stabilising an activated conformation of the RING subunit [5,6].
The Cop9 signalosome (CSN) is an eight-subunit complex that
deneddylates cullins [7]. Six of its subunits (CSN1 to CSN4,
CSN7, CSN8) contain a PCI (for Proteasome Cop9 eIF3) domain
and two (CSN5/6) contain an MPN (for Mpr1/Pad1 N-terminal)
domain. The PCI subunits serve a scaffolding function and,
especially through CSN2, help recruit the neddylated CRL
substrates [8]. Structurally, the PCI-containing subunits arrange
in a horseshoe-like shape, juxtaposed with the two MPN subunits.
This architecture is strikingly similar to that of the 26S proteasome
lid and the eukaryotic translation initiation factor eIF3
[8,9,10,11,12,13].
Among the CSN MPN-containing subunits, CSN6 lacks a
functional catalytic site and belongs to the MPN2 class [14,15,16].
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In contrast, CSN5, also known as Jun-activatory binding protein 1
(Jab1) carries the catalytically competent MPN+/JAMM (Jab1-
MPN-Mov34) motif [15,17]. As defined in the AMSH (Associated
Molecule with the SH3 domain of STAM)-like protein (AMSH-
LP) [18], the MPN domain of CSN5 contains two insertions,
namely Insertion-1 (Ins-1; residues 97–131 in human CSN5) and
Insertion-2 (Ins-2; residues 197–219 in human CSN5). These
regions usually contribute to the regulation of the isopeptidase
activity. For AMSH-LP, the Ins-1 region plays a role in the
binding and competent positioning of the distal ubiquitin [18].
CSN5 by itself is found in an inactive state and the transition from
this stand-alone auto-inhibited to the active form probably
requires conformational changes of the Ins-1 region [17,19]. This
is reminiscent of Rpn11 and BRCC36 (for BRCA1 (for Breast
Cancer 1)/BRCA2 (for Breast Cancer 2)-Containing Complex
subunit 36) found in the 26S proteasome lid and BRCC36-
containing complexes, respectively, that are also inactive in the
stand-alone form [20]. Recently, the crystal structure of Rpn11/
Rpn8 MPN domains brought important insights into the
dimerisation of an MPN+/JAMM enzyme with an MPN2 subunit
[21,22], pointing towards the mechanism underlying the catalytic
activation of inactive MPN+/JAMM enzymes upon integration in
higher order assemblies.
Although the structural and functional understanding of the
CSN/CRL interplay has significantly grown over the recent years,
important questions concerning the association of the MPN
domains and the regulation of CSN activity remain. Here we
report that CSN6 N-terminal domain containing its MPN domain
can form a stable heterodimer with CSN5 catalytic domain in
vitro. Biophysical and activity measurements indicate that CSN6
MPN domain stimulates CSN5’s isopeptidase activity. Compar-
ison with CSN on synthetic substrates reveals that both CSN and
the dimeric MPN module display robust isopeptidase activity
towards C-terminal Nedd8 derivatives, but that CSN is a more
efficient deneddylase towards Cullin1-Nedd8 than the CSN5/
CSN6 MPN complex. This suggests that the MPN2 subunit would
contribute significantly to the catalytic activity of the human CSN,
but efficient substrate recruitment would require additional
elements such as other CSN subunits. Moreover, we provide a
structural context for these observations, combining X-ray
crystallography, NMR and cross-linking coupled to MS (CX-
MS) derived data and flexible molecular docking to produce a
molecular model of the CSN5/CSN6 MPN heterodimer and re-
interpret the molecular model of CSN (8). This analysis suggests
that a major part of the subunit-subunit interactions in CSN are
mediated by a helical bundle, composed of the C-termini of CSN’s
subunits, further highlighting its structural similarity to the 26S
proteasome lid [23]. Our work indicates that, in addition to the
importance of their MPN domains for catalysis, the C-terminal
regions of CSN5 and of CSN6 contribute to their anchoring and
precise positioning in the CSN assembly.
Experimental Procedures
Protein production
The expression and purification of human CSN5 1–257
fragment, in the WT and mutant forms were performed as
previously described in [19]. The human CSN6 cDNA was
subcloned in pGEX-6P1 vector (Novagen). The CSN6 31–211
fragment was found to be solubly expressed in bacteria and was
selected for further work. The 1–257 and 31–211 fragments of
CSN5 and CSN6, corresponding to their MPN domains together
with N- and C-terminal appendices for CSN5 and a C-terminal
extension for CSN6, as illustrated in Figure 1A, are referred to as
CSN5DC and CSN6DC, respectively, in the rest of the manuscript.
Expression of CSN6DC and its variants was performed in E. coli
BL21pLysS cells (Novagen) in LB or 15NH4Cl-supplemented M9
minimal expression medium, as required for NMR experiments.
Protein expression was carried out overnight at 18uC and the
following purification buffer (20 mM Tris pH 7.5, 150 mM NaCl,
0.01% monothioglycerol) was used throughout the purification. A
standard purification protocol for GST-tagged proteins was used,
including a first glutathione sepharose affinity step, a size exclusion
chromatography step and a second affinity step to remove
contaminating GST from the purified protein. Purified CSN6DC
was concentrated to 8 mg mL21 and stored at280uC until further
use. Production of pro-Nedd8 from the pOPIN-E-pro-nedd8
vector (from M. Banfield), was carried out following the protocol
described in [24]. Site directed mutagenesis performed in this
work were done with the QuikChange Lightning Site-Directed
mutagenesis kit (Stratagene) and verified by DNA sequencing.
Production and purification procedures for the CSN and Cullin1-
Nedd8/Rbx1 were carried out following the protocols described in
[8].
Isothermal titration calorimetry
Isothermal titration calorimetry (ITC) experiments were carried
out on a MicroCal ITC200 microcalorimeter (GE Healthcare,
Piscataway, NJ) at 20uC. The protein samples were all buffer
exchanged using PD-10 desalting column (GE Healthcare) into the
ITC buffer (20 mM Na MES pH 6.5, 75 mM NaCl). Protein
concentrations were measured using a NanoDrop 1000 spectro-
photometer (Thermo Scientific, Wilmington, DE), with the
following extinction coefficients: 56,840 M21cm21 and
18,450 M21cm21 for CSN5DC and CSN6DC, respectively. Titra-
tion of CSN5DC (WT and variants; 100 mM) in the cell (200 mL)
was performed by sequential addition of CSN6DC (WT and
variants; 1 mM; 30 injections of 1.8 mL). Integrated raw ITC data
were fitted to a one site nonlinear least squares fit model using the
MicroCal Origin plugin as implemented in Origin 9.1 (Origin
Lab) after the control experiments (titration of the ligand from the
syringe into the buffer) were subtracted.
Fluorescence anisotropy
To obtain quantitative information about the affinity of
CSN5DC to Nedd8, fluorescence anisotropy measurements were
performed at 28uC, using a TECAN safire2 plate reader (Tecan).
The experiments were performed in 20 mM Hepes pH 7.5 and
75 mM NaCl. Alexa Fluor 488 fluorophore (Life Technologies)
was used to label Nedd8 through a standard amine coupling
procedure. The fluorescence was measured using excitation and
emission wavelengths of 495 nm and 519 nm, respectively.
CSN5DC,WT or.R106T at varying concentrations (0–600 mM) was
incubated in the presence of 4 nM Alexa Fluor 488-Nedd8. The
same procedure was followed in the presence of CSN6DC where a
1:1 ratio of CSN5DC/CSN6DC was used to make the complex at
the indicated concentrations. For each data point the measure-
ment was done in triplicates and the recorded data corresponds to
the average anisotropy. The data obtained were plotted and
analysed using the IgorPro software. The Hill Equation was used
for fitting the data in order to be able to deduct an estimate of the
apparent equilibrium dissociation constant (KD) of each complex
between the protein or protein complex and Alexa Fluor 488-
Nedd8. As there exists no evidence of cooperativity, in all cases,
the data were fit with values of cooperativity equal to 1.
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Figure 1. CSN6DC activates CSN5DC. (A) Studied protein fragments (brown). The MPN domain boundaries are indicated with dotted lines. (B)
Binding of CSN5DC and CSN6DC measured by ITC. Titration experiments were carried out by injecting concentrated CSN6DC solution into
100 mM CSN5 variants. (C) KD values of CSN5
DC/CSN6DC pairs obtained from ITC data. (D) Activity towards Nedd8-AMC. Nedd8-AMC
hydrolysis rate plot versus substrate concentration (200 nM CSN5DC alone; 4 nM CSN5DC/CSN6DC complex; 23 nM CSN), with data fitted using the
Michaelis-Menten equation. Below: Associated kinetic parameters of the Nedd8-AMC cleavage derived from the left plot. In the CSN5DC,R106T and
CSN5DC,WT/CSN6DC experiments, substrate saturation conditions were not reached and kapp values were extracted from linear fitting of the kobs versus
substrate concentration data. (E) Time-course deneddylation of Cullin1-Nedd8/Rbx1 (1 mM) by the CSN (4 nM; Top) or CSN5DC,WT/CSN6
(4 nM; Bottom). Samples from each time point were analysed on Coomassie stained 15% Tris-tricine SDS-PAGE. Quantification of the cullin
deneddylation was carried out. The bands corresponding to Cullin1-Nedd8 and to Cullin1 show doublet that arise from Cullin1 degradation. (F)
Deneddylase activity on the Cullin1-Nedd8/Rbx1. Substrate hydrolysis (1 mM) is shown as a function of time for 4 nM enzyme (CSN, triangle;
CSN5DC,WT/CSN6DC, square). For context, CSN5DC,R106T alone at 900 nM concentration produces less than 30% of deneddylated Cullin1 for 120 min
reaction (data point not shown for clarity). Data information: N.D., not significant; -, parameters not measured; error bars = s.d.; experiments done at
least twice.
doi:10.1371/journal.pone.0105688.g001
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Isopeptidase assays
Activity assays have been carried out on synthetic and
physiological substrates. A synthetic substrate, namely Nedd8-
AMC (Nedd8 protein conjugated to a 7-amino-4-methyl-couma-
rin molecule (AMC); from Boston Biochem.), and one physiolog-
ical substrate (Cullin1-Nedd8/Rbx1) were used to assess the
catalytic activities of different proteins and complexes used in this
study. For the Nedd8-AMC substrate, initial rate measurements
were carried out at 37uC by following the increase of fluorescence
intensity (lexcitation =380 nm; lemission =460 nm), in non-binding
surface, flat-bottom, black 384-well plates (Corning), in a volume
of 50 mL (reaction buffer (50 mM Tris-HCl pH 7.5, 50 mM
NaCl)) on a Tecan safire2 plate reader. The following experimen-
tal conditions were used: 0.5 to 6.0 mM Nedd8-AMC in reaction
buffer, 4 nM CSN5DC/CSN6DC binary complex (110 nM
CSN5DC and 200 nM CSN6DC were mixed prior to reaction
and the concentration of the binary complex was calculated using
the value of the apparent KD value determined by ITC), 200 nM
CSN5DC alone or 23 nM CSN. In the case of saturating
concentrations of Nedd8-AMC, initial rate data were fitted to
the Michaelis-Menten equation using least square analysis to
determine kcat and KM in the Prism software (GraphPad). When
saturating concentrations of Nedd8-AMC were not reached, the
value of k2, corresponding to an approximate value of the kcat/KM
ratio was obtained by linear fitting of initial rate data.
Deneddylation assays
The CSN5DC,WT/CSN6DC complex and recombinant CSN,
were diluted to 4 nM in reaction buffer (20 mM Tris-HCl pH 7.5,
50 mM NaCl) and incubated at 37uC in the presence of 1 mM
Cullin1-Nedd8/Rbx1. A time course (0 to 120 minutes) was
recorded for each reaction in independent duplicates. One time
point was performed for CSN5DC,R106T (900 nM) for 2 hours
incubation time. The reactions were stopped in SDS sample buffer
and analysed on Tris-tricine gel stained in Instant Blue solution
(Expedeon, UK). Bands of Cullin-Nedd8/Rbx1were detected and
quantified using Carestream Molecular Imaging instrument
connected to the Gel Logic 2200PRO software (Equilab, White-
stone, NY).
Pro-Nedd8 processing assays
This assay conditions were as follows: reaction buffer (20 mM
Tris-HCl pH 7.5, 50 mM NaCl); 1 mM pro-Nedd8 WT or
variants; CSN5DC (WT or variants), alone or the CSN5DC/
CSN6DC complex was diluted to 900 nM (for CSN5DC alone) or to
4 nM (for the dimer: 110 nM CSN5DC and 200 nM CSN6DC). A
time course at 37uC was performed in independent duplicates for
each reaction. Samples were analysed as described for deneddyla-
tion assays.
Crystallization, data collection and structure
determination
The coordinate and structure factor files have been deposited in
the PDB under the code 4QFT. Purified CSN6DC at 8 mg mL21
was subjected to crystallisation trials using commercial screening
kits. Crystals grown at 18uC, in 0.2 M Tri-Sodium citrate, 0.1 M
Bis-Tris propane pH 6.5 and 20% PEG3350, were harvested,
cryo-protected in the crystallisation solution supplemented with
10% glycerol and flash-frozen in liquid nitrogen. A dataset was
collected at a 1.8 A˚ resolution at ESRF ID29 beamline and
processed using MOSFLM and SCALA from CCP4 suite [25].
The structure was solved by molecular replacement using Phaser
with the chain A of human Rpn8DC (residues 1–187) as the search
model (PDB code 2O95) [26]. The use of human Rpn8 fragment
structure as the search model for molecular replacement is
supported by the fact that (i) the boundaries of the human
CSN6DC, on which we worked, better correspond to those of
human Rpn8 than to those of Drosophila CSN6DC; (ii) the
structure of Drosophila melanogaster CSN6DC that lacks the C-
terminal portion of the MPN domain displays an atypical strand
orientation at its C-terminus; (iii) the crystal structure of the
human Rpn8DC template model is at the highest resolution
(1.95 A˚). The initial model was built by ARP/wARP into the
electron density map [27]. Further refinement procedure was
carried out by alternate cycles of manual rebuilding and
REFMAC refinement. Data collection and refinement statistics
are compiled in Table S1.
NMR
Uniformly 15N-labelled CSN6DC protein samples were dissolved
in 50 mM Tris buffer, 150 mM NaCl (pH adjusted to 6.8) in 90%
H2O/10% D2O. In all experiments, the
1H carrier was centred on
the water resonance and a WATERGATE sequence [28,29] was
incorporated to suppress solvent resonances. CSN6DC assignment.
Spectra were acquired at 298K and pH 6.8, with a 600 mM
CSN6DC protein sample on a 700 MHz Avance Bruker spec-
trometer equipped with triple-resonance (1H, 15N, 13C) z-gradient
cryo-probe (Figure S1A). NMR data were processed using GIFA (v
4.0) [30], and Topspin (v. 2.1). The 3D 1H-15N-NOESY-
heteronuclear single quantum coherence spectroscopy (HSQC)
spectrum was analysed using strip-plots with manual reordering of
the sequential stretches according to the main chain assignment
strategy [31,32,33]. Side chain assignments were carried out using
the 1H-15N-TOCSY-HSQC spectrum. The first two residues Gly-
Pro in the N-terminal tag were not assigned. For the remaining of
the sequence, assignments were obtained for 15N, HN and Ha
atoms (excluding Pro residues, and A71, L89, D101 and H160
residues). The overall assignment completeness for 1HN-15N
resonances was 98% (Tables S2, S3). CSN5DC/CSN6DC complex.
An HSQC spectrum at 308 K was acquired starting from a 15N-
labelled CSN6DC sample at 100 mM (Figure S1B). After addition
of 200 mM unlabelled CSN5DC to the 15N-labelled CSN6DC
sample, another HSQC was recorded (Figure S1B). The
assignments of CSN6DC at 308K were derived from those at
298K, by recording an intermediate CSN6DC HSQC spectrum at
305K.
Protein-protein docking and modelling
CSN5DC and CSN6DC models were treated as rigid bodies and
all six rotational and translational parameters were fully explored
in the ab initio docking program ZDOCK using 6u sampling on
Euler angles. A list of 30 ‘passive’ solvent-accessible residues of
CSN6DC excluded from the interface with CSN5DC derived from
the analysis of non-shifted CSN6DC peaks in HSQC experiments
in the presence of CSN5DC was incorporated in the filtering option
of the ZDOCK procedure (Figure S1B; Table S4). Among the
54,000 models generated, the top 2,000 complexes, ranked
according to ZDOCK were further analyzed. The starting
structures for human CSN5DC and CSN6DC proteins were the
crystal structures solved at 2.6 A˚ and 1.8 A˚ resolution, respective-
ly. Two docking pairs of protein models were used for docking
simulations: (i) the CSN5DC (chain A, PDB code: 4F7O), with Ins-
1 segment (residues 98–132) fitted to the corresponding ubiquitin-
liganded AMSH-LP Ins-1 structure (AMSH-LP structure corre-
sponds to the MPN domain: residues 264–436; PDB code 2ZNV)
using MODELLER9 program, followed by manual fitting (to
avoid steric clash with the C-terminal LRGG residues of ubiquitin
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from AMSH-LP distal ubiquitin), combined with the 38–191
CSN6 fragment (a4 deletion; referred to as CSN6DC,Da4); and (ii)
the same CSN5DC model with the N- and C-terminal appending
segments removed (residues 2–31 and 232–257; referred to as
CSN5DC,D2–31,D232–257) combined with CSN6DC,Da4 (residues 38–
207). We subsequently filtered and re-ranked the 2000 hits using a
dedicated procedure incorporating additional experimental con-
straints in order to identify the correct docking conformations.
These constraints were derived from mutagenesis and biochemical
data (CSN6 H44, V115 residues and CSN5 E115, Y116, Y120
residues were contributing to the CSN5/CSN6 interface).
Additional information was also incorporated in this filtering
procedure: primary sequence conservation data for both CSN5
and CSN6 calculated using the PAT server (sequence conservation
calculated for each residue in the aligned sequences, by pairwise
comparisons using a BLOSUM62 matrix-derived substitution
probability score and averaged/normalized for each position to
have a 100% value for absolute conservation) [34], total buried
area in the dimer interface (calculated using the NACCESS
program (http://www.bioinf.manchester.ac.uk/naccess), surface
shape complementarity (obtained by SC program [25,35]) and
interface parameters derived from the PISA program [36].
Docking simulations were performed on Intel Linux cluster
platforms. The low frequency normal modes of CSN5DC were
computed with WEBnm@ server [37], providing information on
regions with slow collective motions. The six first non-trivial
modes were analyzed.
CX-MS
Roughly 100 ml of 1.2 mg/ml CSN sample were cross-linked at
1 mM disuccinimidyl suberate d0/d12 (DSS, Creative Molecules
Inc.), followed by tryptic digestion and enrichment for cross-linked
peptides, essentially as described [38]. LC-MS/MS analysis was
carried out on an Orbitrap Elite mass spectrometer (Thermo
Electron, San Jose, CA) and data were searched using xQuest [39]
in iontag mode with a precursor mass tolerance of 10 ppm. For
matching of fragment ions tolerances of 0.2 Da for common-ions
and 0.3 Da for cross-link ions were used. False discovery rates
(FDR) of cross-linked peptides were assigned using xProphet
(version 2.5.2) [40]. Cross-linked peptides were identified with a
delta Score ,0.95 and a linear discriminant (ld) score .25 and
additionally analyzed by visual inspection in order to ensure good
matches of ion series on both cross-linked peptide chains for the
most abundant peaks.
Revisiting the topology of CSN
The starting point of the modelling work was the assembly
model generated by [8]. To the individual subunit models of the
initial CSN model, were substituted updated models of the
following subunits generated by Phyre [41]: CSN1 (modelled on a
partial crystal structure of the Arabidopsis thaliana (At) protein;
PDB code 4LCT; [42]); CSN5 (modelled on the CSN5DC crystal
structure; PDB code 4F7O; [19]); CSN6 (modelled on the
CSN6DC crystal structure; this work); CSN7 (modelled on a
partial crystal structure of the At protein; PDB code 3CHM; [43]);
CSN8 (modelled on the crystal structure of eIF3k; PDB code
1RZ4; [44]). First the CSN5DC/CSN6DC dimer model was placed
in the EM density map and its position further refined using the
CSN5DC-Nedd8/CSN6DC ternary model. The remaining newly
modelled CSN subunits were placed in the density at their
respective positions, as established by [8], leaving an unoccupied
portion in the electron density. Parallel with the 26S proteasome
lid suggested that the C-termini portions of the CSN subunits
might occupy this portion. We therefore manually placed the
modelled C-termini of the CSN subunits in this density, exploiting
inter-subunit cross-links (Table S5). In the last step of modelling, a
Molecular Dynamics Flexible Fitting (MDFF) approach was used
to improve this initial fit and the quality of the final assembly
model [45]. To do so, the various CSN subunits were first rigidly
fitted into the EM map (EMD 2173) [8], using the collage program
in SITUS package [46]. We used the MDFF procedure with
implicit solvent and optimized strength of structural restraints and
steering forces [47], together with additional Ca-Ca Lys distance
restraints to constrain the experimental inter-subunit cross-linked
lysine residues. 5000 cycles of minimization were followed by
100,000 cycles of restrained steered MD. The accuracy of the
model was assessed by local correlation between the model and the
EM map, and by analysis of the Ca-Ca distance between cross-
linked Lys residues.
Results
The MPN domains of CSN5 and CSN6 form a stable
heterodimer
Previous structural studies of the CSN suggested that CSN5 and
CSN6 interact [8,48]. We therefore set out to quantify the
association between the CSN MPN subunits. The association of
the 1–257 and 31–211 domains of CSN5 and CSN6, amenable to
soluble bacterial expression, referred to as CSN5DC and CSN6D,
respectively (Figures 1A, S2) was probed by ITC experiments. The
data revealed a KD of 661 mM for the MPN heterodimer
(Figure 1B,C). Compatible with these findings, significant changes
in the HSQC spectra comprising shifts, intensity changes and
disappearance of peaks were observed when CSN5DC was added
to 15N-uniformly labelled CSN6DC (Figure S1B). Moreover,
binding of CSN6DC to a conformationally-relaxed CSN5DC
variant, in which the residue arginine 106 of the Ins-1 is
substituted by a threonine (CSN5DC,R106T) [19] was probed by
ITC. In this previous structural, biochemical and computational
analysis of CSN5DC, the Ins-1 region was identified as an
important region for the activation state of CSN5DC. More
specifically, in the WT inactive form of CSN5DC, the Ins-1 appears
conformationally constrained and folded back onto the zinc-
binding site. The conformational relaxation of the Ins-1, allowing
an activity gain of the enzyme, was achieved in silico by loss of a
salt bridge between the arginine 106 (R106) and the aspartate 151
(D151) upon substitution of R106 by a threonine, as shown in
molecular dynamics simulations. This was mirrored in vitro by an
activation of the enzyme upon Ins-1 conformational relaxation
resulting from the un-anchoring of Ins-1 from the zinc-binding
site. ITC measurements indicated a comparable affinity between
CSN6DC and the conformationally-relaxed CSN5DC,R106T variant,
to that of CSN5DC,WT/CSN6DC (Figure 1C).
CSN6DC confers increased Nedd8 affinity and
isopeptidase activity to CSN5DC
The CSN catalytic subunit lacks enzymatic activity in a stand-
alone form, due to the auto-inhibitory position of Ins-1 [17,19,48].
We hypothesized that, while CSN5 by itself has a very low affinity
for Nedd8, upon activation by an unknown factor, the Ins-1 region
rearranges to form part of a Nedd8 recruitment site groove.
Interestingly, MPN- subunits of the 26S proteasome lid and of
BRCC36-containing complexes are able to activate their other-
wise inactive catalytic subunits, Rpn11/POH1 and BRCC36,
respectively [20]. Having shown that the N-terminal MPN
domains of CSN5 and CSN6 heterodimerize, we went on to
evaluate the effect of CSN6DC on CSN5DC’s affinity for Nedd8
Activity Regulation of CSN5 by CSN6
PLOS ONE | www.plosone.org 5 August 2014 | Volume 9 | Issue 8 | e105688
and its isopeptidase activity on substrates ranging from protein to a
physiological complex.
First we utilized a fluorescence anisotropy assay to assess the
binding affinity of Alexa Fluor 488-labelled Nedd8 for CSN5DC
variants (Figure S3). Consistent with our hypothesis, CSN5DC,WT
alone displays the weakest affinity for Nedd8 (KD=320659 mM),
but conformational relaxation of the Ins-1 region in
CSN5DC,R106T increases the affinity to an apparent KD of
202625 mM. Importantly, the CSN5DC,WT/CSN6DC (or
CSN5DC,R106T/CSN6DC) complex has a similar affinity for
Nedd8, with an apparent KD of 179617 mM (or 144622 mM).
Notably, CSN6DC alone does not appear to greatly contribute to
Nedd8 binding (Figure S3A).
Next the catalytic properties of the enzymes were investigated
on Nedd8-AMC (Figure 1D). Consistent with previous data [19],
200 nM CSN5DC,R106T hydrolysed Nedd8-AMC at a detectable
rate, whilst CSN5DC,WT showed no activity. As saturating
concentrations of the substrate were not reached, we used the
available titration data of CSN5DC,R106T to determine a kapp value
of 5766 M21s21 from the linear fitting of the initial rate data. The
CSN5DC,WT/CSN6DC binary complex at a 4 nM concentration,
obtained by mixing 110 nM CSN5DC,WT and 200 nM CSN6DC,
displayed robust catalytic efficiency (kapp value of
596103616103 M21s21), although the activity of CSN5DC,WT/
CSN6DC complex was not saturable at 6 mM substrate concen-
tration and therefore determination of the kcat/KM ratio was not
possible (Figure 1D). For comparison with the data on the binary
complex, we measured the ability of the holo-CSN to hydrolyse
Nedd8-AMC, which showed saturation by the substrate (Fig-
ure 1D). CSN possesses an estimated kcat/KM ratio value of
176103616103 M21s21 towards Nedd8-AMC.
We subsequently studied the hydrolytic activity of CSN and of
the CSN5DC/CSN6DC dimer on the physiological substrate
Cullin1-Nedd8/Rbx1. The holo-CSN was very efficient at
hydrolysing the isopeptide bond between Nedd8 and Cullin1, as
reported in [49] (Figure 1E,F). Within less than 10 minutes, most
of the Cullin1-Nedd8 substrate at 1 mM, was hydrolysed by 4 nM
CSN, as determined by gel shift assay (Figure 1E). Comparatively,
the activity of 4 nM CSN5DC,WT/CSN6DC dimer on 1 mM
Cullin1-Nedd8 is lower, with a modest proportion of the substrate
processed in the same period (Figure 1E,F). For context, the
processing of 1 mM Cullin1-Nedd8 by 900 nM CSN5DC,R106T
alone (i.e. over 200-fold molar excess of enzyme compared to the
CSN5DC/CSN6DC conditions) after 120 min incubation revealed
that the R106T variant alone has a reduced capacity to hydrolyse
Cullin1-Nedd8 compared to the binary CSN5DC,WT/CSN6DC
complex.
These findings may imply that the heterodimer constituted by
the CSN5/CSN6 MPN domains in the stand-alone state possibly
correspond to the minimal catalytic centre, significantly contrib-
uting to the isopeptidase activity of human CSN, but with low
efficiency on a CSN physiological substrate. As CSN displays
significantly higher deneddylase activity than the CSN5/CSN6
MPN complex on a physiological cullin substrate, this could
suggest that the optimal activity of the CSN5/CSN6 MPN
domains would only be revealed in the context of the holo-CSN
complex. These data suggests a hierarchy in the catalytic activity
over the enzymatic system and the substrate type, with the inactive
CSN5DC,WT form, CSN5DC,R106T that has basal activity, the MPN
heterodimer alone that has robust isopeptidase activity on non-
physiological substrates and the CSN5/CSN6 heterodimer in the
context of CSN that recapitulates strong activity on both non-
physiological and physiological substrates.
CSN6DC crystal structure resembles that of Rpn8DC
To gain additional insights into the molecular mechanism of
CSN5 activation by CSN6, the crystal structure of the MPN2 core
fragment was determined by molecular replacement at 1.76 A˚
resolution, using the human Rpn8DC orthologue as the search
model (PDB code 2O95; Table S1). The CSN6DC structure
encompasses the typical MPN domain fold composed of a central
b-sheet made of seven strands decorated by three a-helices and a
small anti-parallel b-sheet in the Ins-1 region. The MPN core is
extended by a C-terminal appendix (residues 192 to 208) that
includes a small helical portion (a4 201 to 207; Figure 2A). The
asymmetric unit contains one CSN6DC molecule, but the
crystallographic 2-fold symmetry operator generates an a-helix
swapping-stabilised dimer, involving the C-terminal a4 helices
(Figure 2A). The MPN domain dimerisation is structurally well
documented, but, until recently, all the MPN dimers identified
were mediated via different interfaces [14]. Interestingly, despite
their sequence conservation (Figure S4A), the homodimeric
organisation observed in human CSN6DC is different from that
in a CSN6 51–187 fragment from Drosophila melanogaster [16],
but identical to the human Rpn8DC and to the budding yeast
Rpn11DC/Rpn8DC heterodimer crystal structures, comprising the
Rpn8 2–178 or 1–176 and Rpn11 2–239 or 1–220 fragments
[21,22,50] (Figure S4 B–G). Human CSN6DC dimer showed high
structural homology with swapped Rpn8DC dimer, as illustrated in
Figure S4B,C,F,G. 304 equivalent Ca atoms were superimposed
with a rmsd of 1.69 A˚ and a sequence identity of 23% using
LSQMAN program [51]. The same comparison of the monomeric
form of human CSN6DC with human Rpn8DC and Drosophila
CSN6DC gave rmsd values of 1.64 A˚ for 153 Ca pairs and 1.35 A˚
for 84 Ca pairs, respectively.
A highly conserved surface of CSN6DC could mediate the
association with CSN5DC
Crystallisation of the human CSN5DC/CSN6DC heterodimer
has so far been unsuccessful, in spite of extensive trials. Therefore,
to characterise further this complex, we probed the association of
CSN5DC and CSN6DC by NMR to help define the regions
responsible for the interaction. Because of the difficulties to
unambiguously ascribe CSN6DC residues affected by CSN5DC
(owing to size and poor solubility of the binary complex), instead
we extracted, through 15N-CSN6DC HSQC experiments, the
residues that were not perturbed upon addition of CSN5DC (20%
of the residues; Table S4). Although not unambiguous, these
NMR restraints were useful in combination with sequence
conservation pattern and crystal packing information to delineate
a CSN6DC surface potentially impacted by the addition of
CSN5DC. The CSN6DC surface engaged in the binding to
CSN5DC most likely corresponds to the region comprised between
the a1/a2 helices, as delineated in Figure 2B with dotted grey line.
Indeed the functional significance of this particular surface is
strengthened by the facts that: (i) it is a highly conserved surface
among CSN6 family members (Figures 2B,S4A) and (ii) it
corresponds to the homodimer interface found in human CSN6DC
and Rpn8DC crystal structures, as well as to the heterodimer
interface found in budding yeast Rpn11DC/Rpn8DC (Figure-
s 2A,S4B,C,F,G) [21,22].
To further validate this interaction surface, we mutated two
CSN6DC residues, H44 to an alanine and V115 to a glutamic acid,
chosen for their high conservation and their positions on the
putative interaction surface, and determined the effect of these
mutations on the association with CSN5DC by ITC and activity
measurements (Figures S4A,2B,C,D). The H44A variant showed a
slight reduction in heterodimerisation compared with the WT
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Figure 2. CSN6DC binds to CSN5DC. (A) Human CSN6DC displays a classical MPN fold. The crystallised fragment of human CSN6 contains an
MPN core (white ribbon), completed by a C-terminal extension (green ribbon). The asymmetric unit contains one molecule (A); the 2-fold
crystallographic symmetry-related one, A9 is shown in beige as a surface. (B) CSN6DC binding to CSN5DC engages a conserved surface. CSN6
sequence conservation is displayed on the molecular surface of CSN6DC with a colour coding blue to red from variable to conserved, respectively, as
calculated with the PAT server [34]. The dotted line corresponds to the surface fingerprint of CSN5DC,D2–31,D232–257 in the docking model of CSN5DC/
CSN6DC. (C) KD values of CSN5
DC/CSN6DC variant pairs obtained from ITC data. (D) Pro-Nedd8 processing by CSN5DC. Time course assay
of pro-Nedd8 (1 mM) processing by CSN5DC,R106T/CSN6DC (top; 4 nM, obtained from mixing 150 nM CSN5DC,R106T and 200 nM CSN6DC), CSN5DC,R106T/
CSN6DC,H44A (middle; 4 nM) CSN5DC,R106T/CSN6DC,V115E (bottom; 4 nM), were analysed on Coomassie stained SDS-PAGE gels. The time course assay
was analysed on Coomassie stained 15% Tris-tricine SDS-PAGE. Quantification of pro-Nedd8 hydrolysis is specified, when possible, at the bottom of
the gel. Quantification of the pro-Nedd8 processing was carried out as detailed in the Material and Methods section. Although CSN5DC,WT in the
presence of CSN6DC displays robust activity on a range of substrates, as illustrated in Figure 1D,E,F, its level remains lower to that of CSN5DC,R106T in
the presence of CSN6DC. For the pro-Nedd8 gel shift assay, as illustrated in this figure, for detection purpose, it was advantageous to use the best
enzymatic system available.
doi:10.1371/journal.pone.0105688.g002
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Figure 3. JAMM/MPN+-MPN2 assembly. (A,B,C) Ins-1 conformation and UBL binding. Residues discussed in the text are shown in stick
mode and the zinc-coordinating residues in purple. Bottom panel: 90u rotated view with respect to the top panel. (A) AMSH-LP MPN Ins-1 bound
to distal ubiquitin. The binding site of AMSH-LP MPN domain to distal ubiquitin (dark blue), as revealed in [18], is represented in beige and in
yellow, for the Ins-1 region. The position 292, noted A292*, in AMSH-LP MPN has been substituted to an alanine. (B) CSN5DC Ins-1 region in the
stand-alone form (orange) and modelled on the basis of AMSH-LP MPN Ins-1 conformation (noted Ins-1*, yellow). The zone
corresponding to the distal ubiquitin binding site in AMSH-LP MPN (in A) is in beige. (C) Rpn11DC Ins-1 region in the context of the Rpn11DC/
Rpn8DC complex. The Rpn11DC Ins-1 region, together with the zone corresponding to the distal ubiquitin binding site in AMSH-LP MPN (in A) are
presented in yellow and beige, respectively. (D,E,F,G) The structures, in ribbon mode, are, unless specified otherwise, coloured as follows: CSN5DC or
CSN5DC,D2–31,D232–257 in orange (N- and C-terminal extensions in green; Ins-1 region in yellow), CSN6DC,Da4 in violet, Nedd8 in magenta. When visible,
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control, whereas the V115E variant showed a significant 5-fold
reduction in binding (Figures 2C,1C). It is noteworthy that,
although the interaction between CSN5DC and CSN6DC was
impaired by the H44A or to a stronger extent by the V115A
substitution, the effect of these variants remains modest (2 to 5-
fold). The interface mediating the CSN5DC/CSN6DC complex
obtained from the molecular docking encompasses 1,430 to 1,695
A˚2, depending on the type of heterodimer chosen. Prediction of
‘hot spot’ residues making a dominant contribution to the binding
free energy is a difficult task. Here the buried surface is sizeable
and could resist a single substitution not targeting a ‘hot spot’,
whilst affecting a topological modification that would decrease the
activation of CSN5DC by the mutated CSN6DC form(s). We
subsequently probed the hydrolytic activity of the CSN5DC,R106T/
CSN6DC H44A or V115E complex on the Nedd8 precursor, pro-
Nedd8. Indeed, our in vitro work suggested that the CSN5DC/
CSN6DC complex is able to process pro-Nedd8. Although CSN5 is
an unlikely factor for pro-Nedd8 processing [52], we have
exploited it as a reaction tool to substitute for Nedd8-AMC
synthetic substrate, in a gel shift assay, where pro-Nedd8
processing was followed by gel quantification of the appearing
Nedd8 band (Figure 2D). Using this pro-Nedd8 gel shift assay, we
showed that the hydrolytic activity of the CSN5DC,R106T/
CSN6DC,H44A or V115E variant complexes was entirely compro-
mised (Figure 2D).
Taken together and in the context of sequence conservation and
of NMR HSQC data, these results suggest an implication of the
residues H44 and V115 in CSN5DC/CSN6DC binding - although
these residues are possibly not located in a interfacial ‘hotspot’ -
and in CSN6DC-mediated activation of CSN5DC, reinforcing the
view that the CSN5/CSN6 MPN heterodimer is likely to involve a
highly conserved surface exploited in other MPN dimers
[21,22,50]. Further structural confirmation of the involvement of
this surface would be required (see Notes from Authors).
Proposed model of the CSN5/CSN6 MPN domain
heterodimer
Having identified a plausible CSN5DC/CSN6DC interaction
interface, we attempted to further explore the assembly of the
CSN5DC/CSN6DC dimer, molecular docking of the CSN5DC/
CSN6DC complex guided by experimental constraints. It is now
well established that the incorporation of a few biochemical and
NMR-derived constraints in docking methods suffices to deter-
mine the structure of a complex to high precision [53].
To help the docking procedure, a complex composed of
CSN5DC, harbouring an AMSH-LP-like Ins-1 conformation and
of Nedd8, was assembled. To do so, we probed the binding of
Nedd8 on CSN5DC and reciprocally, to investigate whether Nedd8
binds to CSN5DC in a mode reminiscent to that of the distal
ubiquitin to the MPN domain of AMSH-LP (or AMSH). The
choice of the interface residues to be analysed was guided by the
structurally characterised AMSH-LP MPN domain/distal ubiqui-
tin association (Figure 3A,B) [18]. Among the two CSN5DC Ins-1
glutamate positions probed (E115, E122), the E122D variant kept
strong processing activity on pro-Nedd8, whilst the E115D one
displayed weak activity (Fig S5A). The importance of F332 in
AMSH-LP for the distal ubiquitin binding prompted us to
evaluate the role of two aromatic residues in CSN5DC Ins-1
region (Y116, Y120) on the hydrolysis of the Nedd8 precursor (Fig
S5A). Additionally, effects of four pro-Nedd8 variants (T9M,
R42D, K48A, V70D) on processing activity were assessed (Fig
S5B). Activity measurement data on the chosen CSN5DC and pro-
Nedd8 variants showed that the CSN5DC, R106T, E115A,
Y116D.or.Y120D variants have compromised pro-Nedd8 processing
activity and that the pro-Nedd8 ones, namely pro-Nedd8T9M,
R42D, K48A or V70D, are important for hydrolysis by CSN5DC,
validating that Nedd8 on CSN5DC probably orient similarly to the
distal ubiquitin and AMSH-LP MPN (and Sst2, the AMSH
homolog in yeast) (Figures 3A,B, S5A,B) [18,54].
To assemble the CSN5DC-Nedd8 complex we then modelled
the CSN5 Ins-1 segment to resemble that of AMSH-LP MPN.
Interestingly, as a result of the modelling procedure, CSN5DC
modelled Ins-1 resembles the conformation of Rpn11DC Ins-1 in
the binary complex with Rpn8DC (Figure 3C). Exploiting the
above detailed finding that CSN5DC and Nedd8 interaction
proceeds through similar surfaces to that of AMSH-LP-distal
ubiquitin’s (Figures 3A,B, S5A,B), a complex composed of
CSN5DC displaying an AMSH-LP-like Ins-1 conformation and
of Nedd8 was assembled and used to probe the association of
CSN5DC and CSN6DC.
Subsequently, molecular docking simulations of the CSN5DC/
CSN6DC dimer were performed by the software ZDOCK followed
by a tailored post-docking filtering strategy. The simulations
resulted in a cluster of similar docking poses with favourable
interfacial metrics and satisfying all our experimental data
(Figures 3D, S6). In the resulting model, CSN5DC and CSN6DC
are placed in a topology that happens to be close to that observed
in the crystallographic human Rpn8DC and human CSN6DC
homodimers (Figures 3D, S4B,C,F,G) [50].
The surfaces engaged in the CSN5DC/CSN6DC,Da4 model are
highly similar to those of the Rpn11DC/Rpn8DC complex
(Figures 3E, S6). However, superimposition of their MPN+/
JAMM subunits revealed that the CSN6DC,Da4 position on
CSN5DC surface in our model is rotated and translated, relative
to the Rpn8DC position on Rpn11DC (Figure 3E). This difference is
the result of the presence of the CSN5-specific N- and C-terminal
helical appendices on each side of the MPN domain (residues 6 to
17 and 235 to 251, respectively). The CSN5 specific N-terminal
extension wraps around its MPN core and C-terminal helix
(Figure 3F) [19]. For CSN5DC and CSN6DC to arrange in a
Rpn11DC/Rpn8DC-like dimer, it would take the CSN5-specific N-
and C-terminal a-helices to unstaple from its MPN core. To
confirm this, docking carried out on a CSN5DC variant lacking the
N- and C-terminal helices (fragment 32–232) yielded top scoring
solutions corresponding to a pose of the Rpn11DC/Rpn8DC
topology (Figures 3G, S6). These helices were shown to be
the CSN6DC H44 and V115 residues and CSN5DC E115, Y116 and Y120 are shown in stick mode. (D) A CSN5/CSN6 model obtained by data-
driven docking. The best CSN5DC-Nedd8/CSN6DC,Da4 pose obtained from the docking procedure is represented. Right panel: 180u rotated view of
left Panel. (E) Topology of CSN5DC/CSN6DC dockingmodel and Rpn11DC/Rpn8DC-like CSN5DC/CSN6DC. The best CSN5DC-Nedd8/CSN6DC,Da4
pose obtained from filtering ZDOCK solutions is represented, as in (D). To this model, the CSN5DC-Nedd8/CSN6DC,Da4 model built following the
Rpn11DC/Rpn8DC structure has been superimposed. The CSN6DC,Da4 structure that is superimposed onto Rpn8DC is shown in pink to distinguish it
from the CSN6DC,Da4 obtained in our docking solution. Right panel: 180u rotated view of left Panel. (F) The N- and C-terminal helices specific to
CSN5DC. The N- and C-terminal helical extensions of CSN5DC are stacked onto the a3 helix and the loop linking the b6–b7 anti-parallel sheet. The
residues involved in packing are shown in stick mode. (G) CSN5DC,D2–31,D232–257/CSN6DC,Da4 docking pose. The best docking pose using a
CSN5DC model in which the N- and C-terminal extensions were deleted (CSN5DC,D2–31,D232–257) is shown. Right panel: 180u rotated view of left Panel.
(H) The normalized squared displacement of the CSN5DC Ca atoms in the lowest frequency mode 7 from normal mode analysis.
doi:10.1371/journal.pone.0105688.g003
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conformationally malleable by normal mode analysis [55] of
CSN5DC, where a subset of low frequency modes shows their
propensity to undergo large-scale shear and hinge motions
(Figures 3H, S7). These secondary structure elements, stabilised
by numerous weak interactions, could be unhooked from the core
domain (Figure 3F). This analysis could strengthen the view that
CSN5DC and CSN6DC interact through an architecture reminis-
cent of the Rpn11DC/Rpn8DC complex.
The molecular architecture of the intact CSN
Finally, we wanted to interpret our CSN5DC/CSN6DC model in
the context of the full CSN complex. We adopted a hybrid
structural approach, which involved CX-MS of the intact complex
[38], cross-link-guided docking of individual subunits and domains
and molecular dynamics flexible fitting of the obtained model
using MDFF procedure in the CSN density of the previously
published CSN-SCF EM map (EMD 2173; Table S5; Figure S8)
[8,47]. For the docking we used the CSN5DC/CSN6DC model
generated in this study and for the PCI domains and missing
portions of the remaining subunits, we predicted structures using
the server Phyre [41] (Figures 4A, S8; Table S6). CSN1 and
CSN7 models were largely based on their crystal structures (PDB
codes 4LCT, 3CHM, respectively) [42,43]. The CSN5DC/
CSN6DC model described above was fitted as a rigid body
(Figure 4A) and docked in the previously assigned EM density
portion [8]. However, using our ternary complex model composed
of CSN5DC-Nedd8/CSN6DC (Figure 4A) for refinement, resulted
in a slightly different orientation. In our model, CSN6DC moved to
a more peripheral location, relative to the one previously reported
[8]. This resulted in a conspicuous density segment left empty in
the thus re-docked CSN model (Figure 4A, red star).
Multiple cross-links between the extreme C-terminal sequence
portions of peripheral and central subunits, like CSN7-CSN1 or
CSN5-CSN1 indicated that these elements contribute a major,
previously unrecognised binding interface (Table S5, Figure S8).
Importantly, most of these C-terminal elements are predicted to
adopt helical structures (Figure S8). This led us to hypothesize that
they all join in a central helical bundle in a topology reminiscent of
the 26S proteasome lid [23]. To test this hypothesis we generated
models for the C-termini of all CSN subunits and arranged them
in a compact helical bundle like in [23] (Figures 4A,B, S8). The
resulting cluster matched well the corresponding density in shape
and size (Figure 4B), although the precise orientation and topology
of the helices could not be optimized due to the low resolution of
the EM density map. Potential positions of the C-termini portions
contributing to the central bundle and of the CSN subunits were
refined to best satisfy the set of inter-subunit cross-links providing
powerful constraints (21 inter-subunits cross-links between the 8 C-
terminus subunits; Table S5).
The local cross-correlation coefficient between the revisited
CSN assembly and the EM map (ccc = 0.84) has increased
compared to the initial model (ccc = 0.80). Both models for the
eight subunits contained the same number of residues (,2,750),
but positioned differently inside the 25 A˚ resolution map, in the
particular case of CSN5/CSN6 and of the C-terminal segments.
More significantly, the average distance between lysine Cas of the
70 identified intra- and inter- cross-links is 32.9 A˚ (29.5 A˚ if 4 clear
outlier inter-subunit cross-links with distance .60 A˚ are excluded
from the analysis). This results in an improvement over the initial
model for which the average distance of the 55 cross-links was
,38 A˚, suggesting that our CX-MS guided procedure has
improved the overall subunit topology within the CSN. Illustrative
examples of the agreement between identified cross-links with the
revisited model, specifically relevant to the helical bundle and to
the CSN5/CSN6 dimer with respect to the rest of the edifice are
between the C-terminus of CSN1 and CSN3 (distance K467-
K418: 23 A˚); CSN6 and CSN7 (distance K199-K199: 27 A˚);
CSN2 and CSN5 (distance K426-K180: 22 A˚); CSN5 and CSN7
(distance K180-K199: 32 A˚). However it is noteworthy that some
of the observed cross-links linkages are difficult to reconcile with
the overall topology of the molecular model, as for example the
link between CSN1 K97 and CSN2 K415 and between CSN1
K422 and CSN3 K115. Some of these cross-links, for which the
distance in the model exceeds the maximal distance that one can
expect between two cross-linked residues, may arise from
conformational variability within parts of the CSN, as recently
demonstrated for subunits Rpn5 and Rpn6 of the 26S proteasome
lid, corresponding to CSN4 and CSN2, respectively [12,56]. It is
therefore interesting to speculate, that the observed cross-link
distribution may therefore at least partially be influenced by an
intrinsically dynamic behaviour of the CSN [8,11].
Discussion
By dissecting biochemical and structural elements of the CSN,
we have demonstrated that CSN6DC binds to the MPN domain of
the CSN5 catalytic subunit and this association increases CSN5DC
affinity for Nedd8 and enhances its hydrolytic activity on a variety
of substrates, suggesting that the MPN heterodimer could
contribute significantly to the catalytic activity of the human
CSN. The activation of an MPN+/JAMM protein mediated by a
MPN2 subunit was described in two other MPN+/JAMM-MPN2
systems, namely the 26S proteasome lid and BRCC36-containing
complexes [20,21,22]. This mechanism of activity control of
MPN+/JAMM enzymes would therefore appear to be a general
assembly and regulatory principle of the MPN+/JAMM-MPN2
containing complexes and as such would constitute an important
regulatory mechanism of these complexes [14,57].
The stimulating role of CSN6DC in CSN5DC activation
demonstrated here should be considered in the light of the data
on the CSN reported in [58]. The authors probed the function of
CSN6 and its yeast ortholog (Csi1) MPN domain in the human
and yeast CSNs, respectively. These experiments, carried out
using budding yeast and mammalian CSNs and neddylated cullins
purified from yeast and mammalian cells, concluded that only the
C-terminal part of CSN6 is necessary for the deneddylase activity.
Further investigations are needed to reconcile those results with
our observations.
Taken together, our fluorescence anisotropy binding experi-
ments and the activity measurements suggest that CSN6DC does
not contribute significantly to Nedd8 direct recruitment and
activates CSN5DC through at least two mechanisms. First, the
catalytic activity efficiency can be achieved by an increase of
affinity for Nedd8 observed either in the CSN5/CSN6 complex or
by the conformational relaxation of the Ins-1 segment. Secondly,
the increased activity can also result from a yet unknown
mechanism. Indeed, CSN5DC,WT/CSN6DC has a higher catalytic
efficiency than CSN5DC,R106T alone, although their affinity for
Nedd8 is of the same order of magnitude. The contribution of
CSN6DC to CSN5DC activation might therefore not be confined to
the enhancement of substrate binding.
Assessment of the CSN5DC/CSN6DC complex and of CSN on
different Nedd8-derived substrates provides a molecular ranking of
the catalytic activity. The higher hydrolysis rate of CSN on
neddylated Cullin1 than on Nedd8-AMC supports the observation
that CSN is a cullin deneddylase [7], underlying the contribution
of the CSN edifice in the efficient processing of neddylated CRLs.
This is therefore in agreement with the observations in [8], that
Activity Regulation of CSN5 by CSN6
PLOS ONE | www.plosone.org 10 August 2014 | Volume 9 | Issue 8 | e105688
PCI subunits contribute to the recruitment of the CRLs. Indeed
EM studies on CSN/CRL supercomplexes highlighted the direct
interaction between CSN2, and probably CSN4, and the cullin
subunit of the CRL. Taken together, these data show that the
CSN is an intricate assembly that is tailored to function on CRLs.
To further probe CSN assembly, we performed molecular
docking of the CSN5DC/CSN6DC complex guided by experimen-
tal constraints (Figure S6). The MPN domain heterodimerisation
appears to be an important aspect in the regulation of several
multiprotein complexes in eukaryotes. Vexingly, different MPN-
containing domains appear to utilise different dimerisation
Figure 4. The CSN topology. Inter-subunit cross-links between CSN5 or CSN6 Lys and other CSN subunits (Ca distances ,40 A˚) are marked with
red dotted lines. (A) The CSN assembly revisited, displayed in the EM density obtained by [8] (grey mesh). A red star indicates an unoccupied
electron density region. Close-up views of this region are shown after fitting of the helical bundle. (B) CSN5-Nedd8/CSN6 complex positioned in
the EM envelope. CSN5 is shown in orange, CSN6 in purple and Nedd8 in magenta. CSN subunits (other than CSN5 and CSN6) are shown in white
for context.
doi:10.1371/journal.pone.0105688.g004
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surfaces [14], although recent structures (budding yeast Rpn11DC/
Rpn8DC [21,22]; human CSN6DC) exhibit a dimerisation mode
consistent with the one originally described for human Rpn8DC
[50]. Interestingly our model highly resembles the crystal structure
of the Rpn11DC/Rpn8DC dimer [21,22] and the association of
CSN6DC and of Rpn8DC in the direct vicinity of the Ins-1 region of
CSN5DC and Rpn11DC, respectively, further underlines the
essential role of Ins-1 as a regulatory switch in these enzymes.
Moreover, we explored the molecular assembly of the intact
CSN by reinterpreting a published EM density map, using
molecular docking of our model of the CSN5DC/CSN6DC
complex and experimental data from CX-MS experiments. This
work provided an updated model of the CSN structure that
comprises the repositioning of the CSN5DC/CSN6DC dimer and a
central helical bundle, reminiscent of the 26S proteasome lid and
suggests that this bundle may be contributing to the assembly of
the CSN [23]. This structural analysis, complementing our work
on the MPN domains of CSN5 and CSN6 that highlights the
importance of the MPN domain interaction in the catalytic
activity, could suggest that the C-terminal regions of CSN5 and
CSN6 contribute to anchoring and optimal positioning these
subunits within the CSN assembly.
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